WO2011005052A2 - Novel arylpiperazine-containing imidazole 4-carboxamide derivatives and pharmaceutical composition comprising same - Google Patents

Novel arylpiperazine-containing imidazole 4-carboxamide derivatives and pharmaceutical composition comprising same Download PDF

Info

Publication number
WO2011005052A2
WO2011005052A2 PCT/KR2010/004479 KR2010004479W WO2011005052A2 WO 2011005052 A2 WO2011005052 A2 WO 2011005052A2 KR 2010004479 W KR2010004479 W KR 2010004479W WO 2011005052 A2 WO2011005052 A2 WO 2011005052A2
Authority
WO
WIPO (PCT)
Prior art keywords
imidazole
piperazin
carboxamide
propyl
dimethyl
Prior art date
Application number
PCT/KR2010/004479
Other languages
French (fr)
Other versions
WO2011005052A3 (en
WO2011005052A8 (en
Inventor
Jinhwa Lee
Hee Jeong Seo
Suk Youn Kang
Eun-Jung Park
Min Ju Kim
Suk Ho Lee
Jong Yup Kim
Jeongmin Kim
Myung Eun Jung
Hyun Jung Kim
Mi-Soon Kim
Ho Kyun Han
Kwang Woo Ahn
Min Woo Lee
Ki-Nam Lee
Ae Nim Pae
Woo-Kyu Park
Original Assignee
Green Gross Corporation
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Green Gross Corporation filed Critical Green Gross Corporation
Priority to KR1020127003530A priority Critical patent/KR101386679B1/en
Priority to US13/383,143 priority patent/US8835436B2/en
Publication of WO2011005052A2 publication Critical patent/WO2011005052A2/en
Publication of WO2011005052A3 publication Critical patent/WO2011005052A3/en
Publication of WO2011005052A8 publication Critical patent/WO2011005052A8/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4965—Non-condensed pyrazines
    • A61K31/497—Non-condensed pyrazines containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D233/66—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D233/88—Nitrogen atoms, e.g. allantoin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/04—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin

Definitions

  • the present invention relates to a novel arylpiperazine-containing imidazole 4-carboxamide derivative or a pharmaceutically acceptable salt thereof, and a pharmaceutical composition comprising the same as an active ingredient for preventing or treating depressive disorders.
  • BACKGROUND OF THE INVENTION Depressive disorders involve all major bodily functions, mood, and thoughts, affecting the ways in which an individual eats and sleeps, feel about themselves, and think. Without treatment, depression symptoms can last for weeks, months or years. Expression is the leading cause of disability in the United States. An increasing number of treatment options have become more available over the past two decades for individuals with major depression disorder. The clinical description of depression is complex, covering a broad range of symptoms that lack a unifying biological hypothesis. Depression has both genetic and environmental components, with linkage studies suggesting it is a polygenic disorder. Modern treatment for depression, which focuses exclusively on agents that modulate monoamine neurotransmission, began with a monoamine oxidase inhibitor (MAOI). MAOIs increase serotonin and norepinephrine concentrations in the brain by inhibiting the MAO enzyme. They are highly effective in treating depression but are used only scarcely owing to potentially dangerous drug interaction effects.
  • MAOI monoamine oxidase inhibitor
  • Imipramine one such derivative, was exceptionally effective in patients who had severe depression.
  • Imipramine is a tricyclic antidepressant (TCA) that acts by inhibiting cellular reuptake mechanisms for norepinephrine and serotonin to increase activity within these G protein-coupled receptor (GPCR) families.
  • TCA tricyclic antidepressant
  • GPCR G protein-coupled receptor
  • Imipramine retains activity at GPCRs, but this activity contributes to unattractive side effects.
  • structural analogs of diphenhydramine were discovered as novel antidepressants.
  • the phenoxyphenylpropylamine was used to identify fluoxetine, the first selective serotonin reuptake inhibitor (SSRI).
  • SSRIs became a family of antidepressants considered to be the current standard of drug treatment. It is thought that one cause of depression is an inadequate amount of serotonin. SSRIs are said to work by preventing the reuptake of serotonin by the presynaptic neuron, thus maintaining higher levels of 5-HT in the synapse.
  • These antidepressants typically have fewer adverse events and side effects than the tricyclics or the MAOIs, although such effects as drowsiness, dry mouth, nervousness, anxiety, insomnia, decreased appetite, and decreased ability to function sexually may occur.
  • SARI serotonin antagonist/reuptake inhibitor
  • Typical examples are Bristol-Myers Squibb' s nefazodone [DeBattista, C. et al, Biol. Psychiatry, 1998, 44, 341] and Yamanouchi's YM-992 [Hatanaka, K. et al., Neuropharmacology, 1997, 35(11), 1621] and Lilly's LY367265 [Pullar, I. A. et al., Eur. J. Pharmacol. 2000, 407(1-2), 39], the structures thereof being shown below:
  • Nefazodone is most closely related to trazodone in terms of chemical structure [Temple, D. L, Jr. et al, US Patent No. 4,338,317]. Unlike most SSRIs, nefazodone is reported to have no negative effects on libido or sexual functioning.
  • Nefazodone's claimed advantages over other antidepressants include reduced possibility of disturbed sleep or sexual dysfunction, and ability to treat some patients who did not respond to other antidepressant drugs [Greene, D. S. et al, Clin. Pharmacokinet., 1997, 33(4), 260].
  • nefazodone is a potent inhibitor of the CYP3A4 isoenzyme both in vitro and in vivo [Kent, J. M., Lancet, 2000, 355, 91 1-918]. In the end, its sale was discontinued in 2003 in some countries, due to the small possibility of hepatic injury, which could lead to the need for a liver transplant, or even death. At 2004, Bristol-Myers Squibb withdrew nefazodone in the United States.
  • R 1 is hydrogen, C 1-3 alkyl, or C 1-3 alkoxy
  • R 2 is selected from the group consisting of hydrogen, carbocycle, substituted carbocycle, aryl, substituted aryl, heteroaryl, substituted heteroaryl, heterocycle, substituted heterocycle, C ⁇ . % alkyl optionally substituted with hydroxyl or acyloxy, Cj -6 alkoxy, substituted Ci -6 alkoxy, C 3 .
  • R 3 is selected from the group consisting of hydrogen, C M alkyl, substituted
  • R 4 is hydrogen or Ci -3 alkyl
  • R 5 and R 6 are each independently hydrogen, halogen, Ci -3 alkyl, Ci -3 alkoxy, cyano, monofluoromethyl, difluoromethyl or trifluoromethyl; or R 5 and R 6 , together with the carbon atoms to which they are bonded, form a 5- to 7- membered saturated or unsaturated heterocyclic ring or aryl ring which is optionally substituted by one or more Cj -3 alkyl, Ci -3 alkoxy, halogen, trifluoromethyl, or cyano;
  • R 7 is phenyl, furanyl, benzofuranyl, thienyl, benzothienyl, pyridinyl, pyridiminyl, pyrazinyl, pyridizinyl, tetrahydrofuranyl, tetrahydropyranyl, dioxanyl, 1 ,4-benzodioxanyl, or benzo[l,3]dioxolyl, each of which is optionally substituted with one or more halogen, Cj -3 alkyl, or Ci -3 alkoxy, wherein Ci -3 alkyl and Ci -3 alkoxy optionally have one to three fluorine substituents;
  • n is an integer of 0 to 2;
  • X is -CH 2 - when m is 0 or 2, and X is -CH(OH)-, -CHF-, or -CF 2 - when m is 1 ;
  • a pharmaceutical composition for preventing or treating a depressive disorder which comprises the compound of formula (I) or the pharmaceutically acceptable salt thereof as an active ingredient, and a pharmaceutically acceptable carrier.
  • a method for preventing or treating a depressive disorder in a mammal comprising administering the compound of formula (I) or a pharmaceutically acceptable salt thereof to the mammal in need thereof.
  • alkyl refers to a straight or branched chain saturated hydrocarbon radical.
  • alkyl as used herein include, but are not limited to, methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl, t-butyl, n- pentyl, isopentyl and hexyl.
  • substituted alkyl refers to a straight or branched chain saturated hydrocarbon radical, which is optionally substituted with one or more substituents selected from the group consisting of C 1 . 3 alkyl optionally having one to three fluorine substituents, C 2-3 alkenyl, C 2-3 alkynyl, C ⁇ .
  • 2 alkoxy optionally having one to three fluorine substituents, sulfanyl, sulfinyl, sulfonyl, oxo, hydroxy, mercapto, amino, guanidino, carboxy, aminocarbonyl, aryl, aryloxy, heteroaryl, heteroaryloxy, heterocyclic, aminosulfonyl, sulfonylamino, carboxyamide, ureido, nitro, cyano and halogen.
  • alkenyl refers to a straight or branched chain hydrocarbon radical having at least one carbon-carbon double bond.
  • alkenyl as used herein include, but are not limited to, ethenyl and propenyl.
  • substituted alkenyl refers to a straight or branched chain hydrocarbon radical having at least one carbon-carbon double bond, which has optional substituents selected from the group consisting of C 1-3 alkyl optionally having one to three fluorine substituents, amino, aryl, cyano and halogen.
  • alkynyl refers to a straight or branched chain hydrocarbon radical having at least one carbon-carbon triple bond.
  • alkynyl as used herein include, but are not limited to, acetylenyl and 1-propynyl.
  • substituted alkynyl refers to a straight or branched chain hydrocarbon radical having at least one carbon-carbon triple bond, optionally having one or more substituents selected from the group consisting of Cj. 3 alkyl optionally having one to three fluorine substituents, amino, aryl and halogen.
  • halogen refers to fluorine (F), chlorine (Cl), bromine (Br), or iodine (I).
  • carbocycle refers to a non-aromatic cyclic hydrocarbon radical composed of three to seven carbon atoms. Five-to seven- membered rings may contain a double bond in the ring structure.
  • exemplary "carbocycle” groups include, but are not limited to, cyclopropyl, cyclobutyl, cyclopentyl, cyclopentenyl, cyclohexyl, and cycloheptyl.
  • substituted carbocycle refers to a non-aromatic cyclic hydrocarbon radical composed by three to seven carbon atoms, which is optionally substituted with one or more substituents selected from the group consisting of Ci -3 alkyl optionally having one to three fluorine substituents, C 2-3 alkenyl, C 2-3 alkynyl, Ci -2 alkoxy optionally having one to three fluorine substituents, sulfanyl, sulfinyl, sulfonyl, oxo, hydroxy, mercapto, amino, guanidino, carboxy, aminocarbonyl, aryl, aryloxy, heteroaryl, heterocyclic, aminosulfonyl, sulfonylamino, carboxyamide, nitro, ureido, cyano and halogen.
  • substituents selected from the group consisting of Ci -3 alkyl optionally having one to three fluorine substituents, C 2-3 alkenyl, C 2-3 alky
  • aryl refers to an optionally substituted benzene ring or refers to a ring system which may result by fusing one or more optional substituents.
  • exemplary optional substituents include substituted Q -3 alkyl, substituted C 2-3 alkenyl, substituted C 2-3 alkynyl, heteroaryl, heterocyclic, aryl, alkoxy optionally having one to three fluorine substituents, aryloxy, aralkoxy, acyl, aroyl, heteroaroyl, acyloxy, aroyloxy, heteroaroyloxy, sulfanyl, sulfinyl, sulfonyl, aminosulfonyl, sulfonylamino, carboxyamide, aminocarbonyl, carboxy, oxo, hydroxy, mercapto, amino, nitro, cyano, halogen, or ureido.
  • Such a ring or ring system may be optionally fused to aryl rings (including benzene rings) optionally having one or more substituents, carbocycle rings or heterocyclic rings.
  • aryl groups include, but are not limited to, phenyl, naphthyl, tetrahydronaphthyl, biphenyl, indanyl, anthracyl or phenanthryl, as well as substituted derivatives thereof.
  • heteroaryl refers to an optionally substituted monocyclic five to six-membered aromatic ring containing one or more heteroatomic substitutions selected from S, SO, SO 2 , O, N 5 or N-oxide, or refers to such an aromatic ring fused to one or more rings such as heteroaryl rings, aryl rings, heterocyclic rings, or carbocycle rings (e.g., a bicyclic or tricyclic ring system), each having optional subsituents.
  • optional substituents are selected from the group consisting of substituted Ci -3 alkyl, substituted C 2-3 alkenyl, substituted C 2-3 alkynyl, heteroaryl, heterocyclic, aryl, Ci -3 alkoxy optionally having one to three fluorine substituents, aryloxy, aralkoxy, acyl, aroyl, heteroaroyl, acyloxy, aroyloxy, heteroaroyloxy, sulfanyl, sulfinyl, sulfonyl, aminosulfonyl, sulfonylamino, carboxyamide, aminocarbonyl, carboxy, oxo, hydroxy, mercapto, amino, nitro, cyano, halogen or ureido.
  • heteroaryl groups used herein include, but are not limited to, benzoimidazolyl, benzothiazolyl, benzoisothiazolyl, benzothiophenyl, benzopyrazinyl, benzotriazolyl, benzo[l,4]dioxanyl, benzofuranyl, 9H-a- carbolinyl, cinnolinyl, furanyl, furo[2,3-b]pyridinyl, imidazolyl, imidazolidinyl, imidazopyridinyl, isoxazolyl, isothiazolyl, isoquinolinyl, indolyl, indazolyl, indolizinyl, naphthyridinyl, oxazolyl, oxothiadiazolyl, oxadiazolyl, phthalazinyl, pyridyl, pyrrolyl, purinyl, pteridinyl,
  • heterocyclic refers to a three to seven- membered ring containing one or more heteroatomic moieties selected from S, SO, SO 2 , O, N, or N-oxide, optionally substituted with one or more substituents selected from the group which includes substituted C 1-3 alkyl, substituted C 2-3 alkenyl, substituted C 2-3 alkynyl, heteroaryl, heterocyclic, aryl, C 1-3 alkoxy optionally having one to three fluorine substituents, aryloxy, aralkoxy, acyl, aroyl, heteroaroyl, acyloxy, aroyloxy, heteroaroyloxy, sulfanyl, sulfinyl, sulfonyl, aminosulfonyl, sulfonylamino, carboxyamide, aminocarbonyl, carboxy, oxo, hydroxy, mercapto, amino, nitro, cyano, halogen,
  • Such a ring can be saturated or have one or more degrees of unsaturation.
  • Such a ring may be optionally fused to one or more "heterocyclic" ring(s), aryl ring(s), heteroaryl ring(s) or carbocycle ring(s), each having optional substituents.
  • heterocyclic moieties include, but are not limited to, 1,4- dioxanyl, 1,3-dioxanyl, pyrrolidinyl, pyrrolidin-2-onyl, piperidinyl, imidazolidine-2,4-dionepiperidinyl, piperazinyl, piperazine-2,5-dionyl, morpholinyl, dihydropyranyl, dihydrocinnolinyl, 2,3-dihydrobenzo [1,4] dioxinyl, 3,4-dihydro-2H-benzo[b][l,4]-dioxepinyl, tetrahydfopyranyl, 2,3-dihydrofuranyl, 2,3-dihydrobenzofuranyl, dihydrois ⁇ xazolyl, tetrahydrobenzodiazepinyl, tetrahydroquinolinyl, tetrahydrofuranyl,
  • alkoxy refers to the group -OR a , where R a is alkyl as defined above.
  • alkoxy groups useful in the present invention include, but are not limited to, methoxy, difluoromethoxy, trifluoromethoxy, ethoxy, n-propoxy, isopropoxy, n-butoxy and t-butoxy.
  • aralkoxy refers to the group -OR 3 R b , wherein R 3 is alkyl and R b is aryl as defined above.
  • aryloxy refers to the group -OR b , wherein R b is aryl as defined above.
  • heteroaryloxy refers to the group -OC(O)R f , wherein R f is heteroaryl as defined above.
  • mercapto refers to the group -SH.
  • sulfanyl refers to the group -SR 0 , wherein R 0 is substituted alkyl, substituted carbocycle, aryl, heteroaryl or heterocyclic, as defined above.
  • sulfinyl refers to the group -S-(O)R 0 , wherein R 0 is substituted alkyl, substituted carbocycle, aryl, heteroaryl or heterocyclic, as defined above.
  • sulfonyl refers to the group -S(O) 2 R 0 , wherein R 0 is substituted alkyl, substituted carbocycle, aryl, heteroaryl or heterocyclic, as defined above.
  • hydroxy refers to the group -OH.
  • amino refers to the group -NH 2 .
  • the amino group is optionally substituted with substituted alkyl, substituted carbocycle, aryl, heteroaryl or heterocyclic, as defined above.
  • cyano refers to the group -CN.
  • aminosulfonyl refers to the group -S(O) 2 NH 2 .
  • the aminosulfonyl group is optionally substituted with substituted alkyl, substituted carbocycle, aryl, heteroaryl or heterocyclic, as defined above.
  • sulfonylamino refers to the group -NHS(O) 2 R c wherein R 0 is substituted alkyl, substituted carbocycle, aryl, heteroaryl or heterocyclic, as defined above.
  • carboxyamide refers to the group -NHC(O)R 0 wherein R 0 is substituted alkyl, substituted carbocycle, aryl, heteroaryl or heterocyclic, as defined above.
  • carboxy refers to the group -C(O)OH.
  • the carboxy group is optionally substituted with substituted alkyl, substituted carbocycle, aryl, heteroaryl or heterocyclic, as defined above.
  • aminocarbonyl refers to the group -C(O)NH 2 .
  • the aminocarbonyl group is optionally substituted with substituted alkyl, substituted carbocycle, aryl, heteroaryl or heterocyclic, as defined above.
  • ureido refers to the group -NHC(O)NHR c wherein R 0 is hydrogen, alkyl, carbocycle or aryl as defined above.
  • acyl refers to the group -C(O)R 0 , wherein R 0 is alkyl, carbocycle, or heterocyclic as defined above.
  • aroyl refers to the group -C(O)R b , wherein R b is aryl as defined above.
  • heteroaroyl refers to the group -C(O)R d , wherein R ⁇ is heteroaryl as defined above.
  • acyloxy refers to the group -OC(O)R c , wherein R c is alkyl, carbocycle, or heterocyclic as defined above.
  • aroyloxy refers to the group -OC(O)R b , wherein R b is aryl as defined above.
  • heteroaroyloxy refers to the group -OC(O)Rj, wherein R 0 is heteroaryl as defined above.
  • arylpiperazine- containing imidazole 4-carboxamide derivative include:
  • the imidazole derivative (6) is prepared by a conventional method [Bayer Pharmaceuticals, WO 03/040107, 2003], for example, by subjecting a nitrile (2) to a reaction with an aniline derivative (1) using aluminum chloride to produce N- (4-chlorophenyl)-butyrimidamide (3). Subsequent reaction of the resulting compound (3) with ethyl 3-bromo-2-oxopropanoate (4) provides an intermediate ethyl l-(4-chlorophenyl)-2-propyl-lH-imidazole-4-carboxylate (5). An acid form (6) is prepared from the ester (5) using lithium hydroxide, followed by acidification, as shown in Reaction Scheme 1. Reaction Scheme 1
  • a compound (7) is subjected to a reaction with sodium nitrite in acetic acid to give ethyl 2-(hydroxyimino)-3-oxobutanoate (8) in 70% yield.
  • the compound (8) is subjected to a reaction with an anhydride such as acetic anhydride (9) in the presence of a reducing agent such as hydrogen and a catalyst such as Pd on carbon (Pd/C) in EtOH to give an amide (10) [Lange, J. H. M. et al.
  • the amide (10) is subjected to a reaction with an amine such as aniline (Ha or lib) in an inert solvent such as acetonitrile under microwave irradiation to obtain an imidazole derivative (12a or 12b). Hydrolysis of the imidazole derivative (12a or 12b) with lithium hydroxide produces a compound (13a or 13b) as shown in Reaction Scheme 2.
  • an amine such as aniline (Ha or lib) in an inert solvent such as acetonitrile under microwave irradiation to obtain an imidazole derivative (12a or 12b).
  • Hydrolysis of the imidazole derivative (12a or 12b) with lithium hydroxide produces a compound (13a or 13b) as shown in Reaction Scheme 2.
  • the oxazolone (15) is cleaved with in situ generated ethoxide to produce (E)-ethyl 2-acetamido-3-(dimethylamino)but-2-enoate (16).
  • an amine (17) is subjected to a reaction with the compound (16) in acetic acid at rt overnight to give a Michael adduct (18).
  • the crude intermediate (18) is then refluxed together with fine powdered ammonium sulfate in hexamethyldisilazane at 145 ° C to provide the corresponding imidazole ester (19) in 55-73% yield for the three steps from the oxazolone (15).
  • the imidazole ester (19) is hydrolyzed with sodium hydroxide to produce the corresponding sodium carboxylate (20) uneventfully.
  • An imidazole acid derivative (25) is synthesized by adopting a known method [Lange, J. H. M., et al. J. Med. Chem. 2005, 48, 1823-1838; and Kim, J.
  • benzonitrile (21) is subjected to a reaction with aniline (Ha) in the presence of sodium bis(trimethylsilyl)amide (NaHMDS) to produce a corresponding arylbenzamidine
  • N-arylpiperazine (28) is prepared via condensation of the requisite aniline such as 3-chloro-2-methylaniline (26) with bis(2-chloroethyl)amine (27), following a reported procedure [Martin, G. E., et al. J. Med. Chem. 1989, 32, 1052-1056] as shown in Reaction Scheme 5.
  • 8-(piperazin-l-yl)quinoline (33) is prepared as depicted in Reaction Scheme 6 [Zhou, D., et al, Bioorg. Med. Chem. 2008, 16, 6707-6723].
  • Reaction of commercially available 8-hydroxyquinoline (29) with trifluoromethanesulfonic anhydride (triflic anhydride) in the presence of a base produces the corresponding triflate (30).
  • Buchwald coupling [Buchwald, S. L., et al J. Am. Chem. Soc.
  • N-(3-bromopropyl)phthalimide (34) is subjected to a reaction with l-(2,3-dichlorophenyl)piperazine (35) in the presence of potassium carbonate in a suitable solvent such as dimethylformamide (DMF) at room temperature affords the corresponding alkylated compound (36) in 80% yield.
  • a suitable solvent such as dimethylformamide (DMF) at room temperature affords the corresponding alkylated compound (36) in 80% yield.
  • Hydazinolysis of the compound (36) followed by treatment of HCl solution generates 3-(4-(2,3- dichlorophenyl)piperazin-l-yl)propan-l -amine as a HCl salt form (37) in 76% yield.
  • Another variation involves difluorination for compounds such as 3-(4- (2,3-dichlorophenyl)piperazin-l-yl)propan-l -amine (37) as demonstrated in Reaction Scheme 9.
  • the alcohol (39) generated in Reaction Scheme 8 is oxidized using Swern oxidation conditions to provide the corresponding ketone (41) in 89% yield.
  • Treatment of ketone (41) with diethylaminosulfur trifluoride (DAST) give the corresponding difluoride (42) in 21% yield.
  • DAST diethylaminosulfur trifluoride
  • the target compound is prepared by amide bond formation of acid (44) and amine (37) by use of l-ethyl-3-(3'-dimethylaminopropyl)carbedoomide hydrochloride (EDCI), 1-hydroxybenzotriazole (HOBt), N-methylmorphofine (NMM) in a suitable solvent such as DMF to generate a compound (45) in 31% yield as shown in Reaction Scheme 10.
  • EDCI l-ethyl-3-(3'-dimethylaminopropyl)carbedoomide hydrochloride
  • HOBt 1-hydroxybenzotriazole
  • NMM N-methylmorphofine
  • an acid (46) and an amine (47) produce the inventive compound (Ia) in an analogous manner.
  • R 1 , R 2 , R 3 , R 5 and R 6 have the same meanings as defined above.
  • the target compound is prepared by amide bond formation of acid (44) and amine (40) by use of EDCI, HOBt and
  • Ri, R 2 , R 3 , R 5 and R 6 have the same meanings as defined above. Further, the present invention provides a method for preventing or treating a depressive disorder in a mammal, comprising administering the compound of formula (I) or a pharmaceutically acceptable salt thereof to the mammal in need thereof.
  • the present invention provides a pharmaceutical composition for preventing or treating a depressive disorder, which comprises the compound of formula (I) or a pharmaceutically acceptable salt thereof as an active ingredient, and a pharmaceutically acceptable carrier.
  • depression disorders refers to mental illnesses characterized by a profound and persistent feeling of sadness or despair and/or a loss of interest in things that once were pleasurable. Disturbance in sleep, appetite, and mental processes are common accompaniments.
  • the pharmaceutical composition may be administered orally, intramuscularly or subcutaneously.
  • the formulation for oral administration may take various forms such as a syrup, tablet, capsule, cream and lozenge.
  • a syrup formulation will generally contain a suspension or solution of the compound or its salt in a liquid carrier, e.g., ethanol, peanut oil, olive oil, glycerine or water, optionally with a flavoring or coloring agent.
  • a liquid carrier e.g., ethanol, peanut oil, olive oil, glycerine or water
  • any one of pharmaceutical carriers routinely used for preparing solid formulations may be used. Examples of such carriers include magnesium stearate, terra alba, talc, gelatin, acacia, stearic acid, starch, lactose and sucrose.
  • any of the routine encapsulation procedures may be employed, e.g., using the aforementioned carriers in a hard gelatin capsule shell.
  • any of the pharmaceutical carrier routinely used for preparing dispersions or suspensions may be prepared using an aqueous gum, cellulose, silicate or oil.
  • the formulation for intramuscular or subcutaneous administration may take a liquid form such as a solution, suspension and emulsion which includes aqueous solvents such as water, physiological saline and Ringer's solution; or lipophilic solvents such as fatty oil, sesame oil, corn oil and synthetic fatty acid ester.
  • the composition is formulated in a specific dosage form for a particular patient.
  • Each dosage unit for oral administration contains suitably from 0.1 mg to 500 mg/kg, and preferably from 1 mg to 100 mg/kg of the compound of formula (I) or a pharmaceutically acceptable salt thereof.
  • the suitable daily dosage for oral administration is about 0.01 mg/kg to 40 mg/kg of the compound of formula (I) or a pharmaceutically acceptable salt thereof, which may be administered 1 to 6 times a day, depending on the patient's condition.
  • TFA trifluoroacetic acid
  • TEA triethylamine
  • R.T. room temperature
  • brine refers to a saturated aqueous solution of NaCl. Unless otherwise indicated, all temperatures are expressed in°C (degrees Centigrade). All reactions are conducted under an inert atmosphere at room temperature unless otherwise noted, and all solvents are of the highest available purity unless otherwise indicated.
  • Microwave reaction was conducted with a Biotage InitiatorTM microwave synthesizer.
  • Mass spectra were obtained with either a Micromass, Quattro LC Triple Quadruple Tandem Mass Spectometer, ESI or Agilent, 1 lOOLC/MSD, ESI.
  • Step 2 tert-butyl 4-(quinolin-8-yl)piperazine-l-carboxylate (compound 32) t-butyl piperazine-1-carboxylate (compound 31, 8.6 g, 46 mmol) and quinolin-8-yl trifluoromethanesulfonate (compound 30, 11 g, 39.6 mmol) were added to a solution Of Cs 2 CO 3 (18 g, 55 mmol), BINAP (1.07g) and Pd(OAc) 2 (367 mg) in THF (100 ml). The reaction mixture was refluxed for 1 day and then cooled down to room temperature.
  • Step 1 2-(3-(4-(2,3-dichlorophenv ⁇ piperazin-l-yl)propyl)isoindoline-l,3-dione (compound 36)
  • Step 2 3-(4-(2,3-dichlorophenyl)piperazin-l-yl)propan-l-amine dihydrochloride (compound 37)
  • 2-(3-(4-(2,3-dichlorophenyl)piperazin-l- yl)propyl)isoindoline-l,3-dione (compound 36, 1 1.1 g, 26.5 mmol) in EtOH was added hydrazine monohydrate.
  • the reaction mixture was stirred at room temperature for 6 hrs, then the white solid filtered off.
  • the filtrate was concentrated under reduced pressure.
  • the residue was diluted with CH 2 Cl 2 , and washed with water.
  • Step 2j 2-(3-(4-(2,3-dichlorophen ⁇ l)piperazin-l- ⁇ l)-2,2-difluoropropyl) isoindoline-l,3-dione (compound 42)
  • Step 3 3-(4-(2,3-dichlorophenyl)piperazin- 1 -yl)-2,2-difluoropropan- 1 -amine (compound 43)
  • EtOH hydrazine monohydrate
  • the reaction solution was refluxed at 80 ° C for 1 hr.
  • the reaction solution was cooled to R.T. and evaporated.
  • the oily crude compound was extracted with EtOAc/ H 2 O and the organic layer was combined and evaporated.
  • the crude compound was diluted with MeOH (5 mL) and added 2N HCl in ether solution to afford targeted amine HCl salts (1.0 g, 100 %) as white solid.
  • Step 1 N-(4-chlorophenyl)butyrimidamide (compound 3) To a solution of butyronitrile (compound 2, 7.5 mL, 86.2 mmol), AlCl 3 in toluene was added 4-chloroaniline (compound 1, 10.0 g, 78.4 mmol). The reaction mixture was stirred at 115 °C for 5 hrs. The mixture was diluted with water (200 mL) and extracted with EtOAc (200 mL). The aqueous layer was neutralized with saturated NaHCO 3 (500 mL) and extracted with EtOAc (300 mL x 2). The organic layer was dried over anhydrous MgSO 4 , filtered and concentrated in vacuo. The obtained product (9.2 g, pale brown solid) was used for the next step without purification.
  • Step 2 Ethyl l-(4-chlorophenyl)-2-propyl-lH-imidazole-4-carboxylate (compound 5)
  • Step 3 l-(4-chlorophenylV2-propyl-lH-imidazole-4-carboxylic acid (compound 6 ⁇ ).
  • ethyl l-(4-chlorophenyl)-2-propyl-lH-imidazole-4- carboxylate compound 5, 1.28 g, 4.37 mmol
  • T ⁇ F/water 20/20 mL
  • lithium hydroxide monohydrate compound 5
  • the reaction mixture was stirred at 55 ° C for 12 hrs.
  • the mixture was washed with CH 2 Cl 2 , the aqueous layer was acidified with IN-HCl solution (pH ⁇ 6), extracted with CH 2 Cl 2 .
  • the organic layer was dried over anhydrous MgSO 4 , filtered and concentrated in vacuo.
  • the obtained product was washed with hexane to provide the title compound (740 mg, 64 %) as a pale brown solid.
  • Step 4 l-(4-chlorophenv ⁇ -N-(3-(4-(2,3-dichlorophenyl)piperazin-l-yl)-2- hydroxy propyl)-2-propyl- lH-imidazole-4-carboxamide
  • compound 6 lithium l-(4-chlorophenyl)-2-propyl-lH-imidazole-4- carboxylic acid
  • compound 41 l-amino-3-(4-(2,3- dichlorophenyl)piperazin-l-yl)propan-2-ol dihydrochloride
  • EDCI 165 mg, 0.85 mmol
  • ⁇ OBt 154 mg, 1.14 mmol
  • Example 2 l- ⁇ -chlorophenyty- ⁇ S- ⁇ - ⁇ -dichlorophenytypiperaziii-l- yl)propyl)-2-propyl-lH-imidazole-4-carboxamide dihydrochloride
  • Example 3 l-(4-chIorophenyl)-7V-(3-(4-(2,3-dimethylphenyl)piperazin-l- yl)propyl)-2-propyl-li/-imidazole-4-carboxamide
  • Step 1 Ethyl 2-(hvdroxyimino)-3-oxobutanoate (compound 8)
  • Step 2 Ethyl 2-acetamido-3-oxobutanoate (compound 10)
  • the crude product was purified by flash column chromatography (Biotage SP 1TM FLASH Purification System was used for normal phase column chromatography with tetrahydrofuran and hexane) to provide the title compound (9.48 g, 86 %) as a white solid.
  • the crude product was purified by flash column chromatography (Biotage SP 1TM FLASH Purification System was used for normal phase column chromatography with tetrahydrofuran and hexane.) to provide the title compound (4.97 g, 76 %) as a yellow solid.
  • Step 4 Lithium 2,5-dimethyl-l-phenyl-lH-imidazole-4-carboxylate (compound 13a)
  • Step 2 Lithium 2,5-dimethyl-l-(pyridm-2-yl)-lH-imidazole-4-carboxylic acid (compound 13b)
  • Example 6 ⁇ 3-(4-(2,3-dichlorophenyI)piperazin-l-yl)propyl)-2,5-dimethyl- l-phenyI-l//-imidazole-4-carboxamide
  • Example 7 ⁇ S- ⁇ - ⁇ S-dichlorophenyOpiperazin-l-yOpropyO-S-methyl-l- phenyI-2-propyl-l//-imidazole-4-carboxamide dihydrochloride
  • Example 8 ⁇ - ⁇ - ⁇ v B-dichlorophenytypiperazin-l-ytyethyO-l ⁇ -dimethyl-l- phenyI-l/f-imidazole-4-carboxamide
  • Example 11 l- ⁇ -chlorophenyO- ⁇ - ⁇ - ⁇ -dichlorophenytypiperazin-l- yl)propyl)-2,5-dimethyl-l/f-imidazole-4-carboxamide
  • Example 12 iV-(3-(4-(2,3-dichlorophenyl)piperazin-l-yl)propyl)-2-ethyl-5- methyl-l-phenyl-l/f-imidazoIe-4-carboxamide
  • Example 13 ⁇ l- ⁇ - ⁇ v J-dichlorophenyOpiperazin-l-yOethyty-l-ethyl-S- methyl-l-phenyl-l//-imidazole-4-carboxamide
  • Example 17 ⁇ r -(3-(4-(2,3-dimethyIphenyl)piperazin-l-yl)propyl)-5-methyl-l- phenyl-2-propyI-l//-imidazole-4-carboxamide dihydrochloride
  • Example 19 ⁇ 2-(4-(2,3-dimethylphenyl)piperazin-l-yl)ethyl)-5-methyl-l- phenyl-2-propyl-l//-imidazole-4-carboxamide dihydrochloride 1H NMR (400 MHz, DMSO-d 6 ) ⁇ 10.46 (s, IH), 8.41 (br s, IH), 7.61-
  • Example 22 l-(4-chlorophenyI)- ⁇ 3-(4-(2,3-dimethylphenyl)piperazin-l- yl)propyl)-2,5-dimethyI-l//-imidazole-4-carboxamide
  • Example 23 jV-(3-(4-(2,3-dichlorophenyl)piperazin-l-yl)-2-hydroxypropyl)- 2-ethyl-5-methyl-l-phenyl-l//-imidazole-4-carboxamide
  • Example 25 l- ⁇ -chlorophenyO- ⁇ - ⁇ - ⁇ v S-dichlorophenyOpiperaziii-l- y.)propy-)-2-ethyl-5-methy--l/- r -iiii-dazoIe-4-carboxamide
  • Example 27 l-(4-chIorophenyl)- ⁇ V-(2-(4-(2,3-dichlorophenyl)piperazin-l- yl)ethyl)-2,5-dimethyl-l//-imidazole-4-carboxamide
  • Example 31 ⁇ -(3-(4-(2,3-dichIorophenyl)piperazin-l-yl)-2-hydroxypropyl)- 2,5-dimethyl-l-p-tolyl-li/-imidazole-4-carboxamide
  • Example 33 l- ⁇ -chlorophenyty- ⁇ f- ⁇ - ⁇ - ⁇ v S-dichlorophenytypiperazin-l-yl)- 2-hydroxypropyl)-2-ethyl-5-methyl-l//-imidazole-4-carboxamide
  • Example 35 ⁇ L (3-(4-(2,3-dimethylphenyl)piperazin-l-yl)-2-hydroxypropyI)- l ⁇ -fluorophenyl ⁇ jS-dimethyl-l/f-imidazole ⁇ -carboxamide
  • Example 37 ⁇ L (3-(4-(2,3-dimethylphenyl)piperazin-l-yl)propyl)-2,5- dimethyl-l-(4-(trifluoromethyl)phenyl)-l//-imidazole-4-carboxamide 1H NMR (400 MHz, DMSO-d 6 ) ⁇ 8.21 (t, J - 5.6 Hz, IH), 7.94 (d, J -
  • Example 40 l-(2,3-dihydrobenzo[b] [l,4]dioxin-6-yl)-7V-(3-(4-(2,3-dimethyl phenyl)piperazin-l-yl)propyl)-2,5-dimethyl-l//-imidazole-4-carboxamide
  • Example 42 iV-(2-(4-(2,3-dichlorophenyl)piperazin-l-yl)ethyl)-l-(4- methoxyphenyl)-2,5-dimethyI-li/-imidazole-4-carboxamide
  • Example 49 l- ⁇ -chlorophenyty-A ⁇ - ⁇ - ⁇ -dimethylpheiiytypiperazin-l-yl)- 2-hydroxypropyl)-2,5-d-methyl-l//-imidazole-4-carboxamide
  • Example 50 ⁇ L (3-(4-(3-chloro-2-methylphenyI)piperazin-l-yl)propyl)-l-(3- chlorophenyl)-2,5-dimethyl-l//-imidazoIe-4-carboxamide
  • Example 53 7V-(3-(4-(2,3-dimethyIphenyl)piperazin-l-yI)-2-hydroxypropyl)- l-(3-fluorophenyl)-2,5-dimethyl-l//-imidazole-4-carboxamide
  • Example 57 ⁇ - ⁇ - ⁇ -dimethylphenyOpiperazin-l-yOpropyO ⁇ S- dimethyl-l-(4-(methylthio)phenyl)-l//-imidazole-4-carboxamide
  • Example 59 ⁇ 3-(4-(2,3-dimethyIphenyl)piperazin-l-yl)propyl)-l-(3- methoxyphenyl)-2,5-dimethyl-l//-imidazole-4-carboxamide
  • Example 60 ⁇ (3-(4-(2,3-dimethylphenyl)piperazin-l-yl)-2-hydroxypropyl)- l-(3-methoxyphenyl)-2,5-dimethyl-l//-imidazoIe-4-carboxamide
  • Example 61 l-(2,4-dimethoxyphenyl)-7V-(3-(4-(2,3-dimethylphenyl) piperazin-l-yl)propyl)-2,5-dimethyl-17/-imidazole-4-carboxamide 1H NMR (400 MHz, DMSO-d 6 ) ⁇ 8.85 (br s, IH), 7.21-7.17 (m, IH),
  • Example 62 l-(2,4-dimethoxyphenyl)- ⁇ / -(3-(4-(2,3-dimethylphenyl) piperazin-l-yl)-2-hydroxypropyl)-2,5-dimethyl-l//-imidazole-4-carboxaiiiide
  • Example 64 (5)- ⁇ r -(3-(4-(2,3-dichlorophenyl)piperazin-l-yl)-2-hydroxy propyl)-5-methyl-l-phenyl-2-propyl-l//-imidazole-4-carboxamide 1H NMR (400 MHz, DMSO-d «) ⁇ 7.95-7.92 (m, IH), 7.57-7.49 (m, 3H),
  • Example 65 7V-(3-(4-(2,3-dichlorophenyI)piperazin-l-yl)-2,2-difluoro propyl)-2,5-dimethy--l-phenyl-li/-imidazoIe-4-carboxamide 1H NMR (400 MHz, DMSO-d 6 ) ⁇ 8.10-8.07 (m, IH), 7.58-7.49 (m, 3H),
  • Example 66 ⁇ - ⁇ - ⁇ -dichlorophenytypiperazin-l-yl ⁇ -difluoro propyI)-5-methyl-l-phenyl-2-propyl-l/f-imidazole-4-carboxamide ⁇ H NMR (400 MHz, DMSO-d 6 ) ⁇ 8.04 (bs, IH), 7.58-7.52 (m, 3H), 7.36- 7.34 (m, 2H), 7.30-7.25 (m, 2H), 7.12-7.10 (m, IH), 3.84-3.82 (m, 2H), 3.50-3.20
  • Example 68 jV-(3-(4-(2,3-dimethylphenyl)piperazin-l-yl)-2-hydroxypropyl)- l-(2-fluorophenyl)-2,5-dimethyl-l//-imidazole-4-carboxamide
  • Example 70 yV-(3-(4-(3-chloro-2-fluorophenyI)piperazin-l-y l)propyl)-2,5- dimethyl-l-phenyl-l//-imidazole-4-carboxamide
  • Example 72 .V-(3-(4-(3-chloro-2-methylphenyl)piperazin-l-yl)propyl)-2,5- dimethyl-l-phenyl-l//-imidazole-4-carboxamide 1H NMR (400 MHz, CDCl 3 ) ⁇ 7.84 (brs, IH), 7.55-7.50 (m, 3H), 7.17
  • Step 1 4-ri-dimethylamino-ethyl-(Z)-ylidenel-2-methyl-4H-oxazole-5-one (compound 15)
  • N-Acetylglycine (10 g, 85.5 mmol) was dissolved in ⁇ , ⁇ '- dimehtylacetamide (20 mL, 21.4 mmol) and POCl 3 (19.6 ml, 21.4 mmol) was added dropwise slowly at 0°C .
  • the reaction mixture was stirred at 50 °C for 3 hrs and then cooled to room temperature.
  • CH 2 Cl 2 50 mL was added and the mixture poured into ice-water.
  • the resulting solution was basified with ammonium hydroxide to over than pH 8.
  • the organic extracts were washed with 50 ml water, dried over MgSO 4 , filtered and evaporated under reduced pressure. The residue was purified by normal phase preparative column and the desired compound was obtained as an orange solid (6.7 g, 47%).
  • Step 2 (ip-ethyl 2-acetamido-3-(dimethylamino)but-2-enoate (compound 16) 4-[ 1 -dimethylamino-eth-(Z)-y lidene]-2-methy l-4H-oxazole-5-one
  • Example 76 l-cyclopentyl- ⁇ - ⁇ - ⁇ S-dimethylpheiiytypiperaziii-l- yl)propyl)-2,5-dimethyl-l/-r-imidazole-4-carboxamide
  • Example 77 l-cycIopentyl- ⁇ 3-(4-(2,3-dimethylphenyl)piperazin-l-yI)-2- hydroxypropyl)-2,5-d.methy--li/-imidazoIe-4-carboxamide
  • Example 80 l-cyclopentyl- ⁇ '-(4-(4-(2,3-dimethylphenyl)piperazin-l- yl)butyl)-2,5-dimethyl-l//-imidazole-4-carboxamide
  • Example 81 l-cydopentyl- ⁇ '-CZ ⁇ -dichlorophenyOpiperazin-l-yOethyl)- 2,5-dimethyl-l//-imidazole-4-carboxamide
  • Example 82 ⁇ r -(3-(4-(2,3-dimethyIphenyl)piperazin-l-yI)-2-hydroxypropyl)- l-(441uorophenyl)-5-methyl-2-phenyl-l//-imidazole-4-carboxam.de
  • Example 83 7V-(3-(4-(2,3-dimethylphenyl)piperazin-l-yl)propyl)-l-(4- fluorophenyl)-5-methyl-2-phenyl-l/J-imidazole-4-carboxamide
  • Example 85 ⁇ 3-(4-(3-chloro-2-methyIphenyl)piperazin-l-yl)propyl)-l-(4- fluorophenyI)-5-methyl-2-phenyl-l//-imidazole-4-carboxamide 1H NMR (400 MHz, CDCl 3 ) ⁇ 7.97-7.89 (m, IH), 7.34-7.1 1 (m, 9H), 7.04
  • Example 86 ⁇ r -(3-(4-(2,3-dimethylphenyl)piperazin-l-yl)propyl)-5-methyI- l,2-diphenyl-l//-imidazole-4-carboxamide
  • Example 88 l- ⁇ -bromophenyty- ⁇ - ⁇ - ⁇ -chlorophenytypiperazin-l- yl)propyI)-2-(2,4-dichlorophenyl)-5-ethyl-l//-imidazole-4-carboxamide
  • Example 90 l-(4-bromophenyl)-2-(2,4-dichlorophenyl)-A ⁇ (3-(4-(2,3- dimethylphenyOpiperazin-l-y ⁇ propyO-S-ethyl-l/f-imidazole ⁇ -carboxamide
  • Example 92 ⁇ - ⁇ - ⁇ -dimethylphenyOpiperazin-l-ytypropyO-l-isobutyl- 2,5-dimethyl-l//-imidazole-4-carboxamide dihydrochloride 1H NMR (400 MHz, MeOH-d 4 ) ⁇ 7.09-7.06 (m, IH), 7.01-6.96 (m, 2H),
  • Example 94 ⁇ r -(3-(4-(2,3-dimethylphenyl)piperazin-l-yl)-2-hydroxypropyl)- l-isobutyl-2,5-dimethyl-l//-imidazole-4-carboxamide dihydrochloride
  • Example 96 ⁇ - ⁇ - ⁇ S-dimethylphenytypiperazin-l-yl ⁇ -hydroxypropyl)- 2,5-dimethyl-l-propyl-l//-imidazoIe-4-carboxamide dihydrochloride 1H NMR (400 MHz, MeOH-d 4 ) ⁇ 8.04 (brs, IH), 7.22 (m, IH), 7.17-7.15
  • Example 100 .V-(3-(4-(2,3-dimethylphenyl)piperazin-l-yl)-2-hydroxypropyl)- l-(2-methoxyphenyl)-2,5-dimethyl-l/- r -imidazole-4-carboxamide
  • Example 101 l-(2-chlorophenyl)- ⁇ 3-(4-(2,3-dimethylphenyI)piperaziii-l- yl)propyI)-2,5-dimethyl-l//-imidazole-4-carboxamide dihydrochloride
  • Example 102 l-(2-chlorophenyl)-./V-(3-(4-(2,3-diiiiethylpheiiyI)piperaziii-l- y ⁇ -l-hydroxypropy ⁇ -l ⁇ -dimethyl-l/Z-imidazole ⁇ -carboxamide
  • Example 103 l-(2-chlorophenyl)- ⁇ 4-(4-(2,3-dimethyIphenyl)piperazin-l- yl)butyl)-2,5-dimethyl-l//-imidazole-4-carboxamide dihydrochloride 1H NMR (400 MHz, DMSO-d 6 ) ⁇ 10.74 (s, IH), 8.51 (s, IH), 7.82 (dd, J
  • Example 104 N- ⁇ - ⁇ - ⁇ S-dimethylphenytypiperazin-l-ytypropyl) ⁇ - isopropyl-S-methyl-l-phenyl-l/f-imidazole ⁇ -carboxamide dihydrochloride
  • Example 105 l-(3,5-dimethoxyphenyl)-7V-(3-(4-(2,3- dimethylphenyl)piperazin-l-yl)propyl)-2,5-dimethyI-l//-iiiiidazole-4- carboxamide dihydrochloride
  • Example 106 7V-(3-(4-(2,3-dimethyIphenyl)piperazin-l-yl)-2-hydroxypropyl)- 2-isopropyl-5-methyl-l-phenyl-l//-imidazole-4-carboxamide dihydrochloride
  • Example 108 ⁇ /V-(3-(4-(2,3-dimethvlphenvl)piperazin-l-vl)-2-hvdroxvpropyI)- l ⁇ -dimethyl-l- ⁇ - ⁇ rifluoromethytyphenyty-lH-imidazole ⁇ -carboxamide dihydrochloride
  • Example 110 jV-(3-(4-(2,3-dimethylphenyl)piperazin-l-yl)-2-hydroxypropyl)- 5-methyI-l-phenyl-2-propyl-l//-imidazole-4-carboxamide dihydrochloride
  • Example 111 l-(4-chlorophenyl)-N-(3-(4-(2,3-dimethyIphenyl)piperazin-l- yl)-2-hydroxypropyl)-2-propyl-l/-f-imidazole-4-carboxamide dihydrochloride 1 H NMR (400 MHz, DMSO-d 6 ) ⁇ 10.44 (br s, IH), 9.01 (br s, IH), 8.40
  • Example 113 ⁇ 2-(4-(2,3-dimethylphenyl)piperazin-l-yl)ethyI)-2-isopropyl- S-methyl-l-phenyl-l/Z-imidazole ⁇ -carboxamide dihydrochloride
  • Example 114 7V-(2-(4-(2,3-dimethylphenyl)piperazin-l-yl)ethyl)-l-(4- fluorophenyl)-2,5-dimethyl-l/y-imidazoIe-4-carboxamide dihydrochloride
  • Example 116 l-(2,3-dihydrobenzo[Z>] [l,4]dioxin-6-yl)-JV-(2-(4-(2,3- dimethyIphenyl)piperazin-l-y.)ethyl)-2,5-dimethyl-l//-imidazoIe-4- carboxamide dihydrochloride
  • Example 117 ⁇ 3-(4-(2,3-dimethyIphenyI)piperazin-l-yl)propyl)-l-phenyl- 2-propyl-li/-imidazole-4-carboxamide dihydrochloride
  • Example 118 7V-(3-(4-(2,3-dichloropheny l)piperazin-l-yl)propyl)-l-phenyl-2- propyl-l/f-imidazole-4-carboxamide dihydrochloride
  • Example 121 .V-(3-(4-(2,3-dimetliylphenyl)piperaziii-l-vl)-2-hvdroxypropyl)- l-phenyl-2-propyl-l//-imidazole-4-carboxamide dihydrochloride
  • Example 122 ⁇ 3-(4-(2,3-dimethylphenyl)piperazin-l-yl)propyl)-l-(4- methoxyphenyl)-5-methyl-2-propyl-l//-imidazole-4-carboxamide
  • Example 124 7V-(3-(4-(2,3-dimethylphenyl)piperazin-l-yl)propyl)-2,5- dimethyl-l-t ⁇ uinolin- ⁇ -yO-l/f-imidazole ⁇ -carboxamide dihydrochloride
  • Example 125 ⁇ r -(3-(4-(2,3-dichlorophenyl)piperazin-l-yI)-2-hydroxypropyl)- 2,5-dimethyl-l-(quinolin-6-yl)-li/-imidazole-4-carboxamide dihydrochloride
  • Example 130 ⁇ (3-(4-(2,3-dichlorophenyl)piperazin-l-yl)-2-hydroxypropyI)- l,2-diphenyl-l//-imidazoIe-4-carboxamide dihydrochloride
  • Example 131 ⁇ f-(3-(4-(2,3-dimethyIphenyl)piperazin-l-yl)propyl)-l,2- diphenyI-l//-imidazole-4-carboxamide dihydrochloride
  • Example 132 jV-(3-(4-(2,3-dimethylphenyl)piperazin-l-yl)propyl)-2,5- dimethyl-l-(pyridin-2-yl)-l/7-imidazole-4-carboxamide trihydrochloride
  • Example 133 ⁇ A -(3-(4-(2,3-dichlorophenyl)piperazin-l-yl)-2-hydroxypropyl)- l-(4-methoxyphenyl)-2-phenyl-l//-imidazole-4-carboxamide dihydrochloride
  • Example 136 iV- ⁇ - ⁇ - ⁇ S-dichloropheiiy ⁇ piperaziii-l-yl ⁇ -hydroxypropyl)- l-(4-methoxyphenyl)-5-methyl-2-propyl-l//-imidazole-4-carboxa ⁇ iide dihydrochloride 1H NMR (400 MHz 5 DMSO-d 6 ) ⁇ 10.41 (br s, IH) 5 8.68 (br s, IH) 5 7.43(d,
  • Example 137 ⁇ /V-(3-(4-(2,3-dimethvlphenvl)piperazin-l-yl)-2-hvdroxvpropyl)- l-(4-methoxyphenyl)-5-methyl-2-propyl-l/f-imidazole-4-carboxamide dihydrochloride 1H NMR (400 MHz 5 DMSO-d 6 ) ⁇ 10.40 (br s, IH) 5 8.93 (br s, IH) 5 7.48(d 5
  • Example 138 ⁇ 3-(4-(3-chloro-2-methyIpheiiyI)piperaziii-l-yl)propyl)-l-(4- methoxyphenyl)-2,5-dimethyl-l//-imidazole-4-carboxamide dihydrochloride
  • Example 141 (SVl- ⁇ -chlorophenyO-iV- ⁇ - ⁇ - ⁇ S-dichlorophenytypiperazin- l-yl)-2-hydroxypropyl)-2-propyl-l//-imidazole-4-carboxamide dihydrochloride

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

A novel arylpiperazine-containing imidazole 4-carboxamide derivative or a pharmaceutically acceptable salt thereof, and a pharmaceutical composition comprising the same as an active ingredient for preventing or treating a depressive disorder are provided.

Description

NOVEL AR YLPEPERAZEVE-CONT AINING IMIDAZOLE 4-
CARBOXAMIDE DERIVATIVES AND PHARMACEUTICAL
COMPOSITION COMPRISING SAME
FIELD OF THE INVENTION
The present invention relates to a novel arylpiperazine-containing imidazole 4-carboxamide derivative or a pharmaceutically acceptable salt thereof, and a pharmaceutical composition comprising the same as an active ingredient for preventing or treating depressive disorders.
BACKGROUND OF THE INVENTION Depressive disorders involve all major bodily functions, mood, and thoughts, affecting the ways in which an individual eats and sleeps, feel about themselves, and think. Without treatment, depression symptoms can last for weeks, months or years. Expression is the leading cause of disability in the United States. An increasing number of treatment options have become more available over the past two decades for individuals with major depression disorder. The clinical description of depression is complex, covering a broad range of symptoms that lack a unifying biological hypothesis. Depression has both genetic and environmental components, with linkage studies suggesting it is a polygenic disorder. Modern treatment for depression, which focuses exclusively on agents that modulate monoamine neurotransmission, began with a monoamine oxidase inhibitor (MAOI). MAOIs increase serotonin and norepinephrine concentrations in the brain by inhibiting the MAO enzyme. They are highly effective in treating depression but are used only scarcely owing to potentially dangerous drug interaction effects.
A second breakthrough in depression treatment came from chlorpromazine derivatives. Imipramine, one such derivative, was exceptionally effective in patients who had severe depression. Imipramine is a tricyclic antidepressant (TCA) that acts by inhibiting cellular reuptake mechanisms for norepinephrine and serotonin to increase activity within these G protein-coupled receptor (GPCR) families. Imipramine retains activity at GPCRs, but this activity contributes to unattractive side effects. Subsequently, structural analogs of diphenhydramine were discovered as novel antidepressants. The phenoxyphenylpropylamine was used to identify fluoxetine, the first selective serotonin reuptake inhibitor (SSRI). The remarkable success of fluoxetine as an antidepressant extended to the identification of other SSRIs including paroxetine, citalopram, fluvoxamine, and sertraline. SSRIs became a family of antidepressants considered to be the current standard of drug treatment. It is thought that one cause of depression is an inadequate amount of serotonin. SSRIs are said to work by preventing the reuptake of serotonin by the presynaptic neuron, thus maintaining higher levels of 5-HT in the synapse. These antidepressants typically have fewer adverse events and side effects than the tricyclics or the MAOIs, although such effects as drowsiness, dry mouth, nervousness, anxiety, insomnia, decreased appetite, and decreased ability to function sexually may occur.
Although there are a number of treatments currently available, there are still clear opportunities for improvement of existing therapies. Much research has been focused to address unmet medical needs of currently available drug therapies: slow onset of action, inability to achieve full remission, difficulty of targeting significant populations of nonresponding patients, and minimalization of residual side effects including sexual dysfunction. Recent developments include serotonin + norepinephrine reuptake inhibitors (SNRIs), and norepinephrine + dopamine reuptake inhibitors (NDRIs), implying multiple neurotransmitter pathways in the spectrum of disorders that incorporate major depression [Pacher, P. et al, Curr. Med. Chem. 2004, 11, 925-943]. It is the hope that drugs acting by newer mechanisms will meet some, if not all, of these unmet needs.
Along the line, SARI (serotonin antagonist/reuptake inhibitor) drugs that block both the serotonin 5-HT2 receptors and the serotonin transporters have been developed. Typical examples are Bristol-Myers Squibb' s nefazodone [DeBattista, C. et al, Biol. Psychiatry, 1998, 44, 341] and Yamanouchi's YM-992 [Hatanaka, K. et al., Neuropharmacology, 1997, 35(11), 1621] and Lilly's LY367265 [Pullar, I. A. et al., Eur. J. Pharmacol. 2000, 407(1-2), 39], the structures thereof being shown below:
Figure imgf000004_0001
LY367265
Figure imgf000004_0002
nefazodone
These compounds demonstrated improved results in the treatment of central nervous system disorders, compared with either the serotonin 5-HT2 receptors or the selective serotonin reuptake inhibitors only, in clinical effects, side effects, reduction in drug action time, etc. [Avila, A. et al., J. Clin. Psychopharmacol, 2003, 23(5), 509]. Nefazodone is most closely related to trazodone in terms of chemical structure [Temple, D. L, Jr. et al, US Patent No. 4,338,317]. Unlike most SSRIs, nefazodone is reported to have no negative effects on libido or sexual functioning. Nefazodone's claimed advantages over other antidepressants include reduced possibility of disturbed sleep or sexual dysfunction, and ability to treat some patients who did not respond to other antidepressant drugs [Greene, D. S. et al, Clin. Pharmacokinet., 1997, 33(4), 260]. However, nefazodone is a potent inhibitor of the CYP3A4 isoenzyme both in vitro and in vivo [Kent, J. M., Lancet, 2000, 355, 91 1-918]. In the end, its sale was discontinued in 2003 in some countries, due to the small possibility of hepatic injury, which could lead to the need for a liver transplant, or even death. At 2004, Bristol-Myers Squibb withdrew nefazodone in the United States.
In this regard, there is an urgent medical need on the discovery of new drugs that act as a mode of nefazodone, but have better developability characteristics. This new class of antidepressants would significantly broaden the physician's and patient's choice.
SUMMARY OF THE INVENTION
It is a primary object of the present invention to provide a novel compound of formula (I) or a pharmaceutically acceptable salt thereof, which is useful for preventing or treating depressive disorders.
It is another object of the present invention to provide a method for preparing said compound.
It is a further object of the present invention to provide a pharmaceutical composition for preventing or treating depressive disorders, comprising said compound as an active ingredient.
It is a still further object of the present invention to provide a method for preventing or treating depressive disorders in a mammal. In accordance with one aspect of the present invention, there is provided an arylpiperazine-containing imidazole 4-carboxamide compound of formula (I) or a pharmaceutically acceptable salt thereof:
Figure imgf000005_0001
Wherein,
R1 is hydrogen, C1-3 alkyl, or C1-3 alkoxy;
R2 is selected from the group consisting of hydrogen, carbocycle, substituted carbocycle, aryl, substituted aryl, heteroaryl, substituted heteroaryl, heterocycle, substituted heterocycle, C\.% alkyl optionally substituted with hydroxyl or acyloxy, Cj-6 alkoxy, substituted Ci-6 alkoxy, C3.5 alkenyloxy, substituted C3-5 alkenyloxy, C3-5 alkynyloxy, substituted C3-5 alkynyloxy, aryloxy, substituted aryloxy, heteroaryloxy, substituted heteroaryloxy or halogen, C2-6 alkenyl optionally substituted with alkoxy or halogen, C2-6 alkynyl optionally substituted with alkoxy or halogen, -(CH2)n-C3-6 carbocycle optionally substituted with alkoxy or halogen, and -(CH2)n-R7, n being 1 or 2;
R3 is selected from the group consisting of hydrogen, CM alkyl, substituted
Ci-4 alkyl, C3-7 cycloalkyl, substituted C3-7 cycloalkyl, aryl, substituted aryl, heteroaryl, substituted heteroaryl, heterocycloalkyl, and substituted heterocycloalkyl;
R4 is hydrogen or Ci-3 alkyl;
R5 and R6 are each independently hydrogen, halogen, Ci-3 alkyl, Ci-3 alkoxy, cyano, monofluoromethyl, difluoromethyl or trifluoromethyl; or R5 and R6, together with the carbon atoms to which they are bonded, form a 5- to 7- membered saturated or unsaturated heterocyclic ring or aryl ring which is optionally substituted by one or more Cj-3 alkyl, Ci-3 alkoxy, halogen, trifluoromethyl, or cyano;
R7 is phenyl, furanyl, benzofuranyl, thienyl, benzothienyl, pyridinyl, pyridiminyl, pyrazinyl, pyridizinyl, tetrahydrofuranyl, tetrahydropyranyl, dioxanyl, 1 ,4-benzodioxanyl, or benzo[l,3]dioxolyl, each of which is optionally substituted with one or more halogen, Cj-3 alkyl, or Ci-3 alkoxy, wherein Ci-3 alkyl and Ci-3 alkoxy optionally have one to three fluorine substituents;
m is an integer of 0 to 2;
X is -CH2- when m is 0 or 2, and X is -CH(OH)-, -CHF-, or -CF2- when m is 1 ; and
Y is -N= or -iw with the proviso that when Y is -N=, R5 or R6 are not bonded to Y. In accordance with another aspect of the present invention, there is provided a method for preparing a compound of formula (I).
In accordance with a further aspect of the present invention, there is provided a pharmaceutical composition for preventing or treating a depressive disorder which comprises the compound of formula (I) or the pharmaceutically acceptable salt thereof as an active ingredient, and a pharmaceutically acceptable carrier.
In accordance with a still further aspect of the present invention, there is provided a method for preventing or treating a depressive disorder in a mammal, comprising administering the compound of formula (I) or a pharmaceutically acceptable salt thereof to the mammal in need thereof.
DETAILED DESCRIPTION OF THE INVENTION
Hereinafter, a detailed description of the present invention is given.
As used herein, the term "alkyl" refers to a straight or branched chain saturated hydrocarbon radical. Examples of "alkyl" as used herein include, but are not limited to, methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl, t-butyl, n- pentyl, isopentyl and hexyl.
As used herein, the term "substituted alkyl" refers to a straight or branched chain saturated hydrocarbon radical, which is optionally substituted with one or more substituents selected from the group consisting of C 1.3 alkyl optionally having one to three fluorine substituents, C2-3 alkenyl, C2-3 alkynyl, C\.2 alkoxy optionally having one to three fluorine substituents, sulfanyl, sulfinyl, sulfonyl, oxo, hydroxy, mercapto, amino, guanidino, carboxy, aminocarbonyl, aryl, aryloxy, heteroaryl, heteroaryloxy, heterocyclic, aminosulfonyl, sulfonylamino, carboxyamide, ureido, nitro, cyano and halogen.
As used herein, the term "alkenyl" refers to a straight or branched chain hydrocarbon radical having at least one carbon-carbon double bond. Examples of "alkenyl" as used herein include, but are not limited to, ethenyl and propenyl.
As used herein, the term "substituted alkenyl" refers to a straight or branched chain hydrocarbon radical having at least one carbon-carbon double bond, which has optional substituents selected from the group consisting of C1-3 alkyl optionally having one to three fluorine substituents, amino, aryl, cyano and halogen.
As used herein, the term "alkynyl" refers to a straight or branched chain hydrocarbon radical having at least one carbon-carbon triple bond. Examples of
"alkynyl" as used herein include, but are not limited to, acetylenyl and 1-propynyl.
As used herein, the term "substituted alkynyl "refers to a straight or branched chain hydrocarbon radical having at least one carbon-carbon triple bond, optionally having one or more substituents selected from the group consisting of Cj.3 alkyl optionally having one to three fluorine substituents, amino, aryl and halogen.
As used herein, the term "halogen" refers to fluorine (F), chlorine (Cl), bromine (Br), or iodine (I).
As used herein, the term "carbocycle" refers to a non-aromatic cyclic hydrocarbon radical composed of three to seven carbon atoms. Five-to seven- membered rings may contain a double bond in the ring structure. Exemplary "carbocycle" groups include, but are not limited to, cyclopropyl, cyclobutyl, cyclopentyl, cyclopentenyl, cyclohexyl, and cycloheptyl.
As used herein, the term "substituted carbocycle" refers to a non-aromatic cyclic hydrocarbon radical composed by three to seven carbon atoms, which is optionally substituted with one or more substituents selected from the group consisting of Ci-3 alkyl optionally having one to three fluorine substituents, C2-3 alkenyl, C2-3 alkynyl, Ci-2 alkoxy optionally having one to three fluorine substituents, sulfanyl, sulfinyl, sulfonyl, oxo, hydroxy, mercapto, amino, guanidino, carboxy, aminocarbonyl, aryl, aryloxy, heteroaryl, heterocyclic, aminosulfonyl, sulfonylamino, carboxyamide, nitro, ureido, cyano and halogen.
As used herein, the term "aryl" refers to an optionally substituted benzene ring or refers to a ring system which may result by fusing one or more optional substituents. Exemplary optional substituents include substituted Q-3 alkyl, substituted C2-3 alkenyl, substituted C2-3 alkynyl, heteroaryl, heterocyclic, aryl, alkoxy optionally having one to three fluorine substituents, aryloxy, aralkoxy, acyl, aroyl, heteroaroyl, acyloxy, aroyloxy, heteroaroyloxy, sulfanyl, sulfinyl, sulfonyl, aminosulfonyl, sulfonylamino, carboxyamide, aminocarbonyl, carboxy, oxo, hydroxy, mercapto, amino, nitro, cyano, halogen, or ureido. Such a ring or ring system may be optionally fused to aryl rings (including benzene rings) optionally having one or more substituents, carbocycle rings or heterocyclic rings. Examples of "aryl" groups include, but are not limited to, phenyl, naphthyl, tetrahydronaphthyl, biphenyl, indanyl, anthracyl or phenanthryl, as well as substituted derivatives thereof.
As used herein, the term "heteroaryl" refers to an optionally substituted monocyclic five to six-membered aromatic ring containing one or more heteroatomic substitutions selected from S, SO, SO2, O, N5 or N-oxide, or refers to such an aromatic ring fused to one or more rings such as heteroaryl rings, aryl rings, heterocyclic rings, or carbocycle rings (e.g., a bicyclic or tricyclic ring system), each having optional subsituents.
Examples of optional substituents are selected from the group consisting of substituted Ci-3 alkyl, substituted C2-3 alkenyl, substituted C2-3 alkynyl, heteroaryl, heterocyclic, aryl, Ci-3 alkoxy optionally having one to three fluorine substituents, aryloxy, aralkoxy, acyl, aroyl, heteroaroyl, acyloxy, aroyloxy, heteroaroyloxy, sulfanyl, sulfinyl, sulfonyl, aminosulfonyl, sulfonylamino, carboxyamide, aminocarbonyl, carboxy, oxo, hydroxy, mercapto, amino, nitro, cyano, halogen or ureido. Examples of "heteroaryl" groups used herein include, but are not limited to, benzoimidazolyl, benzothiazolyl, benzoisothiazolyl, benzothiophenyl, benzopyrazinyl, benzotriazolyl, benzo[l,4]dioxanyl, benzofuranyl, 9H-a- carbolinyl, cinnolinyl, furanyl, furo[2,3-b]pyridinyl, imidazolyl, imidazolidinyl, imidazopyridinyl, isoxazolyl, isothiazolyl, isoquinolinyl, indolyl, indazolyl, indolizinyl, naphthyridinyl, oxazolyl, oxothiadiazolyl, oxadiazolyl, phthalazinyl, pyridyl, pyrrolyl, purinyl, pteridinyl, phenazinyl, pyrazolyl, pyridyl, pyrazolopyrimidinyl, pyrrolizinyl, pyridazyl, pyrazinyl, pyrimidyl, 4-oxo-l, 2- dihydro-4H-pyrrolo[3,2, l-ij]-quinolin-4-yl, quinoxalinyl, quinazolinyl, quinolinyl, quinolizinyl, thiophenyl, triazolyl, triazinyl, tetrazolopyrimidinyl, triazolopyrimidinyl, tetrazolyl, thiazolyl, thiazolidinyl, and substituted versions thereof.
As used herein, the term "heterocyclic" refers to a three to seven- membered ring containing one or more heteroatomic moieties selected from S, SO, SO2, O, N, or N-oxide, optionally substituted with one or more substituents selected from the group which includes substituted C1-3 alkyl, substituted C2-3 alkenyl, substituted C2-3 alkynyl, heteroaryl, heterocyclic, aryl, C1-3 alkoxy optionally having one to three fluorine substituents, aryloxy, aralkoxy, acyl, aroyl, heteroaroyl, acyloxy, aroyloxy, heteroaroyloxy, sulfanyl, sulfinyl, sulfonyl, aminosulfonyl, sulfonylamino, carboxyamide, aminocarbonyl, carboxy, oxo, hydroxy, mercapto, amino, nitro, cyano, halogen, and ureido. Such a ring can be saturated or have one or more degrees of unsaturation. Such a ring may be optionally fused to one or more "heterocyclic" ring(s), aryl ring(s), heteroaryl ring(s) or carbocycle ring(s), each having optional substituents.
Examples of "heterocyclic" moieties include, but are not limited to, 1,4- dioxanyl, 1,3-dioxanyl, pyrrolidinyl, pyrrolidin-2-onyl, piperidinyl, imidazolidine-2,4-dionepiperidinyl, piperazinyl, piperazine-2,5-dionyl, morpholinyl, dihydropyranyl, dihydrocinnolinyl, 2,3-dihydrobenzo [1,4] dioxinyl, 3,4-dihydro-2H-benzo[b][l,4]-dioxepinyl, tetrahydfopyranyl, 2,3-dihydrofuranyl, 2,3-dihydrobenzofuranyl, dihydroisόxazolyl, tetrahydrobenzodiazepinyl, tetrahydroquinolinyl, tetrahydrofuranyl, tetrahydronaphthyridinyl, tetrahydropurinyl, tetrahydrothiopyranyl, tetrahydrothiophenyl, tetrahydroquinoxalinyl, tetrahydropyridinyl, tetrahydrocarbolinyl, 4H-benzo[l,3]- dioxinyl, benzo[l,3]dioxonyl, 2,2-difluorobenzo-[l,3]-dioxonyl, 2,3-dihydro- phthalazine- 1 , 4-dionyl, and isoindole- 1 ,3-dionyl.
As used herein, the term "alkoxy" refers to the group -ORa, where Ra is alkyl as defined above. Exemplary alkoxy groups useful in the present invention include, but are not limited to, methoxy, difluoromethoxy, trifluoromethoxy, ethoxy, n-propoxy, isopropoxy, n-butoxy and t-butoxy.
As used herein, the term "aralkoxy" refers to the group -OR3Rb, wherein R3 is alkyl and Rb is aryl as defined above.
As used herein, the term "aryloxy" refers to the group -ORb, wherein Rb is aryl as defined above.
As used herein, the term "heteroaryloxy" refers to the group -OC(O)Rf, wherein Rf is heteroaryl as defined above.
As used herein, the term "mercapto" refers to the group -SH. As used herein, the term "sulfanyl" refers to the group -SR0, wherein R0 is substituted alkyl, substituted carbocycle, aryl, heteroaryl or heterocyclic, as defined above.
As used herein, the term "sulfinyl" refers to the group -S-(O)R0, wherein R0 is substituted alkyl, substituted carbocycle, aryl, heteroaryl or heterocyclic, as defined above.
As used herein, the term "sulfonyl" refers to the group -S(O)2R0, wherein R0 is substituted alkyl, substituted carbocycle, aryl, heteroaryl or heterocyclic, as defined above.
As used herein, the term "oxo" refers to the group =0.
As used herein, the term "hydroxy" refers to the group -OH.
As used herein, the term "amino" refers to the group -NH2. The amino group is optionally substituted with substituted alkyl, substituted carbocycle, aryl, heteroaryl or heterocyclic, as defined above.
As used herein, the term "cyano" refers to the group -CN.
As used herein, the term "aminosulfonyl" refers to the group -S(O)2NH2. The aminosulfonyl group is optionally substituted with substituted alkyl, substituted carbocycle, aryl, heteroaryl or heterocyclic, as defined above.
As used herein, the term "sulfonylamino" refers to the group -NHS(O)2Rc wherein R0 is substituted alkyl, substituted carbocycle, aryl, heteroaryl or heterocyclic, as defined above.
As used herein, the term "carboxyamide" refers to the group -NHC(O)R0 wherein R0 is substituted alkyl, substituted carbocycle, aryl, heteroaryl or heterocyclic, as defined above.
As used herein, the term "carboxy" refers to the group -C(O)OH. The carboxy group is optionally substituted with substituted alkyl, substituted carbocycle, aryl, heteroaryl or heterocyclic, as defined above.
As used herein, the term "aminocarbonyl" refers to the group -C(O)NH2. The aminocarbonyl group is optionally substituted with substituted alkyl, substituted carbocycle, aryl, heteroaryl or heterocyclic, as defined above.
As used herein, the term "ureido" refers to the group -NHC(O)NHRc wherein R0 is hydrogen, alkyl, carbocycle or aryl as defined above.
As used herein, the term "guanidino" refers to the group -NHC(=NH)NH2.
As used herein, the term "acyl" refers to the group -C(O)R0, wherein R0 is alkyl, carbocycle, or heterocyclic as defined above.
As used herein, the term "aroyl" refers to the group -C(O)Rb, wherein Rb is aryl as defined above.
As used herein, the term "heteroaroyl" refers to the group -C(O)Rd, wherein R^ is heteroaryl as defined above.
As used herein, the term "acyloxy" refers to the group -OC(O)Rc, wherein Rc is alkyl, carbocycle, or heterocyclic as defined above.
As used herein, the term "aroyloxy" refers to the group -OC(O)Rb, wherein Rb is aryl as defined above.
As used herein, the term "heteroaroyloxy" refers to the group -OC(O)Rj, wherein R0 is heteroaryl as defined above.
In the present invention, representative examples of the arylpiperazine- containing imidazole 4-carboxamide derivative include:
l-(4-chlorophenyl)-N-(3-(4-(2,3-dichlorophenyl)piperazin-l-yl)-2- hydroxypropyl)-2-propyl-lH-imidazole-4-carboxamide;
l-(4-chlorophenyl)-N-(3-(4-(2,3-dichlorophenyl)piperazin- l-yl)propyl)-2- propy 1- 1 H- imidazole-4-carboxamide dihy drochloride;
l-(4-chlorophenyl)-N-(3-(4-(2,3-dimethylphenyl)piperazin- l-yl)propyl)- 2-propyl-lH-imidazole-4-carboxamide;
l-(4-chlorophenyl)-N-(2-(4-(2,3-dichlorophenyl)piperazin- l-yl)ethyl)-2- propyl- lH-imidazole-4-carboxamide;
N-(3-(4-(2,3-dichlorophenyl)piperazin-l-yl)-2-hydroxypropyl)-2,5- dimethyl- 1 -phenyl- IH- imidazole-4-carboxamide;
N-(3-(4-(2,3-dichlorophenyl)piperazin-l-yl)propyl)-2,5-dimethyl-l- phenyl-lH-imidazole-4-carboxamide;
N-(3-(4-(2,3-dichlorophenyl)piperazin-l-yl)propyl)-5-methyl-l-phenyl-2- propyl- lH-imidazole-4-carboxamide dihy drochloride;
N-(2-(4-(2,3-dichlorophenyl)piperazin-l-yl)ethyl)-2,5-dimethyl-l-phenyl- lH-imidazole-4-carboxamide;
N-(2-(4-(2,3-dichlorophenyl)piperazin-l-yl)emyl)-5-methyl-l-phenyl-2- propyl- lH-imidazole-4-carboxamide;
N-(3-(4-(2,3-dichlorophenyl)piperazin- 1 -y l)propyl)- 1 -(4- methoxyphenyl)-2,5-dimethyl-lH-imidazole-4-carboxamide;
1 -(4-chloropheny l)-N-(3-(4-(2,3-dichlorophenyl)piperazin- 1 -yl)propy I)- 2,5-dimethyl-lH-imidazole-4-carboxamide;
N-(3-(4-(2,3-dichlorophenyl)piperazin-l-yl)propyl)-2-ethyl-5-methyl-l- phenyl-lH-imidazole-4-carboxamide; N-(2-(4-(2,3-dichlorophenyl)piperazin-l-yl)ethyl)-2-ethyl-5-methyl- l- pheny 1- 1 H-imidazole-4-carboxamide;
N-(2-(4-(2,3-dimethylρhenyl)piperazin- 1 -yl)ethyl)-2,5-dimethyl- 1 - phenyl- 1 H-imidazole-4-carboxamide;
N-(3-(4-(2,3-dimethylphenyl)piperazin-l-yl)propyl)-2,5-dimethyl-l- phenyl-lH-imidazole-4-carboxamide;
N-(3-(4-(2,3-dimethylphenyl)piperazin- 1 -yl)propyl)-2-ethyl-5-methyl- 1 - phenyl- 1 H-imidazole-4-carboxamide;
N-(3-(4-(2,3-dimethylphenyl)piperazin-l-yl)propyl)-5-methyl-l-phenyl- 2-propy 1- 1 H-imidazole-4-carboxamide dihydrochloride;
N-(2-(4-(2,3-dimethylphenyl)piperazin-l-yl)ethyl)-2-ethyl-5-methyl- l- pheny 1-1 H-imidazole-4-carboxamide;
N-(2-(4-(2,3-dimethylphenyl)piperazin-l-yl)ethyl)-5-methyl-l-phenyl-2- propyl-lH-imidazole-4-carboxamide dihydrochloride;
N-(3-(4-(2,3-dichlorophenyl)piperazin-l-yl)propyl)-l-(4-fluorophenyl)-
2,5-dimethyl-lH-imidazole-4-carboxamide;
N-(2-(4-(2,3-dichlorophenyl)piperazin-l-yl)ethyl)-l-(4-fluorophenyl)-2,5- dimethy 1-1 H-imidazole-4-carboxamide;
l-(4-chlorophenyl)-N-(3-(4-(2,3-dimethylphenyl)piperazin-l-yl)propyl)- 2,5-dimethyl-l H-imidazole-4-carboxamide;
N-(3-(4-(2,3-dichlorophenyl)piperazin-l-yl)-2-hydroxypropyl)-2-ethyl-5- methyl-1 -phenyl- 1 H-imidazole-4-carboxamide;
N-(3-(4-(2,3-dichlorophenyl)piperazin-l-yl)-2-hydroxypropyl)-5-methyl- l-phenyl-2-propyl-l H-imidazole-4-carboxamide;
l-(4-chlorophenyl)-N-(3-(4-(2,3-dichlorophenyl)piperazin- l-yl)propyl)-2- ethyl-5-methyl-lH-imidazole-4-carboxamide;
N-(3-(4-(2,3-dichlorophenyl)piperazin-l-yl)-2-hydroxypropyl)-l-(4- fluorophenyl)-2,5-dimethyl-lH-imidazole-4-carboxamide;
l-(4-chlorophenyl)-N-(2-(4-(2,3-dichlorophenyl)piperazin-l-yl)ethyl)- 2,5-dimethyl- 1 H-imidazole-4-carboxamide;
l-(4-chlorophenyl)-N-(2-(4-(2,3-dichlorophenyl)piperazin-l-yl)ethyl)-2- ethyl-5-methy 1-1 H-imidazole-4-carboxamide;
N-(3-(4-(2,3-dichlorophenyl)piperazin-l-yl)propyl)-2,5-dimethyl-l-p- tolyl-1 H-imidazole-4-carboxamide;
N-(2-(4-(2,3-dichlorophenyl)piperazin- 1 -yl)ethyl)-2,5-dimethyl- 1 -p-toly 1- lH-imidazole-4-carboxamide; N-(3-(4-(2,3-dichlorophenyl)piperazin-l-yl)-2-hydroxypropyl)-2,5- dimethyl- 1 -p-tolyl- lH-imidazole-4-carboxamide;
l-(4-chlorophenyl)-N-(3-(4-(2,3-dichlorophenyl)piperazin-l-yl)-2- hydroxypropyl)-2,5-dimethyl-lH-imidazole-4-carboxamide;
1 -(4-chlorophenyl)-N-(3-(4-(2,3-dichlorophenyl)piperazin- 1 -yl)-2- hydroxypropyl)-2-ethyl-5-methyl-lH-imidazole-4-carboxamide;
N-(3-(4-(2,3-dimethylphenyl)piperazin-l-yl)propyl)-l-(4-fluorophenyl)- 2,5-dimethyl-lH-imidazole-4-carboxamide;
N-(3-(4-(2,3-dimethylphenyl)piperazin-l-yl)-2-hydroxypropyl)-l-(4- fluorophenyl)-2,5-dimethyl-lH-imidazole-4-carboxamide;
N-(3-(4-(2,3-dimethylphenyl)piperazin-l-yl)-2-hydroxypropyl)-2,5- dimethyl- 1 -phenyl- lH-imidazole-4-carboxamide;
N-(3-(4-(2,3-dimethylphenyl)piperazin- 1 -y l)propyl)-2,5-dimethyl- 1 -(4- (trifluoromethyl)phenyl)-lH-imidazole-4-carboxamide;
l-(benzo[ύG[l,3]dioxol-5-yl)-N-(3-(4-(2,3-dimethylphenyl)piρerazin- l- yl)propyl)-2,5-dimethyl-lH-imidazole-4-carboxamide;
l-(benzo[J][ l,3]dioxol-5-yl)-N-(3-(4-(2,3-dimethylphenyl)piperazin- l- yl)-2-hydroxypropyl)-2,5-dimethyl-lH-imidazole-4-carboxamide;
l-(2,3-dihydrobenzo[b][l,4]dioxin-6-yl)-N-(3-(4-(2,3-dimethylphenyl) piperazin-l-yl)propyl)-2,5-dimethyl-lH-imidazole-4-carboxamide;
l-(2,3-dihydrobenzo[b][l,4]dioxin-6-yl)-N-(3-(4-(2,3-dimethylphenyl) piperazin-l-yl)-2-hydroxypropyl)-2,5-dimethyl- lH-imidazole-4-carboxamide;
N-(2-(4-(2,3-dichlorophenyl)piperazin-l-yl)ethyl)-l-(4-methoxyphenyl)- 2,5-dimethyl-lH-imidazole-4-carboxamide;
N-(3-(4-(2,3-dichlorophenyl)piperazin- 1 -yl)-2-hydroxypropyl)- 1 -(4- methoxyphenyl)-2,5-dimethyl-lH-imidazole-4-carboxamide;
N-(3-(4-(2,3-dichlorophenyl)piperazin-l-yl)propyl)-2-ethyl-l-(4- methoxyphenyl)-5-methyl-lH-imidazole-4-carboxamide;
N-(3-(4-(2,3-dichlorophenyl)piperazin-l-yl)-2-hydroxypropyl)-2-ethyl- l- (4-methoxyphenyl)-5-methyl- lH-imidazole-4-carboxamide;
N-(2-(4-(2,3-dimethylphenyl)piperazin-l-yl)ethyl)-l-(4-methoxyphenyl)- 2,5-dimethyl-lH-imidazole-4-carboxamide;
N-(3-(4-(2,3-dimethylphenyl)piperazin-l-yl)propyl)-l-(4- methoxyphenyl)-2,5-dimethyl-lH-imidazole-4-carboxamide;
1 -(3-chlorophenyl)-N-(3-(4-(2,3-dimethylphenyl)piperazin- 1 -yl)propyl)-
2,5-dimethyl-lH-imidazole-4-carboxamide; l-(3-chlorophenyl)-N-(3-(4-(2,3-dimethylphenyl)piperazin- l-yl)-2- hydroxypropyl)-2,5-dimethyl-lH-imidazole-4-carboxamide;
N-(3-(4-(3-chloro-2-methylphenyl)piperazin-l-yl)propyl)-l-(3- chlorophenyl)-2,5-dimethyl-lH-imidazole-4-carboxamide;
N-(3-(4-(3-chloro-2-methylphenyl)piperazin-l-yl)-2-hydroxypropyl)-l-
(3-chlorophenyl)-2,5-dimethyl-lH-imidazole-4-carboxamide;
N-(3-(4-(2,3-dimethylphenyl)piperazin-l-yl)propyl)-l-(3-fluorophenyl)- 2,5-dimethyl-l//-imidazole-4-carboxamide;
N-(3 -(4-(2,3-dimethylpheny l)piperazin- 1 -y l)-2-hydroxypropy I)- 1 -(3 - fluorophenyl)-2,5-dimethyl- lH-imidazole-4-carboxamide;
1 -(3,4-dimethoxyphenyl)-N-(3 -(4-(2,3 -dimethy lphenyl)piperazin- 1 - yl)propyl)-2,5-dimethyl-lH-imidazole-4-carboxamide;
l-(3,4-dimethoxyphenyl)-N-(3-(4-(2,3-dimethylphenyl)piperazin-l-yl)-2- hydroxypropyl)-2,5-dimethyl-lH-imidazole-4-carboxamide;
N-(3-(4-(2,3-dimethylphenyl)piperazin-l-yl)-2-hydroxypropyl)-l-(4- methoxyphenyl)-2,5-dimethyl-lH-imidazole-4-carboxamide;
N-(3-(4-(2,3-dimethylphenyl)piperazin-l-yl)propyl)-2,5-dimethyl-l-(4- (methy lthio)pheny I)- 1 H-imidazole-4-carboxamide;
N-(3-(4-(2,3-dimethylphenyl)piperazin-l-yl)-2-hydroxypropyl)-2,5- dimethyl- 1 -(4-(methylthio)pheny I)- 1 H-imidazole-4-carboxamide;
N-(3-(4-(2,3-dimethylphenyl)piperazin-l-yl)propyl)-l-(3- methoxyphenyl)-2,5-dimethyl-lH-imidazole-4-carboxamide;
N-(3-(4-(2,3-dimethylphenyl)piperazin-l-yl)-2-hydroxypropyl)-l-(3- methoxyphenyl)-2,5-dimethyl-lH-imidazole-4-carboxamide;
l-(2,4-dimethoxyphenyl)-N-(3-(4-(2,3-dimethylphenyl)piperazin-l- yl)propyl)-2,5-dimethyl-lH-imidazole-4-carboxamide;
l-(2,4-dimethoxyphenyl)-N-(3-(4-(2,3-dimethylphenyl)piperazin-l-yl)-2- hydroxypropyl)-2,5-dimethyl-lH-imidazole-4-carboxamide;
(iSr)-N-(3-(4-(2,3-dichlorophenyl)piperazin-l-yl)-2-hydroxypropyl)-2,5- dimethyl- 1 -phenyl- lH-imidazole-4-carboxamide;
(5)-N-(3-(4-(2,3-dichlorophenyl)piperazin- l-yl)-2-hydroxypropyl)-5- methyl-l-phenyl-2-propyl-l H-imidazole-4-carboxamide;
N-(3-(4-(2,3-dichlorophenyl)piperazin-l-yl)-2,2-difluoropropyl)-2,5- dimethyl-1 -phenyl- 1 H-imidazole-4-carboxamide;
N-(3-(4-(2,3-dichlorophenyl)piperazin-l-yl)-2,2-difluoropropyl)-5- methyl-l-phenyl-2-propyl-l H-imidazole-4-carboxamide; N-(3-(4-(2,3-dimethylphenyl)piperazin-l-yl)propyl)-l-(2-fluorophenyl)- 2,5-dimethyl-lH-imidazole-4-carboxamide;
N-(3-(4-(2,3-dimethylphenyl)piperazin-l-yl)-2-hydroxypropyl)-l-(2- fluorophenyl)-2,5-dimethyl-lH-imidazole-4-carboxamide;
N-(2-(4-(3-chloro-2-fluorophenyl)piperazin- 1 -y l)ethyl)-2,5-dimethyl- 1 - phenyl- lH-imidazole-4-carboxamide;
N-(3-(4-(3-chloro-2-fluorophenyl)piperazin- 1 -yl)propyl)-2,5-dimethyl- 1 - phenyl- lH-imidazole-4-carboxamide;
N-(2-(4-(3-chloro-2-methylphenyl)piperazin-l-yl)ethyl)-2,5-dimethyl-l- phenyl- lH-imidazole-4-carboxamide;
N-(3-(4-(3-chloro-2-methylphenyl)piperazin-l-yl)propyl)-2,5-dimethyl-l- phenyl-lH-imidazole-4-carboxamide;
2,5-dimethyl-N-(2-(4-(2-methylquinolin-8-yl)piperazin-l-yl)ethyl)-l- phenyl-lH-imidazole-4-carboxamide;
2,5-dimethy 1- 1 -pheny l-N-(2-(4-(quinolin-8-y l)piperazin- 1 -yl)ethy I)- 1 H- imidazole-4-carboxamide;
N-(3-(4-(3-chloro-2-methylphenyl)piperazin-l-yl)-2-hydroxypropyl)-2,5- dimethyl- 1 -phenyl- lH-imidazole-4-carboxamide;
l-cyclopentyl-N-(3-(4-(2,3-dimethylphenyl)piperazin-l-yl)propyl)-2,5- dimethyl- lH-imidazole-4-carboxamide;
l-cyclopentyl-N-(3-(4-(2,3-dimethylphenyl)piperazin-l-yl)-2- hydroxypropyl)-2,5-dimethyl-lH-imidazole-4-carboxamide;
N-(3-(4-(3-chloro-2-methylphenyl)piperazin- 1 -yl)propyl)- 1 -cyclopenty 1- 2,5-dimethyl-lH-imidazole-4-carboxamide;
N-(3-(4-(3-chloro-2-methy lphenyl)piperazin- 1 -yl)-2-hydroxypropyl)- 1 - cyclopentyl-2,5-dimethyl-lH-imidazole-4-carboxamide;
1 -cyclopenty l-N-(4-(4-(2,3-dimethylphenyl)piperazin- 1 -yl)buty l)-2,5- dimethyl-lH-imidazole-4-carboxamide;
1 -cyclopentyl-N-(2-(4-(2,3-dichlorophenyl)piperazin- 1 -yl)ethyl)-2,5- dimethyl- lH-imidazole-4-carboxamide;
N-(3-(4-(2,3-dimethylphenyl)piperazin- 1 -yl)-2-hydroxypropyl)- 1 -(4- fluorophenyl)-5-methyl-2-phenyl-lH-imidazole-4-carboxamide;
N-(3-(4-(2,3-dimethylphenyl)piperazin- 1 -yl)propy I)- 1 -(4-fluoropheny I)- 5-methyl-2-phenyl-lH-imidazole-4-carboxamide;
N-(3-(4-(3-chloro-2-methylphenyl)piperazin-l-yl)-2-hydroxypropyl)-l-
(4-fluorophenyl)-5-methyl-2-phenyl-lH-imidazole-4-carboxamide; N-(3-(4-(3-chloro-2-methylphenyl)piperazin-l-yl)propyl)-l-(4- fluorophenyl)-5-methyl-2-phenyl-lH-imidazole-4-carboxamide;
N-(3-(4-(2,3-dimethylphenyl)piperazin-l-yl)propyl)-5-methyl-l,2- diphenyl-lH-imidazole-4-carboxamide;
N-(3-(4-(3-chloro-2-methylphenyl)piperazin-l-yl)propyl)-5-methyl-l,2- diphenyl-lH-imidazole-4-carboxamide;
l-(4-bromophenyl)-N-(3-(4-(3-chlorophenyl)piperazin-l-yl)propyl)-2- (2,4-dichlorophenyl)-5 -ethyl- lH-imidazole-4-carboxamide;
l-(4-bromophenyl)-2-(2,4-dichlorophenyl)-N-(3-(4-(2,3- dichlorophenyl)piperazin-l-yl)propyl)-5-ethyl-lH-imidazole-4-carboxamide;
l-(4-bromophenyl)-2-(2,4-dichlorophenyl)-N-(3-(4-(2,3- dimethylphenyl)piperazin-l-yl)propyl)-5-ethyl-lH-imidazole-4-carboxamide;
5-(( IH- 1 ,2,4-triazol- 1 -yl)methyl)-N-(3-(4-(3-chloro-2- methylphenyl)piperazin- 1 -yl)propyl)- 1 ,2-diphenyl- lH-imidazole-4-carboxamide;
N-(3-(4-(2,3-dimethylphenyl)piperazin-l-yl)propyl)- l-isobutyl-2,5- dimethyl-lH-imidazole-4-carboxamide;
N-(3-(4-(3-chloro-2-methylphenyl)piperazin- 1 -yl)propyl)- 1 -isobutyl-2,5- dimethyl-lH-imidazole-4-carboxamide
N-(3-(4-(2,3-dimethylphenyl)piperazin-l-yl)-2-hydroxypropyl)-l- isobutyl-2,5-dimethyl- lH-imidazole-4-carboxamide
N-(3-(4-(2,3-dimethylphenyl)piperazin-l-yl)propyl)-2,5-dimethyl-l- propyl-lH-imidazole-4-carboxamide;
N-(3-(4-(2,3-dimethylphenyl)piperazin-l-yl)-2-hydroxypropyl)-2,5- dimethyl- 1 -propyl- lH-imidazole-4-carboxamide;
N-(3-(4-(3-chloro-2-methylphenyl)piperazin-l-yl)propyl)-2,5-dimethyl-l- propyl-lH-imidazole-4-carboxamide;
N-(3-(4-(3-chloro-2-methylphenyl)piperazin-l-yl)-2-hydroxypropyl)-2,5- dimethyl- 1 -propyl- lH-imidazole-4-carboxamide;
N-(3-(4-(2,3-dimethylphenyl)piperazin- 1 -yl)propyl)- 1 -(2- methoxyphenyl)-2,5-dimethyl-lH-imidazole-4-carboxamide;
N-(3-(4-(2,3-dimethylphenyl)piperazin-l-yl)-2-hydroxypropyl)-l-(2- methoxyphenyl)-2,5-dimethyl-lH-imidazole-4-carboxamide;
l-(2-chlorophenyl)-N-(3-(4-(2,3-dimethylphenyl)piperazin-l-yl)propyl)- 2,5-dimethyl-lH-imidazole-4-carboxamide;
l-(2-chlorophenyl)-N-(3-(4-(2,3-dimethylphenyl)piperazin-l-yl)-2- hydroxypropyl)-2,5-dimethyl-lH-imidazole-4-carboxamide; l-(2-chlorophenyl)-N-(4-(4-(2,3-dimethylphenyl)piperazin-l-yl)butyl)- 2,5-dimethyl- 1 H-imidazole-4-carboxamide;
N-(3-(4-(2,3-dimethylphenyl)piperazin-l-yl)propyl)-2-isopropyl-5- methyl- 1 -phenyl- 1 H-imidazole-4-carboxamide;
l-(3,5-dimethoxyphenyl)-N-(3-(4-(2,3-dimethylphenyl)piperazin-l- yl)propyl)-2,5-dimethyl-lH-imidazole-4-carboxamide;
N-(3-(4-(2,3-dimethylphenyl)piperazin-l-yl)-2-hydroxypropyl)-2- isopropyl-5-methyl-l-phenyl-lH-imidazole-4-carboxamide;
l-(3,5-dimethoxyphenyl)-N-(3-(4-(2,3-dimethylphenyl)piperazin-l-yl)-2- hydroxypropyl)-2,5-dimethyl- lH-imidazole-4-carboxamide;
N-(3-(4-(2,3-dimethylphenyl)piperazin-l-yl)-2-hydroxypropyl)-2,5- dimethyl- 1 -(4-(trifluoromethy l)pheny I)- 1 H-imidazole-4-carboxamide;
N-(3-(4-(2,3-dimethylphenyl)piperazin-l-yl)-2-hydroxypropyl)-2-ethyl-5- methy 1- 1 -phenyl- 1 H-imidazole-4-carboxamide;
N-(3-(4-(2,3-dimethylphenyl)piperazin- l-yl)-2-hydroxypropyl)-5-methyl-
1 -phenyl-2-propyl- lH-imidazole-4-carboxamide;
l-(4-chlorophenyl)-N-(3-(4-(2,3-dimethylphenyl)piperazin-l-yl)-2- hydroxypropyl)-2-propy 1-1 H-imidazole-4-carboxamide;
l-(3,5-dimethoxyphenyl)-N-(2-(4-(2,3-dimethylphenyl)piperazin-l- yl)ethyl)-2,5-dimethyl-lH-imidazole-4-carboxamide;
N-(2-(4-(2,3-dimethylphenyl)piperazin-l-yl)ethyl)-2-isopropyl-5-methyl- 1 -phenyl- 1 H-imidazole-4-carboxamide;
N-(2-(4-(2,3-dimethylphenyl)piperazin-l-yl)ethyl)-l-(4-fluorophenyl)- 2,5-dimethyl-lH-imidazole-4-carboxamide;
l-(benzo[uG[l,3]dioxol-5-yl)-N-(2-(4-(2,3-dimethylphenyl)piperazin-l- yl)ethyl)-2,5-dimethyl-lH-imidazole-4-carboxamide;
l-(2,3-dihydrobenzo[b][l,4]dioxin-6-yl)-N-(2-(4-(2,3- dimethylphenyl)piperazin-l-yl)ethyl)-2,5-dimethyl-lH-imidazole-4-carboxamide;
N-(3-(4-(2,3-dimethylphenyl)piperazin-l-yl)propyl)-l-phenyl-2-propyl- 1 H-imidazole-4-carboxamide;
N-(3-(4-(2,3-dichlorophenyl)piperazin-l-yl)propyl)-l-phenyl-2-propyl- 1 H-imidazole-4-carboxamide;
N-(2-(4-(2,3-dichlorophenyl)piperazin-l-yl)ethyl)-l-phenyl-2-propyl-lH- imidazole-4-carboxamide;
N-(2-(4-(2,3-dimethylphenyl)piperazin- 1 -y l)ethyl)- 1 -phenyl-2-propy 1-
1 H-imidazole-4-carboxamide; N-(3-(4-(2,3-dimethylphenyl)piperazin- 1 -yl)-2-hydroxypropyl)- 1 -phenyl- 2-propyl-lH-imidazole-4-carboxamide;
N-(3 -(4-(2,3 -dimethy lphenyl)piperazin- 1 -y l)propy I)- 1 -(4- methoxyphenyl)-5-methyl-2-propyl-lH-imidazole-4-carboxamide;
N-(2-(4-(2,3-dimethylphenyl)piperazin- 1 -yl)ethyl)- 1 -(4-methoxyphenyl)-
5-methyl-2-propyl-lH-imidazole-4-carboxamide;
N-(3-(4-(2,3-dimethylphenyl)piperazin-l-yl)propyl)-2,5-dimethyl-l- (quinolin-6-yl)-lH-imidazole-4-carboxamide;
N-(3-(4-(2,3-dichlorophenyl)piperazin-l-yl)-2-hydroxypropyl)-2,5- dimethyl- 1 -(quinolin-6-yl)- lH-imidazole-4-carboxamide;
N-(3-(4-(2,3-dichlorophenyl)piperazin- 1 -yl)-2-hydroxypropyl)- 1 -phenyl- 2-propy 1- 1 H-imidazole-4-carboxamide;
N-(3-(4-(2,3-dichlorophenyl)piperazin- 1 -yl)-2-hydroxypropyl)- 1 -(4- fluorophenyl)-2-propyl-lH-imidazole-4-carboxamide;
N-(3-(4-(2,3-dimethylphenyl)piperazin-l-yl)-2-hydroxypropyl)-l-(4- fluorophenyl)-2-propyl-l H-imidazole-4-carboxamide;
N-(3-(4-(2,3-dimethylphenyl)piperazin-l-yl)propyl)-l-(4-fluorophenyl)- 2-propyl- 1 H-imidazole-4-carboxamide;
N-(3-(4-(2,3-dichlorophenyl)piperazin-l-yl)-2-hydroxypropyl)-l,2- dipheny 1-1 H-imidazole-4-carboxamide;
N-(3-(4-(2,3-dimethylphenyl)piperazin-l-yl)propyl)-l,2-diphenyl- lH- imidazole-4-carboxamide;
N-(3-(4-(2,3-dimethylphenyl)piperazin-l-yl)propyl)-2,5-dimethyl-l- (pyridin-2-y I)- 1 H-imidazole-4-carboxamide trihydrochloride;
N-(3-(4-(2,3-dichlorophenyl)piperazin- 1 -yl)-2-hydroxypropyl)- 1 -(4- methoxypheny l)-2-phenyl- 1 H-imidazole-4-carboxamide;
N-(3-(4-(2,3-dimethylphenyl)piperazin-l-yl)propyl)-l-(4- methoxyphenyl)-2-phenyl- 1 H-imidazole-4-carboxamide ;
N-(3 -(4-(3 -chloro-2-methylphenyl)piperazin- 1 -y l)propy I)- 1 -(4- methoxyphenyl)-5-methyl-2-propyl-lH-imidazole-4-carboxamide;
N-(3-(4-(2,3-dichlorophenyl)piperazin- 1 -yl)-2-hydroxypropyl)- 1 -(4- methoxyphenyl)-5-methyl-2-propyl-lH-imidazole-4-carboxamide;
N-(3-(4-(2,3-dimethylphenyl)piperazin-l-yl)-2-hydroxypropyl)-l-(4- methoxyphenyl)-5-methyl-2-propyl-lH-imidazole-4-carboxamide;
N-(3 -(4-(3 -chloro-2-methy lphenyl)piperazin- 1 -y l)propy I)- 1 -(4- methoxyphenyl)-2,5-dimethyl-lH-imidazole-4-carboxamide; (S)-N-(3-(4-(2,3-dimethylphenyl)piperazin-l-yl)-2-hydroxypropyl)-2,5- dimethyl- 1 -phenyl- lH-imidazole-4-carboxamide;
N-((S)-3-(4-(2,3-dimethylphenyl)piperazin-l-yl)-2-hydroxypropyl)-l-(2- fluorophenyl)-2,5-dimethyl-lH-imidazole-4-carboxamide;
(S)-l-(4-chlorophenyl)-N-(3-(4-(2,3-dichlorophenyl)piperazin-l-yl)-2- hydroxypropyl)-2-propyl-lH-imidazole-4-carboxamide;
(S)-N-(3-(4-(3-chloro-2-methylphenyl)piperazin-l-yl)-2-hydroxypropyl)- l-(4-fluorophenyl)-5-methyl-2-phenyl-lH-imidazole-4-carboxamide;
N-(3-(4-(2,3-dichlorophenyl)piperazin-l-yl)propyl)-l-(4- methoxyphenyl)-5-methyl-2-propyl-lH-imidazole-4-carboxamide;
N-(3 -(4-(3-chloro-2-methy lphenyl)piperazin- 1 -yl)propy I)- 1 -(2- methoxyphenyl)-2,5-dimethyl-lH-imidazole-4-carboxamide;
N-(3-(4-(2,3-dichlorophenyl)piperazin- 1 -y l)propy I)- 1 -(2- methoxyphenyl)-2,5-dimethyl-lH-imidazole-4-carboxamide;
N-(3-(4-(2,3-dichlorophenyl)piperazin-l-yl)-2-hydroxypropyl)-l-(2- methoxyphenyl)-2,5-dimethyl-lH-imidazole-4-carboxamide;
N-(3-(4-(2,3-dimethylphenyl)piperazin-l-yl)propyl)-2,5-dimethyl-l-p- tolyl-lH-imidazole-4-carboxamide;
N-(3-(4-(2,3-dimethylphenyl)piperazin-l-yl)-2-hydroxypropyl)-2,5- dimethyl- l-/?-tolyl- lH-imidazole-4-carboxamide;
N-(3-(4-(2,3-dichlorophenyl)piperazin- 1 -yl)-2-hydroxypropyl)- 1 -(2,3- dihydrobenzo[b][l,4]dioxin-6-yl)-2,5-dimethyl-lH-imidazole-4-carboxamide;
N-(3-(4-(2,3-dichlorophenyl)piperazin-l-yl)propyl)-l-(2,3- dihydrobenzo[b][l,4]dioxin-6-yl)-2,5-dimethyl-lH-imidazole-4-carboxamide;
(R)-N-(3-(4-(2,3-dimethylphenyl)piperazin-l-yl)-2-hydroxypropyl)-2,5- dimethyl- 1 -phenyl- lH-imidazole-4-carboxamide;
N-((R)-3-(4-(2,3-dimethylphenyl)piperazin- 1 -yl)-2-hydroxypropyl)- 1 -(2- fluorophenyl)-2,5-dimethyl-lH-imidazole-4-carboxamide;
N-(3-(4-(3-chloro-2-methylphenyl)piperazin-l-yl)propyl)-l-(2- fluorophenyl)-2,5-dimethyl-lH-imidazole-4-carboxamide;
N-(3-(4-(2,3-dichlorophenyl)piperazin-l-yl)propyl)-l-(2-fluorophenyl)- 2,5-dimethyl-lH-imidazole-4-carboxamide;
N-(3-(4-(2,3-dimethylphenyl)piperazin-l-yl)-2-hydroxypropyl)-5-methyl- 1 ,2-diphenyl- lH-imidazole-4-carboxamide;
N-(3-(4-(2,3-dichlorophenyl)piperazin-l-yl)-2-hydroxypropyl)-5-methyl- l,2-diphenyl-lH-imidazole-4-carboxamide; N-(3-(4-(2,3-dichlorophenyl)piperazin-l-yl)-2-hydroxypropyl)-l-(4- fluorophenyl)-5-methyl-2-phenyl-lH-imidazole-4-carboxamide;
N-(3-(4-(2,3-dichlorophenyl)piperazin-l-yl)propyl)-5-methyl-l,2- diphenyl-lH-imidazole-4-carboxamide;
N-(3-(4-(2,3-dichlorophenyl)piperazin-l-yl)propyl)-l-(4-fluorophenyl)-5- methy 1-2-pheny 1- 1 H-imidazole-4-carboxamide;
N-(3-(4-(3-chloro-2-methylphenyl)piperazin-l-yl)-2-hydroxypropyl)-5- methy 1- 1 ,2-dipheny 1- 1 H-imidazole-4-carboxamide;
N-(3-(4-(3-chloro-2-methylphenyl)piperazin- 1 -yl)-2-hydroxypropyl)- 1 - (4-fluorophenyl)-5-methyl-2-propy 1-1 H-imidazole-4-carboxamide;
N-(3-(4-(3 -chloro-2-methy lphenyl)piperazin- 1 -y l)-2-hydroxypropyl)- 1 - (4-fluorophenyl)-2,5-dimethyl-lH-imidazole-4-carboxamide;
l-cyclopentyl-N-(3-(4-(2,3-dichlorophenyl)piperazin-l-yl)propyl)-2,5- dimethy 1-1 H-imidazole-4-carboxamide;
l-cyclopentyl-N-(3-(4-(2,3-dichlorophenyl)piperazin-l-yl)-2- hydroxypropyl)-2,5-dimethyl-lH-imidazole-4-carboxamide;
N-(3-(4-(2,3-dichlorophenyl)piperazin-l-yl)propyl)-2,5-dimethyl-l- propyl-1 H-imidazole-4-carboxamide;
N-(3-(4-(2,3-dichlorophenyl)piperazin-l-yl)-2-hydroxypropyl)-2,5- dimethyl- 1 -propyl- 1 H-imidazole-4-carboxamide;
N-(3-(4-(2,3-dimethylphenyl)piperazin-l-yl)propyl)-l-(2- methoxyphenyl)-5-methyl-2-propyl-lH-imidazole-4-carboxamide;
N-(3-(4-(3-chloro-2-methylphenyl)piperazin- 1 -yl)propyl)- 1 -(2- methoxyphenyl)-5-methyl-2-propyl-lH-imidazole-4-carboxamide;
N-(3-(4-(2,3-dichlorophenyl)piperazin- 1 -yl)propyl)- 1 -(2- methoxyphenyl)-5-methyl-2-propyl-lH-imidazole-4-carboxamide;
N-(3-(4-(2,3-dimethylphenyl)piperazin-l-yl)-2-hydroxypropyl)-l-(2- methoxyphenyl)-5-methyl-2-propyl-lH-imidazole-4-carboxamide;
N-(3-(4-(3-chloro-2-methylphenyl)piperazin-l-yl)-2-hydroxypropyl)-l- (2-methoxyphenyl)-5-methyl-2-propyl-l H-imidazole-4-carboxamide;
N-(3-(4-(2,3-dichlorophenyl)piperazin-l-yl)-2-hydroxypropyl)-l-(2- methoxyphenyl)-5-methyl-2-propyl-lH-imidazole-4-carboxamide;
N-(3-(4-(2,3-dimethylphenyl)piperazin-l-yl)propyl)-2,5-dimethyl-l-(2- (trifluoromethyl)phenyl)-l H-imidazole-4-carboxamide;
N-(3-(4-(3 -chloro-2-methy lphenyl)piperazin- 1 -yl)propy l)-2,5-dimethyl- 1 -
(2-(trifluoromethyl)phenyl)- 1 H-imidazole-4-carboxamide; N-(3-(4-(2,3-dichlorophenyl)piperazin-l-yl)propyl)-2,5-dimethyl-l-(2- (trifluoromethyl)phenyl)-lH-imidazole-4-carboxamide;
N-(3-(4-(3-chloro-2-methylphenyl)piperazin-l-yl)-2-hydroxypropyl)-2,5- dimethyl- 1 -(2-(trifluoromethyl)pheny I)- 1 H-imidazole-4-carboxamide;
N-(3-(4-(2,3-dichlorophenyl)piperazin-l-yl)-2-hydroxypropyl)-2,5- dimethy 1- 1 -(2-(trifluoromethyl)phenyl)- 1 H-imidazole-4-carboxamide;
N-(3-(4-(3-chloro-2-methylphenyl)piperazin- 1 -yl)-2-hydroxypropyl)- 1 - (4-methoxyphenyl)-5-methyl-2-propyl-lH-imidazole-4-carboxamide;
N-(3-(4-(3-chloro-2-methylphenyl)piperazin-l-yl)-2-hydroxypropy I)-I- (2-methoxyphenyl)-2,5-dimethyl- 1 H-imidazole-4-carboxamide;
N-(3-(4-(3-chloro-2-methylphenyl)piperazin- 1 -yl)-2-hydroxypropyl)- 1- (4-chlorophenyl)-2-propyl-/H-imidazole-4-carboxamide;
N-(3-(4-(3-chloro-2-methylphenyl)piperazin- 1 -yl)propyl)- 1 -(4- chlorophenyl)-2-propy 1-1 H-imidazole-4-carboxamide;
N-(3-(4-(3-chloro-2-methylphenyl)piperazin-l-yl)-2-hydroxypropyl)-l-
(2,3-dihydrobenzo[b][l,4]dioxin-6-yl)-2,5-dimethyl-lH-imidazole-4- carboxamide;
N-(3-(4-(3-chloro-2-methylphenyl)piperazin-l-yl)propyl)-l-(2,3- dihydrobenzo[b][l,4]dioxin-6-yl)-2,5-dimethyl-lH-imidazole-4-carboxamide;
l-(2,3-dihydrobenzo[b][l,4]dioxin-6-yl)-N-(3-(4-(2,3- dimethylphenyl)piperazin-l-yl)propyl)-5-methyl-2-propyl-lH-imidazole-4- carboxamide;
N-(3-(4-(2,3-dichIorophenyl)piperazin- 1 -y l)propyl)- 1 -(2,3- dihydrobenzo[b][l,4]dioxin-6-yl)-5-methyl-2-propyl-lH-imidazole-4- carboxamide;
N-(3-(4-(3 -chloro-2-methy lpheny l)piperazin- 1 -yl)propyl)-5 -methyl- 1 - pheny 1-2-propy 1- 1 H-imidazole-4-carboxamide;
N-(3-(4-(3-chloro-2-methylphenyl)piperazin-l-yl)-2-hydroxypropyl)-5- methy 1- 1 -phenyl-2-propy 1- lH-imidazole-4-carboxamide;
N-(3 -(4-(3-chloro-2-methy lpheny l)piperazin- 1 -yl)propy I)- 1 -(2,3 - dihydrobenzo[b][l,4]dioxin-6-yl)-5-methyl-2-propyl-lH-imidazole-4- carboxamide;
N-(3-(4-(3-chloro-2-methylphenyl)piperazin-l-yl)-2-hydroxypropyl)-l- (2,3-dihydrobenzo[ό][l,4]dioxin-6-yl)-5-methyl-2-propyl-lH-imidazole-4- carboxamide;
l-(2,3-dihydrobenzo[b][l,4]dioxin-6-yl)-N-(3-(4-(2,3- dimethylphenyl)piperazin-l-yl)-2-hydroxypropyl)-5-methyl-2-propyl-lH- imidazole-4-carboxamide;
N-(3-(4-(2,3-dichlorophenyl)piperazin-l-yl)-2-hydroxypropyl)-l-(2,3- dihydrobenzo[b][l,4]dioxin-6-yl)-5-methyl-2-propyl-lH-imidazole-4- carboxamide;
N-(3-(4-(2,3-dimethylphenyl)piperazin-l-yl)propyl)-l-(4-fluorophenyl)- 5-methyl-2-propyl-lH-imidazole-4-carboxamide;
N-(3-(4-(2,3-dichlorophenyl)piperazin- 1 -yl)propy I)- 1 -(4-fluoropheny l)-5- methyl-2-propyl-lH-imidazole-4-carboxamide;
N-(3-(4-(2,3-dimethylphenyl)piperazin- 1 -yl)-2-hydroxypropyl)- 1 -(4- fluoropheny l)-5-methy 1-2-propy 1- 1 H-imidazole-4-carboxamide;
N-(3-(4-(2,3-dichlorophenyl)piperazin-l-yl)-2-hydroxypropyl)-l-(4- fluorophenyl)-5-methyl-2-propyl-lH-imidazole-4-carboxamide;
N-(3-(4-(3-chloro-2-methylphenyl)piperazin- 1 -yl)propyl)- 1 -(4- fluorophenyl)-2,5-dimethyl-lH-imidazole-4-carboxamide;
N-(3-(4-(3-chloro-2-methylphenyl)piperazin-l-yl)propyl)-l-(4- fluorophenyl)-5-methyl-2-propyl-lH-imidazole-4-carboxamide;
N-(3-(4-(2,3-dichlorophenyl)piperazin-l-yl)-2-hydroxypropyl)-l-(2- fluorophenyl)-2,5-dimethyl-l H-imidazole-4-carboxamide;
l-(2-chlorophenyl)-Ν-(3-(4-(2,3-dimethylphenyl)piperazin-l-yl)-2- hydroxypropyl)-5-methyl-2-propyl-lH-imidazole-4-carboxamide;
l-(2-chlorophenyl)-N-(3-(4-(2,3-dimethylphenyl)piperazin-l-yl)propyl)- 5-methyl-2-propyl-lH-imidazole-4-carboxamide;
(R)-N-(3-(4-(3-chloro-2-methylphenyl)piperazin-l-yl)-2-hydroxypropyl)- l-(4-fluorophenyl)-5-methyl-2-phenyl-lH-imidazole-4-carboxamide;
(R)-l-(4-chlorophenyl)-N-(3-(4-(2,3-dichlorophenyl)piperazin-l-yl)-2- hydroxypropyl)-2-propy 1-1 H-imidazole-4-carboxamide;
N-(3-(4-(3-chloro-2-methylphenyl)piperazin- 1 -yl)propyl)- 1 -(2- chlorophenyl)-2,5-dimethy 1-1 H-imidazole-4-carboxamide;
N-(3-(4-(3-chloro-2-methylphenyl)piperazin- 1 -yl)-2-hydroxypropyl)- 1 -
(2-fluorophenyl)-2,5-dimethyl-lH-imidazole-4-carboxamide;
N-(3-(4-(3-chloro-2-methylphenyl)piperazin-l-yl)-2-hydroxypropyl)-l- (4-methoxyphenyl)-2,5-dimethyl-lH-imidazole-4-carboxamide;
N-(3-(4-(2,3-dimethylphenyl)piperazin-l-yl)propyl)-l-(4- methoxyphenyl)-5-methyl-2-phenyl-lH-imidazole-4-carboxamide;
N-(3-(4-(3-chloro-2-methylphenyl)piperazin-l-yl)propyl)-l-(4- methoxyphenyl)-5-methyl-2-phenyl-lH-imidazole-4-carboxamide;
N-(3-(4-(2,3-dichloropheny I)piperazin- 1 -yl)propyl)- 1 -(4- methoxyphenyl)-5-methyl-2-phenyl-lH-imidazole-4-carboxamide;
N-(3-(4-(2,3-dimethylphenyl)piperazin-l-yl)-2-hydroxypropyl)-l-(4- methoxyphenyl)-5-methyl-2-phenyl- lH-imidazole-4-carboxamide;
N-(3-(4-(3-chloro-2-methylphenyl)piperazin-l-yl)-2-hydroxypropyl)-l- (4-methoxyphenyl)-5-methyl-2-phenyl-lH-imidazole-4-carboxamide;
N-(3-(4-(2,3-dichlorophenyl)piperazin-l-yl)-2-hydroxypropyl)-l-(4- methoxyphenyl)-5-methyl-2-phenyl-lH-imidazole-4-carboxamide;
1 -(2,3-dihydrobenzo[b] [ 1 ,4]dioxin-6-yl)-N-(3-(4-(2,3- dimethylphenyl)piperazin-l-yl)propyl)-5-methyl-2-phenyl-lH-imidazole-4- carboxamide;
N-(3-(4-(3-chloro-2-methylphenyl)piperazin-l-yl)propyl)-l-(2,3- dihydrobenzo[b][l,4]dioxin-6-yl)-5-methyl-2-phenyl-lH-imidazole-4- carboxamide;
N-(3-(4-(2,3-dichlorophenyl)piperazin-l-yl)propyl)-l-(2,3- dihydrobenzo[b][l,4]dioxin-6-yl)-5-methyl-2-phenyl-lH-imidazole-4- carboxamide;
l-(2,3-dihydrobenzo[b][l,4]dioxin-6-yl)-N-(3-(4-(2,3- dimethylphenyl)piperazin-l-yl)-2-hydroxypropyl)-5-methyl-2-phenyl-lH- imidazole-4-carboxamide;
N-(3-(4-(3-chloro-2-methylphenyl)piperazin-l-yl)-2-hydroxypropyl)-l- (2,3-dihydrobenzo[b][l,4]dioxin-6-yl)-5-methyl-2-phenyl-lH-imidazole-4- carboxamide;
N-(3-(4-(2,3-dichlorophenyl)piperazin-l-yl)-2-hydroxypropyl)-l-(2,3- dihydrobenzo[b][l,4]dioxin-6-yl)-5-methyl-2-phenyl-lH-imidazole-4- carboxamide;
l-(benzo[^][l,3]dioxol-5-yl)-N-(3-(4-(3-chloro-2- methylphenyl)piperazin- 1 -yl)propyl)-2,5-dimethyl- lH-imidazole-4-carboxamide;
l-(benzo[flG[l,3]dioxol-5-yl)-N-(3-(4-(3-chloro-2- methylphenyl)piperazin-l-yl)propyl)-5-methyl-2-propyl-lH-imidazole-4- carboxamide;
N-(3-(4-(2,3-dimethylphenyl)piperazin-l-yl)propyl)-2,5-dimethyl-l-o- tolyl-lH-imidazole-4-carboxamide;
N-(3-(4-(3-chloro-2-methylphenyl)piperazin-l-yl)propyl)-2,5-dimethyl- l- o-toly 1- 1 H-imidazole-4-carboxamide; N-(3-(4-(2,3-dichlorophenyl)piperazin- 1 -yl)propyl)-2,5-dimethyl- 1 -o- tolyl- 1 H-imidazole-4-carboxamide;
N-(3-(4-(2,3-dimethylphenyl)piperazin-l-yl)-2-hydroxypropyl)-2,5- dimethyl-l-o-tolyl-lH-imidazole-4-carboxamide;
N-(3-(4-(3-chloro-2-methylphenyl)piperazin- 1 -yl)-2-hydroxypropy l)-2,5- dimethyl-l-o-tolyl-1 H-imidazole-4-carboxamide;
N-(3-(4-(2,3-dichlorophenyl)piperazin-l-yl)-2-hydroxypropyl)-2,5- dimethyl- 1 -o-tolyl- lH-imidazole-4-carboxamide;
N-(3-(4-(3-chloro-2-methylphenyl)piperazin- 1 -yl)propyl)- 1 -(4- chlorophenyl)-2,5-dimethyl- 1 H-imidazole-4-carboxamide;
l-(4-chlorophenyl)-N-(3-(4-(2,3-dimethylphenyl)piperazin-l-yl)-2- hydroxypropyl)-2,5-dimethyl-l H-imidazole-4-carboxamide;
N-(3-(4-(3-chloro-2-methylphenyl)piperazin-l-yl)-2-hydroxypropyl)-l- (4-chlorophenyl)-2,5-dimethyl-lH-imidazole-4-carboxamide;
l-(4-chlorophenyl)-N-(3-(4-(2,3-dichlorophenyl)piperazin-l-yl)-2- hydroxypropyl)-2,5-dimethyl-lH-imidazole-4-carboxamide;
l-(4-chlorophenyl)-N-(3-(4-(2,3-dimethylphenyl)piperazin-l-yl)propyl)- 5-methyl-2-propy 1-1 H-imidazole-4-carboxamide;
N-(3-(4-(3-chloro-2-methylphenyl)piperazin-l-yl)propyl)-l-(4- chlorophenyl)-5-methyl-2-propyl-lH-imidazole-4-carboxamide;
l-(4-chlorophenyl)-N-(3-(4-(2,3-dichlorophenyl)piperazin-l-yl)propyl)-5- methyl-2-propyl-l H-imidazole-4-carboxamide;
l-(4-chlorophenyl)-N-(3-(4-(2,3-dimethylphenyl)piperazin-l-yl)-2- hydroxypropyl)-5-methyl-2-propyl-lH-imidazole-4-carboxamide;
N-(3-(4-(3-chloro-2-methylphenyl)piperazin- 1 -yl)-2-hydroxypropyl)- 1 -
(4-chlorophenyl)-5-methyl-2-propyl-lH-imidazole-4-carboxamide;
l-(4-chlorophenyl)-N-(3-(4-(2,3-dichlorophenyl)piperazin-l-yl)-2- hydroxypropyl)-5-methyl-2-propyl-lH-imidazole-4-carboxamide;
l-(2-chlorophenyl)-N-(3-(4-(2,3-dichlorophenyl)piperazin-l-yl)-2- hydroxypropyl)-5-methyl-2-propyl- lH-imidazole-4-carboxamide;
l-(2-chlorophenyl)-N-(3-(4-(2,3-dichlorophenyl)piperazin-l-yl)propyl)- 2,5-dimethyl-lH-imidazole-4-carboxamide;
l-(2-chlorophenyl)-N-(3-(4-(2,3-dichlorophenyl)piperazin-l-yl)-2- hydroxypropyl)-2,5-dimethyl-lH-imidazole-4-carboxamide;
N-(3-(4-(3-chloro-2-methylphenyl)piperazin-l-yl)propyl)-l-(2- fluorophenyl)-5-methyl-2-propyl-lH-imidazole-4-carboxamide; N-(3-(4-(2,3-dimethylphenyl)piperazin- 1 -yl)propyl)- 1 -(2- methoxyphenyl)-5-methyl-2-phenyl-lH-imidazole-4-carboxamide;
N-(3-(4-(3-chloro-2-methylphenyl)piperazin-l-yl)propyl)-l-(2- methoxyphenyl)-5-methyl-2-phenyl-lH-imidazole-4-carboxamide;
N-(3-(4-(2,3-dichlorophenyl)piperazin- 1 -yl)propyl)- 1 -(2- methoxyphenyl)-5-methyl-2-phenyl-lH-imidazole-4-carboxamide;
N-(3-(4-(2,3-dimethylphenyl)piperazin-l-yl)propyl)-l-(2-fluorophenyl)- 5-methyl-2-propyl-lH-imidazole-4-carboxamide;
N-(3-(4-(2,3-dimethylphenyl)piperazin-l-yl)-2-hydroxypropyl)-l-(2- fluorophenyl)-5-methyl-2-propyl- lH-imidazole-4-carboxamide;
N-(3-(4-(2,3-dichlorophenyl)piperazin-l-yl)-2-hydroxypropyl)-l-(2- fluorophenyl)-5-methyl-2-propyl-lH-imidazole-4-carboxamide;
N-(3-(4-(2,3-dimethylphenyl)piperazin-l-yl)propyl)-5-methyl-2-propyl-l- o-tolyl-lH-imidazole-4-carboxamide;
N-(3-(4-(3-chloro-2-methylphenyl)piperazin- 1 -yl)propyl)-5-methyl-2- propyl-l-o-tolyl-lH-imidazole-4-carboxamide;
N-(3-(4-(2,3-dichlorophenyl)piperazin-l-yl)propyl)-5-methyl-2-propyl-l- o-tolyl-lH-imidazole-4-carboxamide;
l-(4-chlorophenyl)-N-(3-(4-(2,3-dimethylphenyl)piperazin-l-yl)propyl)- 5-methyl-2-phenyl- lH-imidazole-4-carboxamide;
N-(3-(4-(3-chloro-2-methylphenyl)piperazin- 1 -yl)propyl)- 1 -(4- chlorophenyl)-5-methyl-2-phenyl-lH-imidazole-4-carboxamide;
l-(4-chlorophenyl)-N-(3-(4-(2,3-dichlorophenyl)piperazin-l-yl)propyl)-5- methyl-2-phenyl-lH-imidazole-4-carboxamide;
l-(4-chlorophenyl)-N-(3-(4-(2,3-dimethylphenyl)piperazin-l-yl)-2- hydroxypropyl)-5-methyl-2-phenyl-lH-imidazole-4-carboxamide;
N-(3-(4-(3-chloro-2-methylphenyl)piperazin-l-yl)-2-hydroxypropyl)- l- (4-chlorophenyl)-5-methyl-2-phenyl-lH-imidazole-4-carboxamide;
l-(4-chlorophenyl)-N-(3-(4-(2,3-dichlorophenyl)piperazin-l-yl)-2- hydroxypropyl)-5-methyl-2-phenyl- lH-imidazole-4-carboxamide;
l-(benzo[β?][l,3]dioxol-5-yl)-N-(3-(4-(2,3-dichlorophenyl)piperazin-l- yl)propyl)-2,5-dimethyl-lH-imidazole-4-carboxamide;
l-(benzo[^][l,3]dioxol-5-yl)-N-(3-(4-(2,3-dichlorophenyl)piperazin-l- yl)-2-hydroxypropyl)-2,5-dimethyl-lH-imidazole-4-carboxamide;
l-(benzo[ύG[l,3]dioxol-5-yl)-N-(3-(4-(2,3-dimethylphenyl)piperazin-l- yl)propyl)-5-methyl-2-propyl-lH-imidazole-4-carboxamide; 1 -(benzol [ 1 ,3]dioxol-5-yl)-N-(3-(4-(2,3-dichlorophenyl)piperazin- 1 - yl)propyl)-5-methyl-2-propyl-lH-imidazole-4-carboxamide;
l-(benzo[αf][l,3]dioxol-5-yl)-N-(3-(4-(2,3-dimethylphenyl)piperazin-l- yl)-2-hydroxypropyl)-5-methyl-2-propyl-lH-imidazole-4-carboxamide;
l-(benzo[cf][l,3]dioxol-5-yl)-N-(3-(4-(2,3-dichlorophenyl)piperazin-l- yl)-2-hydroxypropyl)-5-methyl-2-propyl-lH-imidazole-4-carboxamide;
N-(3-(4-(3-chloro-2-methylpheny l)piperazin- 1 -yl)propy l)-2,5-dimethyl- 1 - /Molyl-lH-imidazole^-carboxamide;
N-(3-(4-(2,3-dimethylphenyl)piperazin-l-yl)propyl)-5-methyl-2-propyl-l- p-to\y\- lH-imidazole-4-carboxamide;
N-(3-(4-(3-chloro-2-methylphenyl)piperazin-l-yl)propyl)-5-methyl-2- propyl-l-p-tolyl-lH-imidazole-4-carboxamide;
N-(3-(4-(2,3-dimethylphenyl)piperazin-l-yl)-2-hydroxypropyl)-l-(2- methoxyphenyl)-5-methyl-2-phenyl-lH-imidazole-4-carboxamide;
N-(3-(4-(3-chloro-2-methylphenyl)piperazin-l-yl)-2-hydroxypropyl)-l-
(2-methoxyphenyl)-5-methyl-2-phenyl-lH-imidazole-4-carboxamide;
N-(3-(4-(2,3-dichloropheny l)piperazin- 1 -yl)-2-hydroxypropyl)- 1 -(2- methoxyphenyl)-5-methyl-2-phenyl-lH-imidazole-4-carboxamide;
l-(benzo[fif][l,3]dioxoI-5-yl)-N-(3-(4-(2,3-dimethylphenyl)piperazin-l- yl)propyl)-5-methyl-2-phenyl- lH-imidazole-4-carboxamide;
1 -(benzo[</) [l,3]dioxol-5-yl)-N-(3-(4-(3-chloro-2- methylphenyl)piperazin- 1 -yl)propy l)-5-methyl-2-phenyl- lH-imidazole-4- carboxamide;
l-(benzo[<i][l,3]dioxol-5-yl)-N-(3-(4-(2,3-dichlorophenyl)piperazin-l- yl)propyl)-5-methyl-2-phenyl- lH-imidazole-4-carboxamide;
l-(benzo[αTl[l,3]dioxol-5-yl)-N-(3-(4-(2,3-dimethylphenyl)piperazin-l- yl)-2-hydroxypropyl)-5-methyl-2-phenyl-lH-imidazole-4-carboxamide;
l-(benzo[f/][l,3]dioxol-5-yl)-N-(3-(4-(3-chloro-2- methylphenyl)piperazin-l-yl)-2-hydroxypropyl)-5-methyl-2-phenyl-lH- imidazole-4-carboxamide;
l-(benzo[cT|[l,3]dioxol-5-yl)-N-(3-(4-(2,3-dichlorophenyl)piperazin-l- yl)-2-hydroxypropyl)-5-methyl-2-phenyl-lH-imidazole-4-carboxamide;
N-(3-(4-(2,3-dimethylphenyl)piperazin-l-yl)propyl)-l-(2-fluorophenyl)- 5-methyl-2-phenyl- IH- imidazole-4-carboxamide;
N-(3-(4-(3-chloro-2-methylphenyl)piperazin-l-yl)propyl)-l-(2- fluorophenyl)-5-methyl-2-phenyl-lH-imidazole-4-carboxamide; N-(3-(4-(2,3-dichlorophenyl)piperazin-l-yl)propyl)-l-(2-fluorophenyl)-5- methy 1-2-pheny 1- 1 H-imidazole-4-carboxamide;
N-(3-(4-(2,3-dimethylphenyl)piperazin-l-yl)-2-hydroxypropyl)-l-(2- fluorophenyl)-5-methyl-2-phenyl-l H-imidazole-4-carboxamide;
N-(3-(4-(3-chloro-2-methylphenyl)piperazin- 1 -y l)-2-hydroxypropyl)- 1 -
(2-fluorophenyl)-5-methyl-2-phenyl-lH-imidazole-4-carboxamide;
N-(3-(4-(2,3-dichlorophenyl)piperazin-l-yl)-2-hydroxypropyl)-l-(2- fluorophenyl)-5-methyl-2-phenyl-lH-imidazole-4-carboxamide;
N-(3-(4-(2,3-dichlorophenyl)piperazin-l-yl)propyl)-5-methyl-2-propyl-l- /?-tolyl- 1 H-imidazole-4-carboxamide;
l-(benzo[^[l,3]dioxol-5-yl)-N-(3-(4-(3-chloro-2- methylphenyl)piperazin-l-yl)-2-hydroxypropyl)-2,5-dimethyl-lH-imidazole-4- carboxamide;
l-(benzo[J][l,3]dioxol-5-yl)-N-(3-(4-(3-chloro-2- methylphenyl)piperazin-l-yl)-2-hydroxypropyl)-5-methyl-2-propyl-lH- imidazole-4-carboxamide;
N-(3-(4-(3-chloro-2-methylphenyl)piperazin-l-yl)-2-hydroxypropyl)-2,5- dimethyl- 1 -p-tolyl- 1 H-imidazole-4-carboxamide;
N-(3-(4-(2,3-dimethylphenyl)piperazin-l-yl)-2-hydroxypropyl)-5-methyl- 2-propy 1- 1 -/7-toly 1- 1 H-imidazole-4-carboxamide;
N-(3-(4-(3-chloro-2-methylphenyl)piperazin-l-yl)-2-hydroxypropyl)-5- methyl-2-propyl- 1 -p-tolyl- 1 H-imidazole-4-carboxamide;
N-(3-(4-(2,3-dichlorophenyl)piperazin-.l-yl)-2-hydroxypropyl)-5-methyl- 2-propyl-l-p-tolyl-l H-imidazole-4-carboxamide;
N-(3-(4-(2,3-dimethylphenyl)piperazin- 1 -yl)propyl)-5-methyl-2-pheny 1-
1 -p-toly 1- 1 H-imidazole-4-carboxamide;
N-(3-(4-(3-chloro-2-methylphenyl)piperazin-l-yl)-2-hydroxypropyl)-5- methyl-2-phenyl- 1 -jo-tolyl- 1 H-imidazole-4-carboxamide;
N-(3-(4-(2,3-dichlorophenyI)piperazin-l-yl)propyl)-5-methyl-2-phenyl-l- /?-tolyl- 1 H-imidazole-4-carboxamide;
N-(3-(4-(2,3-dimethylphenyl)piperazin-l-yl)-2-hydroxypropyl)-5-methyl- 2-phenyl- 1 -p-tolyl- 1 H-imidazole-4-carboxamide;
N-(3-(4-(2,3-dichlorophenyl)piperazin-l-yl)-2-hydroxypropyl)-5-methyl- 2-phenyl-l-/?-tolyl-l H-imidazole-4-carboxamide;
N-(3-(4-(3-chloro-2-methylphenyl)piperazin- 1 -y l)-2-hydroxypropyl)- 1 -
(2-chlorophenyl)-2,5-dimethyl-lH-imidazole-4-carboxamide; 1 -(2-chlorophenyl)-N-(3-(4-(2,3-dimethylphenyl)piperazin- 1 -yl)propy I)- 5-methyl-2-phenyl- lH-imidazole-4-carboxamide;
N-(3-(4-(3-chloro-2-methylphenyl)piperazin- 1 -yl)propy I)- 1 -(2- chlorophenyl)-5-methyl-2-phenyl-lH-imidazole-4-carboxamide;
l-(2-chlorophenyl)-N-(3-(4-(2,3-dichlorophenyl)piperazin- l-yl)propyl)-5- methyl-2-phenyl-lH-imidazole-4-carboxamide;
l-(2-chlorophenyl)-N-(3-(4-(2,3-dimethylphenyl)piperazin-l-yl)-2- hydroxypropyl)-5-methyl-2-phenyl-lH-imidazole-4-carboxamide;
N-(3-(4-(3-chloro-2-methylphenyl)piperazin-l-yl)-2-hydroxypropyl)-l- (2-chlorophenyl)-5-methyl-2-phenyl-lH-imidazole-4-carboxamide;
l-(2-chlorophenyl)-N-(3-(4-(2,3-dichlorophenyl)piperazin-l-yl)-2- hydroxypropyl)-5-methyl-2-phenyl-lH-imidazole-4-carboxamide;
N-(3-(4-(2,3-dimethylphenyl)piperazin-l-yl)propyl)-5-methyl-2-phenyl- l-o-tolyl-lH-imidazole-4-carboxamide;
N-(3-(4-(3-chloro-2-methylphenyl)piperazin- 1 -yl)propyl)-5-methyl-2- phenyl-l-o-tolyl-lH-imidazole-4-carboxamide;
N-(3-(4-(2,3-dichlorophenyl)piperazin-l-yl)propyl)-5-methyl-2-phenyl-l- o-tolyl-lH-imidazole-4-carboxamide;
N-(3-(4-(2,3-dimethylphenyl)piperazin-l-yl)-2-hydroxypropyl)-5-methyl- 2-phenyl-l-o-tolyl-lH-imidazole-4-carboxamide;
N-(3-(4-(3-chloro-2-methylphenyl)piperazin-l-yl)-2-hydroxypropyl)-5- methyl-2-phenyl-l-o-tolyl-lH-imidazole-4-carboxamide;
N-(3-(4-(2,3-dichlorophenyl)piperazin-l-yl)-2-hydroxypropyl)-5-methyl- 2-phenyl-l-o-tolyl-lH-imidazole-4-carboxamide;
N-(3-(4-(3-chloro-2-methylpheny l)piperazin- 1 -yl)-2-hydroxypropyl)-2,5- dimethy 1- 1 -(4-(trifluoromethy l)pheny I)- 1 H-imidazole-4-carboxamide;
N-(3-(4-(3-chloro-2-methylphenyl)piperazin-l-yl)propyl)-2,5-dimethyl-l- (4-(trifluoromethyl)pheny I)-I H-imidazole-4-carboxamide;
N-(3-(4-(3-chloro-2-methylphenyl)piperazin-l-yl)propyl)-5-methyl-2- phenyl- 1 -p-tolyl- 1 H-imidazole-4-carboxamide;
N-(3-(4-(3-chloro-2-methylphenyl)piperazin-l-yl)propyl)-N,5-dimethyl- 1 ,2-diphenyl- 1 H-imidazole-4-carboxamide;
N-(3-(4-(2,3-dichlorophenyl)piperazin- 1 -yl)propyl)-N,5-dimethyl- 1 ,2- diphenyl- 1 H-imidazole-4-carboxamide;
N-(3-(4-(2,3-dimethylphenyl)piperazin- 1 -yl)propyl)-N,5-dimethy 1- 1 ,2- diphenyl- lH-imidazole-4-carboxamide; N-(3-(4-(3-chloro-2-methylphenyl)piperazin-l-yl)propyl)-l-cyclopentyl- N,2,5-trimethyl-lH-imidazole-4-carboxamide;
l-cyclopentyl-N-(3-(4-(2,3-dichlorophenyl)piperazin-l-yl)propyl)-N,2,5- trimethyl-lH-imidazole-4-carboxamide;
l-cyclopentyl-N-(3-(4-(2,3-dimethylphenyl)piperazin-l-yl)propyl)-N,2,5- trimethyl-lH-imidazole-4-carboxamide;
N-(3-(4-(2,3-dimethylphenyl)piperazin- 1 -yl)propy I)- 1 -(4- methoxyphenyl)-N,5-dimethyl-2-phenyl-lH-imidazole-4-carboxamide;
l-(3-chlorophenyl)-N-(3-(4-(2,3-dimethylphenyl)piperazin-l-yl)propyl)- N,2,5-trimethyl-lH-imidazole-4-carboxamide;
N-(3-(4-(3-chloro-2-methylphenyl)piperazin-l-yl)propyl)-l-(4- methoxyphenyl)-N,5-dimethyl-2-phenyl-lH-imidazole-4-carboxamide;
N-(3-(4-(3-chloro-2-methylphenyl)piperazin- 1 -yl)propyl)- 1 -(3- chlorophenyl)-N,2,5-trimethyl-lH-imidazole-4-carboxamide;
l-(2-chlorophenyl)-N-(3-(4-(2,3-dimethylphenyl)piperazin-l-yl)propyl)-
N,2,5-trimethyl-lH-imidazole-4-carboxamide;
N-(3-(4-(3-chloro-2-methylphenyl)piperazin-l-yl)propyl)-l-(2- chlorophenyl)-N,2,5-trimethyl-lH-imidazole-4-carboxamide;
l-(2-chlorophenyl)-N-(3-(4-(2,3-dichlorophenyl)piperazin-l-yl)propyl)- N,2,5-trimethyl- lH-imidazole-4-carboxamide;
N-(3-(4-(2,3-dimethylphenyl)piperazin- 1 -yl)propy l)-N,2,5-trimethyl- 1 - phenyl- lH-imidazole-4-carboxamide;
N-(3-(4-(3-chloro-2-methylphenyl)piperazin-l-yl)propyl)-N,2,5- trimethyl- 1 -phenyl- lH-imidazole-4-carboxamide;
N-(3-(4-(2,3-dichlorophenyl)piperazin- 1 -yl)propyl)-N,2,5-trimethyl- 1 - phenyl- lH-imidazole-4-carboxamide;
N-(3-(4-(2,3-dimethylphenyl)piperazin-l-yl)propyl)-l-(4-fluorophenyl)- N,5-dimethyl-2-phenyl-lH-imidazole-4-carboxamide;
N-(3 -(4-(3 -chloro-2-methylphenyl)piperazin- 1 -y l)propy I)- 1 -(4- fluorophenyl)-N,5-dimethyl-2-phenyl-lH-imidazole-4-carboxamide;
N-(3-(4-(2,3-dichlorophenyl)piperazin-l-yl)propyl)-l-(4-fluorophenyl)- N,5-dimethyl-2-phenyl-lH-imidazole-4-carboxamide;
l-(2,3-dihydrobenzo[b][l,4]dioxin-6-yl)-N-(3-(4-(2,3- dimethylphenyl)piperazin-l-yl)propy I)-N, 5-dimethyl-2-pheny 1-1 H-imidazole-4- carboxamide;
N-(3 -(4-(3 -chloro-2-methy lpheny l)piperazin- 1 -y l)propy I)- 1 -(2,3 - dihydrobenzo[b][l,4]dioxin-6-yl)-N,5-dimethyl-2-phenyl-lH-imidazole-4- carboxamide
N-(3-(4-(2,3-dichlorophenyl)piperazin-l-yl)propyl)-l-(2,3- dihydrobenzo[ό][l,4]dioxin-6-yl)-N,5-dimethyl-2-phenyl-lH-imidazole-4- carboxamide;
(R)- 1 -(2,3-dihydrobenzo[b] [ 1 ,4]dioxin-6-yl)-N-(3-(4-(2,3- dimethylphenyl)piperazin-l-yl)-2-hydroxypropyl)-2,5-dimethyl-lH-imidazole-4- carboxamide;
(R)-N-(3-(4-(3-chloro-2-methylphenyl)piperazin-l-yl)-2-hydroxypropyl)- l-(2,3-dihydrobenzo[b][ l,4]dioxin-6-yl)-2,5-dimethyl-lH-imidazole-4- carboxamide; and
(i?)-N-(3-(4-(2,3-dichlorophenyl)piperazin-l-yl)-2-hydroxypropy I)-I- (2,3-dihydrobenzo[b][l,4]dioxin-6-yl)-2,5-dimethyl-lH-imidazole-4-carboxamide. GENERAL SYNTHETIC SEQUENCE
The following synthetic schemes are merely illustrative of the methods by which the compounds of the invention may be prepared and are not intended to limit the scope of the invention as defined in the appended claims.
The imidazole derivative (6) is prepared by a conventional method [Bayer Pharmaceuticals, WO 03/040107, 2003], for example, by subjecting a nitrile (2) to a reaction with an aniline derivative (1) using aluminum chloride to produce N- (4-chlorophenyl)-butyrimidamide (3). Subsequent reaction of the resulting compound (3) with ethyl 3-bromo-2-oxopropanoate (4) provides an intermediate ethyl l-(4-chlorophenyl)-2-propyl-lH-imidazole-4-carboxylate (5). An acid form (6) is prepared from the ester (5) using lithium hydroxide, followed by acidification, as shown in Reaction Scheme 1. Reaction Scheme 1
Figure imgf000031_0001
Figure imgf000031_0002
A compound (7) is subjected to a reaction with sodium nitrite in acetic acid to give ethyl 2-(hydroxyimino)-3-oxobutanoate (8) in 70% yield. The compound (8) is subjected to a reaction with an anhydride such as acetic anhydride (9) in the presence of a reducing agent such as hydrogen and a catalyst such as Pd on carbon (Pd/C) in EtOH to give an amide (10) [Lange, J. H. M. et al.
US 2006/0194779, 2006]. The amide (10) is subjected to a reaction with an amine such as aniline (Ha or lib) in an inert solvent such as acetonitrile under microwave irradiation to obtain an imidazole derivative (12a or 12b). Hydrolysis of the imidazole derivative (12a or 12b) with lithium hydroxide produces a compound (13a or 13b) as shown in Reaction Scheme 2.
Reaction Scheme 2
Figure imgf000032_0001
8 10
Figure imgf000032_0002
1400C, 40 min, 76 % 12a 13a
Figure imgf000032_0003
140 0C, 40 min, 76 % 12b 13b
Another approach toward imidazole intermediate is described in Reaction Scheme 3. The original reaction sequence was published by F. Hoffmann-La Roche AG [F. Hoffmann-La Roche AG, WO 2005/0031 17, 2005]. N- acetylglycine (14) and phosphorous oxychloride are mixed and dimethylacetamide is added thereto dropwise slowly at low temperature (exothermic). The reaction mixture is then stirred and warmed at 45 °C . In this way, (E)-4-(l-(dimethylamino)ethylidene)-2-methyloxazol-5(4H)-one (15) is generated in 50% yield. The oxazolone (15) is cleaved with in situ generated ethoxide to produce (E)-ethyl 2-acetamido-3-(dimethylamino)but-2-enoate (16). Next, an amine (17) is subjected to a reaction with the compound (16) in acetic acid at rt overnight to give a Michael adduct (18). The crude intermediate (18) is then refluxed together with fine powdered ammonium sulfate in hexamethyldisilazane at 145 °C to provide the corresponding imidazole ester (19) in 55-73% yield for the three steps from the oxazolone (15). The imidazole ester (19) is hydrolyzed with sodium hydroxide to produce the corresponding sodium carboxylate (20) uneventfully.
Reaction Scheme 3
Figure imgf000033_0001
14 (50%) 15 16
Figure imgf000033_0002
18 19 20
R: c-pentyl, i-Bu, n-Pr
(73%, 61%, 55%)
An imidazole acid derivative (25) is synthesized by adopting a known method [Lange, J. H. M., et al. J. Med. Chem. 2005, 48, 1823-1838; and Kim, J.
Y., et al. Bioorg. Med. Chem. Lett. 2009, 19, 142-145]. Thus, benzonitrile (21) is subjected to a reaction with aniline (Ha) in the presence of sodium bis(trimethylsilyl)amide (NaHMDS) to produce a corresponding arylbenzamidine
(22). Subsequent reaction of the resulting arylbenzamidine (22) with α- bromoketone (23) generates an intermediate ethyl 5 -methyl- 1,2-diphenyl- IH- imidazole-4-carboxylate (24) in 55% yield. Hydrolysis of the ester (24) with lithium hydroxide produces the corresponding lithium carboxylate (25) as shown in Reaction Scheme 4, Reaction Scheme 4
Figure imgf000034_0001
21 11a 22 23
Figure imgf000034_0002
24 25
N-arylpiperazine (28) is prepared via condensation of the requisite aniline such as 3-chloro-2-methylaniline (26) with bis(2-chloroethyl)amine (27), following a reported procedure [Martin, G. E., et al. J. Med. Chem. 1989, 32, 1052-1056] as shown in Reaction Scheme 5.
Reaction Scheme 5
Figure imgf000034_0003
26 28
Next, 8-(piperazin-l-yl)quinoline (33) is prepared as depicted in Reaction Scheme 6 [Zhou, D., et al, Bioorg. Med. Chem. 2008, 16, 6707-6723]. Reaction of commercially available 8-hydroxyquinoline (29) with trifluoromethanesulfonic anhydride (triflic anhydride) in the presence of a base produces the corresponding triflate (30). Buchwald coupling [Buchwald, S. L., et al J. Am. Chem. Soc. 1998, 120, 4960] between quinolin-8-yl trifluoromethanesulfonate (30) and \-tert- butyl-4-piperazine carboxylate (31) affords compound (32) in 72% yield for the two steps. Deprotection of Boc group of the compound (32) using HCl in refluxed methanol produces quinolinyl piperazine (33). Reaction Scheme 6
HCI, MeOH
reflux
Figure imgf000035_0001
(quantatively)
Figure imgf000035_0002
29 30 32 33 As shown in Reaction Scheme 7, the synthesis of 3-(4-(2,3- dichlorophenyl)piperazin-l-yl)propan-l -amine (37), and the like, wherein the alkyl chain between the piperazine and the terminal amine corresponds to two carbons through four carbons, commences with N-(2-bromoethyl)phthalimide, N- (3-bromopropyl)phthalimide (34), and N-(4-bromobutyl)phthalimide by adopting a reported procedure [Robarge, M. J., et al. J. Med. Chem. 2001, 44, 3175-3186]. For example, N-(3-bromopropyl)phthalimide (34) is subjected to a reaction with l-(2,3-dichlorophenyl)piperazine (35) in the presence of potassium carbonate in a suitable solvent such as dimethylformamide (DMF) at room temperature affords the corresponding alkylated compound (36) in 80% yield. Hydazinolysis of the compound (36), followed by treatment of HCl solution generates 3-(4-(2,3- dichlorophenyl)piperazin-l-yl)propan-l -amine as a HCl salt form (37) in 76% yield.
Reaction Scheme 7
Figure imgf000035_0003
In order to increase hydrophilicity for compounds such as 3-(4-(2,3- dichlorophenyl)piperazin-l-yl)propan-l -amine (37), a compound such as 1- amino-3-(4-(2,3-dichlorophenyl)piperazin-l-yl)propan-2-ol (40) is prepared as shown in Reaction Scheme 8. Thus, commercially available N-(2,3- epoxypropyl)phthalimide (38) is treated with l-(2,3-dichlorophenyl)piperazine (35) in the presence of a base such as triethylamine in a suitable solvent such as tetrahydrofuran (THF) at 800C to produce the alcohol (39) in about 91% yield. Subsequently, hydrazinolysis of the alcohol (39) generates l-amino-3-(4-(2,3- dichlorophenyl)piperazin-l-yl)propan-2-ol (40) as a white solid in 95% yield.
Reaction Scheme 8
Figure imgf000036_0001
Another variation involves difluorination for compounds such as 3-(4- (2,3-dichlorophenyl)piperazin-l-yl)propan-l -amine (37) as demonstrated in Reaction Scheme 9. Thus, the alcohol (39) generated in Reaction Scheme 8 is oxidized using Swern oxidation conditions to provide the corresponding ketone (41) in 89% yield. Treatment of ketone (41) with diethylaminosulfur trifluoride (DAST) give the corresponding difluoride (42) in 21% yield. Treatment of the difluoride (42) with hydrazine produces 3-(4-(2,3-dichlorophenyl)piperazin-l-yl)- 2,2-difluoropropan- 1 -amine (43) in quantitative yield. Reaction Scheme 9
Figure imgf000036_0002
The target compound is prepared by amide bond formation of acid (44) and amine (37) by use of l-ethyl-3-(3'-dimethylaminopropyl)carbedoomide hydrochloride (EDCI), 1-hydroxybenzotriazole (HOBt), N-methylmorphofine (NMM) in a suitable solvent such as DMF to generate a compound (45) in 31% yield as shown in Reaction Scheme 10. Generally, an acid (46) and an amine (47) produce the inventive compound (Ia) in an analogous manner.
Reaction Scheme 10
Figure imgf000037_0001
Wherein,
R1, R2, R3, R5 and R6 have the same meanings as defined above.
As shown in Reaction Scheme 11, the target compound is prepared by amide bond formation of acid (44) and amine (40) by use of EDCI, HOBt and
NMM in a suitable solvent such as DMF to generate an alcohol (49) in 40% yield. Generally, an acid (46) and an amine (50) produce the inventive compound (Ib) in an analogous manner.
Reaction Scheme 11
Figure imgf000037_0002
Wherein,
Ri, R2, R3, R5 and R6 have the same meanings as defined above. Further, the present invention provides a method for preventing or treating a depressive disorder in a mammal, comprising administering the compound of formula (I) or a pharmaceutically acceptable salt thereof to the mammal in need thereof.
Also, the present invention provides a pharmaceutical composition for preventing or treating a depressive disorder, which comprises the compound of formula (I) or a pharmaceutically acceptable salt thereof as an active ingredient, and a pharmaceutically acceptable carrier.
As used herein, the term "depressive disorders" refers to mental illnesses characterized by a profound and persistent feeling of sadness or despair and/or a loss of interest in things that once were pleasurable. Disturbance in sleep, appetite, and mental processes are common accompaniments.
The pharmaceutical composition may be administered orally, intramuscularly or subcutaneously. The formulation for oral administration may take various forms such as a syrup, tablet, capsule, cream and lozenge. A syrup formulation will generally contain a suspension or solution of the compound or its salt in a liquid carrier, e.g., ethanol, peanut oil, olive oil, glycerine or water, optionally with a flavoring or coloring agent. When the composition is in the form of a tablet, any one of pharmaceutical carriers routinely used for preparing solid formulations may be used. Examples of such carriers include magnesium stearate, terra alba, talc, gelatin, acacia, stearic acid, starch, lactose and sucrose. When the composition is in the form of a capsule, any of the routine encapsulation procedures may be employed, e.g., using the aforementioned carriers in a hard gelatin capsule shell. When the composition is formulated in the form of a soft gelatin shell capsule, any of the pharmaceutical carrier routinely used for preparing dispersions or suspensions may be prepared using an aqueous gum, cellulose, silicate or oil. The formulation for intramuscular or subcutaneous administration may take a liquid form such as a solution, suspension and emulsion which includes aqueous solvents such as water, physiological saline and Ringer's solution; or lipophilic solvents such as fatty oil, sesame oil, corn oil and synthetic fatty acid ester.
Preferably the composition is formulated in a specific dosage form for a particular patient. Each dosage unit for oral administration contains suitably from 0.1 mg to 500 mg/kg, and preferably from 1 mg to 100 mg/kg of the compound of formula (I) or a pharmaceutically acceptable salt thereof. The suitable daily dosage for oral administration is about 0.01 mg/kg to 40 mg/kg of the compound of formula (I) or a pharmaceutically acceptable salt thereof, which may be administered 1 to 6 times a day, depending on the patient's condition.
The present invention further described and illustrated in Examples provided below, which are, however, not intended to limit the scope of the present invention. SYNTHETIC EXAMPLES
As used herein the symbols and conventions used describing the processes, schemes and examples of the present invention are consistent with those used in the contemporary scientific literature, for example, the Journal of the American Chemical Society or the Journal of Biological Chemistry. Unless otherwise noted, all starting materials were obtained from commercial suppliers and used without further purification.
Hz (Hertz) TLC (thin layer chromatography)
Tr (retention time)
/-PrOH (isopropanol)
MeOH (methanol)
TFA (trifluoroacetic acid) TEA (triethylamine)
EtOH (ethanol) THF (tetrahydrofuran)
DMSO (dimethylsulfoxide) EtOAc (ethyl acetate)
DCM (dichlromethane) HOAc (acetic acid)
DMF (N.N-dimethylformamide) Ac (acetyl)
Bn (benzyl)
HOBt (1-hydroxybenzotriazole)
Boc (tert-butyloxycarbonyl)
mCPBA (meta-chloroperbenzoic acid)
Cbz (benzyloxycarbonyl)
ΝMM (Ν-methyl morpholine)
EDCI (l-ethyl-3-[3-dimethylaminopropyl]carbodiimide hydrochloride) ;
HPLC (high pressure liquid chromatography)
R.T. (room temperature) All references to ether are to diethyl ether; brine refers to a saturated aqueous solution of NaCl. Unless otherwise indicated, all temperatures are expressed in°C (degrees Centigrade). All reactions are conducted under an inert atmosphere at room temperature unless otherwise noted, and all solvents are of the highest available purity unless otherwise indicated.
Microwave reaction was conducted with a Biotage Initiator™ microwave synthesizer.
1H NMR spectra were recorded on either a Jeol ECX-400, or a Jeol JNM-
LA300 spectrometer. Chemical shifts were expressed in parts per million (ppm, δ units). Coupling constants are in units of hertz (Hz). Splitting patterns describe apparent multiplicities and are designated as s (singlet), d(doublet), t (triplet), q
(quartet), quint (quintet), m (multiplet), br (broad).
Mass spectra were obtained with either a Micromass, Quattro LC Triple Quadruple Tandem Mass Spectometer, ESI or Agilent, 1 lOOLC/MSD, ESI.
For preparative HPLC, ca 100 mg of a product was injected in 1 mL of
DMSO onto a SunFire™ Prep C18 OBD 5 μm 19x100mm Column with a 10 min gradient from 10% CH3CN to 90% CH3CN in H2O (purification systems from Gilson, Inc). Flash chromatography was carried using Merck silica gel 60 (230- 400 mesh). Biotage SP1™ FLASH Purification System and Biotage Isolera™ FLASH Purification System were used for normal phase column chromatography with ethyl acetate and hexane. Most of the reactions were monitored by thin-layer chromatography on 0.25 mm E. Merck silica gel plates (60F-254), visualized with UV light using a 5% ethanolic phosphomolybdic acid or p-anisaldehyde solution. The following synthetic schemes are merely illustrative of the methods by which the compounds of the invention may be prepared and are not intended to limit the scope of the invention as defined in the appended claims.
<Preparation of N-arylpiperazines>
Preparation Example 1: l-(3-chloro-2-methyIphenyl)piperazine (compound
28)
Figure imgf000040_0001
To a stirred solution of 3-chloro-2-methylaniline (compound 26, 21.6 g, 0.15 mol) in n-butanol (200 ml) was added bis(2-chloroethyl)amine hydrochloride (compound 27, 30 g, 0.17 mol) at room temperature and allowed to refluxed temperature for 2 days. After cooled to room temperature Na2CO3 (9 g, 0.08 mol) was added and then reaction mixture was refluxed 30 min. The resulting mixture was filtered with n-butanol (100 ml) and collected solid was dried under reduced pressure to be obtained title compound (24.8 g, 81 %) as a white solid.
MH+ 211. Preparation Example 2: 8-(piperazin-l-yl)quinoline hydrochloride (compound 33)
Figure imgf000041_0001
Step 1 : Quinolin-8-yl trifluoromethanesulfonate (compound 31)
To a solution of quinolin-8-ol (compound 29, 8 g, 0.055 mol) and K2CO3 (15.2 g, 0.1 10 mol) in pyridine (60 ml) at -20 °C were added with trifluoromethanesulfonic anhydride (14 ml, 0.083 mol) dropwise. After stirring for 1 hour at -20 °C , the reaction mixture was stirred at room temperature for 2 days. The resulting solution was quenched with water, and normal work-up was preceded. The residue was purified with normal preparative column to provide title compound (13 g, 85%) as white solid.
MH+278. Step 2: tert-butyl 4-(quinolin-8-yl)piperazine-l-carboxylate (compound 32) t-butyl piperazine-1-carboxylate (compound 31, 8.6 g, 46 mmol) and quinolin-8-yl trifluoromethanesulfonate (compound 30, 11 g, 39.6 mmol) were added to a solution Of Cs2CO3 (18 g, 55 mmol), BINAP (1.07g) and Pd(OAc)2 (367 mg) in THF (100 ml). The reaction mixture was refluxed for 1 day and then cooled down to room temperature. The resulting solution was diluted with Et2O (100 ml) and then filtered with Celite. The organic solution was evaporated under reduced pressure, the residue was purified with normal preparative column to give rise to desired compound (9.3 g, 74% yield) as a light yellow solid. MH+ 314. Step 3: 8-(piperazin-l-vPquinoline hydrochloride (compound 33) t-butyl 4-(quinolin-8-yl)piperazine-l-carboxylate (compound 32, 2.4 g,
7.66 mmol) was dissolved in methanol (50 ml) and SOCl2 was added to the solution dropwise at 0°C . The resulting solution was refluxed for 1 day and evaporated under reduced pressure. EtOAc (50 ml) was added to the residue and stirred for 2 hours to produce light yellow solid. The title compound was collected by fϊlteration (1.7 g, 89%) as light yellow solid.
MH+ 214.
<Preparation of amines containing 7V-aryIpiperazines> Preparation Example 3: 3-(4-(2,3-dichlorophenyl)piperazin-l-yI)propan-l- amine dihydrochloride (compound 37)
Step 1 : 2-(3-(4-(2,3-dichlorophenvπpiperazin-l-yl)propyl)isoindoline-l,3-dione (compound 36)
The mixture of l-(2,3-dichlorophenyl)piperazine hydrochloride (compound 35, 10.0 g, 37.4 mmol), N-(3-bromopropyl)phthalimide (compound 34, 9.09 g, 33.9 mmol) and potassium carbonate (11.7 g, 84.8 mmol) in DMF was stirred at room temperature. The mixture was concentrated under reduced pressure. The residue was diluted with CH2Cl2, and washed with water. The organic layer was dried over anhydrous MgSO4, filtered, and concentrated in vacuo. The obtained product was washed with EtOH to provide the title compound (1 1.2 g, 80 %) as a white solid.
1H ΝMR (400 MHz, CDCl3) δ 7.88-7.83 (m, 2H), 7.74-7.69 (m, 2H), 7.15-7.09 (m, 2H), 6.82 (dd, J = 7.6, 2.4, IH), 3.80 (t, J = 7.2 Hz, 2H), 2.93-2.87 (m, 4H), 2.62-2.56 (m, 4H), 2.51 (t, J= 5.6 Hz, 2H), 1.94-1.87 (m, 2H).
MH+ 418.
Step 2: 3-(4-(2,3-dichlorophenyl)piperazin-l-yl)propan-l-amine dihydrochloride (compound 37) To a suspension of 2-(3-(4-(2,3-dichlorophenyl)piperazin-l- yl)propyl)isoindoline-l,3-dione (compound 36, 1 1.1 g, 26.5 mmol) in EtOH was added hydrazine monohydrate. The reaction mixture was stirred at room temperature for 6 hrs, then the white solid filtered off. The filtrate was concentrated under reduced pressure. The residue was diluted with CH2Cl2, and washed with water. The organic layer was dried over anhydrous MgSO4, filtered, and concentrated in vacuo. To the crude product in diethyl ether was added 2M HCl solution in diethyl ether (10 mL). The obtained product was washed with diethyl ether to provide the title compound (6.98 g, 73 %) as a white solid.
1H NMR (400 MHz, CD3OD) δ 7.22-7.18 (m, 2H), 7.08 (dd, J = 7.2, 2.4,
IH), 3.06-3.02 (m, 6H), 2.72-2.64 (m, 4H), 2.60 (t, J= 6.8 Hz, 2H), 1.90-1.84 (m, 2H).
MH+ 288. <Preparation of amines containing β-hydoroxy-Λr-arylpiperazines>
Preparation Example 4; l-amino-3-(4-(2,3-dichloropheny.)piperazin-l- yl)propan-2-ol (compound 40) To a stirred solution of N-(2,3-epoxypropyl)phthalimide (compound 38,
10 g, 0.049 mol) in THF (100 mL) was added l-(2,3-dichlorophenyl)piperazine HCl (compound 35, 8.7 g, 0.033 mol) and triethylamine (4.6 mL, 0.033 mol) at R.T., and then the resultant solution was heated at 80 °C overnight. The reaction was quenched with H2O and extracted with DCM. The organic layer was washed with brine, dried over MgSO4, filtered, and evaporated. The solid residue was solidified with DCM (20 mL) /diethyl ether (200 mL), filtered and dried in vacuo, which was used for the following synthesis without further purification. To the prepared white solid piperazine (compound 39, 13 g, 0.030 mol) in EtOH was added hydrazine monohydrate (20 mL) and the reaction solution was refluxed at 80 °C for 2 hrs. The reaction solution was cooled to R.T. and evaporated. The oily crude compound was extracted with EtOAc/ H2O and organic layer was combined and evaporated. The pale yellow solid was tritylated with ether to afford pure targeted amine (8.7 g, 95%) as a white solid.
MH+ 304.
<Preparation of amines containing β-difluoiϊde-vV-arylpiperazines> Preparation Example 5: 3-(4-(2,3-dichIorophenyl)piperazin-l-yl)-2,2- difluoropropan-1-amine (compound 43) Step 1 : 2-(3 -(4-(2,3 -dichlorophenvDpiperazin- 1 -yl)-2-oxopropyπisoindoline- 1,3- dione (compound 41 )
To a stirred solution of oxalyl chloride (2.2 mL, 0.025 mol) in DCM (20 mL) was added dropwise a solution of DMSO (4 mL) in DCM (15 mL) at -60 °C . The reaction mixture was warmed to -20 °C before a solution of (+/-)-hydroxy piperazine (compound 39, 5 g, 0.012 mol) in DCM (15 mL) was added. After the reaction mixture was stirred and allowed to warm to -10 °C, triethylamine (8 mL, 0.058 mol) was added. The resultant mixture was warmed to R.T. and stirred for an additional 2h, and then water was added. The aqueous layer was extracted with DCM, and the organic layers were combined, washed with brine, dried over MgSO4, filtered, and evaporated. The oily residue was purified by flash column chromatography (Biotage SP 1™) to obtain 4.4 g of the title compound (0.010 mol; 89 %).
MH+ 432.
Step 2j 2-(3-(4-(2,3-dichlorophenγl)piperazin-l-γl)-2,2-difluoropropyl) isoindoline-l,3-dione (compound 42)
To a stirred solution of ketone (compound 41, 4.4 g, 0.010 mol) in DCM (90 mL) was added dropwise (diethylamino)sulfur trifluoride (DAST, 3.8 mL, 0.029 mol) at -78 °C . The reaction mixture was stirred at room temperature for 3hrs. The reaction was quenched with aqueous NaHCO3 and extracted with DCM/ H2O, and then the organic layers were combined, washed with brine, dried over MgSO4, filtered, and evaporated. The oily residue was purified by flash column chromatography (Biotage SP 1™) to obtain 990 mg of the title compound (2.2 mmol; 21 %).
MH+ 454.
Step 3 : 3-(4-(2,3-dichlorophenyl)piperazin- 1 -yl)-2,2-difluoropropan- 1 -amine (compound 43) To the difluoro-piperazine (compound 42, 1.2 g, 2.53 mmol) in EtOH (15 mL) was added hydrazine monohydrate (1.8 mL) and the reaction solution was refluxed at 80 °C for 1 hr. The reaction solution was cooled to R.T. and evaporated. The oily crude compound was extracted with EtOAc/ H2O and the organic layer was combined and evaporated. The crude compound was diluted with MeOH (5 mL) and added 2N HCl in ether solution to afford targeted amine HCl salts (1.0 g, 100 %) as white solid.
MH+ 360. Example 1: l-(4-chIorophenyl)-jV-(3-(4-(2,3-dichlorophenyl)piperazin-l-yl)-2- hydroxy propyl)-2-propyl-l^-imidazole-4-carboxamide
Step 1 : N-(4-chlorophenyl)butyrimidamide (compound 3) To a solution of butyronitrile (compound 2, 7.5 mL, 86.2 mmol), AlCl3 in toluene was added 4-chloroaniline (compound 1, 10.0 g, 78.4 mmol). The reaction mixture was stirred at 115 °C for 5 hrs. The mixture was diluted with water (200 mL) and extracted with EtOAc (200 mL). The aqueous layer was neutralized with saturated NaHCO3 (500 mL) and extracted with EtOAc (300 mL x 2). The organic layer was dried over anhydrous MgSO4, filtered and concentrated in vacuo. The obtained product (9.2 g, pale brown solid) was used for the next step without purification.
Step 2: Ethyl l-(4-chlorophenyl)-2-propyl-lH-imidazole-4-carboxylate (compound 5)
To a solution of N-(4-chlorophenyl)butyrimidamide (compound 3, 3.5 g, 17.80 mmol), NaHCO3 (3.14 g, 37.38 mmol) in /-PrOH was added ethyl bromopyruvate (compound 4, 4.7 mL, 37.38 mmol) under N2. The reaction mixture was stirred at 85 °C for 72 hrs, then added AcOH (15 mL). After 4 hrs, the mixture was concentrated under reduced pressure. The residue was diluted with H2O, and extracted with CH2Cl2. The organic layer was washed with saturated NaHCO3 and IN-HCl solution, then dried over anhydrous MgSO4, filtered and concentrated in vacuo. The crude product was purified by flash column chromatography (Biotage Isolera™ FLASH Purification System was used for normal phase column chromatography with EtOAc and hexane) to provide the title compound (1.28 g, 25 %) as a brown oil.
1H NMR (400 MHz, CDCl3) δ 7.62 (s, IH), 7.51-7.47 (m, 2H), 7.26-7.23 (m, 2H), 4.39 (q, J = 7.2 Hz, 2H), 2.62 (t, J = 7.6 Hz, 2H), 1.71-1.61 (m, 2H), 1.39 (t, J= 6.8 Hz, 3H), 0.86 (t, J = 7.2 Hz, 3H).
MH+ 293.
Step 3: l-(4-chlorophenylV2-propyl-lH-imidazole-4-carboxylic acid (compound 6} To a solution of ethyl l-(4-chlorophenyl)-2-propyl-lH-imidazole-4- carboxylate (compound 5, 1.28 g, 4.37 mmol) in TΗF/water (20/20 mL) was added lithium hydroxide monohydrate at room temperature. The reaction mixture was stirred at 55 °C for 12 hrs. The mixture was washed with CH2Cl2, the aqueous layer was acidified with IN-HCl solution (pH ~ 6), extracted with CH2Cl2. The organic layer was dried over anhydrous MgSO4, filtered and concentrated in vacuo. The obtained product was washed with hexane to provide the title compound (740 mg, 64 %) as a pale brown solid.
1H NMR (400 MHz, CDCl3) δ 7.71 (s, IH), 7.53-7.50 (m, 2H), 7.31-7.29 (m, 2H), 7.71 (t, J= 7.2 Hz, 2H), 1.73-1.63 (m, 2H), 0.88 (t, J= 7.6 Hz, 3H).
MH+ 265.
Step 4: l-(4-chlorophenvπ-N-(3-(4-(2,3-dichlorophenyl)piperazin-l-yl)-2- hydroxy propyl)-2-propyl- lH-imidazole-4-carboxamide To a mixture of lithium l-(4-chlorophenyl)-2-propyl-lH-imidazole-4- carboxylic acid (compound 6, 150 mg, 0.57 mmol), l-amino-3-(4-(2,3- dichlorophenyl)piperazin-l-yl)propan-2-ol dihydrochloride (compound 41, 260 mg, 0.68 mmol), EDCI (165 mg, 0.85 mmol) and ΗOBt (154 mg, 1.14 mmol) in anhydrous DMF (7 mL) was added ΝMM (190 μH, 1.71 mmol). The reaction mixture was stirred at room temperature for 15 hrs. The mixture was concentrated under reduced pressure. The residue was diluted with CH2Cl2, and washed with water. The organic layer was dried over anhydrous MgSO4, filtered, and concentrated in vacuo. The crude product was purified by preparative HPLC (purification system, Gilson) to provide the title compound (74 mg, 24 %) as a white solid.
1H ΝMR (400 MHz, DMSO-d6) δ 8.00 (t, J = 5.6 Hz, IH), 7.69 (s, IH), 7.59-7.56 (m, 2H)5 7.49-7.45 (m, 2H), 7.29-7.23 (m, 2H), 7.10 (dd, J = 7.2, 2.8 Hz, IH)5 4.88 (br s, IH)5 3.81-3.75 (m, IH)5 3.38-2.29 (m, 2H)5 3.06-2.98 (m, 4H)5 2.62-2.55 (m, 4H)5 2.52-2.48 (m, 2H)5 2.45-2.37 (m, 2H)5 1.53-1.43 (m, 2H)5 0.70 (t, J= 7.2 Hz, 3H).
MH+ 550.
The following compounds of Examples 2 to 4 were obtained by using corresponding starting materials and repeating the procedure of Example 1. Example 2: l-^-chlorophenyty-Λ^S-^-^^-dichlorophenytypiperaziii-l- yl)propyl)-2-propyl-lH-imidazole-4-carboxamide dihydrochloride
1H NMR (400 MHz5 CD3OD) δ 8.17 (s, IH)5 7.71-7.67 (m, 2H)5 7.63- 7.60 (m, 2H)5 7.31-7.25 (m, 2H)5 7.15 (dd, J = 6.8, 2.8 Hz5 IH)5 3.72-3.69 (m, 2H)5 3.55-3.37 (m, 4H)5 3.35-3.33 (m, 4H)5 3.21-3.15 (m, 2H)5 2.88 (d, J = 7.2 Hz5 2H)5 2.18-2.11 (m, 2H), 1.68-1.62 (m, 2H)5 0.89 (t, J = 7.2 Hz5 3H).
MH+ 534.
Example 3: l-(4-chIorophenyl)-7V-(3-(4-(2,3-dimethylphenyl)piperazin-l- yl)propyl)-2-propyl-li/-imidazole-4-carboxamide
1H NMR (400 MHz5 CDCl3) δ 7.60 (br s, IH), 7.55 (s, IH), 7.50-7.46 (m, 2H)5 7.25-7.20 (m, 2H)5 7.08 (d, J= 8.0 Hz5 IH)5 6.98-6.93 (m, 2H), 3.61-3.55 (m, 2H), 3.38-3.13 (m, 6H)5 3.05-2.95 (m, 6H)5 2.56 (t, J = 7.6 Hz5 2H)5 2.26 (s, 3H)5 2.19 (s, 3H), 1.70-1.62 (m, 2H), 0.88 (t, J= 7.2 Hz5 2H).
MH+ 494.
Example 4: l-^-chlorophenyO-Λ^-^-^S-dichlorophenytypiperazin-l- y^ethyl^-propyl-l/Z-imidazoIe^-carboxamide
1H NMR (400 MHz5 DMSO-d6) δ 7.87 (br s, IH)5 7.73 (s, IH)5 7.61-7.58 (m, 2H)5 7.51-7.48 (m, 2H)5 7.35-7.26 (m, 2H)5 7.19-7.10 (m, IH)5 3.57-3.45 (m, 6H)5 3.08-2.96 (m, 4H), 2.55 (t, J = 7.2 Hz, 2H), 1.59-1.50 (m, 2H), 0.79 (t, J = 7.6 Hz, 3H).
MH+ 520. <Preparation of imidazoles containing substituted phenyl ring>
Preparation Example 6: Lithium I^-dimethyl-l-phenyl-l/Z-imidazole-^ carboxylate (compound 13a)
Figure imgf000048_0001
Step 1 : Ethyl 2-(hvdroxyimino)-3-oxobutanoate (compound 8)
To a solution of ethyl acetoacetate (compound 7, 30 g, 0.23 mol) in acetic acid (35mL) was added slowly sodium nitrite (18.0 g, 0.25 mol) in cold water (40 mL) at -10°C . The reaction mixture was stirred for 1 hr, then added cold water
(120 mL) and stirred for 3 hrs. The mixture was extracted with diethyl ether (300 mL). The organic layer was washed with saturated NaHCO3 (400 mL x 2), then dried over anhydrous MgSO4, filtered and concentrated in vacuo. The obtained product (21.46 g, white solid) was used for the next step without purification.
1H NMR (400 MHz, DMSO-d6) δ 13.20 (s, IH), 4.21 (q, J = 7.2 Hz, 2H), 2.32 (s, 3H), 1.92 (t, J = 6.8 Hz, 3H).
Step 2: Ethyl 2-acetamido-3-oxobutanoate (compound 10)
To a mixture of ethyl 2-(hydroxyimino)-3-oxobutanoate (compound 8, 9.32 g, 58.5 mmol), Pd/C (400 mg, palladium on carbon, 10 wt%, support activated carbon, wet, Degussa type ElOl NE/ W) in EtOH was added acetic anhydride (compound 9, 1 1.0 mL, 1 17.0 mmol) at room temperature. The reaction mixture was stirred at room temperature under H2 for 15 hrs. The palladium was filtered off (filter aid, Celite 521 AW), then the filtrate was concentrated in vacuo. The crude product was purified by flash column chromatography (Biotage SP 1™ FLASH Purification System was used for normal phase column chromatography with tetrahydrofuran and hexane) to provide the title compound (9.48 g, 86 %) as a white solid.
1H NMR (400 MHz, CDCl3) δ 6.62 (br s, IH), 5.25 (d, J = 6.4 Hz, IH), 4.28 (q, J= 7.2 Hz, 2H), 2.39 (s, 3H), 2.07 (s, 3H), 1.32 (t, J= 7.2 Hz, 3H). Step 3: Ethyl 2,5-dimethyl-l-phenyl-lH-imidazole-4-carboxylate (compound 12a)
To a solution of ethyl 2-acetamido-3-oxobutanoate (compound 10, 5.0 g, 26.7 mmol), aniline (compound 11a, 7.3 mL, 80.1 mmol) in butyronitrile (10 mL) was added trifluoroacetic acid (6.2 mL, 80.1 mmol) at room temperature. The reaction mixture was irradiated in a microwave reactor (Biotage Initiator™) for 40 minutes at 140°C . The mixture was concentrated under reduced pressure. The residue was diluted with CH2Cl2, and washed with aqueous K2CO3. The organic layer was dried over anhydrous MgSO4, filtered, and concentrated in vacuo. The crude product was purified by flash column chromatography (Biotage SP 1™ FLASH Purification System was used for normal phase column chromatography with tetrahydrofuran and hexane.) to provide the title compound (4.97 g, 76 %) as a yellow solid.
1H NMR (400 MHz, CDCl3) δ 7.57-7.51 (m, 3H), 7.20-7.18 (m, 2H), 4.41 (q, J= 6.8 Hz, 2H), 2.31 (s, 3H), 2.22 (s, 3H), 1.42 (t, J= 7.2 Hz, 3H).
MH+ 245.
Step 4: Lithium 2,5-dimethyl-l-phenyl-lH-imidazole-4-carboxylate (compound 13a)
To a solution of ethyl 2,5-dimethyl-l -phenyl- lH-imidazole-4-carboxylate (compound 12a, 4.97 g, 20.3 mmol) in TΗF/water (15/15 mL) was added lithium hydroxide monohydrate at room temperature. The reaction mixture was stirred at 55 °C for 12 hrs, then the mixture was concentrated in vacuo. The crude solid was washed with diethyl ether to provide the title compound (4.06 g, 90 %) as a white solid. The obtained product was used for the next step without purification.
Free form (non-Li+ salt): 1H NMR (400 MHz, CDCl3) δ 7.60-7.53 (m, 3H), 7.23-7.19 (m, 2H), 2.32 (s, 3H), 2.25 (s, 3H).
MH+ 217.
Preparation Example 7: Lithium 2,5-dimethyl-l-(pyridin-2-yl)-l/-Mmidazole-
4-carboxylic acid (compound 13b)
Figure imgf000049_0001
Step 1 : Ethyl 2,5-dimethyl-l-(pyridin-2-yl)-lH-imidazole-4-carboxylate (compound 12b)
To a solution of ethyl 2-acetamido-3-oxobutanoate (compound 10, 2.0 g, 10.6 mmol), aniline (compound lib, 2.0 g, 21.3 mmol) in butyronitrile (15 mL) was added acetic acid (1.2 mL, 21.3 mmol) at room temperature. The reaction mixture was irradiated in a microwave reactor (Biotage Initiator™) for 40 minutes at 160 °C . The mixture was concentrated under reduced pressure. The crude product was purified by preparative ΗPLC (purification system, Gilson) to provide the title compound (340 mg, 14 %) as a brown oil.
MΗ+ 246.
Step 2: Lithium 2,5-dimethyl-l-(pyridm-2-yl)-lH-imidazole-4-carboxylic acid (compound 13b)
To a solution of ethyl 2,5-dimethyl-l-(pyridin-2-yl)-lΗ-imidazole-4- carboxylate (compound 12b, 340 mg, 1.4 mmol) in THF/water (10/10 mL) was added lithium hydroxide monohydrate at room temperature. The reaction mixture was stirred at 60 °C for 12 hrs, then the mixture was concentrated in vacuo. The crude solid was washed with diethyl ether to provide the title compound as a pale yellow solid. The obtained product was used for the next step without purification.
Free form (non-Li+ salt): 1H NMR (400 MHz, CD3OD) δ 8.97-8.95 (m, IH), 7.93-7.88 (m, IH), 7.63-7.61 (m, IH), 7.32-7.28 (m, IH), 2.40 (s, 3H), 2.18 (s, 3H).
MH+ 218.
Example 5: /V-(3-(4-(2,3-dichlorophenyl)piperazin-l-yl)-2-hydroxypropyI)- 2,5-dimethyl-l-phenyl-l//-imidazole-4-carboxamide
To a mixture of lithium 2,5-dimethyl-l-phenyl-lH-imidazole-4- carboxylate (compound 13a, 150 mg, 0.67 mmol), l-amino-3-(4-(2,3- dichlorophenyl)piperazin-l-yl)propan-2-ol dihydrochloride (compound 41, 300 mg, 0.80 mmol), EDCI (260 mg, 1.34 mmol) and ΗOBt (180 mg, 1.34 mmol) in anhydrous DMF (7 mL) was added NMM (370 μi, 3.35 mmol). The reaction mixture was stirred at room temperature for 15 hrs. The mixture was concentrated under reduced pressure. The residue was diluted with CH2Cl2, and washed with water. The organic layer was dried over anhydrous MgSO4, filtered, and concentrated in vacuo. The crude product was purified by preparative HPLC (purification system, Gilson) to provide the title compound (134 mg, 40 %) as a white solid.
1H NMR (400 MHz, DMSO-d6) δ 7.98 (t, J = 5.6 Hz, IH), 7.57-7.48 (m, 3H), 7.36-7.33 (m, 2H), 7.28-7.23 (m, 2H), 7.11 (dd, J= 7.2, 3.2 Hz, IH), 4.85 (d, J = 4.8 Hz, IH), 3.76-3.74 (m, IH), 3.32-3.27 (m, 2H), 3.03-2.98 (m, 4H), 2.61- 2.56 (m, 4H), 2.40-2.38 (m, 2H), 2.20 (s, 3H), 2.05 (s, 3H).
MH+ 502.
The following compounds of Examples 6 to 331 were obtained by using corresponding starting materials and repeating the procedure of Example 5. Example 6: Λ^3-(4-(2,3-dichlorophenyI)piperazin-l-yl)propyl)-2,5-dimethyl- l-phenyI-l//-imidazole-4-carboxamide
1H NMR (400 MHz, DMSO-d6) δ 8.21 (t, J = 5.6 Hz, IH), 7.57-7.51 (m, 3H), 7.37-7.34 (m, 2H), 7.27-7.23 (m, 2H), 7.11 (dd, J = 6.4, 2.8 Hz, IH), 3.27- 3.25 (m, 2H), 3.07-3.01 (m, 4H), 2.57-2.50 (m, 4H), 2.42-2.39 (m, 2H), 2.20 (s, 3H), 2.04 (s, 3H), 1.69-1.62 (m, 2H).
MH+ 486.
Example 7: Λ^S-^-^S-dichlorophenyOpiperazin-l-yOpropyO-S-methyl-l- phenyI-2-propyl-l//-imidazole-4-carboxamide dihydrochloride
1H NMR (400 MHz, DMSO-d6) δ 1 1.03 (s, IH), 8.85 (br s, IH), 7.65- 7.62 (m, 3H), 7.53-7.51 (m, 2H), 7.36-7.30 (m, 2H), 7.18 (dd, J= 6.8, 2.0 Hz, IH), 3.57-3.54 (m, 2H), 3.42-3.33 (m, 4H), 3.23-3.12 (m, 6H), 2.57 (t, J= 7.6 Hz, 2H), 2.23 (s, 3H), 2.05-1.99 (m, 2H), 1.61-1.51 (m, 2H), 0.76 (t, J= 7.2 Hz, 3H).
MH+ 514.
Example 8: Λ^-^-^vB-dichlorophenytypiperazin-l-ytyethyO-l^-dimethyl-l- phenyI-l/f-imidazole-4-carboxamide
1H NMR (400 MHz, DMSO-d6) δ 7.78 (t, J = 5.6 Hz, IH), 7.58-7.49 (m, 3H), 7.38-7.35 (m, 2H)5 7.28-7.25 (m, 2H), 7.13 (dd, J = 6.4, 3.2 Hz, IH), 3.37- 3.32 (m, 2H), 2.99-2.94 (m, 4H), 2.59-2.54 (m, 4H), 2.50-2.48 (m, 2H), 2.20 (s, 3H), 2.08 (s, 3H).
MH+ 472.
Example 9: 7V-(2-(4-(2,3-dichlorophenyl)piperazin-l-yl)ethyl)-5-niethyl-l- phenyl-2-propyl-l//-imidazo-e-4-carboxamide
1H NMR (400 MHz, DMSO-d6) δ 7.78 (br s, IH), 7.59-7.50 (m, 3H), 7.37-7.34 (m, 2H), 7.29-7.25 (m, 2H), 7.18-7.11 (m, IH), 3.37-3.32 (m, 2H), 3.01-2.92 (m, 4H), 2.61-2.49 (m, 6H), 2.36 (t, J = 7.6 Hz, 2H), 2.19 (s, 3H), 1.52- 1.42 (m, 2H), 0.76 (t, J = 7.2 Hz, 3H).
MH+ 500. Example 10: Λ^(3-(4-(2,3-dichlorophenyl)piperazin-l-yl)propyl)-l-(4- methoxyphenyl)-2,5-dimethyl-l/f-imidazoIe-4-carboxamide
1H NMR (400 MHz, DMSO-(I6) δ 8.14 (t, J = 6.0 Hz, IH), 7.29-7.23 (m, 2H), 7.1 1 (dd, J = 6.4, 2.4 Hz, IH), 7.08-7.04 (m, 2H), 3.80 (s, 3H), 3.27-3.24 (m, 2H), 3.07-3.01 (m, 4H), 2.55-2.50 (m, 4H), 2.41 (t, J = 6.8 Hz, 2H), 2.19 (s, 3H), 2.03 (s, 3H), 1.69-1.62 (m, 2H).
MH+ 516.
Example 11: l-^-chlorophenyO-Λ^-^-^^-dichlorophenytypiperazin-l- yl)propyl)-2,5-dimethyl-l/f-imidazole-4-carboxamide
1H NMR (400 MHz, DMSO-(I6) δ 8.18 (t, J = 5.6 Hz, IH), 7.63-7.59 (m, 2H), 7.44-7.40 (m, 2H), 7.29-7.23 (m, 2H), 7.1 1 (dd, J = 6.8, 2.8 Hz, IH), 3.27- 3.24 (m, 2H), 3.07-3.01 (m, 4H), 2.55-2.50 (m, 4H), 2.42 (t, J= 6.4 Hz, 2H), 2.21 (s, 3H), 2.05 (s, 3H), 1.69- 1.62 (m, 2H).
MH+ 520.
Example 12: iV-(3-(4-(2,3-dichlorophenyl)piperazin-l-yl)propyl)-2-ethyl-5- methyl-l-phenyl-l/f-imidazoIe-4-carboxamide
1H NMR (400 MHz, DMSO-d6) δ 8.10 (t, J = 5.6 Hz, IH), 7.58-7.49 (m, 3H), 7.36-7.33 (m, 2H), 7.29-7.22 (m, 2H), 7.10 (dd, J = 6.8, 2.4 Hz, IH), 3.32- 3.28 (m, 2H), 3.05-3.01 (m, 4H), 2.55-2.52 (m, 4H), 2.42 (t, J= 6.4 Hz, 2H), 2.36 (q, J= 7.6 Hz, 2H), 2.19 (s, 3H), 1.70-1.63 (m, 2H), 0.96 (t, J= 7.6 Hz, 3H).
MH+ 500.
Example 13: Λ^l-^-^vJ-dichlorophenyOpiperazin-l-yOethyty-l-ethyl-S- methyl-l-phenyl-l//-imidazole-4-carboxamide
1H NMR (400 MHz, DMSO-d6) δ 7.77 (t, J = 5.6 Hz, IH), 7.58-7.50 (m, 3H), 7.37-7.35 (m, 2H), 7.30-7.25 (m, 2H), 7.13-7.1 1 (m, IH), 3.39-3.34 (m, 2H), 3.00-2.96 (m, 4H), 2.64-2.56 (m, 4H), 2.51 (t, J= 6.4 Hz, 2H), 2.40 (q, J= 7.6 Hz, 2H), 2.19 (s, 3H), 1.03 (t, J= 7.2 Hz, 3H).
MH+ 486. Example 14: A^Z-^-^^-dimethylphenytypiperazin-l-yOethyO-l^-dimethyl- l-phenyl-l//-imidazole-4-carboxamide
1H NMR (400 MHz, DMSO-d6) δ 7.78 (t, J = 5.6 Hz, IH), 7.58-7.50 (m, 3H), 7.38-7.35 (m, 2H), 7.00 (t, J= 7.6 Hz, IH), 6.86 (d, J = 7.6 Hz, IH), 6.83 (d, J = 7.6 Hz, IH), 3.35-3.33 (m, 2H), 2.79-2.74 (m, 4H), 2.58-2.52 (m, 4H), 2.50- 2.48 (m, 2H), 2.20 (s, 3H), 2.17 (s, 3H), 2.12 (s, 3H), 2.08 (s, 3H).
MH+ 432.
Example 15: Λ^-(4-(2,3-dimethyIpheiiyl)piperazin-l-yl)pr()pyI)-2,5- dimethyl-l-phenyl-l//-imidazole-4-carboxamide
1H NMR (400 MHz, DMSO-d6) δ 8.16 (t, J = 6.0 Hz, IH), 7.58-7.48 (m,
3H), 7.37-7.34 (m, 2H), 6.98 (t, J= 8.0 Hz, IH), 6.86 (d, J= 7.6 Hz, IH), 6.81 (d,
J= 7.6 Hz, IH), 3.27-3.25 (m, 2H), 2.85-2.82 (m, 4H), 2.59-2.52 (m, 4H), 2.40 (t, J = 6.8 Hz, 2H), 2.20 (s, 3H), 2.16 (s, 3H), 2.1 1 (s, 3H), 2.05 (s, 3H), 1.69-1.62
(m, 2H).
MH+ 446.
Example 16: jV-(3-(4-(2,3-dimethyIphenyl)piperazin-l-yl)propyl)-2-ethyI-5- methyl-l-phenyl-l/f-imidazole-4-carboxamide 1H NMR (400 MHz, DMSO-d6) δ 8.08 (t, J = 6.0 Hz, IH), 7.58-7.51 (m,
3H), 7.36-7.33 (m, 2H), 6.98 (t, J = 7.6 Hz, IH), 6.85 (d, J = 7.6 Hz, IH), 6.82 (d,
J = 7.2 Hz5 IH), 3.27-3.25 (m, 2H), 2.85-2.82 (m, 4H), 2.59-2.52 (m, 4H), 2.42-
2.35 (m, 4H), 2.19 (s, 3H)5 2.16 (s, 3H), 2.1 1 (s, 3H), 1.69-1.65 (m, 2H), 0.98 (t, J = 7.2 Hz, 3H).
MH+ 460.
Example 17: Λr-(3-(4-(2,3-dimethyIphenyl)piperazin-l-yl)propyl)-5-methyl-l- phenyl-2-propyI-l//-imidazole-4-carboxamide dihydrochloride
1H NMR (400 MHz, DMSO-d<0 δ 10.63 (s, IH), 8.31 (br s, IH), 7.61- 7.53 (m, 3H), 7.40-7.38 (m, 2H), 7.04 (t, J = 7.6 Hz, IH), 6.91-6.86 (m, 2H), 3.52-3.48 (m, 2H), 3.32 (q, J = 6.4 Hz, 2H)5 3.19-3.13 (m, 4H)5 3.09-3.04 (m, 4H), 2.43-2.41 (m, 2H), 2.20 (s, 3H), 2.18 (s, 3H), 2.13 (s, 3H), 1.99-1.95 (m, 2H), 1.52-1.46 (m, 2H), 0.75 (t, J= 7.6 Hz, 3H).
MH+ 474.
Example 18: 7V-(2-(4-(2,3-dimethylphenyl)piperazin-l-yl)ethyI)-2-ethyl-5- methyl-l-phenyl-lH-imidazole-4-carboxamide
1H NMR (400 MHz, DMSO-d6) δ 7.78 (t, J = 6.0 Hz, IH)5 7.58-7.50 (m, 3H), 7.37-7.35 (m, 2H), 7.01 (d, J= 7.6 Hz, IH), 6.86-6.82 (m, 2H), 3.37-3.33 (m, 2H), 2.78-2.76 (m, 4H)5 2.58-2.52 (m, 4H)5 2.51-2.48 (m, 2H), 2.40 (q, J= 7.6 Hz, 2H), 2.19 (s, 3H)5 2.17 (s, 3H)5 2.12 (s, 3H)5 1.04 (t, J- 7.6 Hz, 3H).
MH+ 446.
Example 19: Λ^2-(4-(2,3-dimethylphenyl)piperazin-l-yl)ethyl)-5-methyl-l- phenyl-2-propyl-l//-imidazole-4-carboxamide dihydrochloride 1H NMR (400 MHz, DMSO-d6) δ 10.46 (s, IH), 8.41 (br s, IH), 7.61-
7.53 (m, 3H), 7.39-7.37 (m, 2H), 7.04 (t, J = 7.6 Hz, IH), 6.91-6.86 (m, 2H), 3.69-3.61 (m, 4H), 3.33-3.30 (m, 2H), 3.29-3.24 (m, 2H), 3.13-3.04 (m, 4H), 2.43-2.41 (m, 2H), 2.21 (s, 3H), 2.18 (s, 3H), 2.14 (s, 3H), 1.52-1.46 (m, 2H), 0.76 (t, J= 7.2 Hz, 3H).
MH+ 460. Example 20: iV-(3-(4-(2,3-dichlorophenyl)piperazin-l-yl)propyl)-l-(4- fluorophenyl)-2,5-dimethyl-l//-imidazole-4-carboxamide
1H NMR (400 MHz, DMSO-d6) δ 8.17 (t, J = 5.6 Hz, IH), 7.46-7.36 (m, 4H), 7.29-7.23 (m, 2H), 7.14-7.1 1 (m, IH), 3.29-3.25 (m, 2H), 3.06-3.01 (m, 4H), 2.54-2.51 (m, 4H), 2.41 (t, J = 6.8 Hz, 2H), 2.20 (s, 3H), 2.04 (s, 3H), 1.69-1.62 (m, 2H).
MH+ 504. Example 21: Λ^-^-^-dichlorophenyOpiperaziii-l-yOethyl)-!-^- fluorophenyl)-2,5-d-methyI-l//-imidazoIe-4-carboxamide
1H NMR (400 MHz, DMSO-d6) δ 7.76 (t, J = 6.0 Hz, IH), 7.47-7.37 (m, 4H), 7.30-7.25 (m, 2H), 7.13 (dd, J = 6.8, 2.8 Hz, IH), 3.37-3.32 (m, 2H), 2.98- 2.92 (m, 4H), 2.58-2.53 (m, 4H), 2.50-2.48 (m, 2H), 2.20 (s, 3H), 2.08 (s, 3H).
MH+ 490.
Example 22: l-(4-chlorophenyI)-Λ^3-(4-(2,3-dimethylphenyl)piperazin-l- yl)propyl)-2,5-dimethyI-l//-imidazole-4-carboxamide
1H NMR (400 MHz, DMSO-d6) δ 8.15 (t, J = 6.0 Hz, IH), 7.62-7.59 (m,
2H), 7.44-7.40 (m, 2H), 6.98 (t, J= 7.6 Hz, IH), 6.86 (d, J= 7.6 Hz, IH), 6.81 (d,
J = 7.6 H, IH), 3.29-3.24 (m, 2H), 2.84-2.81 (m, 4H), 2.53-2.51 (m, 4H), 2.41 (t,
J = 6.8 Hz5 2H), 2.21 (s, 3H), 2.16 (s, 3H), 2.12 (s, 3H), 2.06 (s, 3H), 1.69-1.62 (m, 2H).
MH+ 480.
Example 23: jV-(3-(4-(2,3-dichlorophenyl)piperazin-l-yl)-2-hydroxypropyl)- 2-ethyl-5-methyl-l-phenyl-l//-imidazole-4-carboxamide
1H NMR (400 MHz, DMSO-d6) δ 7.92 (t, J = 6.0 Hz, IH), 7.57-7.49 (m, 3H), 7.35-7.32 (m, 2H), 7.28-7.23 (m, 2H), 7.10 (dd, J= 7.2, 2.8 Hz, IH), 4.86 (d, J = 4.4 Hz, IH), 3.77-3.74 (m, IH), 3.32-3.30 (m, 2H), 3.03-2.98 (m, 4H)5 2.62- 2.56 (m, 4H), 2.40-2.34 (m, 4H), 2.18 (s, 3H), 0.98 (t, J= 7.2 Hz, 3H).
MH+ 516. Example 24: Λ/-(3-(4-(2,3-DdichIorophenvl)piperazin-l-vl)-2-hvdroxvpropyl)- 5-methyI-l-phenyI-2-propyl-l/-r-imidazoIe-4-carboxamide
1H NMR (400 MHz, DMSO-d6) δ 7.94 (t, J = 6.0 Hz, IH), 7.57-7.50 (m, 3H), 7.34-7.32 (m, 2H), 7.28-7.22 (m, 2H), 7.10 (dd, J = 7.2, 2.4 Hz, IH), 4.87 (d,
J = 4.4 Hz, IH), 3.77-3.72 (m, IH), 3.30 (t, J = 6.0 Hz, 2H), 3.03-2.98 (m, 4H),
2.61-2.56 (m, 4H), 2.40 (d, J= 6.4 Hz, 2H), 2.32 (t, J = 7.6 Hz, 2H), 2.18 (s, 3H),
1.43-1.37 (m, 2H), 0.67 (t, J = 7.2 Hz, 3H).
MH+ 530.
Example 25: l-^-chlorophenyO-Λ^-^-^vS-dichlorophenyOpiperaziii-l- y.)propy-)-2-ethyl-5-methy--l/-r-iiii-dazoIe-4-carboxamide
1H NMR (400 MHz, DMSO-d6) δ 8.09 (t, J = 5.2 Hz, IH), 7.61 (d, J = 8.4 Hz,, 2H), 7.41 (d, J = 8.4 Hz, 2H), 7.28-7.24 (m, 2H), 7.10-7.08 (m, IH), 3.28-3.24 (m, 2H), 3.06-3.01 (m, 4H), 2.57-2.52 (m, 4H), 2.41-2.33 (m, 4H), 2.19 (s, 3H), 1.67- 1.63 (m, 2H), 0.96 (t, J = 7.6 Hz, 3H).
MH+ 534. Example 26: A^-^-^^-dichloropheiiytypiperaziii-l-yl^-hydroxypropyl)- l-(4-fluoropheny.)-2,5-dimethyI-l//-imidazoIe-4-carboxamide
1H NMR (400 MHz, DMSO-d6) δ 7.98 (t, J = 5.6 Hz, IH), 7.46-7.35 (m, 4H), 7.28-7.23 (m, 2H), 7.10 (dd, J = 6.4, 2.4 Hz, IH), 4.85 (d, J = 4.4 Hz, IH), 3.77-3.72 (m, IH), 3.35-3.22 (m, 2H), 3.03-2.97 (m, 4H), 2.61-2.45 (m, 4H), 2.40-2.38 (m, 2H), 2.19 (s, 3H), 2.04 (s, 3H).
MH+ 520.
Example 27: l-(4-chIorophenyl)-^V-(2-(4-(2,3-dichlorophenyl)piperazin-l- yl)ethyl)-2,5-dimethyl-l//-imidazole-4-carboxamide
1H NMR (400 MHz, DMSO-d6) δ 7.77 (t, J = 5.6 Hz, IH), 7.63-7.60 (m, 2H), 7.44-7.41 (m, 2H), 7.29-7.24 (m, 2H), 7.12 (dd, J = 6.8, 3.2 Hz, IH), 3.36- 3.27 (m, 2H), 2.98-2.92 (m, 4H), 2.58-2.53 (m, 4H), 2.50-2.48 (m, 2H), 2.20 (s, 3H), 2.08 (s, 3H).
MH+ 506. Example 28: l-(4-chlorophenyl)-7V-(2-(4-(2,3-dichlorophenyl)piperazin-l- yI)ethyl)-2-ethyI-5-methyl-l//-imidazole-4-carboxamide 1H NMR (400 MHz, DMSO-d6) δ 7.76 (t, J = 5.6 Hz, IH), 7.63-7.59 (m,
2H), 7.44-7.40 (m, 2H), 7.29-7.24 (m, 2H), 7.1 1 (dd, J = 6.4, 2.8 Hz, IH), 3.37- 3.33 (m, 2H), 2.98-2.92 (m, 4H), 2.58-2.53 (m, 4H), 2.51-2.49 (m, 2H), 2.39 (q, J = 7.6 Hz, 2H), 2.19 (s, 3H), 1.03 (t, J = 7.2 Hz, 3H).
MH+ 520.
Example 29: N-(3-(4-(2,3-dichlorophenyl)piperazin-l-yl)propyl)-2,5- dimethyI-l-p-tolyl-lH-imidazole-4-carboxamide
1H NMR (400 MHz, DMSO-d6) δ 8.14 (t, J = 5.6 Hz, IH), 7.34 (d, J = 8.4 Hz5, 2H), 7.28-7.20 (m, 4H), 7.11 (dd, J= 6.8, 2.8 Hz, IH), 3.28-2.24 (m, 2H), 3.04-3.01 (m, 4H), 2.57-2.52 (m, 4H), 2.40 (t, J = 6.4 Hz, 2H), 2.36 (s, 3H), 2.18 (s, 3H), 2.03 (s, 3H), 1.67-1.63 (m, 2H).
MH+ 500. Example 30: A^-^-^^-dichloropheny^piperazin-l-yOethyl^S-dimethyl- l-p-tolyl-l/Z-imidazole^-carboxamide
1H NMR (400 MHz, DMSO-d6) δ 7.74 (t, J = 6.0 Hz, IH), 7.34 (d, J = 8.4 Hz, 2H), 7.29-7.21 (m, 4H), 7.12 (dd, J = 6.8, 3.2 Hz, IH), 3.36-3.33 (m, 2H), 2.98-2.92 (m, 4H), 2.58-2.52 (m, 4H), 2.49-2.45 (m, 2H), 2.36 (s, 3H), 2.18 (s, 3H), 2.06 (s, 3H).
MH+ 486.
Example 31: Λ^-(3-(4-(2,3-dichIorophenyl)piperazin-l-yl)-2-hydroxypropyl)- 2,5-dimethyl-l-p-tolyl-li/-imidazole-4-carboxamide
1H NMR (400 MHz, DMSO-d6) δ 7.95 (t, J = 5.6 Hz, IH), 7.34 (d, J = 8.0 Hz, 2H), 7.28-7.20 (m, 4H), 7.10 (dd, J = 6.8, 2.4 Hz, IH), 4.84 (br s, IH), 3.76-3.73 (m, IH), 3.35-3.22 (m, 2H), 3.03-2.97 (m, 4H), 2.61-2.55 (m, 4H), 2.40-2.37 (m, 2H), 2.36 (s, 3H), 2.18 (s, 3H), 2.03 (s, 3H).
MH+ 516. Example 32: l-(4-chIorophenyl)-iV-(3-(4-(2,3-dichlorophenyl)piperazin-l-yl)- 2-hydroxypropyl)-2,5-dimethyl-l//--midazole-4-carboxamide 1H NMR (400 MHz5 DMSO-d6) δ 7.97 (t, J = 5.6 Hz, IH), 7.62-7.59 (m,
2H), 7.44-7.40 (m, 2H), 7.28-7.23 (m, 2H), 7.10 (dd, J = 6.8, 2.8 Hz, IH), 4.84 (br s, IH), 3.76-3.73 (m, IH), 3.34-3.23 (m, 2H), 3.03-2.97 (m, 4H), 2.61-2.56 (m, 4H), 3.40-2.38 (m, 2H), 2.20 (s, 3H), 2.05 (s, 3H).
MH+ 536.
Example 33: l-^-chlorophenyty-Λf-β-^-^vS-dichlorophenytypiperazin-l-yl)- 2-hydroxypropyl)-2-ethyl-5-methyl-l//-imidazole-4-carboxamide
1H NMR (400 MHz, DMSO-d6) δ 7.92 (t, J = 6.0 Hz, IH), 7.62-7.59 (m, 2H), 7.43-7.40 (m, 2H), 7.28-7.23 (m, 2H), 7.10 (dd, J = 7.2, 2.8 Hz, IH), 4.85 (br s, IH), 3.75-3.73 (m, IH), 3.35-3.28 (m, 2H), 3.03-2.97 (m, 4H), 2.61-2.56 (m, 4H), 2.40-2.34 (m, 4H), 2.19 (s, 3H), 0.98 (t, J= 7.6 Hz, 3H).
MH+ 550. Example 34: 7V-(3-(4-(2,3-dimethylphenyI)piperaziii-l-yl)propyl)-l-(4- fluorophenyl)-2,5-dimethyl-l//-imidazole-4-carboxamide
1H NMR (400 MHz, DMSO-d6) δ 8.15 (t, J = 5.6 Hz, IH), 7.45-7.35 (m, 4H), 6.97 (t, J = 7.6 Hz, IH), 6.85 (d, J = 7.6 Hz, IH), 6.81 (d, J = 7.6 Hz, IH), 3.29-3.24 (m, 2H), 2.84-2.81 (m, 4H), 2.58-2.49 (m, 4H), 2.19 (s, 3H), 2.15 (s, 3H), 2.11 (s, 3H), 2.04 (s, 3H), 1.68-1.61 (m, 2H).
MH+ 464.
Example 35: ΛL(3-(4-(2,3-dimethylphenyl)piperazin-l-yl)-2-hydroxypropyI)- l^-fluorophenyl^jS-dimethyl-l/f-imidazole^-carboxamide
1H NMR (400 MHz, DMSO-d6) δ 7.98 (t, J = 5.6 Hz, IH), 7.47-7.36 (m, 4H), 6.99 (t, J = 7.6 Hz, IH), 6.86 (d, J = 7.6 Hz, IH), 6.82 (d, J = 7.2 Hz, IH), 4.84 (br s, IH), 3.77-3.75 (m, IH), 3.36-3.24 (m, 2H), 2.88-2.82 (m, 4H), 2.45- 2.35 (m, 4H), 2.21 (s, 3H), 2.17 (s, 3H), 2.12 (s, 3H), 2.06 (s, 3H).
MH+ 480. Example 36: Λ^-^-^vJ-dimethylphenyOpiperazin-l-yl^-hydroxypropyl)- 2,5-dimethyl-l-phenyl-l//-imidazole-4-carboxamide 1H NMR (400 MHz, DMSO-d6) δ 7.96 (t, J = 5.6 Hz, IH), 7.57-7.48 (m,
3H), 7.36-7.32 (m, 2H), 6.97 (t, J - 7.6 Hz, IH), 6.85 (d, J- 7.6 Hz, IH), 6.81 (d, J = 7.6 Hz, IH), 4.83 (br s, IH), 3.77-3.74 (m, IH), 3.35-3.23 (m, 2H), 2.76-2.66 (m, 4H), 2.59-2.55 (m, 4H)5 2.39-2.38 (m, 2H), 2.19 (s, 3H), 2.15 (s, 3H), 2.10 (s, 3H), 2.05 (s, 3H).
MH+ 462.
Example 37: ΛL(3-(4-(2,3-dimethylphenyl)piperazin-l-yl)propyl)-2,5- dimethyl-l-(4-(trifluoromethyl)phenyl)-l//-imidazole-4-carboxamide 1H NMR (400 MHz, DMSO-d6) δ 8.21 (t, J - 5.6 Hz, IH), 7.94 (d, J -
8.4 Hz, 2H), 7.65 (d, J= 8.0 Hz, 2H), 6.99 (t, J= 8.0 Hz, IH), 6.86 (d, J= 7.6 Hz, IH), 6.82 (d, J= 7.2 Hz, IH), 3.29-3.25 (m, 2H), 2.88-2.83 (m, 4H), 2.61-2.52 (m, 4H), 2.43-2.39 (m, 2H), 2.24 (s, 3H), 2.17 (s, 3H), 2.12 (s, 3H), 2.06 (s, 3H), 1.70-1.66 (m, 2H).
MH+ 514.
Example 38: l-(benzo[rf] [l,3]dioxol-5-yl)-Λ^-(3-(4-(2,3-dimethylphenyl) piperazin-l-yl)propyI)-2,5-dimethyl-l/f-imidazole-4-carboxamide 1H NMR (400 MHz, DMSO-d6) δ 8.12 (t, J = 6.0 Hz, IH), 7.05-6.97 (m,
3H), 6.87-6.77 (m, 3H), 6.12 (s, 2H), 3.28-3.24 (m, 2H), 2.84-2.81 (m, 4H), 2.59- 2.51 (m, 4H), 2.41-2.36 (m, 2H), 2.21 (s, 3H), 2.17 (s, 3H), 2.12 (s, 3H), 2.06 (s, 3H), 1.68-1.64 (m, 2H).
MH+ 490.
Example 39_i l-(benzo[d] [l,3]dioxol-5-yl)-ΛK3-(4-(2,3-dimethyl phenyl)piperazin-l-yl)-2-hydroxypropyl)-2,5-dimethyl-l//-imidazole-4- carboxamide 1H NMR (400 MHz, DMSO-d6) δ 7.93 (t, J = 5.6 Hz, IH), 7.05-6.96 (m,
3H), 6.86-6.78 (m, 3H), 6.12 (s, 2H), 4.83 (br s, IH), 3.76-3.72 (m, IH), 3.32- 3.25 (m, 2H), 2.85-2.77 (m, 4H), 2.59-2.55 (m, 4H), 2.38 (d, J = 5.6 Hz, 2H), 2.21 (s, 3H), 2.16 (s, 3H), 2.11 (s, 3H), 2.06 (s, 3H).
MH+ 506. Example 40: l-(2,3-dihydrobenzo[b] [l,4]dioxin-6-yl)-7V-(3-(4-(2,3-dimethyl phenyl)piperazin-l-yl)propyl)-2,5-dimethyl-l//-imidazole-4-carboxamide
1H NMR (400 MHz, DMSO-d6) δ 8.1 1 (t, J - 5.6 Hz, IH), 7.00-6.96 (m, 2H), 6.92 (d, J = 2.8 Hz, IH), 6.85 (d, J = 7.6 Hz, IH), 6.81 (U1 J = 7.2 Hz, IH), 6.78 (dd, J= 8.8, 2.8 Hz, IH), 4.28 (s, 4H), 3.28-3.23 (m, 2H), 2.83-2.81 (m, 4H), 2.56-2.49 (m, 4H), 2.39 (t, J= 6.8 Hz, 2H), 2.19 (s, 3H), 2.16 (s, 3H), 2.11 (s, 3H), 2.05 (s, 3H), 1.68-1.61 (m, 2H).
MH+ 504. Example 41: l-(2,3-dihydrobenzo[b][l,4]dioxin-6-yl)-7V-(3-(4-(2,3- dimethylphenyl)piperazin-l-yl)-2-hydroxypropyl)-2,5-dimethyl-liy- imidazole-4-carboxamide
1H NMR (400 MHz, DMSO-d6) δ 7.93 (t, J = 5.6 Hz, IH), 7.00-6.96 (m, 2H), 6.92 (d, J = 2.0 Hz, IH), 6.85 (d, J = 7.6 Hz, IH), 6.81 (d, J = 7.2 Hz, IH),
6.78 (dd, J = 8.4, 2.4 Hz, IH), 4.84 (br s, IH), 4.28 (s, 4H), 3.76-3.72 (m, IH),
3.35-3.22 (m, 2H), 2.87-2.76 (m, 4H), 2.59-2.55 (m, 4H), 2.39-2.37 (m, 2H), 2.19
(s, 3H), 2.16 (s, 3H), 2.11 (s, 3H), 2.05 (s, 3H).
MH+ 520.
Example 42: iV-(2-(4-(2,3-dichlorophenyl)piperazin-l-yl)ethyl)-l-(4- methoxyphenyl)-2,5-dimethyI-li/-imidazole-4-carboxamide
1H NMR (400 MHz, CDCl3) δ 7.40 (t, J = 6.0 Hz, IH), 7.15-7.13 (m, 2H), 7.12-7.07 (m, 2H), 7.03-6.99 (m, 2H), 6.98-6.96 (m, IH), 3.88 (s, 3H), 3.58 (q, J = 6.0 Hz, 2H), 3.11 (br s, 4H), 2.73 (br s, 4H), 2.70 (q, J = 6.4 Hz, 2H), 2.34 (s, 3H), 2.17 (s, 3H).
MH+ 502. Example 43: 7V-(3-(4-(2,3-dichlorophenyl)piperazin-l-yl)-2-hydroxypropyl)- l-(4-methoxyphenyl)-2,5-dimethyl-l/f-imidazole-4-carboxamide 1H NMR (400 MHz, CDCl3) δ 7.55 (t, J= 6.0 Hz, IH), 7.18-7.14 (m, 2H), 7.12-7.08 (m, 2H), 7.03-7.00 (m, 2H), 6.97-6.95 (m, IH), 4.03 (br s, IH), 3.87 (s, 3H)5 3.68-3.62 (m, 2H), 3.49-3.43 (m, 2H), 3.13 (br s, 4H), 2.91-2.62 (m, 4H), 2.32 (s, 3H), 2.16 (s, 3H).
MH+ 532.
Example 44: 7V-(3-(4-(2,3-dichlorophenyl)piperazin-l-yl)propyl)-2-ethyl-l-(4- methoxyphenyl)-5-methyl-l//-im-dazole-4-carboxamide
1H NMR (400 MHz, CDCl3) δ 7.77 (t, J= 5.6 Hz, IH), 7.15-7.08 (m, 4H), 7.01-6.95 (m, 3H), 3.87 (s, 3H), 3.52 (q, J= 6.4 Hz, 2H), 3.15 (br s, 4H), 2.68 (br s, 4H), 2.70 (t, J = 7.2 Hz, 2H), 2.43 (q, J = 7.6 Hz, 2H)5 2.32 (s, 3H)5 1.87-1.80 (m, 2H), 1.10 (t, J= 7.2 Hz5 3H).
MH+ 530.
Example 45: 7V-(3-(4-(2,3-dichIorophenyI)piperazin-l-yl)-2-hydroxypropyl)- 2-ethyl-l-(4-methoxyphenyl)-5-methyI-l//-imidazole-4-carboxamide 1H NMR (400 MHz5 CDCl3) δ 7.59 (t, J = 6.4 Hz, IH), 7.17-7.08 (m, 4H),
7.02-6.94 (m, 3H)5 3.97 (br s, IH)5 3.87 (s, 3H)5 3.69-3.63 (m, 2H), 3.49-3.37 (m, 2H), 3.07 (br s, 4H), 2.84 (br s, 2H), 2.65 (br s, 2H), 2.48 (q, J= 7.2 Hz, 2H)5 2.31 (s, 3H), 1.15 (t, J= 7.2 Hz, 3H).
MH+ 546.
Example 46: 7V-(2-(4-(2,3-dimethylphenyl)piperazin-l-yl)ethyl)-l-(4- methoxyphenyl^S-dimethyl-l/J-imidazole^-carboxamide
1H NMR (400 MHz5 CDCl3) δ 7.40 (t, J= 5.6 Hz5 IH)5 7.10-7.00 (m, 4H), 6.94-6.88 (m, 3H), 3.78 (s, 3H), 3.58 (q, J = 6.4 Hz, 2H), 2.94 (t, J= 4.4 Hz, 4H), . 2.69-2.66 (m, 6H), 2.33 (s, 3H), 2.26 (s, 3H), 2.22 (s, 3H), 2.17 (s, 3H).
MH+ 462.
Example 47: iV-(3-(4-(2,3-dimethylphenyl)piperazin-l-yl)propyl)-l-(4- methoxypheny l^S-dimethyl-l/y-imidazole^-carboxamide 1H NMR (400 MHz, CDCl3) δ 7.79 (t, J = 5.6 Hz, IH), 7.10-6.99 (m, 5H), 6.94-6.87 (m, 3H), 3.78 (s, 3H), 3.51 (q, J = 6.4 Hz, 2H), 2.97 (t, J = 4.4 Hz, 4H), 2.65 (br s, 4H), 2.65 (t, J = 7.2 Hz, 2H), 2.33 (s, 3H), 2.26 (s, 3H), 2.22 (s, 3H), 2.14 (s, 3H), 1.87- 1.80 (m, 2H) .
MH+ 476.
Example 48: l-(3-chlorophenyI)-Λ^3-(4-(2,3-dimethylphenyl)piperazin-l- yl)propyl)-2,5-dimethyl-l//-imidazoIe-4-carboxamide 1H NMR (400 MHz, CDCl3) 5 7.87 (t, J= 6.0 Hz, IH), 7.51-7.45 (m, 2H),
7.20-7.10 (m, IH), 7.10-7.03 (m, 2H), 6.93 (d, J = 8.0 Hz, IH), 6.87 (d, J = 7.6 Hz, IH), 3.54 (q, J= 6.4 Hz, 2H), 2.98 (t, J= 4.4 Hz, 4H), 2.65 (br s, 4H), 2.57 (t, J= 6.4 Hz, 2H), 2.36 (s, 3H), 2.26 (s, 3H), 2.22 (s, 3H), 2.17 (s, 3H).
MH+480.
Example 49: l-^-chlorophenyty-A^-^-^^-dimethylpheiiytypiperazin-l-yl)- 2-hydroxypropyl)-2,5-d-methyl-l//-imidazole-4-carboxamide
1H NMR (400 MHz, CDCl3) δ 7.64 (t, J= 6.0 Hz, IH), 7.52-7.46 (m, 2H), 7.22-7.21 (m, IH), 7.15-7.05 (m, 2H), 6.92 (d, J = 2.8 Hz, IH), 6.90 (d, J = 2.0 Hz, IH), 4.08-4.00 (m, IH), 3.70-3.62 (m, IH), 3.48-3.39 (m, IH), 2.95-2.92 (m, 4H), 2.90 (br s, 2H), 2.72 (br s, 2H), 2.60-2.58 (m, 2H), 2.35 (s, 3H), 2.26 (s, 3H), 2.20 (s, 3H), 2.19 (s, 3H).
MH+496.
Example 50: ΛL(3-(4-(3-chloro-2-methylphenyI)piperazin-l-yl)propyl)-l-(3- chlorophenyl)-2,5-dimethyl-l//-imidazoIe-4-carboxamide
1H NMR (400 MHz, CDCl3) δ 7.87 (t, J = 6.0 Hz, IH), 7.51-7.45 (m, 2H), 7.21(br s, IH), 7.10-7.03 (m, 3H), 6.94 (dd, J = 2.8, 3.2 Hz, IH), 3.52 (q, J = 6.0 Hz, 2H), 2.98 (t, J= 4.8 Hz, 4H), 2.65 (br s, 2H), 2.57 (t, J= 6.4 Hz, 2H), 2.36 (s, 3H), 2.34 (s, 3H), 2.15 (s, 3H), 1.86-1.80 (m, 2H).
MH+500. Example 51^ iV-β-^-^-chloro-l-methylphenylJpiperaziii-l-y.)^- hydroxypropyl)-l-(3-chlorophenyl)-2,5-dimethyl-l/T-imidazole-4- carboxamide
1H NMR (400 MHz, CDCl3) δ 7.55 (t, J= 5.6 Hz, IH), 7.52-7.46 (m, 2H), 7.22(br s, IH), 7.1 1-7.05 (m, 3H), 6.94-6.91 (m, IH), 3.98-3.93 (m, IH), 3.65- 3.62 (m, IH), 3.45-3.42 (m, IH), 2.94-2.89 (m, 4H), 2.80 (br s, 2H), 2.60 (br s, 2H), 2.52-2.50 (m, 2H), 2.39 (s, 3H), 2.36 (s, 3H), 2.19 (s, 3H).
MH+516.
Example 52: 7V-(3-(4-(2,3-dimethyIphenyI)piperazin-l-yl)propyl)-l-(3- fluorophenyl)-2,5-dimethyl-l/-Mmidazole-4-carboxamide
1H NMR (400 MHz, CDCl3) δ 7.86 (t, J= 6.4 Hz, IH), 7.53-7.48 (m, IH), 7.25-7.20 (m, 2H), 7.06-6.98 (m, 2H), 6.93 (d, J = 8.4 Hz, IH), 6.88(d, J = 7.2Hz, IH), 3.52(q, J = 6.4 Hz, 2H), 2.98 (t, J = 4.8Hz, 4H), 2.65 (br s, 4H), 2.57 (t, J = 6.8Hz, 2H), 2.36 (s, 3H), 2.26 (s, 3H), 2.17s, 3H), 1.87- 1.80(m, 2H).
MH+464.
Example 53: 7V-(3-(4-(2,3-dimethyIphenyl)piperazin-l-yI)-2-hydroxypropyl)- l-(3-fluorophenyl)-2,5-dimethyl-l//-imidazole-4-carboxamide
1H NMR (400 MHz, CDCl3) δ 7.57-7.49 (m, 3H), 7.23-7.21 (m, IH), 7.07 (t, J= 7.6 Hz, IH), 7.00 (d, J= 7.6 Hz, IH), 6.95-6.89 (m, 2H), 3.98-3.92 (m, IH), 3.69-3.63 (m, IH), 3.49-3.40 (m, IH), 2.94-2.86 (m, 4H), 2.81 (br s, 2H), 2.60 (br s, 2H), 2.52-2.50 (m, 2H), 2.36 (s, 3H), 2.26 (s, 3H), 2.21 (s, 3H), 2.19 (s, 3H). MH+480.
Example 54_i l-(3,4-dimethoxyphenyl)-Λr-(3-(4-(2,3-dimethyl phenyl)piperazin-l-yl)propyl)-2,5-dimethyl-l//-imidazole-4-carboxamide 1H NMR (400 MHz, CDCl3) δ 7.79 (t, J= 6.4 Hz, IH), 7.07-7.03 (m, IH),
6.96-6.92 (m, 2H), 6.88 (d, J= 7.2 Hz, IH), 6.75 (dd, J= 8.4, 2.0 Hz, IH), 6.64 (d, J = 2.4 Hz, IH), 3.95 (s, 3H), 3.87 (s, 3H), 3.51 (q, J = 6.4 Hz, 2H), 2.98 (br s, 4H), 2.65 (br s, 4H), 2.57 (br s, 2H), 2.35 (s, 3H), 2.26 (s, 3H), 2.22 (s, 3H), 2.16 (s, 3H), 1.84 (t, J= 6.0 Hz, 2H).
MH+506. Example 55^ l-(3,4-dimethoxyphenyl)-jV-(3-(4-(2,3-dimethyl phenyl)piperazin-l-yl)-2-hydroxypropyI)-2,5-dimethyl-l//-imidazole-4- carboxamide 1H NMR (400 MHz, CDCl3) δ 7.54 (t, J= 6.4 Hz, IH), 7.09-7.05 (m, IH),
6.97-6.89 (m, 2H), 6.75 (dd, J- 8.4, 2.4 Hz, IH), 6.65 (d, J = 2.4 Hz, IH), 3.95 (s, 3H), 3.88 (s, 3H)5 3.69-3.63 (m, IH), 3.49-3.40 (m, IH), 2.86 (br s, 4H), 2.80 (br s, 2H), 2.60 (br s, 2H), 2.52 (d, J = 12 Hz, 2H), 2.35 (s, 3H), 2.26 (s, 3H), 2.21 (s, 3H), 2.18 (s, 3H).
MH+522.
Example 56: 7V-(3-(4-(2,3-dimethylphenyl)piperaziii-l-yl)-2-hydroxypropyl)- l-(4-methoxyphenyl)-2,5-dimethy--l/-r--midazole-4-carboxamide 1H NMR (400 MHz, CDCl3) δ 7.55 (t, J= 5.6 Hz, IH), 7.10-7.00 (m, 4H),
6.92-6.89 (m, 3H), 3.98-3.94 (m, IH), 3.87(s, 3H), 3.68-3.62 (m, IH), 3.47-3.40 (m, IH), 2.95-2.92 (m, 4H), 2.81 (br s, 2H), 2.61 (br s, 2H), 2.52 (d, J = 6.8Hz, 2H), 2.33 (s, 3H), 2.26 (s, 3H), 2.21 (s, 3H), 2.16 (s, 3H).
MH+492.
Example 57: Λ^-^-^^-dimethylphenyOpiperazin-l-yOpropyO^S- dimethyl-l-(4-(methylthio)phenyl)-l//-imidazole-4-carboxamide
1H NMR (400 MHz, DMSO-d6) δ 8.90 (br s, IH), 7.48 (s, 4H), 7.06-7.01 (m, IH), 6.91-6.84 (m, 2H), 3.50 (d, J = 11.2 Hz, 2H), 3.38 (q, J = 6.0 Hz, 2H), 3.23-3.02 (m, 8H), 2.52 (s, 3H), 2.34 (s, 3H), 2.26 (s, 3H), 2.19 (s, 3H), 2.14 (s, 3H), 2.05-1.98 (m, 2H).
MH+ 492. Example 58: 7V-(3-(4-(2,3-dimethylphenyl)piperazin-l-yl)-2-hydroxypropyl)- 2,5-dimethyl-l-(4-(methylthio)phenyl)-l//--m-dazole-4-carboxamide
1H NMR (400 MHz, DMSO-d6) δ 10.15 (br s, IH), 8.54 (br s, IH), 7.45 (dd, J= 16.4, 8.8 Hz, 4H), 7.04 (t, J= 8.0 Hz, IH), 6.89 (dd, J= 10.4, 8.0 Hz, 2H), 4.19-3.98 (m, 3H), 3.60 (d, J= 11.6 Hz, IH), 3.53 (d, J= 1 1.6 Hz, IH), 3.38-3.27
(m, 4H), 3.17-3.01 (m, 4H), 2.52 (s, 3H), 2.28 (s, 3H), 2.25 (s, 3H), 2.18 (s, 3H), 2.13 (s, 3H).
MH+ 508.
Example 59: Λ^3-(4-(2,3-dimethyIphenyl)piperazin-l-yl)propyl)-l-(3- methoxyphenyl)-2,5-dimethyl-l//-imidazole-4-carboxamide
1H NMR (400 MHz, DMSO-O6) δ 8.79 (br s, IH), 7.54 (t, J = 8.0 Hz, IH), 7.21-7.16 (m, 2H), 7.05 (dd, J = 16.4, 8.8 Hz, 2H), 6.89 (t, J = 8.8 Hz, 2H), 3.79 (s, 3H), 3.50 (d, J = 10.8 Hz, 2H), 3.37 (q, J = 6.0 Hz, 2H), 3.28-3.07 (m, 8H), 2.33 (s, 3H), 2.27 (s, 3H), 2.19 (s, 3H), 2.14 (s, 3H), 2.08-2.00 (m, 2H).
MH+ 476.
Example 60: Λ^(3-(4-(2,3-dimethylphenyl)piperazin-l-yl)-2-hydroxypropyl)- l-(3-methoxyphenyl)-2,5-dimethyl-l//-imidazoIe-4-carboxamide
1H NMR (400 MHz, DMSO-d6) δ 10.01 (br s, IH), 8.41 (br s, IH), 7.52 (t, J = 8.0 Hz, IH), 7.16 (dd, J = 8.0, 2.4 Hz, IH), 7.07-7.00 (m, 3H), 6.89 (dd, J = 10.4, 8.0 Hz, 2H), 3.79 (s, 3H), 3.78-3.51 (m, 3H), 3.37-3.28 (m, 4H), 3.18-2.99 (m, 6H), 2.26 (s, 3H), 2.25 (s, 3H), 2.18 (s, 3H), 2.13 (s, 3H).
MH+ 492.
Example 61: l-(2,4-dimethoxyphenyl)-7V-(3-(4-(2,3-dimethylphenyl) piperazin-l-yl)propyl)-2,5-dimethyl-17/-imidazole-4-carboxamide 1H NMR (400 MHz, DMSO-d6) δ 8.85 (br s, IH), 7.21-7.17 (m, IH),
7.10-7.02 (m, 2H), 6.91-6.85 (m, 3H), 3.84 (s, 3H), 3.78 (s, 3H), 3.50 (d, J = 1 1.2 Hz, 2H), 3.38 (d, J = 5.6 Hz, 2H), 3.23-3.08 (m, 8H), 2.34 (s, 3H), 2.27 (s, 3H), 2.19 (s, 3H), 2.14 (s, 3H), 2.04-2.01 (m, 2H).
MH+ 506.
Example 62: l-(2,4-dimethoxyphenyl)-Λ/-(3-(4-(2,3-dimethylphenyl) piperazin-l-yl)-2-hydroxypropyl)-2,5-dimethyl-l//-imidazole-4-carboxaiiiide
1H NMR (400 MHz, DMSO-d6) δ 7.95 (t, J = 5.6 Hz, IH), 7.90 (br s, IH), 7.19 (dd, J= 8.8, 3.2 Hz, IH), 7.00-6.94 (m, 2H), 6.86-6.81 (m, 3H), 3.81 (s, 3H),
3.77 (s, 3H), 3.75-3.72 (m, IH), 2.81 (br s, 4H), 2.74 (br s, 2H), 2.55 (br s, 4H), 2.39 (d, J= 6.0 Hz5 2H), 2.22 (s, 3H), 2.16 (s, 3H), 2.1 1 (s, 3H), 2.08 (s, 3H).
MH+ 522.
Example 63: (_S)-Λ'-(3-(4-(2,3-dichlorophenyl)piperazin-l-yl)-2-hydroxy propyl)-2,5-dimethyl-l-phenyl-l^r-imidazole-4-carboxamide
1H NMR (400 MHz, DMSO-d6) δ 7.99-7.97 (m, IH), 7.58-7.51 (m, 3H), 7.36-7.34 (m, 2H), 121-1 Al (m, 2H), 7.12-7.10 (m, IH), 4.85 (bs, IH), 3.76 (bs, IH), 3.34-3.24 (m ,4H), 3.02 (bs, 4H), 2.59 (m ,4H), 2.20 (s, 3H), 2.05 (s, 3H).
MH+ 501.
Example 64: (5)-Λr-(3-(4-(2,3-dichlorophenyl)piperazin-l-yl)-2-hydroxy propyl)-5-methyl-l-phenyl-2-propyl-l//-imidazole-4-carboxamide 1H NMR (400 MHz, DMSO-d«) δ 7.95-7.92 (m, IH), 7.57-7.49 (m, 3H),
7.34-7.32 (m, 2H), 7.28-7.22 (m, 2H), 7.11-7.08 (m, IH), 4.84(d, J=4.4 Hz, IH), 3.76-3.74 (m, IH), 3.32-3.30 (m, 2H), 3.02 (m, 4H), 2.61-2.57 (m, 4H), 2.40 (d, J=6.0 Hz, 2H), 2.32 (t, J=7.6 Hz, 2H), 2.18 (s, 3H), 1.43-1.38 (m, 2H), 0.66 (t, J= 7.2 Hz, 3H).
MH+ 529.
Example 65: 7V-(3-(4-(2,3-dichlorophenyI)piperazin-l-yl)-2,2-difluoro propyl)-2,5-dimethy--l-phenyl-li/-imidazoIe-4-carboxamide 1H NMR (400 MHz, DMSO-d6) δ 8.10-8.07 (m, IH), 7.58-7.49 (m, 3H),
7.38-7.35 (m, 2H), 7.29-7.24 (m, 2H), 7.13-7.11 (m, IH), 3.81 (td, J=14.4, 6.4 Hz, 2H), 3.04-3.02 (m, 4H), 2.92-2.85 (m, 2H), 2.73-2.69 (m, 4H), 2.20 (s, 3H), 2.05 (s, 3H).
MH+ 523.
Example 66: Λ^-^-^^-dichlorophenytypiperazin-l-yl^^-difluoro propyI)-5-methyl-l-phenyl-2-propyl-l/f-imidazole-4-carboxamide λH NMR (400 MHz, DMSO-d6) δ 8.04 (bs, IH), 7.58-7.52 (m, 3H), 7.36- 7.34 (m, 2H), 7.30-7.25 (m, 2H), 7.12-7.10 (m, IH), 3.84-3.82 (m, 2H), 3.50-3.20
(m, 2H), 3.06 (m, 4H), 2.74 (m, 4H), 2.33 (t, J=7.6 Hz, 2H), 2.19 (s, 3H), 1.45- 1.39 (m, 2H), 0.66 (t, J= 7.2 Hz5 3H).
MH+ 551.
Example 67; Λ^-(3-(4-(2,3-dimethylphenyl)piperazin-l-yl)propyI)-l-(2-fluoro phenyl)-2,5-dimethyI-l//-imidazole-4-carboxamide
1H NMR (400 MHz, CDCl3) δ 7.59 (bs, IH), 7.56-7.50 (m, IH), 7.35- 7.30 (m, 2H), 7.27-7.22 (m, IH), 7.10-7.06 (m, IH), 6.98-6.93 (m, 2H), 3.61-3.50 (m, 3H), 3.37-2.99 (m, HH), 2.35 (s, 3H), 2.27 (s, 3H), 2.21 (s, 3H), 2.18 (s, 3H), 2.19-2.10 (m, 2H).
MH+ 464.
Example 68: jV-(3-(4-(2,3-dimethylphenyl)piperazin-l-yl)-2-hydroxypropyl)- l-(2-fluorophenyl)-2,5-dimethyl-l//-imidazole-4-carboxamide
1U NMR (400 MHz, CDCl3) δ 8.05 (m, IH), 7.62-7.57 (m, IH), 7.40- 7.25 (m, 3H), 7.1 1-7.07 (m, IH), 6.99-6.95 (m, 2H), 4.56-4.54 (m, IH), 3.81-3.74 (m, 2H), 3.66-3.63 (m, 2H), 3.61-3.49 (m, 2H), 3.40-3.18 (m, 4H), 3.11 (m, 2H), 2.37 (s, 3H), 2.31 (s, 3H), 2.27 (s, 3H), 2.19 (s, 3H).
MH+ 480.
Example 69: 7V-(2-(4-(3-chloro-2-fluorophenyl)piperazin-l-yl)ethyl)-2,5- dimethyl-l-phenyl-l//-imidazole-4-carboxamide 1H NMR (400 MHz, CDCl3) δ 7.56-7.50 (m, 3H), 7.42 (t, J = 5.2 Hz),
7.20-7.16 (m, 2H), 7.01-6.95 (m, 2H), 6.87-6.82 (m, IH), 3.57 (q, dd = 12.4, 6.4 Hz, 2H), 3.52 (t, J = 4.8 Hz, IH), 2.72-2.66 (m, 6H), 2.35 (s, 3H), 2.18 (s, 3H).
MH+ 456. Example 70: yV-(3-(4-(3-chloro-2-fluorophenyI)piperazin-l-y l)propyl)-2,5- dimethyl-l-phenyl-l//-imidazole-4-carboxamide
1H NMR (400 MHz, CDCl3) δ 7.90 (brs, IH), 7.55-7.47 (m, 3H), 7.17
(dd, J = 7.6, 1.6 Hz, 2H), 6.99-6.93 (m , 2H), 6.87-6.82 (m, IH), 3.52 (q, J = 6.4 Hz, 2H), 3.21 (t, J = 4.8 Hz, 2H), 2.67 (brs, 4H), 2.57 (t, J= 6.8 Hz, 2H), 2.35 (s,
3H), 2.11 (s, 3H), 1.86-1.80 (m, IH). MH+ 470.
Example 71: A^-^-P-chloro^-methylpheny^piperazin-l-yOethyl)^^- dimethyl-l-phenyI-l//-imidazole-4-carboxamide
1H NMR (400 MHz, CDCl3) δ 7.56-7.49 (m, 3H), 7.42 (m, IH), 7.18 (dd, J = 8.0, 1.6 Hz, 2H), 7.08 (dd, J = 4.8, 0.8 Hz, 2H), 6.97-6.93 (m, IH), 3.59 (q, J = 6.4 Hz, 2H), 2.95 (t, J = 4.8 Hz, 4H), 2.68 (t, J = 6.4 Hz, 6H), 2.38 (s, 3H), 2.34 (s, 3H), 2. 19 (s, 3H).
MH+ 452.
Example 72: .V-(3-(4-(3-chloro-2-methylphenyl)piperazin-l-yl)propyl)-2,5- dimethyl-l-phenyl-l//-imidazole-4-carboxamide 1H NMR (400 MHz, CDCl3) δ 7.84 (brs, IH), 7.55-7.50 (m, 3H), 7.17
(dd, J = 8.4, 2.0 Hz, 2H), 7.08-7.03 (m, 2H), 6.97-6.94 (m, 1H),3.53 (q, J = 6.4 Hz, 2H), 3.00 (t, J= 4.8 Hz, 4H), 2.66 (brs, 3H), 2.58 (t, J= 6.8 Hz, 3H), 2.35 (s, 3H), 2.34 (s, 3H), 2.15 (s, 3H).
MH+ 466.
Example 73: 2,5-dimethyI-jV-(2-(4-(2-methylquinoIin-8-yl)piperazin-l-yl) ethyl)-l-phenyl-l//-imidazoIe-4-carboxamide
1H NMR (400 MHz, CDCl3) δ 7.98 (d, J = 8.4 Hz, IH), 7.54-7.51 (m, 3H), 7.38-7.36 (m, 2H), 7.23-7.12 (m, 3H), 3.64 (dd, J = 5.8, 6.0 Hz, 2H), 3.51 (brs, 3H), 2.90 (brs, 3H), 2.76-2.73 (m, IH), 2.74 (s, 3H), 2.3.6 (s, 3H), 2.19 (s, 3H).
MH+ 469. Example 74: 2,5-dimethyl-l-phenyl-Λ^-(2-(4-(quinolin-8-yl)piperazin-l- ytyethyty-liZ-imidazole^-carboxamide
1H NMR (400 MHz, CDCl3) δ 8.89 (dd, J= 2.4, 4.4 Hz, IH), 8.11 (dd, J
= 1.6, 8.0 Hz, IH), 7.56-7.44 (m, H), 7.38 (dd, J = 4.4, 8.4 Hz, IH), 7.21-7.16 (m, 3H), 3.65 (dd, J = 5.4, 6.0 Hz, 2H), 3.50 (brs, 4H), 2.91 (brs, 4H), 2.77 (brs, 2H),
2.37 (s, 3H), 2.20 (s, 3H). • MH+ 455.
Example 75^ 7V-(3-(4-(3-chloro-2-methylphenyl)piperazin-l-yl)-2- hydroxypropyl)-2,5-dimethyl-l-phenyI-l/f-imidazoIe-4-carboxamide
1H NMR (400 MHz, CDCl3) δ 7.58-7.47 (m, 3H), 7.18 (dd, J = 2.0, 8.4 Hz, 2H), 7.11-7.06 (m, 2H), 6.95-6.91 (m, IH), 3.99-3.93 (m, IH), 3.69-3.63 (m, IH), 3.48-3.41 (m, IH), 2.95-2.88 (m, 4H), 2.80 (brs, 2H), 2.60 (brs, 2H), 2.52 (d, J= 6.8 Hz, 2H), 2.35 (s, 3H), 2.33 (s, 3H), 2.18 (s, 3H).
MH+ 482.
<Preparation of imidazoles containing carbocyclic ring>
Preparation Example 8: Ethyl l-cyclopentyI-2,5-dimethyl-l//-imidazole-4- carboxylate (compound 19)
Figure imgf000069_0001
Step 1 : 4-ri-dimethylamino-ethyl-(Z)-ylidenel-2-methyl-4H-oxazole-5-one (compound 15)
N-Acetylglycine (10 g, 85.5 mmol) was dissolved in Ν,Ν'- dimehtylacetamide (20 mL, 21.4 mmol) and POCl3 (19.6 ml, 21.4 mmol) was added dropwise slowly at 0°C . The reaction mixture was stirred at 50 °C for 3 hrs and then cooled to room temperature. CH2Cl2 (50 mL) was added and the mixture poured into ice-water. The resulting solution was basified with ammonium hydroxide to over than pH 8. The organic extracts were washed with 50 ml water, dried over MgSO4, filtered and evaporated under reduced pressure. The residue was purified by normal phase preparative column and the desired compound was obtained as an orange solid (6.7 g, 47%).
MH+ 169.
Step 2: (ip-ethyl 2-acetamido-3-(dimethylamino)but-2-enoate (compound 16) 4-[ 1 -dimethylamino-eth-(Z)-y lidene]-2-methy l-4H-oxazole-5-one
(compound 15, 7.54 g, 44.8 mmol) was dissolved in ethanol (50 mL) and sodium hydride (179 mg, 4.5 mmol, 60% dispersion in mineral oil) wad added at room temperature. The solution was refluxed for lhr. The solvent was evaporated and the crude product was used without any further purification for the next step.
MΗ+ 215.
Step 3: (ip-Ethyl 2-acetamido-3-(cyclopentylamino)but-2-enoate (compound 18)
(E)-ethyl 2-acetamido-3-(dimethylamino)but-2-enoate (compound 16, 1 g, 4.67 mmol) and cyclopentylamine (0.5 mL) were stirred at room temperature in AcOH (10 mL) for overnight. The reaction mixture was diluted slowly with water (10 mL) and evaporated under reduced pressure to obtain the desired product as a dark brown oil, which could be used without any further purification for the next step.
MH+ 256.
Step 4: Ethyl l-cyclopentyl^^-dimethyl-lH-imidazole^-carboxylate (compound 19)
Ammonium sulfate (100 mg) was added to a solution of (ϋT)-ethyl 2- acetamido-3-(cyclopentylamino)but-2-enoate (compound 18, 1.5 g, 5.9 mmol) and hexamethyldisilazane (15 mL) and refluxed overnight at 150 °C . The reaction mixture was evaporated and extracted with EA and water. The organic layer was evaporated and the residue was purified with 20% methanol in CH2Cl2 to produce as a light brown solid (1.0 g, 71.4 % yield).
1H NMR (400 MHz, CDCl3) δ 4.31 (q, J= 6.5, 2H), 3.77 (m, IH), 2.59 (s, 3H), 2.33 (s, 3H), 2.15-2.06 (m, 2H), 1.83-1.80 (m, 2H), 1.72-1.54 (m, 2H), 1.32 (t, J = 6.5 3H).
MH+ 237.
Example 76: l-cyclopentyl-Λ^-^-^S-dimethylpheiiytypiperaziii-l- yl)propyl)-2,5-dimethyl-l/-r-imidazole-4-carboxamide
1H NMR (400 MHz, CDCl3) δ 8.03 (brs, IH), 7.20-7.18 (m, IH), 7.11- 7.06 (m, 2H), 3.79-3.75 (m, IH), 3.65 (t, J- 6.9 Hz, 2H), 2.91 (brs, 3H), 2.86 (brs, 4H), 2.74-2.70 (m, 2H), 2.52 (s, 3H), 2.33 (s, 3H), 2.25 (s, 3H), 2.1 1-1.95 (m, 4H), 1.73-1.36 (m, 6H).
MH+ 438.
Example 77: l-cycIopentyl-Λ^3-(4-(2,3-dimethylphenyl)piperazin-l-yI)-2- hydroxypropyl)-2,5-d.methy--li/-imidazoIe-4-carboxamide
1H NMR (400 MHz, CDCl3) δ 7.21-7.18 (m, IH), 7.12-7.07 (m, 2H), 3.80-3.75 (m, IH), 3.66 (d, J = 6.9 Hz, 2H), 3.49-3.47 (m, IH), 3.1 1 (brs, 2H),
2.94 (brs, 4H), 2.79-2.77 (m, 2H), 2.53 (s, 3H), 2.34 (s, 3H), 2.25 (s, 3H), 2.11-
1.95 (m, 4H), 1.77-1.44 (m, 4H).
MH+ 454. Example 78: jV-(3-(4-(3-chloro-2-methylphenyl)piperazin-l-yl)propyl)-l- cyclopentyl-2,5-dimethyl-l//-imidazole-4-carboxamide
1H NMR (400 MHz, CDCl3) δ 7.24-7.19 (m, IH), 7.1 1-7.07 (m, 2H), 6.94 (brs, IH), 3.82-3.79 (m, IH), 3.71 (t, J = 6.6 Hz, 2H), 3.21 (brs, 3H), 2.89 (brs, 4H), 2.79-2.77 (m, 2H), 2.59 (s, 3H), 2.20 (s, 3H), 2.1 1-1.95 (m, 4H), 1.77-1.44 (m, 4H).
MH+ 458.
Example 79l Λ^3-(4-(3-chloro-2-methylphenyl)piperazin-l-yl)-2- hydroxypropyl)-l-cyclopentyI-2,5-dimethyl-l//-imidazole-4-carboxamide
1H NMR (400 MHz, CDCl3) δ 7.24-7.19 (m, IH), 7.1 1-7.07 (m, 2H), 6.94 (brs, IH), 3.84-3.80 (m, IH), 3.69-3.65 (m, 2H), 3.44-3.40 (m, IH), 3.20 (brs, 3H), 2.81 (brs, 4H), 2.79-2.77 (m, 2H), 2.59 (s, 3H), 2.20 (s, 3H), 2.1 1-1.95 (m, 4H), 1.77-1.44 (m, 4H).
MH+ 474.
Example 80: l-cyclopentyl-Λ'-(4-(4-(2,3-dimethylphenyl)piperazin-l- yl)butyl)-2,5-dimethyl-l//-imidazole-4-carboxamide
1H NMR (400 MHz, CDCl3) δ 8.20 (brs, IH), 7.24 (d, J = 7.2 Hz, IH), 7.1 1-7.07 (m, 2H), 3.82 (t, J = 6.4 Hz5 2H), 3.54 (m, IH), 3.30 (brs, 3H), 2.81 (brs, 4H), 2.79-2.77 (m, 2H), 2.59 (s, 3H), 2.20 (s, 3H), 2.11-1.85 (m, 5H), 1.77-1.44 (m, 5H).
MH+ 452.
Example 81: l-cydopentyl-Λ'-CZ^^^-dichlorophenyOpiperazin-l-yOethyl)- 2,5-dimethyl-l//-imidazole-4-carboxamide
1H NMR (400 MHz, CDCl3) δ 7.90 (brs, IH), 7.26 (d, J = 7.1 Hz, IH), 7.14-7.07 (m, 2H), 3.88 (t, J= 7.2 Hz, 2H), 3.64 (m, IH), 3.21 (brs, 3H), 2.98 (brs, 5H), 2.74-2.60 (m, 2H), 2.54 (s, 3H), 2.44 (s, 3H), 2.1 1-1.85 (m, 4H), 1.77-1.44 (m, 4H).
MH+ 464. <Preparation of diary limidazoles>
Preparaion Example 9: Ethyl 5-methyl-l,2-diphenyI-l//-imidazole-4- carboxylate (compound 24)
Figure imgf000072_0001
Step 1 : N-Phenylbenzimidamide (compound 23)
To ΝaHMDS (49 mL, 48.5 mmol, 1.0 M solution in THF) was added dropwise a solution of aniline (compound 11a, 4.5 mL, 48.5 mmol) in anhydrous THF (10 mL) under N2. After 20 min, a solution of benzonitrile (compound 21, 5.0 mL, 48.5 mmol) in anhydrous THF (10 mL) was slowly added. The reaction mixture was stirred for 12 hrs, poured into cold water and extracted with EtOAc. The organic layer was dried over anhydrous MgSO4, filtered, and concentrated in vacuo.
Step 2: Ethyl 5-methyl-L2-diphenyl-lH-imidazole-4-carboxylate (compound 24)
A mixture of N-phenylbenzimidamide (compound 22, 1.0 g, 5.10 mmol), 3-bromo-2-oxovalerate (compound 23, 1.3 g, 6.12 mmol) and NaHCO3 in /-PrOH was stirred at 90 °C for 12 hrs. The reaction mixture was concentrated under reduced pressure, then the residue was diluted with EtOAc and washed with H2O. The organic layer was dried over anhydrous MgSO4, filtered, and concentrated in vacuo. The crude product was purified by flash column chromatography (Biotage Isolera™ FLASH Purification System was used for normal phase column chromatography with EtOAc and hexane) to provide the title compound (0.86 g, 55 %) as a yellow solid. Example 82: Λr-(3-(4-(2,3-dimethyIphenyl)piperazin-l-yI)-2-hydroxypropyl)- l-(441uorophenyl)-5-methyl-2-phenyl-l//-imidazole-4-carboxam.de
1H NMR (400 MHz, CDCl3) δ 7.92-7.79 (m, IH), 7.38-7.31 (m, 2H), 7.28-7.16 (m, 7H), 7.07 (t, J = 9.6 Hz, IH), 6.89 (d, J= 8.0 Hz, 2H), 4.05-3.95 (m, IH), 3.87 (br s, IH), 3.76-3.68 (m, IH), 3.53-3.42 (m, IH), 2.99-2.74 (m, 6H), 2.68-2.51 (m, 4H), 2.44 (s, 3H), 2.26 (s, 3H), 2.21 (s, 3H).
MH+ 542.
Example 83: 7V-(3-(4-(2,3-dimethylphenyl)piperazin-l-yl)propyl)-l-(4- fluorophenyl)-5-methyl-2-phenyl-l/J-imidazole-4-carboxamide
1H NMR (400 MHz, CDCl3) δ 7.89-7.82 (m, IH), 7.34-7.12 (m, 9H), 6.97 (t, J = 8.0 Hz, IH), 6.86 (d, J= 8.0 Hz, IH), 6.74 (d, J = 8.0 Hz, IH), 3.55 (q, J = 6.0 Hz, 2H), 2.93 (t, J= 4.8 Hz, 4H), 2.75-2.52 (m, 6H), 2.45 (s, 3H), 2.25 (s, 3H), 2.20 (s, 3H), 1.87 (quint, J = 6.8 Hz, 2H).
MH+ 526.
Example 84^ ΛL(3-(4-(3-chloro-2-methylphenyI)piperazin-l-yl)-2- hydroxypropyl)-l-(441uorophenyl)-5-methyl-2-phenyI-li/-imidazole-4- carboxamide
1H NMR (400 MHz, CDCl3) δ 7.73 (t, J = 6.0 Hz, IH), 7.37-7.13 (m, 9H), 7.12-7.05 (m, 2H), 6.93-6.89 (m, IH), 4.04-3.95 (m, IH), 3.80 (br s, IH), 3.75- 3.66 (m, IH), 3.53-3.44 (m, IH), 2.99-2.76 (m, 6H), 2.67-2.52 (m, 4H), 2.44 (s, 3H), 2.33 (s, 3H).
MH+ 562. Example 85: Λ^3-(4-(3-chloro-2-methyIphenyl)piperazin-l-yl)propyl)-l-(4- fluorophenyI)-5-methyl-2-phenyl-l//-imidazole-4-carboxamide 1H NMR (400 MHz, CDCl3) δ 7.97-7.89 (m, IH), 7.34-7.1 1 (m, 9H), 7.04
(d, J = 7.2 Hz, IH), 6.95 (t, J= 8.0 Hz, IH), 6.70 (d, J = 12 Hz, IH), 3.55 (q, J = 6.4 Hz, 2H), 2.94 (t, J= 4.8 Hz, 4H), 2.67-2.54 (m, 6H), 2.45 (s, 3H), 2.32 (s, 3H), 1.86 (quint, J= 6.4 Hz, 2H).
MH+ 546.
Example 86: Λr-(3-(4-(2,3-dimethylphenyl)piperazin-l-yl)propyl)-5-methyI- l,2-diphenyl-l//-imidazole-4-carboxamide
1H NMR (400 MHz, CDCl3) δ 9.34 (br s, IH), 7.69-7.43 (m, 5H), 7.41- 7.24 (m, 5H), 7.09 (t, J = 7.6 Hz, IH), 7.01-6.92 (m, 2H), 3.71-3.61 (m, 4H), 3.59-3.48 (m, 2H), 3.47-3.37 (m, 2H), 3.23-3.04 (m, 4H), 2.52 (s, 3H), 2.47-2.36 (m, 2H), 2.27 (s, 3H), 2.19 (s, 3H).
MH+ 508. Example 87: Λ^-^-^-chloro^-methylphenytypiperaziii-l-ytypropyiy-S- methyl-l,2-dipheny--l//-imidazole-4-carboxamide
1H NMR (400 MHz, CDCl3) δ 7.99 (br s, IH), 7.56-7.463 (m, 3H), 7.40- 7.35 (m, 2H), 7.33-7.14 (m, 6H), 7.1 1 (t, J = 8.0 Hz, IH), 7.01 (dd, J = 8.0 , 0.8 Hz, IH), 3.73-3.54 (m, 6H), 3.31-3.22 (m, 2H), 3.17-3.01 (m, 4H), 2.45 (s, 3H), 2.41-2.33 (m, 2H), 2.31 (s, 3H).
MH+ 528.
Example 88: l-^-bromophenyty-Λ^-^-^-chlorophenytypiperazin-l- yl)propyI)-2-(2,4-dichlorophenyl)-5-ethyl-l//-imidazole-4-carboxamide
1H NMR (400 MHz, CDCl3) δ 8.52 (br s, IH), 7.47 (d, J = 8.0 Hz, 2H), 7.11-7.07 (m, 3H), 6.98-6.94 (m, 3H), 6.78 (d, J = 8.0 Hz, IH), 6.72 (s, IH), 6.59 (d, J = 8.4 Hz, IH), 3.57 (q, J = 5.6 Hz, 2H), 3.21-3.18 (m, 4H), 2.96 (q, J = 7.2 Hz, 2H), 2.62-2.55 (m, 6H), 1.85- 1.79 (m, 2H), 1.05 (t, J= 7.2 Hz, 3H).
MH+ 674. Example 89: l-(4-bromophenyl)-2-(2,4-dichlorophenyl)-.V-(3-(4-(2,3- dichlorophenyl)piperazin-l-yI)propyl)-5-ethyl-lH-imidazoIe-4-carboxamide 1H NMR (400 MHz, CDCl3) δ 8.27 (br s, IH), 7.49 (d, J = 8.4 Hz, 2H),
7.21 (d, J = 8.4 Hz, 2H), 7.14-7.09 (m, 2H), 7.04-6.98 (m, 3H), 6.59 (dd, J = 8.4, 1.6 Hz5 IH), 3.56 (q, J= 6.0 Hz, 2H), 3.11-3.06 (m, 4H), 3.00-2.92 (m, 2H), 2.67- 2.62 (m, 4H), 2.60-2.57 (m, 2H), 1.86-1.79 (m, 2H), 1.06 (t, J = 7.2 Hz, 3H).
MH+ 708.
Example 90: l-(4-bromophenyl)-2-(2,4-dichlorophenyl)-A^(3-(4-(2,3- dimethylphenyOpiperazin-l-y^propyO-S-ethyl-l/f-imidazole^-carboxamide
1H NMR (400 MHz, CDCl3) δ 7.49-7.46 (m, 2H), 7.26 (d, J = 2.0 Hz, IH), 7.22 (d, J = 8.4 Hz, IH), 7.13 (dd, J = 8.0, 2.0 Hz, IH), 7.00-6.96 (m, 3H),
6.87 (d, J = 7.2 Hz, IH), 6.67 (d, J= 8.0 Hz, IH), 3.53 (q, J = 6.4 Hz, 2H), 2.96-
2.90 (m, 6H), 2.78-2.57 (m, 6H), 2.23 (s, 3H), 2.16 (s, 3H), 1.93-1.85 (m, 2H),
1.04 (t, J= 7.2 Hz, 3H).
MH+ 668.
Example 91: 5-((lJ^-l,2,4-triazol-l-yl)methyl)-^-(3-(4-(3-chloro-2- methylphenyl)piperazin-l-yI)propyl)-l,2-diphenyl-l//-imidazoIe-4- carboxamide 1H NMR (400 MHz, CDCl3) δ 8.27 (s, IH), 8.22 (t, J= 5.2 Hz, IH), 7.80
(s, IH), 7.54-7.42 (m, 3H), 7.30 (d, J = 8.4 Hz, 2H), 7.28-7.18 (m, 3H), 7.17-7.09 (m, 2H), 7.03 (d, J = 7.6 Hz, IH), 6.90 (t, J = 8.0 Hz, IH), 6.63 (d, J = 8.0 Hz, IH), 5.65 (s, 2H), 3.60 (q, J = 6.0 Hz, 2H), 2.95 (t, J= 4.8 Hz, 4H), 2.81-2.56 (m, 6H), 2.32 (s, 3H), 1.87 (q, J= 6.4 Hz, 2H).
MH+ 595.
Example 92: Λ^-^-^^-dimethylphenyOpiperazin-l-ytypropyO-l-isobutyl- 2,5-dimethyl-l//-imidazole-4-carboxamide dihydrochloride 1H NMR (400 MHz, MeOH-d4) δ 7.09-7.06 (m, IH), 7.01-6.96 (m, 2H),
3.99 (d, J = 8.0 Hz, 2H), 3.71-3.68 (m, 2H), 3.63 (s, 3H), 3.56 (t, J = 6.4 Hz, 2H), 3.42-3.38 (m 2H), 3.36-3.34 (m, 4H), 3.33-3.5 (m, 4H), 2.68 (s, 3H), 2.58 (s, 3H)5 2.25 (s, 6H), 2.20-2.12 (m, 2H), 0.99 (s, 3H), 0.98 (s, 3H).
MH+ 426 (-2HC1). Example 93: Λ^3-(4-(3-chloro-2-methyIphenyl)piperazin-l-yl)propyl)-l- isobuty--2,5-dimethyl-l/f-imidazoIe-4-carboxamide dihydrochloride
1H NMR (400 MHz, MeOH-d4) δ 8.21 (brs, IH), 7.22 (d, J= 7.0 Hz, IH), 7.15-7.12 (m, 2H), 3.88 (t, J = 6.3 Hz, 2H), 3.53 (m, 2H), 3.30 (brs, 3H), 2.80- 2.77 (m, IH), 2.64 (s, 3H), 2.58 (s, 3H), 2.54-2.49 (m, 2H), 2.22 (s, 3H), 2.09 (s, 3H), 1.14 (s, 3H), 0.88 (s, 3H).
MH+ 447 (-2HC1).
Example 94: Λr-(3-(4-(2,3-dimethylphenyl)piperazin-l-yl)-2-hydroxypropyl)- l-isobutyl-2,5-dimethyl-l//-imidazole-4-carboxamide dihydrochloride
1H NMR (400 MHz, MeOH-d4) δ 8.11 (brs, IH), 7.24 (d, J= 6.9 Hz, IH), 7.17-7.14 (m, 2H), 3.94 (t, J= 6.3 Hz, 2H), 3.47 (m, IH), 3.53 (m, 2H), 3.29 (brs, 3H), 2.82-2.79 (m, IH), 2.64 (s, 3H), 2.58 (s, 3H), 2.22 (s, 3H), 2.01 (s, 3H), 1.13 (s, 3H), 0.94 (s, 3H).
MH+442 (-2HC1).
Example 95: iV-(3-(4-(2,3-dimethylphenyl)piperazin-l-yl)propyl)-2,5- dimethyl-l-propyl-l//-imidazole-4-carboxamide dihydrochloride
1H NMR (400 MHz, MeOH-d4) δ 7.92 (brs, IH), 7.18 (d, J= 7.2 Hz, IH), 7.15-7.10 (m, 2H), 3.94 (t, J = 6.2 Hz, 2H), 3.53 (m, 2H), 3.29-3.25 (m, 5H), 2.82-2.79 (m, IH), 2.64 (s, 3H), 2.58 (s, 3H), 2.42-2.40 (m, 2H), 2.22 (s, 3H), 2.01 (s, 3H), 1.70 (m, 2H), 0.93 (t, J = 3.4 Hz, 3H).
MH+412 (-2HC1).
Example 96: Λ^β-^-^S-dimethylphenytypiperazin-l-yl^-hydroxypropyl)- 2,5-dimethyl-l-propyl-l//-imidazoIe-4-carboxamide dihydrochloride 1H NMR (400 MHz, MeOH-d4) δ 8.04 (brs, IH), 7.22 (m, IH), 7.17-7.15
(m, 2H), 3.89 (t, J = 5.4 Hz, 2H), 3.71-3.69 (m, IH), 3.53-3.51 (m, 2H), 3.29-3.25 (m, 5H)5 2.83-2.80 (m, IH)5 2.63 (s, 3H), 2.57 (s, 3H)5 2.42-2.40 (m, IH)5 2.27 (s, 3H)5 2.03 (s, 3H)5 1.79 (m, 2H)5 0.97 (t, J = 3.8 Hz5 3H).
MH+428 (-2HC1). Example 97: Λ^-(4-(3-chloro-2-methyIphenyl)piperaziii-l-yl)propyl)-2,5- dimethyl-l-propyI-l//-imidazole-4-carboxamide dihydrochloride
1H NMR (400 MHz, MeOH-d4) δ 8.05 (brs, IH)5 7.23 (m, IH), 7.18-7.15 (m, 2H), 3.88 (t, J= 6.4 Hz5 2H)5 3.55-3.53 (m, 2H), 3.29-3.25 (m, 5H), 2.83-2.80 (m, IH), 2.63 (s, 3H), 2.57 (s, 3H)5 2.42-2.40 (m, IH), 2.23-2.21 (m, 2H)5 2.03 (s, 3H), 1.79 (m, 2H), 0.97 (t, J = 3.8 Hz5 3H).
MH+432 (-2HC1).
Example 98i 7V-(3-(4-(3-chloro-2-methylphenyl)piperazin-l-yl)-2- hydroxypropyl)-2,5-dimethyl-l-propyl-l//-imidazole-4-carboxamide dihydrochloride
1H NMR (400 MHz, MeOH-d4) δ 8.07 (brs, IH), 7.20 (m, IH), 7.19-7.15 (m, 2H)5 3.88 (t, J = 6.4 Hz, 2H)5 3.73-3.70 (m, IH), 3.55-3.53 (m, 2H), 3.29-3.25 (m, 5H), 2.83-2.80 (m, IH), 2.63 (s, 3H), 2.57 (s, 3H), 2.42-2.40 (m, IH), 2.03 (s, 3H), 1.80 (m, 2H), 0.97 (t, J = 3.9 Hz, 3H).
MH+448 (-2HC1).
Example 99: 7V-(3-(4-(2,3-dimethylphenyI)piperazin-l-yl)propyl)-l-(2- methoxyphenyI)-2,5-dimethyl-l//-imidazole-4-carboxamide dihydrochloride
1H NMR (400 MHz, CDCl3) δ 7.76 (t, J - 5.6 Hz, IH), 7.45 (td, J = 8.8, 1.6 Hz IH), 7.13-7.02 (m, 4H)5 6.94-6.86 (m, 2H)5 3.77 (s, 3H), 3.51 (q, J = 6.4 Hz, 2H)5 2.97 (t, J = 4.8 Hz, 4H), 2.90 (br s, 2H)5 2.65 (t, J = 5.6 Hz, 4H)5 2.56 (t, J= 6.8 Hz, 2H), 2.29 (s, 3H)5 2.26 (s, 3H)5 2.22 (s, 3H), 2.09 (s, 3H).
MH+ 476.
Example 100: .V-(3-(4-(2,3-dimethylphenyl)piperazin-l-yl)-2-hydroxypropyl)- l-(2-methoxyphenyl)-2,5-dimethyl-l/-r-imidazole-4-carboxamide
dihydrochloride 1H NMR (400 MHz, CDCl3) δ 7.55 (t, J = 5.6 Hz, IH), 7.45 (td, J = 8.4,
2.0 Hz IH), 7.13-7.05 (m, 4H), 6.90 (t, J - 6.8 Hz, 2H), 3.99-3.93 (m, IH), 3.78
(s, 3H), 3.69-3.62 (m, IH), 3.47-3.40 (m, IH), 2.94-2.86 (m, 4H), 2.80 (br s, 2H),
2.60 (br.s, 2H), 2.52 (d, J = 6.4 Hz, 4H), 2.29 (s, 3H), 2.26 (s, 3H), 2.21 (s, 3H), 2.1 1 (s, 3H).
MH+ 492.
Example 101: l-(2-chlorophenyl)-Λ^3-(4-(2,3-dimethylphenyI)piperaziii-l- yl)propyI)-2,5-dimethyl-l//-imidazole-4-carboxamide dihydrochloride
1H NMR (400 MHz, DMSO-d6) δ 10.97 (s, IH), 8.66 (s, IH), 7.85 (m, IH), 7.71-7.61 (m, 3H), 7.04 (t, J= 7.6 Hz, IH), 6.91-6.86 (m, 2H), 3.52-3.49 (m, 2H), 3.38-3.34 (m, 2H), 3.23-3.15 (m, 4H), 3.10-3.06 (m, 4H), 2.23 (s, 3H), 2.20 (s, 3H), 2.19 (s, 3H), 2.14 (s, 3H), 2.06-1.98 (m, 2H).
MH+ 480.
Example 102: l-(2-chlorophenyl)-./V-(3-(4-(2,3-diiiiethylpheiiyI)piperaziii-l- y^-l-hydroxypropy^-l^-dimethyl-l/Z-imidazole^-carboxamide
dihydrochloride
1H NMR (400 MHz, DMSO-d6) δ 10.30 (s, IH), 8.48 (s, IH), 7.82 (m, IH), 7.70-7.61 (m, 3H), 7.04 (t, J= 7.6 Hz, IH), 6.91-6.86 (m, 2H), 4.23-4.22 (m, IH), 3.62-3.52 (m, 2H), 3.36-3.28 (m, 5H), 3.17-3.08 (m, 5H), 2.21 (s, 3H), 2.19 (s, 3H), 2.18 (s, 3H), 2.13 (s, 3H).
MH+ 496.
Example 103: l-(2-chlorophenyl)-Λ^4-(4-(2,3-dimethyIphenyl)piperazin-l- yl)butyl)-2,5-dimethyl-l//-imidazole-4-carboxamide dihydrochloride 1H NMR (400 MHz, DMSO-d6) δ 10.74 (s, IH), 8.51 (s, IH), 7.82 (dd, J
= 8.0, 1.6 Hz, IH), 7.70-7.60 (m, 3H), 7.04 (t, J= 7.6 Hz, IH), 6.91-6.86 (m, 2H), 3.51-3.48 (m, 2H), 3.28 (q, J= 6.8 Hz, 2H), 3.16-3.12 (m, 4H), 3.08-3.03 (m, 4H), 2.20 (s, 3H), 2.18 (s, 6H), 2.14 (s, 3H), 1.83-1.75 (m, 2H), 1.60-1.53 (m, 2H).
MH+ 494.
Example 104: N-^-^-^S-dimethylphenytypiperazin-l-ytypropyl)^- isopropyl-S-methyl-l-phenyl-l/f-imidazole^-carboxamide dihydrochloride
1H NMR (400 MHz, DMSO-d6) δ 10.9 (br s, IH), 9.19 (br s, IH), 7.66-
7.63 (m, 3H), 7.59-7.49 (m, 2H), 7.05 (t, J = 7.6 Hz, IH), 6.92-6.87 (m, 2H)5 3.52-3.50 (m, 2H), 3.41-3.36 (m, 2H), 3.27-3.13 (m, 4H), 3.10-3.08 (m, 4H),
2.80-2.74 (m, IH), 2.22 (s, 3H), 2.19 (s, 3H), 2.15 (s, 3H), 2.06-2.02 (m, 2H),
1.27 (d, J= 7.2 Hz, 6H).
MH+ 474. Example 105: l-(3,5-dimethoxyphenyl)-7V-(3-(4-(2,3- dimethylphenyl)piperazin-l-yl)propyl)-2,5-dimethyI-l//-iiiiidazole-4- carboxamide dihydrochloride
1H NMR (400 MHz, DMSO-Cl6) δ 1 1.24 (br s, IH), 8.95 (br s, IH), 7.05 (t, J= 7.6 Hz, IH), 6.91-6.87 (m, 2H), 6.78-6.74 (m, 3H), 3.78 (s, 6H), 3.51-3.48 (m, 2H), 3.41-3.36 (m, 2H), 3.26-3.13 (m, 4H), 3.10-3.06 (m, 4H), 2.39 (s, 3H), 2.31 (s, 3H), 2.19 (s, 3H), 2.14 (s, 3H), 2.08-2.02 (m, 2H).
MH+ 506. Example 106: 7V-(3-(4-(2,3-dimethyIphenyl)piperazin-l-yl)-2-hydroxypropyl)- 2-isopropyl-5-methyl-l-phenyl-l//-imidazole-4-carboxamide dihydrochloride
1H NMR (400 MHz, DMSO-d6) δ 10.23 (br s, IH), 8.90 (br s, IH), 7.66-
7.63 (m, 3H), 7.56-7.54 (m, 2H), 7.04 (t, J = 7.6 Hz, IH), 6.91-6.86 (m, 2H), 4.25-4.23 (m, IH), 3.62-3.60 (m, IH), 3.55-3.52 (m, IH), 3.43-3.39 (m, 2H),
3.35-3.28 (m, 2H), 3.20-3.09 (m, 6H), 2.79-2.74 (m, IH), 2.22 (s, 3H), 2.18 (s,
3H), 2.14 (s, 3H), 1.25 (U1 J= 6.8 Hz, 6H).
MH+ 490. Example 107: l-(3,5-dimethoxyphenyl)-7V-(3-(4-(2,3-dimethylphenyl) piperazin-l-yI)-2-hydroxypropyl)-2,5-dimethyl-l//-imidazole-4-carboxamide dihydrochloride
1H NMR (400 MHz, DMSO-d6) δ 10.49 (br s, IH), 8.65 (br s, IH), 7.06- 7.02 (m, IH), 6.91-6.86 (m, 2H), 6.74-6.71 (m, 3H), 4.24-4.22 (m, IH), 3.77 (s,
6H), 3.62-3.60 (m, IH), 3.54-3.51 (m, IH), 3.38-3.35 (m, 2H), 3.29-3.27 (m, 2H), 3.16-3.08 (m, 6H), 2.35 (s, 3H), 2.29 (s, 3H), 2.18 (s, 3H), 2.13 (s, 3H).
MH+ 522.
Example 108:■/V-(3-(4-(2,3-dimethvlphenvl)piperazin-l-vl)-2-hvdroxvpropyI)- l^-dimethyl-l-^-^rifluoromethytyphenyty-lH-imidazole^-carboxamide dihydrochloride
1H NMR (400 MHz, DMSO-d6) δ 10.29 (br s, IH), 8.50 (br s, IH), 8.02
(d, J = 8.4 Hz, 2H), 7.78 (d, J = 8.4 Hz, 2H), 7.06-7.02 (m, IH), 6.90-6.86 (m, 2H), 4.23-4.20 (m, IH), 3.61-3.59 (m, IH), 3.54-3.51 (m, IH), 3.38-3.35 (m, 2H),
3.33-3.27 (m, 2H), 3.17-3.08 (m, 6H), 2.28 (s, 3H), 2.27 (s, 3H), 2.18 (s, 3H),
2.13 (s, 3H).
MH+ 530. Example 109: Λr-(3-(4-(2,3-dimethyIphenyl)piperazin-l-yl)-2-hydroxypropyl)- 2-ethyl-5-methyl-l-phenyl-l//-imidazole-4-carboxamide dihydrochloride
1H NMR (400 MHz, DMSO-d6) δ 10.47 (br s, IH), 8.92 (br s, IH), 7.66-
7.63 (m, 3H), 7.56-7.54 (m, 2H), 7.06-7.02 (m, IH), 6.91-6.86 (m, 2H), 4.27-4.24 (m, IH), 3.62-3.61 (m, IH), 3.53-3.51 (m, IH), 3.44-3.41 (m, 2H), 3.32-3.27 (m,
2H), 3.17-3.08 (m, 6H), 2.64 (q, J = 7.6 Hz, 2H), 2.25 (s, 3H), 2.18 (s, 3H), 2.13
(s, 3H), 1.16 (t, J= 7.6 Hz, 3H).
MH+ 476. Example 110: jV-(3-(4-(2,3-dimethylphenyl)piperazin-l-yl)-2-hydroxypropyl)- 5-methyI-l-phenyl-2-propyl-l//-imidazole-4-carboxamide dihydrochloride
1H NMR (400 MHz, DMSO-d6) δ 10.34 (br s, IH), 8.67 (br s, IH), 7.65- 7.62 (m, 3H), 7.52-7.50 (m, 2H), 7.06-7.02 (m, IH), 6.90-6.86 (m, 2H), 4.24-4.22 (m, IH), 3.62-3.60 (m, IH), 3.55-3.52 (m, IH), 3.39-3.37 (m, 2H), 3.30-3.27 (m, 2H), 3.15-3.08 (m, 6H), 2.57 (t, J= 7.6 Hz, 2H), 2.24 (s, 3H), 2.19 (s, 3H), 2.14 (s, 3H), 1.59-1.53 (m, 2H), 0.77 (t, J= 7.6 Hz, 3H).
MH+ 490. Example 111: l-(4-chlorophenyl)-N-(3-(4-(2,3-dimethyIphenyl)piperazin-l- yl)-2-hydroxypropyl)-2-propyl-l/-f-imidazole-4-carboxamide dihydrochloride 1H NMR (400 MHz, DMSO-d6) δ 10.44 (br s, IH), 9.01 (br s, IH), 8.40
(s, IH), 7.70 (d, J = 8.8 Hz, 2H), 7.63 (d, J = 8.8 Hz, 2H), 7.06-7.02 (m, IH),
6.91-6.85 (m, 2H), 4.26-4.24 (m, IH), 3.63-3.60 (m, IH), 3.53-3.50 (m, IH), 3.38-3.35 (m, 2H), 3.31-3.23 (m, 2H), 3.17-3.03 (m, 6H), 2.72 (t, J= 7.6 Hz, 2H),
2.18 (s, 3H), 2.13 (s, 3H), 1.58-1.52 (m, 2H), 0.77 (t, J = 6.8 Hz, 3H).
MH+ 510.
Example 112^ l-(3,5-dimethoxyphenyl)-iV-(2-(4-(2,3- dimethylphenyl)piperazin-l-yl)ethyl)-2,5-dimethyl-l//-imidazole-4- carboxamide dihydrochloride
1H NMR (400 MHz, DMSO-d6) δ 11.07 (br s, IH), 8.90 (br s, IH), 7.05 (t, J= 7.6 Hz, IH), 6.91-6.86 (m, 2H), 6.75-6.73 (m, 3H), 3.78 (s, 6H), 3.76-3.73 (m, 2H), 3.64-3.61 (m, 2H), 3.36-3.28 (m, 4H), 3.13-3.10 (m, 4H), 2.36 (s, 3H), 2.30 (s, 3H), 2.19 (s, 3H), 2.14 (s, 3H).
MH+ 492.
Example 113: Λ^2-(4-(2,3-dimethylphenyl)piperazin-l-yl)ethyI)-2-isopropyl- S-methyl-l-phenyl-l/Z-imidazole^-carboxamide dihydrochloride
1H NMR (400 MHz, DMSO-d6) δ 10.77 (br s, IH), 9.11 (br s, IH), 7.65-
7.62 (m, 3H), 7.55-7.53 (m, 2H), 7.05 (t, J = 7.6 Hz, IH), 6.91-6.87 (m, 2H), 3.76-3.71 (m, 2H), 3.65-3.62 (m, 2H), 3.38-3.27 (m, 4H), 3.1 1-3.09 (m, 4H), 2.79-2.76 (m, IH), 2.22 (s, 3H), 2.19 (s, 3H), 2.15 (s, 3H), 1.24 (d, J - 7.2 Hz,
6H).
MH+ 460.
Example 114: 7V-(2-(4-(2,3-dimethylphenyl)piperazin-l-yl)ethyl)-l-(4- fluorophenyl)-2,5-dimethyl-l/y-imidazoIe-4-carboxamide dihydrochloride
1H NMR (400 MHz, DMSO-d6) δ 11.23 (br s, IH), 9.08 (br s, IH), 7.67-
7.63 (m, 2H), 7.53-7.49 (m, 2H), 7.04 (t, J = 7.6 Hz, IH), 6.91-6.86 (m, 2H), 7.53 (q, J = 6.0 Hz, 2H), 3.63-3.59 (m, 2H), 3.37-3.28 (m, 4H), 3.18-3.06 (m, 4H), 2.34 (s, 3H), 2.27 (s, 3H), 2.19 (s, 3H), 2.14 (s, 3H).
MH+ 450. Example 115i l-(benzo[rf] [l,3]dioxol-5-yl)-7V-(2-(4-(2,3- dimethyIphenyl)piperazin-l-yl)ethyl)-2,5-dimethy--l//-imidazole-4- carboxamide dihydrochloride
1H NMR (400 MHz, DMSO-(I6) δ 11.22 (br s, IH), 9.09 (br s, IH), 7.20- 7.19 (m, IH), 7.15 (d, J = 8.4 Hz, IH), 7.06-7.02 (m, 2H), 6.90-6.86 (m, 2H)5 6.17 (s, 2H), 3.76 (q, J = 6.0 Hz, 2H), 3.63-3.59 (m, 2H), 3.37-3.28 (m, 4H), 3.17-3.06 (m, 4H), 2.36 (s, 3H), 2.29 (s, 3H), 2.19 (s, 3H), 2.14 (s, 3H).
MH+ 476.
Example 116: l-(2,3-dihydrobenzo[Z>] [l,4]dioxin-6-yl)-JV-(2-(4-(2,3- dimethyIphenyl)piperazin-l-y.)ethyl)-2,5-dimethyl-l//-imidazoIe-4- carboxamide dihydrochloride
1H NMR (400 MHz, DMSO-d6) δ 11.17 (br s, IH), 9.08 (br s, IH), 7.16 (d, J = 2.4 Hz, IH), 7.09 (d, J = 8.4 Hz, IH), 7.04 (t, J = 7.6 Hz, IH), 6.99 (dd, J = 6.0 Hz, 2.4 Hz, IH), 6.90-6.86 (m, 2H), 4.30 (s, 4H), 3.77-3.73 (m, 2H), 3.63- 3.59 (m, 2H), 3.37-3.28 (m, 4H), 3.17-3.06 (m, 4H), 2.34 (s, 3H), 2.27 (s, 3H), 2.18 (s, 3H), 2.14(s, 3H).
MH+ 490.
Example 117: Λ^3-(4-(2,3-dimethyIphenyI)piperazin-l-yl)propyl)-l-phenyl- 2-propyl-li/-imidazole-4-carboxamide dihydrochloride
1H NMR (400 MHz, CD3OD) δ 8.24 (s, IH), 7.69-7.64 (m, 3H), 7.62-
7.59 (m, 2H), 7.05 (t, J = 7.6 Hz, IH), 6.96-6.92 (m, 2H), 3.68-3.65 (m, 2H), 3.54
(t, J= 6.4 Hz, 2H), 3.36-3.34 (m, 4H), 3.22-3.08 (m, 4H), 2.89 (t, J= 7.6 Hz, 2H),
2.25 (s, 3H), 2.23 (s, 3H), 2.19-2.12 (m, 2H), 1.69-1.59 (m, 2H), 0.88 (t, J = 7.2 Hz, IH).
MH+ 460.
Example 118: 7V-(3-(4-(2,3-dichloropheny l)piperazin-l-yl)propyl)-l-phenyl-2- propyl-l/f-imidazole-4-carboxamide dihydrochloride
1H NMR (400 MHz, CD3OD) δ 8.27 (s, IH), 7.69-7.67 (m, 3H), 7.65- 7.62 (m, 2H), 7.30-7.25 (m, 2H), 7.17-7.14 (m, IH), 3.73-3.69 (m, 2H), 3.56-3.50 (m, 4H), 3.29-3.28 (m, 4H), 3.25-3.18 (m, 2H), 2.91 (t, J- 7.6 Hz, 2H), 2.19-2.14 (m, 2H), 1.70-1.59 (m, 2H), 0.88 (t, J= 7.6 Hz, 3H).
MH+ 500.
Example 119: ΛL(2-(4-(2,3-dichIorophenyl)piperazin-l-yl)ethyl)-l-phenyl-2- propyl-lH-imidazoIe-4-carboxamide dihydrochloride
1H NMR (400 MHz, CD3OD) δ 8.28 (s, IH), 7.71-7.67 (m, 3H), 7.63- 7.61 (m, 2H), 7.29-7.27 (m, 2H), 7.17-7.14 (m, IH), 3.89-3.84 (m, 4H), 3.53-3.50 (m, 4H), 3.47-3.31 (m, 4H), 2.91 (t, J= 7.6 Hz, 2H), 1.69-1.59 (m, 2H), 0.88 (t, J = 7.6 Hz, 3H) .
MH+ 486. Example 120: Λ^-(2-(4-(2,3-dimethylplienyl)piperazin-l-yl)ethyl)-l-phenyl-2- propyl-l/f-imidazoIe-4-carboxamide dihydrochloride
1H NMR (400 MHz, CD3OD) δ 8.30 (s, IH), 7.69-7.67 (m, 3H), 7.64- 7.61 (m, 2H), 7.09-7.04 (m, IH), 6.99-6.94 (m, 2H), 3.89-3.82 (m, 4H), 3.53-3.50 (m, 2H), 3.47-3.42 (m, 2H), 3.28-3.26 (m, 4H), 2.92 (t, J = 7.6 Hz, 2H), 2.25 (s, 6H), 1.69-1.59 (m, 2H), 0.88 (t, J= 7.2 Hz, 3H).
MH+ 446.
Example 121: .V-(3-(4-(2,3-dimetliylphenyl)piperaziii-l-vl)-2-hvdroxypropyl)- l-phenyl-2-propyl-l//-imidazole-4-carboxamide dihydrochloride
1H NMR (400 MHz, CD3OD) δ 8.27 (s, IH), 7.69-7.67 (m, 3H), 7.63- 6.61 (m, 2H), 7.07-7.03 (m, IH), 6.97-6.92 (m, 2H), 4.34 (br s, IH), 3.73-3.70 (m, 2H), 3.55-3.51 (m, 2H), 3.47-3.41 (m, 4H), 3.24-3.11 (m, 4H), 2.91 (t, J= 7.6 Hz, 2H), 2.24 (s, 6H), 1.68- 1.61 (m, 2H), 0.88 (t, J= 7.2 Hz, 3H).
MH+ 476.
Example 122: Λ^3-(4-(2,3-dimethylphenyl)piperazin-l-yl)propyl)-l-(4- methoxyphenyl)-5-methyl-2-propyl-l//-imidazole-4-carboxamide
dihydrochloride 1H NMR (400 MHz, CD3OD) δ 7.43 (d, J = 8.4 Hz, 2H), 7.19 (d, J = 7.6 Hz, 2H), 7.08-7.03 (m, IH), 6.98-6.92 (m, 2H), 3.90 (s, 3H), 3.70-3.67 (m, 2H), 3.58-3.54 (m, 2H), 3.37-3.31 (m, 4H), 3.23-3.13 (m, 4H), 2.76 (t, J= 7.2 Hz, 2H), 2.32 (s, 3H), 2.17 (s, 6H), 1.69-1.63 (m, 2H), 0.90 (t, J= 7.2 Hz, 3H).
MH+ 504.
Example 123: A^-^-^^-dimethylpheiiyOpiperaziii-l-yOetliyl)-!-^- methoxyphenyl)-5-methyl-2-propyl-l//-imidazole-4-carboxamide
dihydrochloride
1H NMR (400 MHz, CD3OD) δ 7.44 (d, J - 8.8 Hz, 2H), 7.20 (d, J = 9.2
Hz, 2H), 7.08-7.04 (m, IH), 6.98-6.93 (m, 2H), 3.93-3.87 (m, 2H), 3.89 (s, 3H),
3.86-3.82 (m, 2H), 3.53-3.50 (m, 2H), 3.47-3.37 (m, 2H), 3.29-3.22 (m, 4H), 2.76
(t, J = 7.2 Hz, 2H), 2.33 (s, 3H), 2.25 (s, 6H), 1.70-1.62 (m, 2H), 0.92-0.88 (t, J = 7.6 Hz, 3H).
MH+ 490.
Example 124: 7V-(3-(4-(2,3-dimethylphenyl)piperazin-l-yl)propyl)-2,5- dimethyl-l-tøuinolin-ό-yO-l/f-imidazole^-carboxamide dihydrochloride
1H NMR (40Q MHz, CD3OD) δ 9.47 (d, J= 5.2 Hz, IH), 9.41 (d, J = 8.4 Hz, IH), 8.77 (s, IH), 8.60 (d, J= 9.2 Hz, IH), 8.34 (d, J= 9.2 Hz, IH), 8.32-8.29 (m, IH), 7.09-7.05 (m, IH), 6.99-6.94 (m, 2H), 3.72-3.69 (m, 2H), 3.60-3.57 (m, 2H), 3.49-3.41 (m, 4H), 3.29-3.15 (m, 4H), 2.56 (s, 3H), 2.42 (s, 3H), 2.25 (s, 6H), 2.22-2.16 (m, 2H).
MH+ 497.
Example 125: Λr-(3-(4-(2,3-dichlorophenyl)piperazin-l-yI)-2-hydroxypropyl)- 2,5-dimethyl-l-(quinolin-6-yl)-li/-imidazole-4-carboxamide dihydrochloride
1H NMR (400 MHz, CD3OD) δ 9.43 (d, J = 4.8 Hz, IH), 9.33 (d, J = 8.0 Hz, IH), 8.73 (s, IH), 8.57 (d, J= 9.2 Hz, IH), 8.31 (d, J= 8.8 Hz, IH), 8.27-8.24 (m, IH), 7.30-7.28 (m, 2H), 7.18-7.15 (m, IH), 4.40-4.37 (m, IH), 3.79-3.76 (m, 2H), 3.62-3.55 (m, 2H), 3.54-3.39 (m, 4H), 3.35-3.17 (m, 4H), 2.55 (s, 3H), 2.42 (s, 3H).
MH+ 553. Example 126; 7V-(3-(4-(2,3-dichlorophenyl)piperazin-l-yl)-2-hydroxypropyI)- l-phenyl-2-propyl-l//-imidazole-4-carboxamide dihydrochloride 1H NMR (400 MHz, CD3OD) δ 8.25 (s, IH), 7.69-7.65 (m, 3H), 7.63-
7.60 (m, 2H), 7.30-7.25 (m, 2H), 7.18-7.14 (m, IH), 4.35-4.33 (m, IH), 3.77-3.73 (m, 2H), 3.54-3.38 (m, 6H), 3.32-3.19 (m, 4H), 2.91 (t, J= 7.6 Hz, 2H), 1.67-1.61 (m, 2H), 0.88 (t, J = 7.2 Hz, 3H).
MH+ 516.
Example 127; 7V-(3-(4-(2,3-Ddichlorophenyl)piperazin-l-yl)-2- hydroxypropyO-l^-fluorophenyl^-propyl-l/f-imidazole^-carboxamide dihydrochloride 1H NMR (400 MHz, CD3OD) δ 8.21 (s, IH), 7.69-7.65 (m, 2H), 7.44-
7.39 (m, 2H), 7.29-7.27 (m, 2H), 7.17-7.15 (m, IH), 4.35-4.33 (m, IH), 3.77-3.73 (m, 2H), 3.54-3.35 (m, 6H), 3.32-3.19 (m, 4H), 2.87 (t, J = 7.6 Hz, 2H), 1.67-1.62 (m, 2H), 0.89 (t, J- 7.2 Hz, 3H).
MH+ 534.
Exampje_128; 7V-(3-(4-(2,3-dimethyIphenyl)piperazin-l-yl)-2-hydroxypropyl)- l-(4-fluorophenyl)-2-propyl-l//-imidazole-4-carboxamide dihydrochloride
1H NMR (400 MHz, CD3OD) δ 8.18 (s, IH), 7.68-7.64 (m, 2H), 7.43- 7.39 (m, 2H), 7.07-7.03 (m, IH), 6.96-6.92 (m, 2H), 4.34-4.32 (m, IH), 3.72-3.69 (m, 2H), 3.57-3.47 (m, 2H), 3.44-3.32 (m, 4H), 3.24-3.06 (m, 4H), 2.86 (t, J= 7.2 Hz, 2H), 2.24 (s, 3H), 2.23 (s, 3H), 1.69-1.60 (m, 2H), 0.89 (t, J= 7.6 Hz, 3H).
MH+ 494. Example 129; Λ^-(3-(4-(2,3-dimethylphenyl)piperazin-l-yl)propyl)-l-(4- fluorophenyl)-2-propyl-lH-imidazole-4-carboxamide dihydrochloride
1H NMR (400 MHz, CD3OD) δ 8.14 (s, IH), 7.65- 7.59 (m, 2H), 7.49-
7.46 (m, 2H), 7.10-6.93 (m, 3H), 3.69-3.62 (m, 2H), 3.59-3.52 (m, 2H), 3.20-3.09 (m, 4H), 3.87-3.83 (m, 4H), 2.23 (s, 6H), 2.15-2.13 (m, 2H), 1.69-1.61 (m, 2H),
0.92-0.86 (m, 3H). MH+ 478;
Example 130: Λ^(3-(4-(2,3-dichlorophenyl)piperazin-l-yl)-2-hydroxypropyI)- l,2-diphenyl-l//-imidazoIe-4-carboxamide dihydrochloride
1H NMR (400 MHz, CD3OD) δ 8.37 (s, IH), 7.59-7.51 (m, 4H), 7.49- 7.43 (m, 6H)5 7.30-7.28 (m, 2H), 7.17-7.14 (m, IH), 4.36-4.34 (m, IH), 3.77-3.74 (m, 2H), 3.61-3.50 (m, 4H), 3.47-3.32 (m, 4H), 3.23-3.15 (m, 2H).
MH+ 550.
Example 131: Λf-(3-(4-(2,3-dimethyIphenyl)piperazin-l-yl)propyl)-l,2- diphenyI-l//-imidazole-4-carboxamide dihydrochloride
1H NMR (400 MHz, CD3OD) δ 8.41 (s, IH), 7.58-7.53 (m, 4H), 7.52- 7.46 (m, 6H), 7.08-7.04 (m, IH), 6.97-6.93 (m, 2H), 3.69-3.67 (m, 2H), 3.60-3.56 (m, 2H), 3.36-3.20 (m, 6H), 3.14-3.11 (m, 2H), 2.25 (s, 6H), 2.18-2.16 (m, 2H).
MH+ 494.
Example 132: jV-(3-(4-(2,3-dimethylphenyl)piperazin-l-yl)propyl)-2,5- dimethyl-l-(pyridin-2-yl)-l/7-imidazole-4-carboxamide trihydrochloride
1H NMR (400 MHz, CD3OD) δ 8.76 (d, J - 4.4 Hz, IH), 8.21 (t, J = 6.8 Hz, IH), 7.78-7.72 (m, 2H), 7.09-7.04 (m, IH), 7.00-6.94 (m, 2H), 3.71-3.68 (m, 2H), 3.65-3.61 (m, 2H), 3.49-3.32 (m, 4H), 3.30-3.14 (m, 4H), 2.55 (s, 3H), 2.42 (s, 3H), 2.25 (s, 6H), 2.22-2.13 (m, 2H).
MH+ 447.
Example 133: ΛA-(3-(4-(2,3-dichlorophenyl)piperazin-l-yl)-2-hydroxypropyl)- l-(4-methoxyphenyl)-2-phenyl-l//-imidazole-4-carboxamide dihydrochloride
1H NMR (400 MHz, CD3OD) δ 8.34 (s, IH), 7.58-7.56 (m, IH), 7.50- 7.46 (m, 4H), 7.37 (d, J= 8.4 Hz, 2H), 7.30-7.28 (m, 2H), 7.17-7.15 (m, IH), 7.04 (d, J = 8.4 Hz, 2H), 4.36-4.35 (m, IH), 3.83 (s, 3H), 3.77-3.74 (m, 2H), 3.59-3.53 (m, 2H), 3.52-3.32 (m, 6H), 3.24-3.16 (m, 2H).
MH+ 580. Example 134: Λ^3-(4-(2,3-dimethyIphenyl)piperazin-l-yI)propyl)-l-(4- methoxyphenyl)-2-phenyI-l//-imidazole-4-carboxamide dihydrochloride
1H NMR (400 MHz, DMSO-d6) δ 8.35 (s, IH), 7.61-7.57 (m, IH)5 7.50- 7.45 (m, 4H), 7.37 (d, J = 9.2 Hz, 2H), 7.08-7.03 (m, 3H), 6.95 (t, J = 6.8 Hz, 2H), 3.83 (s, 3H), 3.69-3.66 (m, 2H)5 3.59-3.55 (m, 2H)5 3.38-3.32 (m, 4H)5 3.23-3.20 (m, 2H)5 3.14-3.08 (m, 2H)5 2.25 (s, 3H)5 2.24 (s, 3H)5 2.20-2.13 (m, 2H).
MH+ 524. Example 135: N-P-^-^-chloro^-methylphenytypiperazin-l-ytypropyl)-!-^- methoxyphenyl)-5-methyl-2-propyl-l//-imidazole-4-carboxamide
dihydrochloride
1H NMR (400 MHz5 DMSO-d6) δ 11.01 (br S5 IH)5 9.01 (br s, IH)5 7.47(d, J = 8.8 Hz , 2H)5 7.18-7.14 (m, 4H), 7.02 (dd, J = 6.8, 2.0 Hz5 IH)5 3.82 (s, 3H)5 3.52-3.49(m, 2H)5 3.36 (q, J = 6.4 Hz5 2H)5 3.23-3.11 (m, 6H), 2.59 (t, J= 7.6 Hz, 2H), 2.26 (s, 3H)5 2.22 (s, 3H)5 2.04-2.00 (m, 2H)5 1.63-1.54 (m, 2H)5 0.77 (t, J = 7.6 Hz5 3H).
MH+ 523.
Example 136: iV-φ-^-^S-dichloropheiiy^piperaziii-l-yl^-hydroxypropyl)- l-(4-methoxyphenyl)-5-methyl-2-propyl-l//-imidazole-4-carboxaπiide dihydrochloride 1H NMR (400 MHz5 DMSO-d6) δ 10.41 (br s, IH)5 8.68 (br s, IH)5 7.43(d,
J= 8.8 Hz , 2H)5 7.36-7.30 (m, 2H), 7.18-7.13 (m, 3H)5 4.22-4.20 (m, IH)5 3.82 (s, 3H)5 3.66-3.55(m5 2H)5 3.42-3.34 (m, 5H), 3.30-3.13 (m, 5H)5 2.55 (t, J = 7.6 Hz5 2H)5 2.22 (s, 3H)5 1.60-1.51 (m, 2H)5 0.77 (t, J= 7.6 Hz5 3H).
MH+ 560.
Example 137:■/V-(3-(4-(2,3-dimethvlphenvl)piperazin-l-yl)-2-hvdroxvpropyl)- l-(4-methoxyphenyl)-5-methyl-2-propyl-l/f-imidazole-4-carboxamide dihydrochloride 1H NMR (400 MHz5 DMSO-d6) δ 10.40 (br s, IH)5 8.93 (br s, IH)5 7.48(d5
J= 8.8 Hz , 2H)5 7.16 (d, J = 8.8 Hz5 2H)5 7.03 (t, J = 7.6 Hz5 IH)5 6.90-6.86 (m, 2H), 4.25-4.23 (m, IH), 3.82 (s, 3H), 3.63-3.5 l(m, 2H), 3.44-3.24 (m, 5H), 3.20- 3.08 (m, 5H), 2.61 (t, J = 7.6 Hz, 2H), 2.23 (s, 3H), 2.18 (s, 3H), 2.13 (s, 3H), 1.63-1.54 (m, 2H), 0.77 (t, J= 7.6 Hz, 3H).
MH+ 520.
Example 138: Λ^3-(4-(3-chloro-2-methyIpheiiyI)piperaziii-l-yl)propyl)-l-(4- methoxyphenyl)-2,5-dimethyl-l//-imidazole-4-carboxamide dihydrochloride
1H NMR (400 MHz, DMSO-d6) δ 11.22 (br s, IH), 8.92 (br s, IH), 7.48(d, J= 7.2 Hz , 2H), 7.20-7.15 (m, 4H), (dd, J - 6.8, 2.4 Hz , IH), 3.82 (s, 3H), 3.51- 3.48(m, 2H), 3.37 (q, J = 6.4 Hz , 2H), 3.22-3.12 (m, 8H), 2.32 (s, 3H), 2.26 (s, 3H), 2.24 (s, 3H), 2.06-1.99 (m, 2H).
MH+ 496. Example 139: (5)-iV-(3-(4-(2,3-dimethylphenyI)piperaziii-l-yl)-2- hydroxypropyl)-2,5-dimethyl-l-phenyI-l//-imidazoIe-4-carboxamide dihydrochloride
1H NMR (400 MHz, DMSO-d6) δ 10.15 (br s, IH), 8.54 (br s, IH), 7.66- 7.59 (m, 3H), 7.50-7.48 (m, 2H), 7.04 (t, J = 7.2 Hz, IH), 6.88 (dd, J = 7.6, 8.0 Hz , 2H), 4.21-4.19 (m, IH), 3.61-3.51 (m, 2H), 3.38-3.24 (m, 5H), 3.17-3.01(m, 5H), 2.27 (s, 3H), 2.25 (s, 3H), 2.18 (s, 3H), 2.13 (s, 3H).
MH+ 462. Example 140: jV-((5)-3-(4-(2,3-dimethylphenyl)piperazin-l-yl)-2- hydroxypropyl)-l-(2-fluorophenyl)-2,5-dimethy.-l//-imidazoIe-4- carboxamide dihydrochloride
1H NMR (400 MHz, DMSO-d6) δ 10.06 (br s, IH), 8.30 (br s, IH), 7.69- 7.54 (m, 3H), 7.44 (t, J = 7.6 Hz, IH), 7.03 (t, J = 7.6 Hz, IH), 6.87 (dd, J = 7.6, 8.0 Hz , 2H), 4.19-4.17 (m, IH), 3.59-3.51 (m, 2H), 3.40-3.28 (m, 5H), 3.14- 3.00(m, 5H), 2.23 (s, 3H), 2.19 (s, 3H), 2.18 (s, 3H), 2.13 (s, 3H).
MH+ 480. Example 141: (SVl-^-chlorophenyO-iV-β-^-^S-dichlorophenytypiperazin- l-yl)-2-hydroxypropyl)-2-propyl-l//-imidazole-4-carboxamide dihydrochloride
1H NMR (400 MHz, DMSO-d6) δ 10.73 (br S5 IH), 9.16 (br S5 IH), 8.50 (br s, IH), 7.72-7.64 (m, 4H), 7.34-7.29 (m, 2H), 7.16 (dd, J = 2.4, 2.8 Hz , IH)5 4.27-4.25 (m, IH), 3.67-3.53 (m, 2H), 3.41-3.30 (m, 5H), 3.27-3.12 (m, 5H), 2.72 (t, J= 7.2Hz, 2H), 1.56-1.49 (m, 2H), 0.75 (t, J= 7.6 Hz, 3H).
MH+ 550.
Example 142: (5)-Λ^-(3-(4-(3-chIoro-2-methyIphenyl)piperazin-l-yI)-2- hydroxypropyty-l-^-fluorophenyty-S-methyl^-phenyl-l/iMiiiidazole^- carboxamide dihydrochloride
1H NMR (400 MHz, DMSO-d6) δ 10.42 (br s, IH), 8.40 (t, J = 5.6 Hz, IH), 7.48-7.44 (m, 2H), 7.38 (d, J= 8.8 Hz, IH), 7.35-7.27 (m, 6H), 7.19-7.14 (m, 2H), 7.00 (dd, J= 2.4, 2.0 Hz , IH), 4.25-4.23 (m, IH), 3.63-3.51 (m, 2H), 3.38 (t, J= 5.6 Hz, 2H), 3.32-3.29 (m, 3H), 3.13-3.07 (m, 5H), 2.31 (s, 3H), 2.25 (s, 3H).
MH+ 562.
Example 143: 7V-(3-(4-(2,3-dichlorophenyl)piperazin-l-yl)propyl)-l-(4- methoxyphenyl)-5-methyl-2-propyl-l//-imidazole-4-carboxamide
dihydrochloride
1H NMR (400 MHz, DMSO-d6) δ 10.87 (br s, IH), 8.80 (br s, IH), 7.43 (d, J = 8.8 Hz, 2H), 7.36-7.32 (m, 2H), 7.19-7.13 (m, 3H), 3.81 (s, 3H)5 3.56- 3.54(m, 2H), 3.41-3.34 (m, 4H)5 3.21-3.16 (m, 6H), 2.55 (t, J = 7.6 Hz, 2H), 2.21 (s, 3H)5 2.02-1.98 (m, 2H), 1.58-1.53 (m, 2H)5 0.77 (X, J= 7.2 Hz, 3H).
MH+ 544.
Example 144: 7V-(3-(4-(3-chloro-2-methylphenyl)piperazin-l-yl)propyl)-l-(2- methoxyphenyl)-2,5-dimethyl-l//-imidazole-4-carboxamide dihydrochloride
1H NMR (400 MHz, DMSO-d6) δ 10.77 (br s, IH), 8.64 (br s, IH)5 7.63-
7.58(m5 IH)5 7.45 (d, J = 8.0 Hz , IH)5 7.33 (d, J = 8.4 Hz , IH), 7.20-7.14 (m,
3H), (dd, J = 2.0, 2.4 Hz , IH)5 3.78 (s, 3H)5 3.53-3.50 (m, 2H)5 3.35 (q, J = 6.4 Hz , 2H)5 3.21-3.06 (m, 8H), 2.26 (s, 3H), 2.22 (s, 3H)5 2.17 (s, 3H)5 2.02-1.98 (m,
2H). MH+ 496.
Example 145: Λ^-^-^^-dichlorophenytypiperazin-l-ylJpropyl)-!-^- methoxyphenyI)-2,5-dimethyl-l//-imidazoIe-4-carboxamide dihydrochloride
1H NMR (400 MHz, DMSO-d6) δ 11.03 (br s, IH), 8.67 (br s, IH), 7.60 (t, J = 7.6 Hz , IH)5 7.46 (d, J = 7.2 Hz , IH), 7.34-7.30 (m, 3H), 7.18-7.14 (m, 2H), 3.78 (s, 3H), 3.56-3.54 (m, 2H), 3.41-3.34 (m, 4H), 3.24-3.14 (m, 6H), 2.23 (s, 3H), 2.17 (s, 3H), 2.00-1.96 (m, 2H).
MH+ 516.
Example 146: 7V-(3-(4-(2,3-dichlorophenyl)piperaziii-l-yl)-2-hydroxypropyl)- l-(2-methoxyphenyl)-2,5-dimethyl-l/y-imidazoIe-4-carboxainide
dihydrochloride
1H NMR (400 MHz, DMSO-d6) δ 10.44 (br s, IH), 8.55 (br s, IH), 7.60 (t, J = 7.6 Hz, IH), 7.46 (d, J = 7.6 Hz IH), 7.36-7.30 (m, 3H), 7.18-7.14 (m, 2H), 4.22-4.20 (m, IH), 3.78 (s, 3H), 3.67-3.55 (m, 2H), 3.42-3.31 (m, 4H), 3.28-3.12 (m, 6H), 2.23 (s, 3H), 2.18 (s, 3H).
MH+ 532.
Example 147: 7V-(3-(4-(2,3-dimethylphenyl)piperazin-l-yl)propyl)-2,5- dimethyl-l-/7-tolyl-l//-imidazole-4-carboxamide dihydrochloride 1H NMR (400 MHz, DMSO-d6) δ 1 1.19 (br s, IH), 8.97 (br s, IH), 7.46-
7.41 (m, 4H), 7.04 (t, J = 7.6 Hz, IH), 6.90-6.85 (m, 2H), 3.51-3.48 (m, 2H), 3.40-3.35 (m, 2H), 3.26-3.17 (m, 4H), 3.14-3.05 (m, 4H), 2.39 (s, 3H), 2.34 (s, 3H), 2.25 (s, 3H), 2.18 (s, 3H), 2.13 (s, 3H), 2.08-2.00 (m, 2H).
MH+ 460.
Example 148: N-(3-(4-(2,3-dimethylphenyl)piperazin-l-yl)-2-hydroxypropyl)- 2,5-dimethyl-l-/;-toIyl-l//-imidazole-4-carboxamide dihydrochloride
1H NMR (400 MHz, DMSO-d6) δ 10.56 (br s, IH), 8.82 (br s, IH), 7.46- 7.41 (m, 4H), 7.04 (t, J = 8.0 Hz, IH), 6.90-6.85 (m, 2H), 4.26-2.24 (m, IH),
3.64-3.61 (m, IH), 3.54-3.51 (m, IH), 3.43-3.38 (m, 2H), 3.36-3.27 (m, 4H), 3.18-3.08 (m, 4H), 2.39 (s, 3H), 2.34 (s, 3H), 2.25 (s, 3H), 2.18 (s, 3H), 2.13 (s, 3H).
MH+ 476. Example 149: 7V-(3-(4-(2,3-dichlorophenyl)piperazin-l-yl)-2-hydroxypropyl)- l-(2,3-dihydrobenzo[Λ][l,4]dioxin-6-yI)-2,5-dimethyl-l//-imidazoIe-4- carboxamide dihydrochloride
1H NMR (400 MHz, DMSO-d6) δ 10.65 (br s, IH), 8.69 (br s, IH), 7.36- 7.30 (m, 2H), 7.18-7.07 (m, 2H), 6.98 (d, J = 2.4 Hz, IH), 6.96 (d, J = 2.4 Hz, IH), 4.30 (s, 4H), 4.27-4.23 (m, IH), 3.67-3.63 (m, 2H), 3.56-3.54 (m, 2H), 3.42- 3.33 (m, 4H), 3.25-3.17 (m, 4H), 2.32 (s, 3H), 2.26 (s, 3H).
MH+ 560. Example 150: Λ^-^-^S-dichlorophenytypiperazin-l-ytypropyl)-!-^^- dihydrobenzo[Z>] [l,4]dioxin-6-yl)-2,5-dimethyl-l/Mmidazole-4-carboxamide dihydrochloride
1H NMR (400 MHz, DMSO-d6) δ 1 1.32 (br s, IH), 8.87 (br s, IH), 7.36- 7.30 (m, 2H), 7.20-7.07 (m, 2H), 7.00 (d, J = 2.4 Hz, IH), 6.97 (d, J - 2.4 Hz, IH), 4.30 (s, 4H), 3.56-3.53 (m, 2H), 3.41-3.34 (m, 4H), 3.25-3.11 (m, 6H), 2.32 (s, 3H), 2.52 (s, 3H), 2.05-1.98 (m, 2H).
MH+ 544. Example 151: (/?)-7V-(3-(4-(2,3-dimethylphenyl)piperazin-l-yl)-2- hydroxypropyl^jS-dimethyl-l-phenyl-l/f-imidazole^-carboxamide dihydrochloride
1H NMR (400 MHz, DMSO-d6) δ 10.51 (s, IH), 8.75 (s, IH), 7.68-7.50 (m, 5H), 7.04 (t, J= 7.6 Hz, IH), 6.90-6.86 (m, 2H), 4.26-4.24 (m, IH), 3.64-3.51 (m, 2H), 3.43-3.33 (m, 3H), 3.32-3.27 (m,2H), 3.20-3.08 (m, 5H), 2.33 (s, 3H), 2.26 (s, 3H), 2.18 (s, 3H), 2.13 (s, 3H).
MH+ 462. Example 152: iV-((Λ)-3-(4-(2,3-dimethylphenyl)piperazin-l-yl)-2- hydroxypropyl)-l-(241uorophenyl)-2,5-dimethyl-l/y-imidazole-4- carboxamide dihydrochloride
1H NMR (400 MHz, DMSO-d6) δ 10.33 (s, IH), 8.45 (s, IH), 7.72-7.51 (m, 3H), 7.46 (t, J = 7.6 Hz, IH), 7.04 (t, J = 7.6 Hz, IH), 6.90-6.86 (m, 2H), 4.23-4.21 (m, IH), 3.62-3.51 (m, 2H), 3.41-3.27 (m, 5H), 3.13-3.02 (m,5H), 2.24 (s, 6H), 2.18 (s, 3H), 2.13 (s, 3H).
MH+ 480.
Example 153: yV-(3-(4-(3-chIoro-2-niethyIpheiiyl)piperaziii-l-y-)propyl)-l-(2- fluorophenyl)-2,5-dimethyl-l//-imidazole-4-carboxamide dihydrochloride
1H NMR (400 MHz, DMSO-d6) δ 11.15 (s, IH)5 8.70 (s, IH)5 7.74-7.67 (m, 2H), 7.60 (t, J= 8.8 Hz, IH), 7.48 (t, J = 7.6 Hz5 IH), 7.20-7.14 (m, 2H)5 7.01 (dd, J = 6.8, 2.0 Hz, IH), 3.52-3.49 (m, 2H), 3.36-3.35 (m, 2H), 3.22-3.13 (m, 8H), 2.30 (s, 3H), 2.26 (s, 3H), 2.25 (s, 3H), 2.03-2.00 (m, 2H).
MH+ 484.
Example 154: iV-(3-(4-(2,3-dichlorophenyI)piperazin-l-yl)propyl)-l-(2- fluorophenyl)-2,5-dimethyl-l//-imidazole-4-carboxamide dihydrochloride
1H NMR (400 MHz, DMSO-d6) δ 11.17 (s, IH), 8.60 (s, IH), 7.72-7.64 (m, 2H)5 7.59 (t, J= 9.2 Hz, IH), 7.47 (t, J = 7.6 Hz5 IH)5 7.35-7.30 (m, 2H), 7.01 (dd, J = 7.2, 2.4 Hz, IH), 3.56-3.53 (m, 2H)5 3.41-3.33 (m, 4H)5 3.24-3.13 (m, 6H), 2.26 (s, 3H), 2.24 (s, 3H), 2.02-1.98 (m, 2H).
MH+ 504.
Example 155:■/V-(3-(4-(2,3-dimethvlphenvl)piperazin-l-yl)-2-hydroxypropyl)- 5-methyl-l,2-diphenyl-l//-imidazole-4-carboxamide dihydrochloride 1H NMR (400 MHz5 DMSO-d6) δ 10.28 (s, IH), 8.41 (s, IH), 7.58-7.23
(m, HH), 7.07 (t, J = 8.0 Hz5 IH)5 6.90 (d, J = 8.4 Hz, 2H), 4.33-4.19 (m, IH), 3.67-3.54 (m, 2H), 3.49-3.23 (m, 6H)5 3.20-3.03 (m, 6H), 2.45 (s, 3H)5 2.26 (s, 3H), 2.21 (s, 3H).
MH+ 524.
Example 156: Λ^-(3-(4-(2,3-dichlorophenyl)piperazin-l-yl)-2-hydroxypropyl)- 5-methyl-l,2-diphenyl-l//-imidazole-4-carboxamide dihydrochloride
1H NMR (400 MHz, DMSO-d6) δ 10.35 (s, IH), 8.39 (s, IH)5 7.55-7.21 (m, 13H), 6.93 (dd, J = 7.2, 2.4 Hz, IH), 4.35-4.21 (m, IH), 3.71-3.55 (m, 2H), 3.50-3.23 (m, 6H), 3.21-3.01 (m, 6H), 2.45 (s, 3H).
MH+ 564.
Example 157: Λr-(3-(4-(2,3-dichlorophenyI)piperazin-l-yl)-2-hydroxypropyl)- l-(4-fluorophenyI)-5-methyl-2-phenyl-li/-imidazole-4-carboxamide
dihydrochloride
1H NMR (400 MHz, DMSO-d6) δ 10.30 (s, IH), 8.39 (s, IH), 7.55-7.21 (m, 12H), 6.93 (dd, J = 7.2, 2.4 Hz, IH), 4.33-4.19 (m, IH), 3.69-3.53 (m, 2H), 3.48-3.20 (m, 6H), 3.19-3.02 (m, 6H), 2.44 (s, 3H), 2.33 (s, 3H).
MH+ 562.
Example 158: 7V-(3-(4-(2,3-dichlorophenyl)piperazin-l-yl)propyl)-5-methyl- l,2-diphenyI-l//-imidazole-4-carboxamide dihydrochloride 1H NMR (400 MHz, DMSO-d6) δ 10.52 (s, IH), 8.45 (s, IH), 7.59-7.20
(m, 13H), 6.97 (dd, J = 7.2, 2.4 Hz, IH), 3.81-3.68 (m, 2H), 3.65-3.51 (m, 2H), 3.50-3.31 (m, 4H), 2.77-2.60 (m, 4H), 2.45 (s, 3H), 2.09-1.95 (m, 2H).
MH+ 548. Example 159: .V-(3-(4-(2,3-dichlorophenyl)piperazin-l-yl)propyl)-l-(4- fluorophenyI)-5-methyl-2-phenyl-l//-imidazole-4-carboxamide
dihydrochloride
1H NMR (400 MHz, DMSO-d6) δ 10.35 (s, IH), 8.45 (s, IH), 7.55-7.21 (m, 12H), 6.97 (dd, J = 7.2, 2.4 Hz, IH), 3.77-3.65 (m, 2H), 3.63-3.51 (m, 2H), 3.49-3.28 (m, 4H), 2.79-2.59 (m, 4H), 2.44 (s, 3H), 2.09-1.94 (m, 2H).
MH+ 566.
Example 160: jV-(3-(4-(3-chloro-2-methylphenyl)piperazin-l-yl)-2- hydroxypropyl)-5-methyl-l,2-diphenyI-l//-imidazole-4-carboxamide dihydrochloride 1H NMR (400 MHz, DMSO-(I6) δ 10.33 (s, IH), 8.36 (s, IH), 7.55-7.46 (m, 3H), 7.44-6.97 (m, 10H), 4.33-4.18 (m, IH), 3.68-3.52 (m, 2H), 3.46-3.22 (m, 6H), 3.20-3.05 (m, 6H), 2.35 (s, 3H), 2.29 (s, 3H).
MH+ 544.
Example 161: 7V-(3-(4-(3-chloro-2-methylphenyI)piperazin-l-yl)-2- hydroxypropyl)-l-(4-fluorophenyl)-5-methyl-2-propyl-l//-imidazole-4- carboxamide dihydrochloride
1H NMR (400 MHz, DMSO-d6) δ 10.53 (s, IH), 8.83 (s, 2H), 7.71-7.62 (m, 2H), 7.59-7.47 (m, 2H), 7.27-7.16 (m, 2H), 7.09-7.01 (m, IH), 4.34-4.25 (m, IH), 3.71-3.55 (m, 3H), 3.48 -3.27 (m, 6H), 3.25-3.11 (m, 6H), 2.62 (t, J= 7.2 Hz, 2H), 2.31 (s, 3H), 2.27 (s, 3H), 1.66-1.54 (m, 2H), 0.87 (t, J = 1.2 Hz, 3H).
MH+ 528.
Example 162: 7V-(3-(4-(3-chloro-2-methylphenyl)piperazin-l-yl)-2- hydroxypropyl)-l-(4-fluorophenyl)-2,5-dimethyl-l//-imidazole-4- carboxamide dihydrochloride
1H NMR (400 MHz, DMSO-d6) δ 10.51 (s, IH), 8.90 (s, 2H)5 7.75-7.63 (m, 2H), 7.60-7.49 (m, 2H), 7.27-7.15 (m, 2H), 7.09-6.99 (m, IH), 4.40-4.31 (m, IH), 3.71-3.49 (m, 3H), 3.44 -3.23 (m, 6H), 3.21-3.07 (m, 6H), 2.34 (s, 3H), 2.33 (s, 3H), 2.18 (s, 3H).
MH+ 500.
Example 163: l-cyclopentyl-./V-(3-(4-(2,3-dichlorophenyl)piperaziii-l- ytypropyO^S-dimethyl-liZ-imidazole^-carboxamide dihydrochloride 1H NMR (400 MHz, MeOH-d4) δ 7.30-7.26 (m, 2H), 7.18-7.15 (m, IH),
3.71 (d, J = 8.0 Hz, 2H), 3.64 (s, 3H), 3.58 (s, 3H), 3.53-3.50 (m, 4H), 3.37-3.34 (m, 3H), 3.30-3.28 (m, 2H), 3.22-3.18 (m., 2H), 2.72 (s, 3H), 2.64 (s, 3H), 2.31- 2.25 (m, 2H), 2.18-2.13 (m, 2H), 2.04-1.95 (m, 4H), 1.79-1.78 (m, 2H).
MH+ 478 (-2HC1).
Example 164: l-cyclopentyl--V-(3-(4-(2,3-dichlorophenyl)piperazin-l-yl)-2- hydroxypropyI)-2,5-dimethyI-l//-imidazole-4-carboxamide dihydrochloride
1H NMR (400 MHz, MeOH-d4) δ 7.31-7.26 (m, 2H), 7.17-7.15 (m, 2H), 4.34-4.31 (m, IH)5 3.74 (d, J = 12.0 Hz, 2H), 3.57-3.35 (m, 8H), 3.20-3.15 (m, 3H), 2.72 (s, 3H), 2.61 (s, 3H), 2.28-2.25 (m, 2H), 2.05-1.96 (m, 4H), 1.79-1.82 (m, 2H).
MH+ 494 (-2HC1).
Example 165: iV-(3-(4-(2,3-dichlorophenyl)piperazin-l-yI)propyl)-2,5- dimethyl-l-propyl-l//-imidazoIe-4-carboxamide dihydrochloride
1H NMR (400 MHz, MeOH-d4) δ 7.31-7.23 (m, 2H), 7.18-7.16 (m, IH), 4.09 (t, J = 8.0 Hz, 2H), 3.71 (d, J = 9.2 Hz, 2H), 3.53 (t, J = 6.4 Hz, 4H), 3.37- 3.31 (m, 3H), 3.30-3.28 (m, 4H), 3.22-3.21 (m, 2H), 2.67 (s, 3H), 2.58 (s, 3H), 2.18-2.1 1 (m, 2H), 1.82- 1.77 (m, 2H), 1.01 (t, J = 6.4 Hz, 3H).
MH+452 (-2HC1).
Example 166: 7V-(3-(4-(2,3-dichlorophenyl)piperazin-l-yl)-2-hydroxypropyl)- 2,5-dimethyl-l-propyl-l//-imidazole-4-carboxamide dihydrochloride
1H NMR (400 MHz, MeOH-d4) δ 7.28-7.27 (m, 2H), 7.19-7.17 (m, IH), 4.36-4.34 (m, IH), 4.10 (t, J = 8.0 Hz, 2H), 3.78-3.7 (m, 2H), 3.53-3.42 (m, 7H), 3.21-2.60 (m, 3H), 2.69 (s, 3H), 2.60 (s, 3H), 1.83-1.77 (m, 2H), 1.01 (t, J = 7.2 Hz, 3H).
MH+468 (-2HC1).
Example 167: Λ^3-(4-(2,3-dimethyIphenyl)piperaziii-l-yl)pr()pyl)-l-(2- methoxyphenyl)-5-methyl-2-propyl-l//-imidazole-4-carboxamide
dihydrochloride
1H NMR (400 MHz, DMSO-d6) δ 10.95 (br s, IH), 9.06 (br s, IH), 7.64 (t, J= 7.6 Hz , IH), 7.54 (dd, J = 8.6, 1.2 Hz, IH), 7.03 (d, J = 8.0 Hz, IH)5 7.18 (td, J = 7.6, 0.8 Hz5 IH), 7.03 (t, J = 7.6 Hz, IH), 6.90-6.86 (m, 2H)5 3.78 (s, 3H)5 3.52-3.49 (m, 2H)5 3.38-3.36 (m, 2H)5 3.26-3.07 (m, 8H)5 2.60-2.56 (m, 2H)5 2.18 (s, 6H)5 2.13 (s, 3H), 2.06-1.99 (m, 2H), 1.59-1.51 (m, 2H), 0.75 (t, J = 7.6 Hz5
3H). MH+ 504.
Example 168: Λ^3-(4-(3-chloro-2-methylphenyl)piperazin-l-yl)propyl)-l-(2- methoxyphenyl)-5-methyl-2-propyI-l//-imidazole-4-carboxaiiiide
dihydrochloride
1H NMR (400 MHz, DMSO-d6) δ 10.81 (br s, IH), 8.86 (br s, IH), 7.62 (t, J = 8.0 Hz , IH), 7.49 (d, J = 7.6 Hz, IH), 7.34 (d, J= 8.0 Hz, IH), 7.20-7.15 (m, 3H), 7.05-7.01 (m, IH), 3.78 (s, 3H), 3.53-3.50 (m, 2H), 3.37-3.35 (m, 2H), 3.23- 3.06 (m, 8H), 2.53 (t, J = 7.6 Hz, 2H), 2.27 (s, 6H), 2.17 (s, 3H), 2.04-1.99 (m, 2H), 1.58-1.49 (m, 2H), 0.75 (t, J= 7.6 Hz, 3H).
MH+ 524.
Example 169: 7V-(3-(4-(2,3-dichIorophenyl)piperazin-l-yl)propyl)-l-(2- methoxyphenyl)-5-methyl-2-propyI-l//-imidazole-4-carboxamide
dihydrochloride
1H NMR (400 MHz, DMSO-d6) δ 1 1.06 (br s, IH), 8.91 (br s, IH), 7.62 (t, J= 8.0 Hz , IH), 7.51 (d, J= 7.6 Hz, IH), 7.51 (d, J = 6.8 Hz, IH), 7.35-7.32 (m, 3H), 7.20-7.15 (m, 2H), 3.78 (s, 3H), 3.59-3.54 (m, 2H), 3.41-3.35 (m, 4H), 3.26- 3.17 (m, 6H), 2.54 (t, J = 7.2 Hz, 2H), 2.17 (s, 6H), 2.04-1.99 (m, 2H), 1.59-1.50 (m, 2H), 0.73 (t, J= 7.2 Hz, 3H).
MH+ 544. Example 170: Λ^-(4-(2,3-dimethylphenyl)piperazin-l-yl)-2-hydroxypropyl)- l-(2-methoxyphenyI)-5-methyl-2-propyI-l/-r-imidazole-4-carboxamide dihydrochloride
1H NMR (400 MHz, DMSO-d6) δ 10.26 (br s, IH), 8.79 (br s, IH), 7.64 (t, J = 7.6 Hz , IH), 7.50 (d, J = 8.0 Hz, IH), 7.35 (d, J = 7.6 Hz, IH), 7.17 (td, J = 7.6, 0.8 Hz, IH), 7.03 (t, J = 7.6 Hz, IH), 6.90-6.86 (m, 2H), 4.24-4.22 (m, IH), 3.78 (s, 3H), 3.52-3.40 (m, 2H), 3.38-3.27 (m, 5H), 3.16-3.05 (m, 5H), 2.56- 2.53 (m, 2H), 2.18 (s, 6H), 2.13 (s, 3H), 1.57-1.51 (m, 2H), 0.76 (t, J = 7.6 Hz, 3H).
MH+ 520. Example 171: Λ'-β-^-β-cliloro^-inethylpheiiytypiperaziii-l-yl)^- hydroxypropyl)-l-(2-methoxyphenyl)-5-methyl-2-propyl-l//-imidazole-4- carboxamide dihydrochloride 1H NMR (400 MHz, DMSO-(I6) δ 10.68 (br s, IH), 8.54 (br s, IH), 7.59 (t,
J = 8.0 Hz , IH), 7.43 (d, J = 7.6 Hz, IH), 7.32 (d, J = 8.0 Hz, IH), 7.18-7.13 (m, 3H), 7.03-7.01 (m, IH)5 4.21-4.19 (m, IH), 3.76 (s, 3H), 3.62-3.52 (m, 2H), 3.37- 3.25 (m, 5H), 3.18-3.04 (m, 7H), 2.26 (s, 3H), 2.16 (s, 3H), 1.54-1.48 (m, 2H), 0.75 (t, J= 7.6 Hz, 3H).
MH+ 540.
Example 172: Λf-β-^-^^-dichlorophenytypiperaziii-l-yl^-hydroxypropyl)- l-(2-methoxyphenyl)-5-methyl-2-propyl-l//-imidazoIe-4-carboxamide dihydrochloride
1H NMR (400 MHz, DMSO-d6) δ 10.41 (br s, IH), 8.66 (br s, IH), 7.61 (t, J = 8.0 Hz , IH), 7.60 (d, J = 7.6 Hz, IH), 7.35-7.32 (m, 3H), 7.18-7.15 (m, 2H), 4.23-4.21 (m, IH), 3.77 (s, 3H), 3.64-3.56 (m, 2H), 3.42-3.32 (m, 5H), 3.28-3.12 (m, 7H), 2.51 (t, J = 7.6 Hz, 2H), 2.17 (s, 3H), 1.56-1.50 (m, 2H), 0.75 (t, J = 7.6 Hz, 3H).
MH+ 560.
Example 173: iV-(3-(4-(2,3-dimethylpheiiyl)piperaziii-l-yl)propyl)-2,5- dimethyl-l-(2-(trifluoromethyl)phenyl)-li/-imidazoIe-4-carboxamide dihydrochloride
1H NMR (400 MHz, MeOH-d4) δ 8.11 (d, J = 7.6 Hz, IH), 8.04-7.95 (m, 2H), 7.78 (d, J = 3.6 Hz, IH), 7.06 (t, J = 7.2 Hz, IH), 6.95 (t, J = 7.2 Hz, 2H), 3.70-3.60 (m, 3H), 3.58-3.52 (m, 4H), 3.40-3.21 (m, 4H), 3.16-3.09 (m, 6H), 2.43 (s, 3H), 2.29 (s, 3H), 2.25 (s, 3H), 2.24 (s, 3H), 2.20-2.13 (m, 2H).
MH+514 (-2HC1).
Example 174: 7V-(3-(4-(3-chloro-2-methylphenyl)piperazin-l-yl)propyl)-2,5- dimethyl-l-(2-(trifluoromethyI)phenyl)-l/7-iinidazoIe-4-carboxamide dihydrochloride 1H NMR (400 MHz, MeOH-d4) δ 8.11 (d, J - 3.2 Hz, IH), 8.01-7.97 (m, 2H), 7.76 (d, J = 4.0 Hz, IH), 7.17 (d, J = 4.4 Hz, 2H), 7.09-7.06 (m, IH), 3.72- 3.65 (m, 3H), 3.64 (s, 3H), 3.61-3.54 (m, 3H), 3.40-3.26 (m, 4H), 3.17-3.09 (m, 2H), 2.41 (s, 3H), 2.37 (s, 3H), 2.28 (s, 3H), 2.18-2.14 (m, 2H).
MH+534 (-2HC1).
Example 175: Λr-(3-(4-(2,3-dichlorophenyl)piperazin-l-yI)propyl)-2,5- dimethyl-l-(2-(trifluoromethyl)phenyl)-l//-imidazole-4-carboxamide dihydrochloride
1H NMR (400 MHz, MeOH-d4) δ 8.12 (d, J = 6.3 Hz, IH), 8.08-7.96 (m, 2H), 7.78 (d, J = 7.3 Hz, IH), 7.31-7.25 (m, 2H), 7.19-7.13 (m, IH), 3.73-3.65 (m, 3H), 3.66 (s, 3H), 3.62-3.54 (m, 3H), 3.41-3.26 (m, 4H), 3.17-3.09 (m, 2H), 2.41 (s, 3H), 2.28 (s, 3H), 2.18-2.14 (m, 2H).
MH+534 (-2HC1).
Example 176: jV-(3-(4-(3-chloro-2-methy!phenyl)piperazin-l-yl)-2- hydroxypropyl)-2,5-dimethyI-l-(2-(trifluoromethyI)phenyl)-l//-imidazole-4- carboxamide dihydrochloride
1H NMR (400 MHz, MeOH-d4) δ 8.11 (d, J = 6.4 Hz, IH), 8.07-7.95 (m, 2H), 7.77 (d, J = 7.2 Hz, IH), 7.31-7.26 (m, 2H), 7.19-7.10 (m, IH), 4.37-4.32 (m, IH), 3.74-3.67 (m, 3H), 3.65 (s, 3H), 3.61-3.54 (m, 3H), 3.40-3.26 (m, 4H), 3.17- 3.09 (m, 2H), 2.42 (s, 3H), 2.30 (s, 3H).
MH+550 (-2HC1).
Example 177: yV-β-^-^S-dichlorophenytypiperazin-l-yl^-liydroxypropyl)-
2,5-dimethyl-l-(2-(trifluoromethyl)phenyl)-li/-imidazole-4-carboxainide dihydrochloride
1H NMR (400 MHz, MeOH-d4) δ 8.12 (d, J = 7.2 Hz, IH), 8.08-7.95 (m, 2H), 7.79-7.77 (m, IH), 7.16 (d, J = 4.0 Hz, 2H), 7.10-7.01 (m, IH), 4.35-4.32 (m, IH), 3.74-3.67 (m, 3H), 3.65 (s, 3H), 3.61-3.54 (m, 3H), 3.40-3.26 (m, 4H), 3.17- 3.09 (m, 2H), 2.43 (s, 3H).
MH+570 (-2HC1). Example 178: ./V-(3-(4-(3-chIoro-2-methylpheiiyl)piperazin-l-yl)-2- hydroxypropyl)-l-(4-methoxyphenyl)-5-methyl-2-propyl-l//-imidazole-4- carboxamide dihydrochloride 1H NMR (400 MHz, DMSO-d6) δ 10.35 (br s, IH), 8.81 (br s, IH), 7.45
(d, J = 8.4 Hz , 2H), 7.20-7.14 (m, 4H), 7.01 (dd, J = 6.8, 2.4 Hz, IH), 4.23-4.21 (m, IH), 3.82 (s, 3H), 3.63-3.52 (m, 2H), 3.41-3.28 (m, 6H), 3.19-3.06 (m, 4H), 2.58 (t, J = 7.6 Hz, 2H), 2.26 (s, 3H), 2.23 (s, 3H), 1.60-1.53 (m, 2H), 0.75 (t, J = 7.2 Hz, 3H).
MH+ 540.
Example 179: yV-^-^-^-chloro^-methylphenytypiperaziii-l-yl)^- hydroxypropyl)-l-(2-methoxyphenyl)-2,5-dimethyI-l/-r-imidazole-4- carboxamide dihydrochloride
1H NMR (400 MHz, DMSO-Ci6) δ 10.34 (br s, IH), 8.62 (br s, IH), 7.61 (t, J= 8.0 Hz , IH), 7.60 (d, J= 7.6 Hz, IH), 7.34 (d, J= 8.8 Hz, IH), 7.20-7.15 (m, 3H), 7.02 (dd, J= 8.0, 2.4 Hz, IH), 4.22-4.20 (m, IH), 3.78 (s, 3H), 3.63-3.52 (m, 2H), 3.41-3.28 (m, 5H), 3.19-3.06 (m, 5H), 2.26 (s, 3H), 2.25 (s, 3H), 2.18 (s, 3H), 1.54-1.48 (m, 2H), 0.75 (t, J= 7.6 Hz, 3H).
MH+ 512.
Example 180: iV-(3-(4-(3-chIoro-2-methylphenyl)piperazin-l-yl)-2- hydroxypropyl)-l-(4-chlorophenyl)-2-propyl-///-imidazole-4-carboxamide dihydrochloride
1H NMR (400 MHz, DMSO-d6) δ 10.38 (br s, IH), 8.31 (br s, IH), 7.71
(d, J= 6.8 Hz, 2H), 7.63 (d, J = 6.8 Hz, 2H), 7.22-7.18 (m, 2H), 7.04 (d, J = 5.6
Hz, IH), 4.26-4.24 (m, IH), 3.65-3.62 (m, IH), 3.56-3.53 (m, IH), 3.39-3.71 (m, 2H), 3.32-3.27 (m, 2H), 3.20-3.09 (m, 6H), 2.71 (t, J = 6.0 Hz, 2H), 2.29 (s, 3H),
1.61-1.53 (m, 2H), 0.80 (t, J= 6.0 Hz, 3H).
MH+ 530.
Example 181: 7V-(3-(4-(3-chloro-2-methylphenyl)piperazin-l-yl)propyl)-l-(4- chlorophenyl)-2-propyl-l//-imidazole-4-carboxamide dihydrochloride 1U NMR (400 MHz, DMSO-d6) δ 10.98 (br s, IH), 8.29 (br s, IH), 7.71 (d, J = 6.8 Hz, 2H), 7.64 (d, J = 12 Hz, 2H), 7.20-7.19 (m, 2H), 7.04 (d, J = 5.6 Hz, IH), 3.54-3.51 (m, 2H), 3.42-3.38 (m, 2H), 3.28-3.15 (m, 8H), 2.75-2.73 (m, 2H), 2.30 (s, 3H), 2.05-2.01 (m, 2H), 1.59-1.53 (m, 2H), 0.80 (t, J= 5.6 Hz, 3H).
MH+ 514.
Example 182: Λ43-(4-(3-chloro-2-methylphenyl)piperazin-l-yl)-2- hydroxypropyl)-l-(2,3-dihydrobenzo[Λ][l,4]dioxin-6-yl)-2,5-dimethyl-l//- imidazole-4-carboxamide dihydrochloride
1H NMR (400 MHz, DMSO-d6) δ 10.61 (br s, IH), 8.76 (br s, IH), 7.20-
7.13 (m, 3H), 7.09 (d, J= 8.4 Hz, IH), 7.03-6.97 (m, 2H), 4.30 (s, 4H), 4.26-4.22 (m, IH), 3.65-3.62 (m, IH), 3.54-3.51 (m, IH), 3.42-3.27 (m, 6H), 3.20-3.09 (m, 4H), 2.34 (s, 3H), 2.27 (s, 3H), 2.26 (s, 3H).
MH+ 540.
Example 183: 7V-(3-(4-(3-chloro-2-methylphenyl)piperazin-l-yl)propyl)-l- (2,3-dihydrobenzo[Z>][l,4]dioxin-6-yl)-2,5-dimethyl-l/-r-imidazoIe-4- carboxamide dihydrochloride
1H NMR (400 MHz, DMSO-d6) δ 11.26 (br s, IH), 8.92 (br s, IH), 7.20-
7.14 (m, 3H), 7.09 (d, J = 8.8 Hz, IH), 7.03-6.98 (m, 2H), 4.30 (s, 4H), 3.51-3.48 (m, 2H), 3.39-3.34 (m, 2H), 3.26-3.20 (m, 4H), 3.18-3.12 (m, 4H), 2.33 (s, 3H), 2.27 (s, 3H), 2.26 (s, 3H), 2.06-1.99 (m, 2H).
MH+ 524.
Example 184: l-(2,3-dihydrobenzo[Λ] [l,4]dioxin-6-yl)-.V-(3-(4-(2,3- dimethylphenyl)piperazin-l-yl)propyl)-5-methyl-2-propyl-l//-imidazole-4- carboxamide dihydrochloride
1H NMR (400 MHz, DMSO-(I6) δ 1 1.19 (br s, IH), 9.23 (br s, IH), 7.20 (d, J = 2.4 Hz, IH), 7.09 (d, J = 8.4 Hz, IH), 7.06-7.01 (m, 2H), 6.90-6.85 (m, 2H), 4.30 (s, 4H), 3.50-3.47 (m, 2H), 3.39-3.35 (m, 2H), 3.27-3.17 (m, 4H), 3.14- 3.05 (m, 4H), 2.66-2.62 (m, 2H), 2.25 (s, 3H), 2.18 (s, 3H), 2.13 (s, 3H), 2.07- 2.04 (m, 2H), 1.68-1.58 (m, 2H), 0.79 (t, J= 7.2 Hz, 3H).
MH+ 532. Example 185: 7V-(3-(4-(2,3-dichlorophenyl)piperazin-l-yl)propyl)-l-(2,3- dihydrobenzo[Z>][l,4]dioxin-6-yl)-5-methyl-2-propyI-l//-iiiiidazoIe-4- carboxamide dihydrochloride
1H NMR (400 MHz, DMSO-d6) δ 11.21 (br s, IH), 9.04 (br s, IH), 7.36- 7.30 (m, 2H), 7.18 (d, J = 2.4 Hz, IH), 7.17-7.07 (m, IH), 7.00 (d, J - 2.4 Hz, IH), 6.98 (d, J = 2,4 Hz, IH), 4.30 (s, 4H), 3.55-3.53 (m, 2H), 3.41-3.33 (m, 4H), 3.24-3.12 (m, 6H), 2.61 (t, J = 7.2 Hz5 2H), 2.24 (s, 3H), 2.05-1.98 (m, 2H), 1.66- 1.56 (m, 2H), 0.79 (t, J = 7.2 Hz5 3H).
MH+ 572.
Example 186: 7V-(3-(4-(3-chIoro-2-methyIphenyl)piperazin-l-yl)propyl)-5- methyl-l-phenyl-2-propyl-l/y-imidazole-4-carboxaiiiide dihydrochloride
1H NMR (400 MHz, DMSO-d6) δ 11.08 (br s, IH), 9.01 (br s, IH), 7.66-
7.62 (m, 3H), 7.56-7.53 (m, 2H)5 7.20-7.15 (m, 2H), 7.03-7.01 (m, IH), 3.52-3.49
(m, 2H), 3.40-3.34 (m, 2H), 3.24-3.22 (m, 4H)5 3.19-3.12 (m, 4H), 2.59 (t, J = 12
Hz, 2H)5 2.27 (s, 3H), 2.24 (s, 3H), 2.06-1.99 (m, 2H), 1.62-1.53 (m, 2H), 0.77 (t, J= 7.6 Hz, 3H).
MH+ 494.
Example 187: iV-(3-(4-(3-chloro-2-methylphenyl)piperazin-l-yl)-2- hydroxypropyl)-5-methyl-l-phenyl-2-propyl-l//-imidazoIe-4-carboxamide dihydrochloride
1H NMR (400 MHz, DMSO-d6) δ 10.47 (br s, IH)5 8.82 (br s, IH), 7.65- 7.62 (m, 3H)5 7.55-7.52 (m, 2H)5 7.20-7.14 (m, 2H), 7.03-7.01 (m, IH)5 4.25-4.23 (m, IH), 3.65-3.61 (m, IH)5 3.55-3.52 (m, IH), 3.42-3.27 (m, 6H)5 3.19-3.08 (m, 4H)5 2.59 (t, J= 1.2 Hz, 2H)5 2.27 (s, 3H)5 2.24 (s, 3H), 1.62- 1.52 (m, 2H), 0.77 (t, J= 7.2 Hz, 3H).
MH+ 510.
Example 188: vV-(3-(4-(3-chloro-2-methylpheiiyl)piperaziii-l-yl)propyl)-l- (2,3-dihydrobenzo[Z>] [l,4]dioxin-6-yl)-5-methyl-2-propyl-l//-imidazole-4- carboxamide dihydrochloride 1H NMR (400 MHz, DMSO-d6) δ 1 1.10 (br s, IH), 9.08 (br s, IH), 7.20-
7.14 (m, 3H), 7.08 (d, J = 8.8 Hz, IH), 7.03-6.98 (m, 2H), 4.30 (s, 4H), 3.52-3.48 (m, 2H), 3.39-3.34 (m, 2H), 3.23-3.18 (m, 4H), 3.15-3.12 (m, 4H), 2.62 (t, J = 6,4 Hz, 2H), 2.27 (s, 3H), 2.24 (s, 3H), 2.06-1.99 (m, 2H), 1.66-1.57 (m, 2H), 0.79 (t, J = 7.2 Hz, 3H).
MH+ 552.
Example 189; 7V-(3-(4-(3-chloro-2-methylphenyI)piperazin-l-yl)-2- hydroxypropyl)-l-(2,3-dihydrobenzo[A] [l,4]dioxin-6-yI)-5-methyl-2-propyl- l/f-imidazole-4-carboxamide dihydrochloride
1H NMR (400 MHz, DMSO-d6) δ 10.48 (br s, IH), 8.87 (br s, IH), 7.20-
7.15 (m, 3H), 7.08 (d, J = 8.4 Hz, IH), 7.03-6.97 (m, 2H), 4.30 (s, 4H), 4.26-4.23 (m, IH), 3.64-3.61 (m, IH), 3.54-3.51 (m, IH), 3.42-3.26 (m, 6H), 3.19-3.08 (m,
4H), 2.61 (t, J= 7.2 Hz, 2H), 2.26 (s, 3H), 2.24 (s, 3H), 1,65-1.56 (m, 2H), 0.79 (t, J= 7.2 Hz, 3H).
MH+ 568. Example 190: l-(2,3-dihydrobenzo[Λ][l,4]dioxin-6-yI)-7V-(3-(4-(2,3- dimethylphenyl)piperazin-l-yl)-2-hydroxypropyl)-5-methyl-2-propyl-l//- imidazole-4-carboxamide dihydrochloride
1H NMR (400 MHz, DMSO-d6) δ 10.47 (br s, IH), 8.99 (br s, IH), 7.18 (d, J = 2.4 Hz, IH), 7.09 (d, J = 8.4 Hz, IH), 7.06-6.99 (m, 2H), 6.90-6.85 (m,
2H), 4.30 (s, 4H), 4.30-4.21 (m, IH), 3.64-3.61 (m, IH), 3.54-2.51 (m, IH), 3.45-
3.26 (m, 4H), 3.20-3.08 (m, 6H), 2.64 (t , J = 6.4 Hz, 2H), 2.25 (s, 3H), 2.18 (s,
3H), 2.12 (s, 3H), 1.67-1.57 (m, 2H), 0.79 (t, J= 7.2 Hz, 3H).
MH+ 548.
Example 191: yV-(3-(4-(2,3-dichlorophenyl)piperazin-l-yl)-2-hydroxypropyl)- l-(2,3-dihydrobenzo[Λ][l,4]dioxin-6-yl)-5-methyl-2-propyl-l//-imidazole-4- carboxamide dihydrochloride 1H NMR (400 MHz, DMSO-d6) δ 10.58 (br s, IH), 8.84 (br s, IH), 7.36-
7.29 (m, 2H), 7.20-7.14 (m, 2H), 7.08 (d, J = 8.4 Hz, IH), 6.98 (dd, J = 8.4, 2.4 Hz, IH), 4.30 (s, 4H), 4.24-4.22 (m, IH), 3.67-3.65 (m, IH), 3.58-3.55 (m, IH), 3.42-3.32 (m, 4H), 3.22-3.12 (m, 6H), 2.60 (t, J- 7.2 Hz, 2H), 2.24 (s, 3H), 1.65- 1.55 (m, 2H), 0.79 (t, J = 7.2 Hz, 3H).
MH+ 588.
Example 192: Λ^-^-^S-dimethylphenytypiperazin-l-yOpropyl)-!-^- fluorophenyl)-5-methyl-2-propyI-l//-imidazole-4-carboxamide
dihydrochloride 1H NMR (400 MHz, DMSO-d6) δ 11.25 (s, IH), 9.05 (s, IH), 7.95-7.81
(m, 2H), 7.77-7.61 (m, 2H), 7.39-7.27 (m, 2H), 7.25-7.13 (m, IH), 3.76-3.66 (m, 2H), 3.65-3.51 (m, 2H), 3.49-3.31 (m, 4H), 2.91-2.63 (m, 6H), 2.43 (s, 3H), 2.31 (quartet, J = 3.2 Hz, 2H), 2.22 (s, 3H),1.58 (sextet, J = 2.0 Hz, 2H), 0.85 (t, J = 2.0 Hz, 3H).
MH+ 492.
Example 193: 7V-(3-(4-(2,3-dichlorophenyl)piperazin-l-yI)propyl)-l-(4- fluorophenyl)-5-methyl-2-propyl-l//-imidazo-e-4-carboxamide
dihydrochloride
1H NMR (400 MHz, DMSO-d6) δ 1 1.21 (s, IH), 9.01 (s, IH), 7.95-7.81 (m, 2H), 7.77-7.61 (m, 2H), 7.39-7.27 (m, 2H), 7.25-7.13 (m, IH), 3.80-3.69 (m, 2H), 3.55-3.41 (m, 4H), 2.96-2.65 (m, 8H), 2.62 (quartet, J= 8.0 Hz, 2H), 2.32 (s, 3H), 1.55 (sextet, J= 8.0 Hz, 2H), 0.80 (t, J= 7.6 Hz, 3H).
MH+ 532.
Example 194: Λ^3-(4-(2y?Udimethylpheiiyl)piperaziii-l-yr)-2-hydroxypropyr)- l-(4-fluorophenyl)-5-methyl-2-propyl-l/f-imidazoIe-4-carboxamide
dihydrochloride
1H NMR (400 MHz, DMSO-d6) δ 10.48 (s, IH), 8.84 (s, IH), 7.72-7.61 (m, 2H), 7.59-7.48 (m, 2H), 7.07 (t, J = 8.0 Hz, IH), 6.92 (t, J = 9.2 Hz, 2H), 4.34-4.23 (m, IH), 3.69-3.62 (m, IH), 3.60-3.52 (m, IH), 3.48-3.25 (m, 6H), 3.23-3.05 (m, 6H), 2.62 (t, J = 7.6 Hz, 2H), 2.27 (s, 3H), 2.22 (s, 3H), 2.17 (s, 3H), 1.62 (sextet, J = 7.6 Hz, 2H), 0.81 (t, J = 7.2 Hz, 3H).
MH+ 508. Example 195: Λ^3-(4-(2,3-dichIorophenyl)piperaziii-l-yl)-2-hydroxypropyl)- l-(4-fluorophenyl)-5-methy--2-propyl-l/-r-imidazole-4-carboxamide
dihydrochloride
1H NMR (400 MHz5 DMSO-d6) δ 10.50 (s, IH), 8.87 (s, IH), 7.74-7.60
(m, 2H), 7.55-7.45 (m, 2H), 7.15-6.99 (m, IH), 6.91-6.81 (m, 2H), 4.30-4.21 (m,
IH), 3.75-3.62 (m, IH), 3.60-3.55 (m, IH), 3.50-3.27 (m, 6H), 3.25-3.10 (m, 6H),
2.55 (t, J = 7.6 Hz, 2H), 2.31 (s, 3H), 1.62 (sextet, J = 7.6 Hz, 2H), 0.91 (t, J = 7.2 Hz, 3H).
MH+ 548.
Example 196: 7V-(3-(4-(3-chloro-2-methylphenyl)piperaziii-l-yl)propyl)-l-(4- fluorophenyl)-2,5-dimethyI-l//-imidazole-4-carboxamide dihydrochloride
1H NMR (400 MHz, DMSO-d6) δ 11.32 (s, IH), 9.01 (s, IH), 7.87-7.78 (m, 2H), 7.75-7.65 (m, 2H), 7.41-7.32 (m, 2H), 7.25-7.17 (m, IH), 3.76-3.66 (m, 2H), 3.62-3.52 (m, 2H), 3.47-3.29 (m, 6H), 2.66 (quartet, J = 2.0 Hz, 4H), 2.47 (s, 3H), 2.43 (s, 3H), 2.27-2.16 (m, 2H).
MH+ 484.
Example 197: iV-(3-(4-(3-chloro-2-methyIphenyl)piperaziii-l-yl)propyI)-l-(4- fluoropheny.)-5-methyl-2-propyl-l//-imidazole-4-carboxamide
dihydrochloride
1H NMR (400 MHz, DMSO-d6) δ 10.50 (s, IH), 8.85 (s, IH), 7.91-7.81 (m, 2H), 7.77-7.60 (m, 2H), 7.41-7.27 (m, 2H), 7.25-7.11 (m, IH), 3.77-3.61 (m, 2H), 3.58-3.47 (m, 2H), 3.45-3.31 (m, 4H), 2.90-2.67 (m, 6H), 2.36 (s, 3H), 2.31 (s, 3H).
MH+ 512.
Example 198: iV-(3-(4-(2,3-dichlorophenyl)piperazin-l-yI)-2-hydroxypropyl)- l-(2-fluorophenyl)-2,5-dimethyI-l//-imidazole-4-carboxamide
dihydrochloride
1H NMR (400 MHz, DMSO-d6) δ 10.34 (s, IH), 8.31 (s, IH), 7.70-7.55 (m, 3H), 7.45 (t, J = 7.6 Hz, IH), 7.36-7.30 (m, 2H), 7.17 (dd, J = 7.2, 2.4 Hz, IH), 4.21-4.19 (m, IH), 3.35-3.55 (m, 2H), 3.42-3.10 (m, 10H), 2.23 (s, 3H), 2.20 (s, 3H).
MH+ 520.
Example 199: l-(2-chlorophenyl)-Λ^3-(4-(2,3-dimethylphenyl)piperazin-l- yl)-2-hydroxypropyI)-5-methyI-2-propyl-l//-imidazole-4-carboxamide dihydrochloride 1H NMR (400 MHz, DMSO-d6) δ 10.23 (s, IH), 8.43 (s, IH), 7.82-7.80
(m, IH), 7.68-7.59 (m, 3H), 7.04 (t, J = 7.6 Hz, IH), 6.91-6.86 (m, 2H), 4.23-4.21 (m, IH), 3.62-3.52 (m, 2H), 3.36-3.25 (m, 6H), 3.17-3.04 (m, 4H), 2.44-2.41 (m, 2H), 2.18 (s, 6H), 2.13 (s, 3H), 1.57-1.51 (m, 2H), 0.79 (t, J = 7.2 Hz, 3H).
MH+ 524.
Example 200: l-(2-chlorophenyl)-Λ^-(3-(4-(2,3-dimethylphenyl)piperazin-l- yl)propyl)-5-methyl-2-propyl-l//-imidazo-e-4-carboxamide dihydrochloride
1H NMR (400 MHz, DMSO-d6) δ 11.04 (s, IH), 8.85 (s, IH), 7.83 (dd, J = 8.0, 1.2 Hz, IH), 7.75-7.62 (m, 3H), 7.04 (t, J = 7.6 Hz, IH), 6.91-6.86 (m, 2H),
3.52-3.49 (m, 2H), 3.36 (q, J= 6.4 Hz, 2H), 3.23-3.13 (m, 4H), 3.10-3.08 (m, 4H),
2.53-2.50 (m, 2H), 2.19 (s, 3H), 2.18 (s, 3H), 2.13 (s, 3H), 2.06-2.01 (m, 2H),
1.61-1.55 (m, 2H), 0.79 (t, J = 7.2 Hz, 3H).
MH+ 508.
Example 201: (J-?)-7V-(3-(4-(3-chloro-2-methylphenyl)piperazin-l-yl)-2- hydroxypropyl)-l-(4-fluoropheny.)-5-methyl-2-phenyl-l//-imidazole-4- carboxamide dihydrochloride 1H NMR (400 MHz, DMSO-d6) δ 10.43 (s, IH), 8.39 (s, IH), 7.48-7.45
(m, 2H), 7.40-7.27 (m, 7H), 7.20-7.14 (m, 2H), 7.01 (dd, J = 7.2, 2.4 Hz, IH), 4.25-4.23 (m, IH), 3.63-3.52 (m, 2H), 3.40-3.37 (m, 2H), 3.33-3.13 (m, 5H), 3.10-3.08 (m, 5H), 2.31 (s, 3H), 2.26 (s, 3H).
MH+ 562.
Example 202: (Λ)-l-(4-chlorophenyl)-Λ':-(3-(4-(2,3-dichlorophenyl)piperazin- l-yl^-hydroxypropyl^-propyl-l/Z-imidazole^-carboxamide dihydrochloride
1H NMR (400 MHz, DMSO-d6) δ 10.52 (s, IH)5 8.94 (s, IH), 8.35 (s, IH), 7.69 (d, J- 6.8 Hz, 2H), 7.62 (d, J = 8.4 Hz, 2H), 7.36-7.30 (m, 2H), 7.16 (dd, J - 6.8, 2.8 Hz, IH), 4.24-4.22 (m, IH), 3.66-3.54 (m, 2H), 3.42-3.34 (m, 5H), 3.29- 3.11 (m, 5H), 2.70 (t, J = 7.6 Hz, 2H), 1.59-1.49 (m, 2H), 0.77 (t, J= 7.6 Hz, 3H).
MH+ 550. Example 203: iV-(3-(4-(3-chloro-2-methyIphenyl)piperazin-l-yl)propyl)-l-(2- chlorophenyl)-2,5-dimethyl-l/J-imidazole-4-carboxamide dihydrochloride
1H NMR (400 MHz, DMSO-d6) δ 10.95 (s, IH), 8.57 (s, IH), 7.81 (d, J = 7.6 Hz, IH), 7.69-7.60 (m, 3H), 7.20-7.12 (m, 2H), 7.01 (dd, J = 6.8, 2.4 Hz, IH), 3.52-3.50 (m, 2H), 3.36-3.32 (m, 2H), 3.21-3.02 (m, 8H), 2.27 (s, 3H), 2.19 (s, 3H), 2.18 (s, 3H), 2.04-1.96 (m, 2H).
MH+ 500.
Example 204: Λ^-(4-(3-chloro-2-methylphenyl)piperazin-l-yl)-2- hydroxypropyl)-l-(2-fluorophenyl)-2,5-dimethyl-l/-r-iinidazole-4- carboxamide dihydrochloride
1H NMR (400 MHz, DMSO-d6) δ 10.38 (s, IH), 8.44 (s, IH), 7.81-7.76 (m, IH), 7.73-7.59 (m, 2H), 7.54-7.48 (m, IH), 7.23-7.18 (m, 2H), 7.04 (d, J - 6.0 Hz, IH), 4.25-4.24 (m, IH), 3.66-3.51 (m, 2H), 3.43-3.31 (m, 5H), 3.24-3.01 (m, 5H), 2.29 (s, 3H), 2.27 (s, 6H).
MH+ 500.
Example 205: jV-(3-(4-(3-chloro-2-methylphenyl)piperazin-l-yl)-2- hydroxypropyl)-l-(4-methoxyphenyI)-2,5-dimethyl-l/-r-imidazole-4- carboxamide dihydrochloride
1H NMR (400 MHz, DMSO-d6) δ 10.05 (br s, IH), 8.40 (br s, IH), 7.41
(d, J = 8.8 Hz , 2H), 7.24-7.15 (m, 3H), 7.05 (dd, J = 2.8, 2.0 Hz, IH), 4.22-4.20 (m, IH), 3.85 (s, 3H), 3.61-3.55 (m, 2H), 3.40-3.30 (m, 4H), 3.19-3.08 (m, 6H),
2.30 (s, 3H), 2.26 (s, 3H), 2.24 (s, 3H). MH+ 512.
Example 206: iV-(3-(4-(2,3-dimethylphenyl)piperazin-l-yl)propyl)-l-(4- methoxyphenyty-S-methyl^-phenyl-l/f-imidazole^-carboxamide
dihydrochloride
1H NMR (400 MHz, DMSO-d6) δ 10.98 (br s, IH), 8.76 (br s, IH), 7.39- 7.29 (m, 7H), 7.05-7.01 (m, 3H), 6.90-6.82 (m, 2H)5 3.77 (s, 3H), 3.51-3.48 (m, 2H), 3.37-3.36 (m, 2H), 3.18-3.07 (m, 8H), 2.29 (s, 3H), 2.17 (s, 3H), 2.12 (s, 3H), 1.96-1.86 (m, 2H).
MH+ 512.
Example 207: 7V-(3-(4-(3-chIoro-2-methylphenyl)piperazin-l-yI)propyl)-l-(4- methoxyphenyl)-5-methyl-2-phenyl-l//-imidazole-4-carboxamide
dihydrochloride
1H NMR (400 MHz, DMSO-d6) δ 10.85 (br s, IH), 8.58 (br s, IH), 7.37- 7.27 (m, 7H), 7.18-7.1 1 (m, 2H), 7.06-7.00 (m, 3H), 3.77 (s, 3H), 3.52-3.20 (m, 2H), 3.38-3.37 (m, 2H), 3.18-3.07 (m, 8H), 2.29 (s, 3H), 2.26 (s, 3H), 2.02-1.98 (m, 2H).
MH+ 558.
Example 208: 7V-(3-(4-(2,3-dichlorophenyl)piperazin-l-yl)propyl)-l-(4- methoxyphenyl)-5-methyl-2-phenyl-l//-imidazoIe-4-carboxamide
dihydrochloride
1H NMR (400 MHz, DMSO-d6) δ 11.19 (br s, IH)5 8.65 (br s, IH), 7.38- 7.27 (m, 9H), 7.18-7.15 (m, IH), 7.06-7.02 (m, 2H), 3.77 (s, 3H), 3.59-3.54 (m, 2H), 3.40-3.34 (m, 4H), 3.24-3.12 (m, 6H)5 2.29 (s, 3H), 2.04-1.97 (m, 2H).
MH+ 578.
Example 209: 7V-(3-f4-(2,3-dimethylphenyl)piperazin-l-yl)-2-hydroxypropyl)- l-(4-methoxyphenyl)-5-methyl-2-phenyl-lH-imidazole-4-carboxamide dihydrochloride
1H NMR (400 MHz, DMSO-d6) δ 10.40 (br s, IH), 8.60 (br s, IH)5 7.45- 7.29 (m, 7H), 7.09-7.01 (m, 3H), 6.90-6.85 (m, 2H), 4.26-4.24 (m, IH), 3.77 (s, 3H), 3.62-3.51 (m, 2H), 3.40-3.27 (m, 5H), 3.17-3.02 (m, 5H), 2.30 (s, 3H), 2.17 (s, 3H), 2.12 (s, 3H).
MH+ 554.
Example 210: 7V-(3-(4-(3-chloro-2-methyIphenyl)piperazin-l-yl)-2- hydroxypropyl)-l-(4-methoxyphenyl)-5-methyl-2-phenyI-l//-iinidazoIe-4- carboxamide dihydrochloride 1H NMR (400 MHz, DMSO-d6) δ 10.37 (br s, IH), 8.45 (br s, IH), 7.37-
7.27 (m, 7H), 7.19-7.10 (m, 2H), 7.05-6.98 (m, 3H), 4.24-4.23 (m, IH), 3.77 (s, 3H), 3.63-3.52 (m, 2H), 3.39-3.27 (m, 5H), 3.14-3.07 (m, 5H), 2.29 (s, 3H), 2.26 (s, 3H).
MH+ 574.
Example 211: iV-(3-(4-(2,3-dichlorophenyl)piperazin-l-yl)-2-hydroxypropyl)- l-(4-methoxyphenyl)-5-methyl-2-phenyl-l/f-imidazole-4-carboxamide dihydrochloride 1H NMR (400 MHz, DMSO-d6) δ 10.51 (br s, IH), 8.46 (br s, IH), 7.37-
7.27 (m, 9H), 7.19-7.15 (m, IH), 7.05-7.03 (m, 2H), 4.25-4.23 (m, IH), 3.77 (s, 3H), 3.66-3.55 (m, 2H), 3.41-3.31 (m, 5H), 3.28-3.10 (m, 5H), 2.32 (s, 3H).
MH+ 594. Example 212: l-(2,3-dihydrobenzo[£][l,4]dioxin-6-yl)-JV-(3-(4-(2,3- dimethylphenyI)piperazin-l-yI)propyI)-5-methyl-2-phenyl-l//-imidazoIe-4- carboxamide dihydrochloride
1H NMR (400 MHz, DMSO-d6) δ 11.02 (br s, IH), 8.81 (br s, IH), 7.44- 7.41 (m, 2H), 7.40-7.31 (m, 3H), 7.05-7.01 (m, 2H), 6.97 (d, J = 8.8 Hz, IH), 6.90-6.85 (m, 3H), 4.27-4.24 (m, 4H), 3.51-3.48 (m, 2H), 3.39-3.35 (m, 2H), 3.19-3.13 (m, 4H), 3.10-3.05 (m, 4H), 2.31 (s, 3H), 2.17 (s, 3H), 2.13 (s, 3H), 2.04-2.00 (m, 2H).
MH+ 566.
Example 213: Λf-(3-(4-(3-chIoro-2-methylphenyl)piperaziii-l-yl)propyl)-l- (2,3-dihydrobenzo[Λ][l,4]dioxin-6-yl)-5-methyl-2-phenyl-li/-imidazoIe-4- carboxamide dihydrochloride
1H NMR (400 MHz, DMSO-d6) δ 11.09 (br s, IH), 8.74 (br s, IH), 7.43- 7.38 (m, 2H), 7.37-7.31 (m, 3H), 7.20-7.14 (m, 2H), 7.02-6.96 (m, 3H), 6.87-6.84 (m, IH), 4.27-4.24 (m, 4H), 3.52-3.49 (m, 2H), 3.39-3.34 (m, 2H), 3.21-3.17 (m, 4H), 3.15-3.12 (m, 4H), 2.30 (s, 3H), 2.26 (s, 3H), 2.05-1.98 (m, 2H).
MH+ 586. Example 214; Λf-β-^-^vS-dichlorophenyOpiperazin-l-yOpropyl)-!-^^- dihydrobenzo[A] [l,4]dioxin-6-yl)-5-methyl-2-phenyl-l//-iniidazoIe-4- carboxamide dihydrochloride
1H NMR (400 MHz, DMSO-(I6) δ 1 1.10 (br s, IH), 8.65 (br s, IH), 7.4 (d, J =7.2 Hz, 2H), 7.38-7.29 (m, 5H), 7.17 (dd, J = 7.2, 2.4 Hz, IH), 7.00-6.99 (m,
IH), 6.97 (d, J = 8.4 Hz, IH), 6.83 (dd, J = 8.4, 2.4 Hz, IH), 4.27-4.24 (m, 4H),
3.56-3.53 (m, 2H), 3.40-3.33 (m, 4H), 3.24-3.12 (m, 6H), 2.30 (s, 3H), 2.02-1.99
(m, 2H).
MH+ 606.
Example 215: l-(2,3-dihydrobenzo[Z>) [l,4]dioxin-6-yl)-7V-(3-(4-(2,3- dimethylphenyl)piperazin-l-yl)-2-hydroxypropyl)-5-methyI-2-pheiiyl-l/-f- imidazoIe-4-carboxamide dihydrochloride 1H NMR (400 MHz, DMSO-d6) δ 10.44 (br s, IH), 8.65 (br s, IH), 7.44-
7.41 (m, 2H), 7.40-7.32 (m, 3H), 7.05-7.01 (m, 2H), 6.98 (d, J = 8.8 Hz, IH), 6.90-6.85 (m, 3H), 4.27-4.24 (m, 5H), 3.63-3.60 (m, IH), 3.54-3.51 (m, IH), 3.40-3.17 (m, 2H), 3.34-3.27 (m, 2H), 3.17-3.03 (m, 6H), 2.31 (s, 3H), 2.17 (s, 3H), 2.12 (s, 3H).
MH+ 582.
Example 216: N-P-^-P-chloro^-methylphenytypiperazin-l-yl)^- hydroxypropyl)-l-(2,3-dihydrobenzo[Λ][l,4]dioxin-6-yl)-5-methyl-2-phenyl- l//-imidazole-4-carboxamide dihydrochloride
1H NMR (400 MHz, DMSO-d6) δ 10.42 (br s, IH), 8.48 (br s, IH), 7.41- 7.39 (m, 2H), 7.38-7.30 (m, 3H), 7.20-7.13 (m, 2H), 7.04-6.06 (m, 3H), 6.83 (dd, J =8.4, 2.4 Hz, IH), 4.28-4.24 (m, 5H), 3.63-3.60 (m, IH)5 3.55-3.52 (m, IH), 3.39-3.36 (m, 2H), 3.32-3.25 (m, 2H), 3.13-3.07 (m, 6H), 2.31 (s, 3H), 2.26 (s, 3H).
MH+ 602.
Example 217: 7V-(3-(4-(2,3-dichlorophenyl)piperazin-l-yl)-2-hydroxypropyl)- l-(2,3-dihydrobenzo[Δ][l,4]dioxin-6-yl)-5-methyl-2-phenyl-l//-imidazole-4- carboxamide dihydrochloride
1H NMR (400 MHz, DMSO-d6) δ 10.57 (br s, IH), 8.51 (br s, IH), 7.42- 7.38 (m, 2H), 7.34-7.29 (m, 5H), 7.17 (dd, J = 7.2, 2.4 Hz, IH), 7.00 (d, J = 2.4 Hz, IH), 6.97 (d, J = 8.4 Hz, IH), 6.84 (dd, J = 8.4, 2.4 Hz, IH), 4.26-4.24 (m, 5H), 3.67-3.64 (m, IH), 3.58-3.55 (m, IH), 3.41-3.36 (m, 2H), 3.34-3.25 (m, 2H), 3.23-3.11 (m, 6H), 2.30 (s, 3H).
MH+ 622.
Example 218i l-(benzo[rf| [l,3]dioxol-5-yl)-Λ43-(4-(3-chloro-2- methylphenyl)piperazin-l-yl)propyl)-2,5-dimethyl-l//-imidazole-4- carboxamide dihydrochloride
1H NMR (400 MHz, DMSO-d6) δ 11.24 (br s, IH), 8.92 (br s, IH), 7.25- 7.13 (m, 4H), 7.08-7.00 (m, 2H), 6.17 (s, 2H), 3.51-3.48 (m, 2H), 3.39-3.35 (m, 2H), 3.24-3.18 (m, 4H), 3.16-3.12 (m, 4H), 2.35 (s, 3H), 2.27 (s, 6H), 2.06-1.99 (m, 2H).
MH+ 510.
Example 219i l-(benzo[</j [l,3]dioxol-5-yl)-7V-(3-(4-(3-chloro-2- methylphenyl)piperazin-l-yl)propyl)-5-methyl-2-propyl-l//-imidazole-4- carboxamide dihydrochloride
1H NMR (400 MHz, DMSO-d6) δ 1 1.24 (br s, IH), 9.19 (br s, IH), 7.23
(d, J = 2.0 Hz, IH), 7.20-7.13 (m, 3H), 7.06 (dd, J = 8.0, 2.0 Hz, IH), 7.02 (dd, J
= 6.8, 2.0 Hz, IH), 6.17 (s, 2H), 3.51-3.48 (m, 2H), 3.40-3.35 (m, 2H), 3.27-3.22 (m, 4H), 3.22-3.12 (m, 4H), 2.65 (t, J = 7.6 Hz, 2H), 2.27 (s, 3H), 2.26 (s, 3H),
2.07-2.00 (m, 2H), 1.68-1.58 (m, 2H), 0.79 (t, J= 7.2 Hz, 3H). MH+ 538.
Example 220: Λ43-(4-(2,3-dimethylphenyl)piperazin-l-yl)propyl)-2,5- dimethyl-l-o-toIyl-l//-imidazole-4-carboxamide dihydrochloride
1H NMR (400 MHz, MeOH-d4) δ 7.62-7.59 (m, 2H), 7.51 (t, J = 7.2 Hz, IH)5 7.40 (d, J = 3.2 Hz, IH), 7.06 (t, J = 3.6 Hz, IH), 6.95 (t, J = 7.6 Hz, 2H), 4.15-4.14 (m, IH), 3.72-3.71 (m, 2H), 3.64-3.32 (m, 6H), 3.24-3.18 (m, 4H), 2.41 (s, 3H), 2.28 (s, 3H), 2.25 (s, 3H), 2.24 (s, 3H), 2.10 (s, 3H).
MH+460 (-2HC1).
Example 221: N-(3-(4-(3-chloro-2-methylphenyl)piperazin-l-yl)propyl)-2,5- dimethyl-l-o-tolyl-l//-imidazole-4-carboxamide dihydrochloride 1H NMR (400 MHz, MeOH-d4) δ 7.63-7.58 (m, 2H), 7.52 (t, J = 7.1 Hz,
IH), 7.40 (d, J = 3.3 Hz, IH), 7.11 (t, J = 3.8 Hz, IH), 6.97 (t, J = 7.6 Hz, 2H), 4.17-4.13 (m, IH), 3.73-3.70 (m, 2H), 3.65-3.32 (m, 6H), 3.23-3.18 (m, 4H), 2.41 (s, 3H), 2.27 (s, 3H), 2.20 (s, 3H), 2.04 (s, 3H).
MH+480 (-2HC1).
Example 222: 7V-(3-(4-(2,3-dichlorophenyl)piperazin-l-yl)propyl)-2,5- dimethyl-l-o-toIyl-l//-imidazole-4-carboxamide dihydrochloride
1H NMR (400 MHz, MeOH-d4) δ 7.61-7.57 (m, 2H), 7.50 (t, J - 7.2 Hz, IH), 7.41 (d, J = 3.4 Hz, IH), 7.10 (t, J - 3.7 Hz, IH), 6.98 (t, J = 7.6 Hz, 2H), 4.18-4.13 (m, IH), 3.75-3.71 (m, 2H), 3.66-3.42 (m, 5H), 3.33-3.18 (m, 5H), 2.43 (s, 3H), 2.19 (s, 3H), 2. l l (s, 3H).
MH+500 (-2HC1). Example 223: 7V-(3-(4-(2,3-dimethylphenyl)piperazin-l-yl)-2-hydroxypropyl)- 2,5-dimethyl-l-o-tolyl-l//-imidazole-4-carboxamide dihydrochloride
1H NMR (400 MHz, MeOH-d4) δ 7.64-7.57 (m, 2H), 7.51 (t, J = 7.2 Hz,
IH), 7.41 (d, J = 8.0 Hz, IH), 7.06 (t, J - 7.2 Hz, IH), 6.95 (t, J = 7.6 Hz, 2H), 4.15-4.13 (m, IH), 3.71 (d, J = 10.4 Hz, 2H), 3.57-3.54 (m, 2H), 3.46-3.32 (m,
4H), 3.30-3.18 (m, 5H), 2.41 (s, 3H), 2.28 (s, 3H), 2.25 (s, 3H), 2.24 (s, 3H), 2.10 (s, 3H).
MH+476 (-2HC1).
Example 224: Λ/-(3-(4-(3-chloro-2-methylphenyl)piperazin-l-yl)-2- hydroxypropyl)-2,5-dimethyl-l-o-toIyl-l//-iinidazole-4-carboxainide dihydrochloride
1H NMR (400 MHz, MeOH-d4) δ 7.64-7.57 (m, 2H), 7.51 (t, J = 7.2 Hz, IH), 7.44-7.42 (m, IH), 7.16 (d, J = 4.0 Hz, 2H), 7.08 (t, J - 4.4 Hz, IH), 4.37- 4.35 (m, IH), 3.75-3.73 (m, 2H)5 3.67-3.49 (m, 4H), 3.48-3.32 (m, 4H), 3.30-3.11 (m, 4H), 2.42 (s, 3H), 2.37 (s, 3H), 2.29 (s, 3H), 2.10 (s, 3H).
MH+496 (-2HC1).
Example 225: iV-(3-(4-(2,3-dichIorophenyl)piperaziii-l-yl)-2-hydroxypropyl)- 2,5-dimethyl-l-o-tolyl-l/-r-imidazole-4-carboxamide dihydrochloride
1H NMR (400 MHz, MeOH-d4) δ 7.64-7.57 (m, 2H), 7.51 (t, J = 7.2 Hz, IH), 7.40 (d, J = 7.2 Hz, IH), 7.31-7.26 (m, 2H), 7.16 (dd, J = 6.8, 3.2 Hz, IH), 4.38-4.31 (m, IH), 3.76 (d, J = 11.2 Hz, 2H), 3.57-3.33 (m, 6H), 3.24-3.18 (m, 4H), 2.41 (s, 3H), 2.28 (s, 3H), 2.10 (s, 3H).
MH+516 (-2HC1).
Example 226: 7V-(3-(4-(3-chloro-2-methylpheiiyl)piperaziii-l-yl)propyl)-l-(4- chlorophenyl)-2,5-dimethyl-l//-imidazole-4-carboxamide dihydrochloride
1H NMR (400 MHz, MeOH-d4) δ 7.72-7.70 (m, 2H), 7.59-7.57 (m 2H), 7.15-7.14 (m, 2H), 7.08-7.07 (m, IH), 4.92 (brs, 6H), 3.72-3.70 (m, 2H), 3.59- 3.57 (m, 3H)5 3.41-3.25 (m, 6H), 2.49 (s, 3H), 2.36 (s, 6H).
MH+500 (-2HC1).
Example 227: l-(4-chlorophenyl)-Λ^3-(4-(2,3-dimethylphenyl)piperazin-l- yl)-2-hydroxypropyl)-2,5-dimethyl-l//-imidazole-4-carboxamide
dihydrochloride 1H NMR (400 MHz, MeOH-d4) δ 7.72 (s, 2H), 7.56 (brs, 2H)5 7.06 (t, J =
7.6 Hz, IH), 6.95 (t, J = 7.6 Hz, 2H)5 4.36 (s, IH), 3.74-3.63 (m, 2H), 3.60-3.54 (m, 4H)5 3.42-3.36 (m, 3H), 3.24-3.15 (m, 3H), 2.48 (s, 3H), 2.36 (s, 3H), 2.25 (s, 6H).
MH+496 (-2HC1). Example 228: iV-(3-(4-(3-chloro-2-methyIphenyl)piperazin-l-yl)-2- hydroxypropyl)-l-(4-chlorophenyl)-2,5-dimethyl-l//-imidazole-4- carboxamide dihydrochloride
1H NMR (400 MHz, MeOH-d4) δ 7.71 (s, 2H), 7.57 (s, IH), 7.14-7.13 (m, 2H), 7.08-7.07 (m, 2H), 4.41-4.33 (m, IH), 3.74-3.70 (m, 2H), 3.67-3.55 (m, 3H), 3.43-3.36 (m, 3H), 3.29 (s, 3H), 3.28-3.15 (m, 5H), 2.48 (brs, IH), 2.35 (s, 6H).
MH+516 (-2HC1).
Example 229; l-(4-chlorophenyl)-iV-(3-(4-(2,3-dichlorophenyI)piperazin-l- yl)-2-hydroxypropyl)-2,5-dimethyI-l//-imidazole-4-carboxamide
dihydrochloride
1H NMR (400 MHz, MeOH-(I4) δ 7.72 (d, J - 6.8 Hz, 2H), 7.55 (d, J = 6.0 Hz, 2H), 7.30-7.26 (m, 2H), 7.17-7.15 (m, IH), 4.42-4.33 (m, IH), 3.77-3.71 (m, 2H), 3.67-3.59 (m, 4H), 3.57-3.37 (m, 4H), 3.43-3.36 (m, 3H), 3.24-3.15 (m, 2H), 2.47 (s, 3H), 2.35 (s, 3H).
MH+536 (-2HC1).
Example 230: l-(4-chloropheny-)-yV-(3-(4-(2,3-dimethylphenyl)piperaziii-l- yl)propyl)-5-methyl-2-propyl-l/y-imidazole-4-carboxamide dihydrochloride
1H NMR (400 MHz, MeOH-d4) δ 7.72 (d, J = 5.2 Hz, 2H), 7.56 (m, 2H), 7.06 (t, J - 7.6 Hz, IH), 6.95 (t, J - 7.2 Hz, 2H), 3.67-3.65 (m, 2H), 3.59-3.56 (m, 3H), 3.42-3.21 (m, 6H), 3.13-3.10 (m, 2H), 2.75-2.73 (m, 2H), 2.33 (s, 3H), 2.25 (s, 3H), 2.24 (s, 3H), 2.22-2.16 (m, IH), 0.91 (t, J = 6.8 Hz, 3H).
MH+508 (-2HC1).
Example 231: τV-(3-(4-(3-chloro-2-methylphenyl)piperazin-l-yl)propyl)-l-(4- chlorophenyl)-5-methyl-2-propyl-l/f-imidazole-4-carboxamide
dihydrochloride 1H NMR (400 MHz, MeOH-d4) δ 7.73 (d, J = 6.4 Hz5 2H)5 7.56 (d, J = 6.8 Hz5 2H), 7.16-7.15 (m, 2H)5 7.10-7.06 (m, IH)5 3.75-3.63 (m, 3H)5 3.62-3.51 (m, 4H), 3.46-3.36 (m, 5H), 3.30-3.26 (m, 2H)5 3.18-3.12 (m, 2H)5 2.77 (t, J = 6.8 Hz5 2H)5 2.37 (s, 3H)5 2.25 (s, 3H)5 0.91 (t, J = 6.8 Hz5 3H).
MH+528 (-2HC1).
Example 232: l-(4-chloropheiiyl)-./V-(3-(4-(2,3-dichloropheiiyl)piperaziii-l- yl)propyl)-5-methyl-2-propyl-li/-imidazole-4-carboxamide dihydrochloride 1H NMR (400 MHz5 MeOH-d4) δ 7.72-7.70 (m, 2H), 7.57 (brs, 2H)5 7.30-
7.29 (m, 2H)5 7.17-7.16 (m, IH), 3.74-3.73 (m, 3H), 3.62-3.51 (m, 4H)5 3.46-3.36 (m, 5H), 3.30-3.28 (m, 2H)5 3.18-3.12 (m, 2H), 2.77 (t, J = 6.8 Hz, 2H), 2.38 (s, 3H), 0.91 (t, J = 6.8 Hz, 3H).
MH+548 (-2HC1).
Example 233: l-(4-chlorophenyl)-iV-(3-(4-(2,3-dimethylpheiiyl)piperaziii-l- yl)-2-hydroxypropyl)-5-methyl-2-propyl-l//-iinidazole-4-carboxamide dihydrochloride 1H NMR (400 MHz5 MeOH-d4) δ 7.72 (d, J = 8.0 Hz5 2H)5 7.56 (d, J =
8.4 Hz5 2H)5 7.06 (t, J = 7.6 Hz, IH)5 6.95 (t, J = 9.2 Hz, 2H)5 4.36-4.33 (m, IH)5 3.74-3.71 (m. 2H)5 3.67-3.64 (m, IH)5 3.61-3.57 (m, 3H)5 3.56-3.50 (m, 2H), 3.47-3.37 (m, 3H)5 3.25-3.09 (m, 5H), 2.78 (t, J = 8.0 Hz5 2H)5 2.34 (s, 3H), 2.25 (s, 6H), 1.70-1.65 (m, 2H), 0.91 (t, J = 7.2 Hz, 3H).
MH+524 (-2HC1).
Example 234: yV-(3-(4-(3-chloro-2-methylphenyl)piperazin-l-yl)-2- hydroxypropyl)-l-(4-chlorophenyl)-5-methyl-2-propyl-l//-imidazoIe-4- carboxamide dihydrochloride
1H NMR (400 MHz, MeOH-d4) δ 7.73 (d, J = 8.0 Hz, 2H), 7.57 (d, J - 8.4 Hz, H), 7.11 (m, 2H)5 6.98 (t, J = 7.2 Hz5 IH)5 4.38-4.34 (m, IH)5 3.75-3.71 (m, 2H), 3.68-3.60 (m, IH), 3.64-3.57 (m, 3H), 3.56-3.50 (m, 2H)5 3.47-3.37 (m, 3H), 3.24-3.11 (m, 5H), 2.79 (t, J = 8.6 Hz, 2H), 2.34 (s, 3H)5 2.24 (s, 3H), 1.70- 1.65 (m, 2H), 0.92 (t, J = 7.6 Hz5 3H).
MH+544 (-2HC1). Example 235: l-^-chloropheny^-A^-^-^S-dichloropheny^piperazin-l- yl)-2-hydroxypropyl)-5-methyl-2-propyl-l/-r-imidazole-4-carboxamide dihydrochloride
1H NMR (400 MHz, MeOH-d4) δ 7.72 (d, J = 7.6 Hz, 2H), 7.56 (d, J =
8.0 Hz, 2H), 7.31-7.26 (m, 2H), 7.19-7.15 (m, IH), 4.36-4.34 (m, IH), 3.76 (d, J
= 10.2 Hz, 2H), 3.66-3.65 (m, IH), 3.61-3.50 (m, 4H), 3.49-3.37 (m, 6H), 3.25-
3.12 (m, 3H), 2.77 (t, J = 7.6 Hz, 2H), 2.34 (s, 3H), 1.68-1.65 (m, 2H), 0.91 (t, J = 7.2 Hz, 3H).
MH+564 (-2HC1).
Example 236: l-^-chloropheiiyty-./V-^-^-^^-dichlorophenytypiperaziii-l- yI)-2-hydroxypropyl)-5-methyl-2-propyl-l//-imidazole-4-carboxamide dihydrochloride
1H NMR (400 MHz, DMSO-d6) δ 10.29 (s, IH), 8.25 (s, IH), 7.66 (d, J = 7.6 Hz, IH), 7.67-7.58 (m, 3H), 7.36-7.32 (m, 2H), 7.18-7.16 (m, IH), 4.19 (m, IH), 3.65-3.56 (m, 2H), 3.42-3.28 (m, 4H), 3.24-3.1 1 (m, 6H), 2.43-2.36 (m, 2H), 2.16 (s, 3H), 1.55-1.47 (m, 2H), 0.79 (t, J= 7.2 Hz, 3H).
MH+ 564.
Example 237: l-(2-chloropheiiyl)-./V-(3-(4-(2,3-dichloropheny-)piperaziii-l- ytypropyl^S-dimethyl-l/y-iinidazole^-carboxamide dihydrochloride
1H NMR (400 MHz, DMSO-d6) δ 1 1.35 (s, IH), 8.69 (s, IH), 7.82 (dd, J = 8.0, 1.6 Hz, IH), 7.72-7.61 (m, 3H), 7.35-7.29 (m, 2H), 7.17 (dd, J = 6.8, 2.8 Hz, IH), 4.19 (m, IH), 3.56-3.53 (m, 2H), 3.41-3.33 (m, 4H), 3.26-3.13 (m, 6H), 2.24 (s, 3H), 2.19 (s, 3H), 2.06-1.99 (m, 2H).
MH+ 520.
Example 238: l-(2-chlorophenyl)-7V-(3-(4-(2,3-dichlorophenyl)piperazin-l- yl)-2-hydroxypropyl)-2,5-dimethyl-l//-imidazole-4-carboxamide
dihydrochloride
1H NMR (400 MHz, DMSO-d6) δ 10.52 (s, IH), 8.39 (s, IH), 7.80 (d, J = 7.2 Hz, IH), 7.68-7.59 (m, 3H), 7.35-7.30 (m, 2H), 7.17 (dd, J = 6.8, 2.4 Hz, IH), 4.23-4.21 (m, IH), 3.67-3.56 (m, 2H), 3.42-3.12 (m, 10H), 2.18 (s, 6H), 2.06-1.99 (m, 2H).
MH+ 536.
Example 239; -V-β-^-β-chloro^-methylphenytypiperaziii-l-yrjpropyl)-!-^- fluorophenyl)-5-methyl-2-propyl-l//-imidazole-4-carboxamide
dihydrochloride 1H NMR (400 MHz, DMSO-d6) δ 10.93 (s, IH), 8.56 (s, IH), 7.71-7.55
(m, 3H), 7.46 (t, J = 7.26Hz, IH), 7.20-7.15 (m, 2H), 7.02 (dd, J = 6.8, 1.6 Hz, IH), 3.52-3.49 (m, 2H), 3.35-3.34 (m, 2H), 3.20-3.08 (m, 8H), 2.52-2.47 (m, 2H), 2.27 (s, 3H), 2.22 (s, 3H), 2.05-1.98 (m, 2H), 1.58-1.49 (m, 2H), 0.76 (t, J = 12 Hz, 3H).
MH+ 512.
Example 240: 7V-(3-(4-(2,3-dimethylphenyl)piperazin-l-yl)propyl)-l-(2- methoxyphenyl)-5-methyl-2-pheiiyl-l//-imidazoIe-4-carboxamide
dihydrochloride
1H NMR (400 MHz, DMSO-d6) δ 11.05 (br s, IH), 8.72 (br s, IH), 7.54- 7.50 (m, 2H), 7.37-7.23 (m, 6H), 7.06-7.03 (m, 2H), 6.90-6.85 (m, 2H), 3.66 (s, 3H), 3.51-3.48 (m, 2H), 3.38-3.37 (m, 2H), 3.28-3.26 (m, 3H), 3.20-3.02 (m, 5H), 2.23 (s, 3H), 2.17 (s, 3H), 2.13 (s, 3H), 2.05-1.99 (m, 2H).
MH+ 538.
Example 241: 7V-(3-(4-(3-chloro-2-methyIphenyl)piperazin-l-yl)propyl)-l-(2- methoxyphenyl)-5-methyl-2-phenyl-l//-imidazole-4-carboxamide
dihydrochloride
1H NMR (400 MHz, DMSO-d6) δ 10.82 (br s, IH), 8.45 (br s, IH), 7.53- 7.48 (m, 2H), 7.33-7.24 (m, 6H), 7.20-7.14 (m, 2H), 7.11-7.02 (m, 2H), 3.65 (s, 3H), 3.53-3.50 (m, 2H), 3.36-3.35 (m, 2H), 3.21-3.08 (m, 8H), 2.26 (s, 3H), 2.22 (s, 3H), 2.02-1.98 (m, 2H).
MH+ 558. Example 242: iV-(3-(4-(2,3-dichlorophenyl)piperazin-l-yl)propyl)-l-(2- methoxyphenyl)-5-methyl-2-phenyl-l//-imidazole-4-carboxamide
dihydrochloride 1H NMR (400 MHz, DMSO-d6) δ 1 1.00 (br s, IH), 8.47 (br s, IH), 7.53-
7.48 (m, IH), 7.38-7.22 (m, 8H), 7.19-7.10 (m, IH), 7.06-7.02 (m, 2H), 3.65 (s, 3H), 3.57-3.54 (m, 2H), 3.40-3.35 (m, 4H), 3.20-3.12 (m, 6H), 2.22 (s, 3H), 2.04- 1.99 (m, 2H).
MH+ 578.
Example 243: 7V-(3-(4-(2,3-dimethyIphenyI)piperazin-l-yl)propyl)-l-(2- fluorophenyl)-5-methyl-2-propyI-l//-im-dazole-4-carboxamide
dihydrochloride 1H NMR (400 MHz, DMSO-d6) δ 1 1.07 (s, IH), 8.86 (s, IH), 7.85-7.74
(m, 2H), 7.67-7.62 (m, IH), 7.54-7.50 (m, IH), 7.08 (t, J = 8.0 Hz, IH), 6.94-6.87 (m, 2H), 3.55-3.52 (m, 2H), 3.41-3.39 (m, 2H), 3.24-3.06 (m, 10H), 2.62 (t, J = 7.2Hz , 2H), 2.28 (s, 3H), 2.17 (s, 3H), 2.1 1-2.04 (m, 2H), 1.66-1.57 (m, 2H),
0.81 (W= 7.2 Hz, 3H).
MH+ 492.
Example 244: 7V-(3-(4-(2,3-dimethvlphenvl)piperazin-l-vl)-2-hydroxypropyl)- l-(2-fluorophenyl)-5-methyl-2-propyl-liy-imidazole-4-carboxamide
dihydrochloride
1H NMR (400 MHz, DMSO-d6) δ 10.42 (s, IH), 8.60 (s, IH), 7.79-7.70 (m, 2H), 7.65 (t, J = 9.2 Hz, IH), 7.53 (t, J = 7.6 Hz, IH), 7.09 (t, J = 7.6 Hz, IH), 6.96-6.89 (m, 2H), 4.30-4.28 (m, IH), 3.68-3.57 (m, 2H), 3.42-3.27 (m, 5H), 3.19-3.13 (m, 5H), 2.61-2.57 (m, IH), 2.29 (s, 3H), 2.24 (s, 3H), 2.19 (s, 3H), 1.65-1.56 (m, 2H), 0.83 (t, J- 7.2 Hz, 3H).
MH+ 508.
Example 245: 7V-(3-(4-(2,3-dichlorophenyl)piperaziii-l-yl)-2-hydroxypropyI)- l-(2-fluorophenyl)-5-methyl-2-propyl-l/y-imidazole-4-carboxamide
dihydrochloride 1H NMR (400 MHz, DMSO-d6) δ 10.51 (s, IH), 8.42 (s, IH), 7.75-7.60 (m, 3H), 7.50 (t, J = 7.6 Hz, IH)5 7.40-7.34 (m, 2H), 7.21 (dd, J = 6.8, 2.4 Hz, IH), 4.27-4.26 (m, IH), 3.71-3.60 (m, 2H), 3.46-3.15 (m, 10H), 2.55-2.51 (m, 2H), 2.27 (s, 3H), 1.62-1.53 (m, 2H), 0.81 (t, J= 7.6 Hz, 3H).
MH+ 548.
Example 246: Λ^3-(4-(23-dimethylphenyl)piperazin-l-yl)propyl)-5-inethyl- 2-propyl-l-o-tolyl-l//-imidazoIe-4-carboxamide dihydrochloride 1H NMR (400 MHz, MeOH-d4) δ 7.65-7.57 (m, 2H), 7.51 (t, J = 7.6 Hz,
IH), 7.44 (d, J = 8.0 Hz, IH), 7.06 (t, J = 8.0 Hz, IH), 6.95 (t, J = 8.8 Hz, 2H), 3.67-3.64 (m, 3H), 3.61-3.58 (m, 3H), 3.42-3.36 (m, 2H), 3.30-3.11 (m, 6H), 2.77-2.75 (m, IH), 2.66-2.63 (m, IH), 2.27 (s, 3H), 2.24 (s, 6H), 2.09 (s, 3H), 1.71-1.65 (m, 2H), 0.91 (t, J = 7.6 Hz, 3H).
MH+488 (-2HC1).
Example 247: Λ^3-(4-(3-chloro-2-methyIphenyl)piperaziii-l-yl)propyl)-5- methyl-2-propyl-l-o-tolyl-l//-imidazole-4-carboxamide dihydrochloride 1H NMR (400 MHz, MeOH-d4) δ 7.64-7.57 (m, 2H), 7.51 (t, J = 7.6 Hz,
IH), 7.41 (d, J = 7.6 Hz, IH), 7.19-7.16 (m, 2H), 7.10-7.07 (m, IH), 3.71-3.65 (m, 2H), 3.61-3.55 (m, 3H), 3.40-3.33 (m, 3H), 3.30-3.28 (m, 4H), 3.16 (d, J = 12.0 Hz, 2H), 2.75-2.73 (m, IH), 2.64-2.62 (m, IH), 2.37 (s, 3H), 2.27 (s, 3H), 2.16- 2.14 (m, 2H), 2.09 (s, 3H), 1.70-1.64 (m, 2H), 0.91 (t, J = 7.6 Hz, 3H).
MH+508 (-2HC1).
Example 248:■/V-(3-(4-(2,3-dichlorophenyl)piperazin-l-yl)propyl)-5-methyl-2- propyI-l-o-tolyI-l/f-imidazole-4-carboxamide dihydrochloride 1H NMR (400 MHz, MeOH-d4) δ 7.65-7.57 (m, 2H), 7.51 (t, J = 7.2 Hz,
IH), 7.43 (d, J = 7.6 Hz, IH), 7.31-7.27 (m, 2H), 7.20-7.16 (m, IH), 3.75-3.72 (m, 2H), 3.68-3.65 (m, IH), 3.62-3.56 (m, 8H), 3.41-3.36 (m, 4H), 3.33-3.28 (m, 2H), 3.26-3.22 (m, 3H), 2.89-2.88 (m, 2H), 2.75-2.73 (m, IH), 2.64-2.62 (m, IH), 2.28 (s, 3H), 2.20-2.18 (m, 2H), 2.09 (s, 3H), 1.69-1.67 (m, 2H), 0.91 (t, J = 7.6 Hz, 3H).
MH+528 (-2HC1). Example 249: l-(4-chlorophenyl)-yV-(3-(4-(2,3-diitiethylphenyl)piperazin-l- yl)propyl)-5-methyl-2-phenyl-l/-r-imidazole-4-carboxainide dihydrochloride 1H NMR (400 MHz, MeOH-(I4) δ 7.62 (d, J = 8.0 Hz, 2H), 7.57 (t, J - 7.2
Hz, IH), 7.52-7.45 (m, 5H), 7.08 (t, J = 8.0 Hz, IH), 6.97 (t, J = 7.2 Hz, 2H), 3.72-3.65 (m, 2H), 3.62-3.59 (m, 3H), 3.44-3.37 (m, 4H), 3.31-3.14 (m, 4H), 2.45 (s, 3H), 2.27 (s, 3H), 2.26 (s, 3H), 2.21-2.19 (m, 2H).
MH+542 (-2HC1).
Example 250: ./V-(3-(4-(3-chIoro-2-inethyIpheiiyl)piperaziii-l-yl)propyl)-l-(4- chIoropheny-)-5-methyl-2-phenyI-l//-imidazoIe-4-carboxamide
dihydrochloride 1H NMR (400 MHz, MeOH-d4) δ 7.62 (d, J = 6.4 Hz, 2H), 7.58-7.55 (m,
IH), 7.50-7.45 (m, 5H), 7.19-7.16 (m, 2H), 7.11-7.09 (m, IH), 3.73-3.69 (m, 2H), 3.63-3.60 (m, 3H), 3.45-3.35 (m, 3H), 3.21-3.18 (m, 2H), 2.46 (s, 3H), 2.39 (s, 3H), 2.22-2.21 (m, 2H).
MH+562 (-2HC1).
Example 251: l-^-chlorophenyty-./V-β-^-^^-dichloropheiiytypiperaziii-l- yl)propyI)-5-methyl-2-phenyl-l//-imidazole-4-carboxamide dihydrochloride
1H NMR (400 MHz, MeOH-(I4) δ 7.62 (d, J - 8.0 Hz, 2H), 7.59-7.53 (m, IH), 7.51-7.45 (m, 5H), 7.32-7.28 (m, 2H), 7.19-7.17 (m, IH), 3.76 (d, J = 10.2 Hz, 2H), 3.69-3.65 (m, IH), 3.62-3.54 (m, 5H), 3.44-3.37 (m, 3H), 3.26-3.17 (m, 3H), 2.45 (s, 3H), 2.22-2.19 (m, 2H).
MH+582 (-2HC1). Example 252: l-(4-chloropheny l)-.V-(3-(4-(2,3-dimethylphenyl)piperazin-l- yI)-2-hydroxypropyl)-5-methyl-2-phenyl-l//-imidazole-4-carboxamide dihydrochloride
1H NMR (400 MHz, MeOH-d4) δ 7.63-7.49 (m, 10H), 7.08 (t, J = 7.6 Hz, IH), 7.01-6.96 (m, 2H), 4.44-4.43 (m, IH), 3.76-3.73 (m, 2H), 3.69-3.66 (m, IH),
3.63-3.57 (m, 3H), 3.50-3.44 (m, 2H), 3.23 (brs, 4H), 2.48 (s, 3H), 2.27 (s, 6H). MH+558 (-2HC1).
Example 253: N-(3-(4-(3-chloro-2-methylphenyl)piperazin-l-yl)-2- hydroxypropyl)-l-(4-chlorophenyl)-5-methyl-2-phenyl-liy-imidazole-4- carboxamide dihydrochloride
1H NMR (400 MHz, MeOH-d4) δ 7.60 (d, J = 7.2 Hz, 2H), 7.55-7.42 (m, 6H), 7.17 (d, J - 4.4 Hz, 2H), 7.09-7.07 (m, IH), 4.17-4.13 (m, IH), 3.72-3.70 (m, 2H), 3.67-3.65 (m, IH), 3.63-3.57 (m, 3H), 3.50-3.44 (m, 2H), 3.21-3.10 (brs, 4H), 2.45 (s, 3H), 2.38 (s, 3H).
MH+578 (-2HC1).
Example 254: l-^-chlorophenyO-Λ^-^-^^-dichlorophenyOpiperazin-l- yl)-2-hydroxypropyI)-5-methyl-2-phenyl-l//-imidazole-4-carboxaiiiide dihydrochloride
1H NMR (400 MHz, MeOH-d4) δ 7.62 (d, J = 8.0 Hz, 2H), 7.56-7.43 (m, 6H), 7.32-7.28 (m, 2H), 7.19-7.17 (m, IH), 4.38-4.36 (m, IH), 3.76-3.70 (m, 2H), 3.69-3.65 (m, IH), 3.63-3.57 (m, 3H), 3.50-3.44 (m, 2H), 3.21-3.15 (m, 4H), 2.45 (s, 3H).
MH+598 (-2HC1).
Example 255: l-(benzo[</] [l,3]dioxol-5-yl)-.V-(3-(4-(2,3-dichlorophenyl) piperazin-l-yl)propyl)-2,5-dimethyl-li/-iιiiidazole-4-carboxamide
dihydrochloride
1H NMR (400 MHz, DMSO-d6) δ 1 1.33 (br s, IH), 8.87 (br s, IH), 7.40- 7.33 (m, 2H), 7.24-7.19 (m, 2H), 7.17 (d, J = 8.4 Hz, IH), 7.05 (dd, J = 8.0, 2.0 Hz, IH), 6.20 (s, 2H)5 3.59-3.56 (m, 2H), 3.45-3.37 (m, 2H), 3.29-3.23 (m, 4H), 3.21-3.15 (m, 4H), 2.36 (s, 3H)5 2.30 (s, 3H), 2.09-2.02 (m, 2H).
MH+ 530.
Example 256: l-(benzo[rf] [l,3]dioxol-5-yl)-Λ^-(3-(4-(2,3-dichlorophenyl) piperazin-l-yl)-2-hydroxypropyl)-2,5-dimethyl-l/_MmidazoIe-4-carboxamide dihydrochloride 1H NMR (400 MHz, DMSO-d6) δ 10.70 (br s, IH), 8.68 (br s, IH), 7.40-
7.34 (m, 2H), 7.24-7.20 (m, 2H), 7.17 (d, J - 8.4 Hz, IH), 7.03 (dd, J = 8.4, 2.0 Hz, IH), 6.20 (s, 2H), 4.29-4.26 (m, IH), 3.72-3.70 (m, IH), 3.62-3.59 (m, IH), 3.46-3.36 (m, 6H), 3.29-3.17 (m, 4H), 2.36 (s, 3H), 2.31 (s, 3H).
MH+ 546.
Example 257: l-(benzo[</] [l,3]dioxol-5-yl)-7V-(3-(4-(2,3-dimethyIphenyl) piperazin-l-yl)propyl)-5-methyl-2-propyl-l//-iinidazole-4-carboxainide dihydrochloride
1H NMR (400 MHz, DMSO-d6) δ 11.23 (br s, IH), 9.24 (br s, IH), 7.27 (d, J = 2.0 Hz, IH), 7.18 (d, J = 8.0 Hz, IH), 7.11-7.06 (m, 2H), 6.95-6.90 (m, 2H), 6.21 (s, 2H), 3.55-3-52 (m, 2H), 3.44-3.39 (m, 2H), 3.31-3.21 (m, 4H), 3.19- 3.09 (m, 4H), 2.70 (t, J = 7.6 Hz, 2H), 2.30 (s, 3H), 2.23 (s, 3H), 2.18 (s, 3H), 2.12-2.04 (m, 2H), 1.73-1.63 (m, 2H), 0.84 (t, J= 7.2 Hz, 3H).
MH+ 518.
Example 258: l-(benzo[rf] [l,3]dioxol-5-yl)-7V-(3-(4-(2,3-dichlorophenyl) piperazin-l-yl)propyl)-5-methyl-2-propyl-l//-imidazole-4-carboxamide dihydrochloride
1H NMR (400 MHz, DMSO-d6) δ 11.31 (br s, IH), 9.05 (br s, IH), 7.41-
7.35 (m, 2H), 7.25-7.21 (m, 2H), 7.18 (d, J = 8.4 Hz, IH), 7.07 (dd, J = 8.4, 2.0 Hz, IH), 6.22 (s, 2H), 3.61-3.58 (m, 2H), 2.46-3.39 (m, 4H), 3.30-3.17 (m, 6H), 2.68 (t, J = 7.6 Hz, 2H), 2.30 (s, 3H), 2.1 1-2.04 (m, 2H), 1.71-1.62 (m, 2H), 0.85 (t, J= 7.6 Hz, 3H).
MH+ 558.
Example 259: l-(benzo[rf] [l,3]dioxol-5-yl)-Λ43-(4-(2,3-dimethylphenyl) piperazin-l-yl)-2-hydroxypropyl)-5-methyl-2-propyl-li/-imidazoIe-4- carboxamide dihydrochloride
1H NMR (400 MHz, DMSO-d6) δ 10.63 (br s, IH), 9.07 (br s, IH), 7.29
(s, IH), 7.21 (d, J = 8.4 Hz, IH), 7.12-7.08 (m, 2H), 6.97-6.92 (m, 2H), 6.24 (s, 2H), 4.33-4.31 (m, IH), 3.71-3.68 (m, IH), 3.61-3.57 (m, IH), 3.51-3.48 (m, 2H),
3.46-3.43 (m, 2H), 3.42-3.33 (m, 2H), 3.27-3.1 1 (m, 4H), 2.72 (d. J = 7.2 Hz, 2H), 2.33 (s, 3H), 2.25 (s, 3H), 2.20 (s, 3H), 1.72-1.66 (m, 2H), 0.87 (t, J = 12 Hz, 3H).
MH+ 534.
Example 260: l-(benzo [d\ [ 1 ,3] dioxoI-5-y l)-Λ43-(4-(2,3-dichloropheny 1) piperazin-l-yl)-2-hydroxypropyl)-5-methyl-2-propyl-l//-imidazole-4- carboxamide dihydrpchloride
1H NMR (400 MHz, DMSO-d6) δ 10.64 (br s, IH), 8.83 (br s, IH), 7.40-
7.34 (m, 2H), 7.23-7.20 (m, 2H), 7.17 (d, J = 8.4 Hz, IH), 7.05 (dd, J = 8.4, 1.6 Hz, IH), 6.21 (s, 2H), 4.29-4.27 (m, IH), 3.72-3.69 (m, IH), 3.63-3.60 (m, IH),
3.47-3.41 (m, 6H), 3.30-3.17 (m, 6H), 2.66 (t, J = 7.6 Hz, 2H), 2.30 (s, 3H), 1.69- 1.60 (m, 2H), 0.84 (t, J= 7.2 Hz, 3H).
MH+ 574. Example 261: Λ^P-^-β-chloro^-methylphenyOpiperazin-l-yOpropyl)^^- dimethyl-l-/Molyl-l//-imidazole-4-carboxamide dihydrochloride
1H NMR (400 MHz, DMSO-d6) δ 1 1.31 (br s, IH), 8.95 (br s, IH), 7.50- 7.45 (m, 4H), 7.25-7.19 (m, 2H), 7.07 (dd, J= 6.8, 2.0 Hz, IH), 3.56-3.53 (m, 2H), 3.45-3.40 (m, 2H), 3.31-3.25 (m, 4H), 3.21-3.17 (m, 4H), 2.44 (s, 3H), 2.37 (s, 3H), 2.32 (s, 3H), 2.29 (s, 3H), 2.13-2.04 (s, 2H).
MH+ 480.
Example 262: 7V-(3-(4-(2,3-dimethyIphenyl)piperazin-l-yI)propyl)-5-methyl- 2-propyl-l-p-tθ-yl-l//-imidazole-4-carboxamide dihydrochloride
1H NMR (400 MHz, DMSO-d6) δ 1 1.26 (br s, IH), 9.27 (br s, IH), 7.52- 7.47 (m, 4H), 7.11-7.06 (m, IH), 6.95-6.91 (m, 2H), 3.55-3.52 (m, 2H), 3.45-3.40 (m, 2H), 3.31-3.19 (m, 4H), 3.17-3.10 (m, 4H), 2.68 (t, J = 7.6 Hz, 2H), 2.44 (s, 3H), 2.29 (s, 3H), 2.23 (s, 3H), 2.18 (s, 3H), 2.13-2.06 (m, 2H), 1.71-1.61 (m, 2H), 0.82 (t, J= 6.8 Hz, 3H).
MH+ 488.
Example 263: iV-(3-(4-(3-chloro-2-methylphenyl)piperazin-l-yl)propyl)-5- methyl-2-propyl-l-/Molyl-l/-f-imidazole-4-carboxainide dihydrochloride 1H NMR (400 MHz, DMSO-d6) δ 1 1.37 (br s, IH), 9.23 (br s, IH), 7.53- 7.48 (m, 4H), 7.21-7.17 (m, 2H), 7.05 (dd, J= 6.8, 2.0 Hz, IH), 3.55-3.52 (m, 2H), 3.44-3.39 (m, 2H), 3.31-3.24 (m, 4H), 3.23-3.12 (m, 4H), 2.66 (t, J = 8.0 Hz, 2H), 2.43 (s, 3H), 2.30 (s, 3H), 2.27 (s, 3H), 2.12-2.04 (m, 2H), 1.69-1.59 (m, 2H), 0.81 (t, J = 7.2 Hz, 3H).
MH+ 508.
Example 264: Λ^3-(4-(2v3-dimethvlphenv.)piperazin-l-vl)-2-hvdroxvpropyr)- l-(2-methoxyphenyl)-5-methyl-2-phenyl-l//-imidazole-4-carboxamide dihydrochloride
1H NMR (400 MHz, DMSO-d6) δ 10.55 (br s, IH), 8.66 (br s, IH), 7.59-
7.55 (m, IH), 7.42-7.33 (m, 6H), 7.30-7.28 (m, IH), 7.12-7.05 (m, 2H), 6.94-6.89
(m, 2H), 4.32-4.30 (m, IH), 3.70 (d, J = 3.6 Hz, 3H), 3.68-3.65 (m, IH), 3.59- 3.56 (m, IH), 3.49-3.32 (m, 5H), 3.29-3.08 (m, 5H), 2.28 (s, 3H), 2.21 (s, 3H),
2.14 (s, 3H). MH+ 554.
Example 265: vV-(3-(4-(3-chIoro-2-methylpheiiyl)piperazin-l-yl)-2- hydroxypropyl)-l-(2-methoxyphenyl)-5-methyI-2-pheiiyl-l//-iiiiidazoIe-4- carboxamide dihydrochloride
1H NMR (400 MHz, DMSO-Cl6) δ 10.56 (br s, IH), 8.42 (br s, IH), 7.59- 7.55 (m, IH), 7.39-7.28 (m, 7H), 7.25-7.19 (m, 2H), 7.13-7.08 (m, 2H), 4.31-4.29 (m, IH), 3.71 (d, J = 4.0 Hz, 3H), 3.65-3.62 (m, 2H), 3.46-3.38 (m, 5H), 3.34- 3.15 (m, 5H), 2.31 (s, 3H), 2.28 (s, 3H).
MH+ 574.
Example 266: 7V-(3-(4-(2,3-dichlorophenyl)piperazin-l-yl)-2-hydroxypropyl)- l-^-methoxyphenyty-S-methyl^-phenyl-l/f-imidazole^-carboxamide dihydrochloride
1H NMR (400 MHz, DMSO-d6) δ 10.54 (br s, IH), 8.42 (br s, IH), 7.57- 7.53 (m, IH), 7.37-7.29 (m, 7H), 7.27-7.18 (m, 2H), 7.1 1-7.04 (m, 2H), 4.29-4.28 (m, IH), 3.69 (d, J = 4.0 Hz, 3H), 3.64-3.57 (m, 2H), 3.48-3.30 (m, 6H), 3.27- 3.12 (m, 4H), 2.30 (s, 3H).
MH+ 594. Example 267: 1 -(benzol [l,3]dioxol-5-yl)-JV-(3-(4-(2,3-dimethyIphenyl) piperazin-l-yl)propyl)-5-methyl-2-phenyl-l//-imidazole-4-carboxamide dihydrochloride
1H NMR (400 MHz, DMSO-d6) δ 1 1.23 (br s, IH), 9.00 (br s, IH), 7.53- 7.40 (m, 5H), 7.18 (s, IH), 7.11-7.07 (m, 2H), 6.98-6.91 (m, 3H), 6.18 (s, 2H), 3.56-3.53 (m, 2H), 3.46-3.41 (m, 2H)5 3.27-3.10 (m, 8H), 2.39 (s, 3H), 2.23 (s, 3H), 2.18 (s, 3H), 2.13-2.07 (m, 2H).
MH+ 552.
Example 268: l-(benzo[έ/l[l,3]dioxol-5-yl)-iV-(3-(4-(3-chloro-2-methyIphenyl) piperazin-l-yl)propyI)-5-methyl-2-phenyl-l//-imidazole-4-carboxamide dihydrochloride
1H NMR (400 MHz, DMSO-d6) δ 1 1.17 (br s, IH), 8.80 (br s, IH), 7.50-
7.47 (m, 2H), 7.44-78.36 (m, 3H), 7.24-7.19 (m, 2H), 7.15 (d, J = 2.0 Hz, IH), 7.08-7.04 (m, 2H), 6.92 (dd, J = 8.4, 2.4 Hz, IH), 6.17 (s, 2H), 3.56-3.53 (m, 2H), 3.44-3.39 (m, 2H), 3.27-3.24 (m, 4H), 3.22-3.20 (m, 4H), 2.37 (s, 3H), 2.31 (s, 3H), 2.10-2.03 (m, 2H).
MH+ 572.
Example 269: l-(benzo[rf] [l,3]dioxol-5-yl)-Λ43-(4-(2,3-dichlorophenyl) piperazin-l-yl)propyl)-5-methyl-2-phenyl-l//-imidazole-4-carboxamide dihydrochloride
1H NMR (400 MHz, DMSO-d6) δ 1 1.34 (br s, IH), 8.82 (br s, IH), 7.50-
7.48 (m, 2H), 7.46-7.34 (m, 5H), 7.21 (dd, J = 2.8, 2.4 Hz, IH), 7.15 (d, J = 2.0 Hz, IH), 7.07 (d, J = 8.4 Hz, IH), 6.93 (dd, J = 2.0, 1.6 Hz, IH), 6.17 (s, 2H), 3.61-3.58 (m, 2H), 3.45-3.40 (m, 4H), 3.31-3.17 (m, 6H), 2.38 (s, 3H), 2.11-2.04 (m, 2H).
MH+ 592.
Example 270: l-(benzo[έ/l[l,3]dioxol-5-yl)-Λ^-(3-(4-(2,3-dimethylphenyl) piperazin-l-yI)-2-hydroxypropyI)-5-methy.-2-phenyl-l//-imidazole-4- carboxamide dihydrochloride 1H NMR (400 MHz, DMSO-(I6) δ 10.60 (br s, IH)5 8.74 (br s, IH), 7.50- 7.37 (m, 5H), 7.15 (d, J = 1.6 Hz, IH), 7.09-7.05 (m, 2H), 6.94-6.89 (m, 3H), 6.16 (s, 2H), 4.31-4.30 (m, IH), 3.67-3.64 (m, IH), 3.58-3.55 (m, IH), 3.44-3.31 (m, 5H), 3.21-3.06 (m, 5H), 2.37 (s, 3H), 2.21 (s, 3H), 2.16 (s, 3H).
MH+ 568.
Example 271; l-(benzo[</][l,3]dioxol-5-yI)-J/V-(3-(4-(3-chloro-2-methylphenyI) piperazin-l-yl)-2-hydroxypropyl)-5-methyl-2-phenyI-l//-imidazole-4- carboxamide dihydrochloride
1H NMR (400 MHz, DMSO-d6) δ 10.48 (br s, IH), 8.49 (br s, IH), 7.48- 7.36 (m, 5H), 7.26-7.08 (m, 5H), 6.89 (dd, J = 1.6, 1.6 Hz, IH), 6.18 (s, 2H), 4.31-4.29 (m, IH), 3.69-3.66 (m, IH), 3.61-3.58 (m, IH), 3.46-3.32 (m, 5H), 3.24-3.14 (m, 5H), 2.38 (s, 3H), 2.16 (s, 3H).
MH+ 588.
Example 272: HbenzorøllvSldioxo.-S-yO-Λφ-^-^-dich.orophenyl) piperazin-l-yl)-2-hydroxypropyl)-5-methyl-2-phenyl-l//-imidazoIe-4- carboxamide dihydrochloride
1H NMR (400 MHz, DMSO-d6) δ 10.60 (br s, IH), 8.47 (br s, IH), 7.46-
7.44 (m, 2H), 7.38-7.33 (m, 5H), 7.20 (dd, J = 2.0, 2.4 Hz, IH), 7.15 (d, J = 1.6
Hz, IH), 7.05 (d, J = 8.0 Hz, IH), 6.87 (dd, J = 2.0, 2.0 Hz, IH), 6.16 (s, 2H), 4.29-4.27 (m, IH), 3.71-3.68 (m, IH), 3.63-3.60 (m, IH), 3.45-3.36 (m, 5H),
3.22-3.17 (m, 5H), 2.36 (s, 3H).
MH+ 608.
Example 273: .V-(3-(4-(2,3-dimethylphenyl)piperaziii-l-yl)propyl)-l-(2- fluorophenyl)-5-methyl-2-phenyl-l//-imidazole-4-carboxamide
dihydrochloride
1H NMR (400 MHz, DMSO-d6) δ 11.17 (s, IH), 8.52-8.49 (m, IH), 7.66-
7.62 (m, 2H), 7.51-7.46 (m, IH), 7.44-7.40 (m, IH), 7.40-7.31 (m, 5H), 7.07 (t, J = 7.6 Hz, IH), 6.94-6.89 (m, 2H), 3.56-3.53 (m, 2H), 3.43-3.38 (m, 2H), 3.26-
3.06 (m, 8H), 2.34 (s, 3H), 2.22 (s, 3H), 2.17 (s, 3H), 2.12-2.03 (m, 2H). MH+ 526.
Example 274: iV-(3-(4-(3-chloro-2-methyIphenyl)piperazin-l-yl)propyl)-l-(2- fluorophenyl)-5-methyl-2-phenyl-l/T-imidazole-4-carboxamide
dihydrochloride
1H NMR (400 MHz5 DMSO-(I6) δ 1 1.06 (s, IH), 8.45 (s, IH), 7.69-7.65 (m, 2H)5 7.55-7.50 (m, IH)5 7.47-7.44 (m, IH)5 7.39-7.38 (m, 5H)5 7.24 (m, 2H)5 7.10-7.09 (m, IH), 3.61-3.44 (m, 4H), 3.23 (m, 8H)5 2.37 (s, 3H)5 2.35 (s, 3H)5 2.09 (m, 2H). MH+ 546.
Example 275: N-β-^-^S-dichlorophenytypiperazin-l-ytypropyl)-!-^- fIuorophenyl)-5-methyl-2-phenyl-l//-imidazole-4-carboxamide
dihydrochloride
1H NMR (400 MHz5 DMSO-d6) δ 1 1.13 (s, IH)5 8.43-8.40 (m, IH)5 7.65-
7.61 (m, 2H)5 7.51-7.47 (m, IH)5 7.44-7.40 (m, IH)5 7.38-7.31 (m, 7H), 7.21 (dd, J = 7.2, 2.4 Hz IH), 3.62-3.59 (m, 2H)5 3.45-3.39 (m, 4H)5 3.30-3.18 (m, 6H)5 2.34 (s, 3H), 2.07-2.03 (m, 2H).
MH+ 566.
Example 276:■/V-(3-(4-(2,3-dimethvlphenvl)piperazin-l-vl)-2-hydroxvpropvl)- l-(2-fluorophenyl)-5-methyl-2-phenyl-l/T-imidazole-4-carboxamide
dihydrochloride
1H NMR (400 MHz, DMSO-d6) δ 10.30 (s, IH)5 8.31-8.27 (m, IH)5 7.69-
7.62 (m, 2H)5 7.53-7.49 (m, IH), 7.46-7.42 (m, IH)5 7.41-7.32 (m, 4H)5 7.10 (t, J = 8.0 Hz IH)5 6.97-6.92 (m, 2H)5 4.31-4.29 (m, IH)5 3.68-3.59 (m, 2H)5 3.49-3.35 (m, 5H)5 3.20-3.09 (m, 5H)5 2.36 (s, 3H)5 2.24 (s, 3H)5 2.24 (s, 3H).
MH+ 542.
Example 277: ΛL(3-(4-(3-chloro-2-methylphenyl)piperazin-l-yl)-2- hydroxypropyl)-l-(2-fluorophenyl)-5-methyl-2-phenyl-li7-imidazoIe-4- carboxamide dihydrochloride
1H NMR (400 MHz5 DMSO-d6) δ 10.29 (s, IH), 8.27-8.26 (m, IH), 7.68- 7.61 (m, 2H), 7.52-7.48 (m, IH), 7.45-7.42 (m, IH), 7.36-7.32 (m, 4H), 7.25-7.20 (m, 2H), 7.08-7.06 (m, 2H), 4.28 (m, IH), 3.68-3.58 (m, 2H), 3.48-3.35 (m, 5H), 3.23-3.12 (m, 5H), 2.35 (s, 3H), 2.32 (s, 3H).
MH+ 562.
Example 278: N-^-^-^^-dichlorophenyOpiperazin-l-yl^-hydroxypropyl)- l-(2-fluorophenyl)-5-methyl-2-phenyl-l//-imidazole-4-carboxamide
dihydrochloride 1H NMR (400 MHz, DMSO-d6) δ 10.42 (s, IH), 8.29-8.26 (m, IH), 7.69-
7.62 (m, 2H), 7.51-7.46 (m, IH), 7.44-7.42 (m, IH), 7.42-7.32 (m, 7H), 7.23 (dd, J = 7.2, 2.4 Hz, IH), 4.30-4.28 (m, IH), 3.72-3.63 (m, 2H), 3.48-3.16 (m, 10H), 2.36 (s, 3H).
MH+ 582.
Ex^m_p_le_^79i Λ'r-(3-(4-(2,3-dichlorophenyl)piperazin-l-yl)propyI)-5-methyl-2- propyl-l-/Molyl-l//-imidazoIe-4-carboxamide dihydrochloride
1H NMR (400 MHz, DMSO-Cl6) δ 1 1.42 (br s, IH), 9.21 (br s, IH), 7.55- 7.50 (m, 4H), 7.41-7.35 (m, 2H), 7.30 (dd, J = 12, 2.8 Hz, IH), 3.62-3.58 (m, 2H), 3.47-3.41 (m, 4H), 3.34-3.18 (m, 6H), 2.68 (t, J = 7.2 Hz, 2H), 2.45 (s, 3H), 2.92 (s, 3H), 2.31-2.06 (m, 2H), 1.71-1.61 (m, 2H), 0.83 (t, J= 7.2 Hz, 3H).
MH+ 528. Example 280: Hbenzo^ll^ldioxol-S-yO-Λ^-^-β-chloro^-methylphenyl) piperazin-l-yl)-2-hydroxypropyI)-2,5-dimethyl-l//-imidazole-4-carboxamide dihydrochloride
1H NMR (400 MHz, CD3OD) δ 7.17-7.15 (m, 2H), 7.10-7.04 (m, 3H), 6.99 (dd, J = 8.0, 2.0 Hz, IH), 6.15 (s, 2H), 4.38-4.35 (m, IH), 3.76-3.72 (m, 2H), 3.60-3.50 (m, 2H), 3.48-3.37 (m, 4H), 3.31-3.12 (m, 4H), 2.48 (s, 3H), 2.37 (s, 3H), 2.36 (s, 3H).
MH+ 526. Example 281: l-(benzo[rf] [l,3]dioxol-5-yl)-7V-(3-(4-(3-chloro-2-methylphenyl) piperazin-l-yl)-2-hydroxypropyl)-5-methyl-2-propyl-l-Hr-imidazole-4- carboxamide dihydrochloride
1H NMR (400 MHz, CD3OD) δ 7.17-7.15 (m, 2H), 7.10-7.05 (m, 3H), 7.00 (dd, J = 8.4, 2.4 Hz, IH), 6.16 (s, 2H), 4.38-4.34 (m, IH), 3.76-3.72 (m, 2H), 3.60-3.50 (m, 2H), 3.48-3.34 (m, 4H), 3.31-3.12 (m, 4H), 2.37 (s, 3H), 2.35 (s, 3H), 1.73-1.67 (m, 2H), 0.93 (t, J = 7.6 Hz, 3H).
MH+ 554.
Example 282: Λr-(3-(4-(3-chloro-2-methyIphenyI)piperazin-l-yl)-2- hydroxypropyl)-2,5-dimethyl-l-p-tolyl-l//-imidazoIe-4-carboxamide dihydrochloride
1H NMR (400 MHz, CD3OD) δ 7.50 (d, J = 8.4 Hz, 2H), 7.39 (d, J = 8.4 Hz, 2H), 7.17-7.15 (m, 2H), 7.10-7.07 (m, IH), 4.38-4.34 (m, IH), 3.76-3.72 (m, 2H), 3.60-3.50 (m, 2H), 3.48-3.37 (m, 4H), 3.30-3.12 (m, 4H), 2.48 (s, 3H), 2.46 (s, 3H), 2.37 (s, 3H), 2.34 (s, 3H).
MH+ 496.
Example 283: ΛM3-(4-(23-dimethylphenyl)piperazin-l-yr)-2-hvdroxvpropyr)- 5MnethyI-2-propy--l-/Molyl-l//-imidazoIe-4-carboxamide dihydrochloride
1H NMR (400 MHz, CD3OD) δ 7.51 (d, J = 8.4 Hz, 2H), 7.41 (d, J = 8.4
Hz, 2H), 7.10-7.06 (m, IH), 7.02-6.99 (m, 2H), 4.41-4.36 (m, IH), 3.76-3.74 (m,
2H), 3.61-3.53 (m, 2H), 3.51-3.47 (m, 4H), 3.56-3.24 (m, 4H), 2.78 (t, J= 7.6 Hz, 2H)5 2.49 (s, 3H), 2.33 (s, 3H), 2.65 (s, 3H), 1.70-1.63 (m, 2H), 0.90 (t, J= 7.6 Hz,
3H).
MH+ 504.
Example 284: τV-(3-(4-(3-chIoro-2-methyIphenyl)piperazin-l-yl)-2- hydroxypropyl)-5-methyl-2-propyl-l-p-tolyl-li/-imidazole-4-carboxamide dihydrochloride
1H NMR (400 MHz, CD3OD) δ 7.51 (d, J = 8.0 Hz, 2H), 7.40 (d, J = 8.4
Hz, 2H), 7.17-7.15 (m, 2H), 7.1 1-7.07 (m, IH), 4.40-4.35 (m, IH), 3.76-3.73 (m, 2H), 3.61-3.51 (m, 2H), 3.49-3.31 (m, 4H), 3.30-3.12 (m, 4H), 2.77 (X, J = 8.0 Hz,
2H), 2.49 (s, 3H), 2.37 (s, 3H), 2.33 (s, 3H), 1.70-1.62 (m, 2H), 0.90 (U J = 7.6 Hz, 3H).
MH+ 524.
Example 285: .V-(3-(4-(2,3-dichIorophenyl)piperazin-l-yl)-2-hydroxypropyl)- 5-methyl-2-propyl-l-/Molyl-l//-imidazoIe-4-carboxamide dihydrochloride
1H NMR (400 MHz, CD3OD) δ 7.51 (d, J = 8.0 Hz, 2H), 7.39 (d, J = 8.4 Hz, 2H), 7.31-7.26 (m, 2H), 7.19-7.16 (m, IH), 4.39-4.35 (m, IH), 3.79-3.75 (m, 2H), 3.61-3.59 (m, 2H), 3. 57-3.38 (m, 4H), 3.34-3.30 (m, 4H), 2.77 (t, J= 7.6 Hz, 2H), 2.48 (s, 3H), 2.33 (s, 3H), 1.69- 1.62 (m, 2H), 0.90 (t, J = 8.0 Hz, 3H).
MH+ 544.
Example 286: 7V-(3-(4-(2,3-dimethyIphenyl)piperazin-l-yl)propyI)-5-methyl- 2-phenyI-l-/;-to-yl-l//-iinidazoIe-4-carboxamide dihydrochloride
1H NMR (400 MHz, CD3OD) δ 7.58-7.50 (m, 3H), 7.46-7.39 (m, 4H), 7.36-7.34 (m, 2H), 7.09-7.05 (m, IH), 6.99-6.94 (m, 2H), 3.72-3.69 (m, 2H), 3.62-3.58 (m, 2H), 3.42-3.33 (m, 4H), 3.26-3.14 (m, 4H), 2.42 (s, 3H), 2.25 (s, 3H), 2.23-2.17 (m, 2H).
MH+ 522.
Example 287: ΛL(3-(4-(3-chIoro-2-methyIphenyl)piperazin-l-yl)-2- hydroxypropyl)-5-methyl-2-phenyl-l-p-tolyl-l//-imidazole-4-carboxamide dihydrochloride
1H NMR (400 MHz, CD3OD) δ 7.57-7.49 (m, 3H), 7.45-7.39 (m, 4H), 7.35-7.33 (m, 2H), 7.17-7.16 (m, 2H), 7.09-7.07 (m, IH), 4.41-4.38 (m, IH), 3.77-3.73 (m, 2H), 3.61-3.57 (m, 2H), 3.51-3.32 (m, 4H), 3.29-3.14 (m, 4H), 2.43 (s, 3H), 2.42 (s, 3H), 2.37 (s, 3H).
MH+ 558.
Example 288:■/V-(3-(4-(2,3-dichlorophenyl)piperazin-l-yl)propyl)-5-methyl-2- phenyl-l-/Molyl-l//-imidazole-4-carboxamide dihydrochloride 1H NMR (400 MHz, CD3OD) δ 7.57-7.49 (m, 3H), 7.45-7.39 (m, 4H),
7.35-7.33 (m, 2H), 7.31-7.26 (m, 2H), 7.19-7.16 (m, IH), 3.76-3.72 (m, 2H), 3.63-3.58 (m, 2H), 3.56-3.52 (m, 2H), 3.42-3.35 (m, 4H)5 3.30-3.19 (m, 2H), 2.42 (s, 6H), 2.26-2.17 (m, 2H).
MH+ 562. Example 289: AM3-(4-(2,3-dimethvlphenvl)piperazin-l-yl)-2-hvdroxvpropvr)- 5-methyI-2-phenyI-l-/7-tolyl-l//-imidazole-4-carboxamide dihydrochloride
1H NMR (400 MHz, CD3OD) δ 7.58-7.50 (m, 3H), 7.46-7.39 (m, 4H), 7.37-7.34 (m, 2H), 7.09-7.05 (m, IH), 7.00-6.94 (m, 2H), 4.42-4.38 (m, IH), 3.77-3.74 (m, 2H), 3.61-3.58 (m, 2H), 3.52-5.48 (m, 2H), 3.37-3.30 (m, 2H), 3.28-3.23 (m, 4H), 2.44 (s, 3H), 2.42 (s, 3H), 2.25 (s, 6H).
MH+ 538.
Example 290: -V-(3-(4-(2,3-dichlorophenyl)piperazin-l-yl)-2-hydroxypropyl)- 5-methyl-2-phenyl-l-/Molyl-l//-imidazoIe-4-carboxamide dihydrochloride
1H NMR (400 MHz, CD3OD) δ 7.57-7.49 (m, 3H), 7.45-7.35 (m, 4H), 7.33-7.31 (m, 2H), 7.30-7.26 (m, 2H), 7.19-7.16 (m, IH), 4.42-4.37 (m, IH), 3.79-3.76 (m, 2H), 3.64-3.55 (m, 2H), 3.54-3.38 (m, 4H), 3.30-3.18 (m, 4H), 2.43 (s, 3H), 2.42 (s, 3H).
MH+ 578.
Example 291: ./V-(3-(4-(3-chIoro-2-methyIphenyl)piperaziii-l-yl)-2- hydroxypropyl)-l-(2-chlorophenyl)-2,5-dimethyl-l//-imidazole-4- carboxamide dihydrochloride
1H NMR (400 MHz, DMSO-d6) δ 7.85-7.83 (m, IH), 7.78-7.72 (m, IH), 7.71-7.66 (m, 2H), 7.18-7.15 (m, 2H), 7.11-7.08 (m, IH), 4.39-4.35 (m, IH), 3.76-3.73 (m, 2H), 3.59-3.54 (m, 4H), 3.48-3.37 (m, 2H), 3.28-3.14 (m, 4H), 2.46 (s, 3H), 2.38 (s, 3H), 2.33 (s, 3H).
MH+ 516.
Example 292: l-(2-chlorophenyl)-yV-(3-(4-(2,3-dimethylphenyl)piperazin-l- yl)propyl)-5-methyl-2-phenyl-lH-imidazole-4-carboxamide dihydrochloride
1H NMR (400 MHz, DMSO-d6) δ 11.14 (s, IH), 8.54-8.51 (m, IH), 7.79- 7.72 (m, 2H), 7.68-7.59 (m, 2H), 7.42-7.33 (m, 5H), 7.10 (t, J = 7.6 Hz, IH), 6.98-6.93 (m, 2H), 3.59-3.57 (m, 2H), 3.46-3.41 (m, 2H), 3.30-3.12 (m, 8H), 2.31 (s, 3H), 2.25 (s, 3H), 2.20 (s, 3H), 2.15-2.06 (m, 2H).
MH+ 542.
Example 293: N-P-^-P-chloro^-methylphenytypiperaziii-l-ylJpropyl)-!-^- chlorophenyl)-5-methyl-2-phenyl-l//-imidazole-4-carboxamide
dihydrochloride 1H NMR (400 MHz, DMSO-(I6) δ 10.97 (s, IH)5 8.44-8.41 (m, IH), 7.75-
7.67 (m, 2H), 7.64-7.55 (m, 2H), 7.38-7.29 (m, 5H), 7.24-7.15 (m, 2H), 7.06-7.05 (m, IH), 3.58-3.55 (m, 2H), 3.42-3.38 (m, 2H), 3.23-3.17 (m, 8H), 2.31 (s, 3H), 2.28 (s, 3H), 2.09-2.02 (m, 2H).
MH+ 562.
Example 294: l-(2-chlorophenyl)-7V-(3-(4-(2,3-dichIorophenyl)piperazin-l- yl)propyl)-5-methyl-2-phenyl-l//-imidazole-4-carboxamide dihydrochloride
1H NMR (400 MHz, DMSO-d6) 5 1 1.1 1 (s, IH), 8.45-8.42 (m, IH), 7.77- 7.69 (m, 2H), 7.66-7.57 (m, 2H), 7.44-7.30 (m, 7H), 7.24-7.22 (m, IH), 3.63-3.61 (m, 2H), 3.47-3.39 (m, 4H), 3.31-3.12 (m, 6H), 2.29 (s, 3H), 2.13-2.03 (m, 2H).
MH+ 582.
Example 295: l-(2-chlorophenyI)-7V-(3-(4-(2,3-dimethylphenyl)piperazin-l- yl)-2-hydroxypropyl)-5-methyI-2-phenyl-l//-imidazole-4-carboxamide dihydrochloride
1H NMR (400 MHz, DMSO-d6) δ 10.41 (s, IH), 8.33-8.30 (m, IH), 7.78- 7.66 (m, 2H), 7.65-7.58 (m, 2H), 7.39-7.32 (m, 5H), 7.12 (m, IH), 6.96-6.92 (m, 2H), 4.32-4.30 (m, IH), 3.69-3.59 (m, 2H), 3.44-3.35 (m, 5H), 3.21-3.09 (m, 5H), 2.30 (s, 3H), 2.24 (s, 3H), 2.19 (s, 3H).
MH+ 558.
Example 296: jV-(3-(4-(3-chloro-2-methylphenyl)piperazin-l-yl)-2- hydroxypropyl)-l-(2-chlorophenyI)-5-methyl-2-phenyI-l/f-imidazole-4- carboxamide dihydrochloride 1H NMR (400 MHz, DMSO-d6) δ 10.34 (s, IH), 8.29-8.26 (m, IH), 7.76-
7.57 (m, 4H), 7.38-7.30 (m, 5H), 7.25-7.19 (m, 2H)5 7.09-7.05 (m, IH), 4.29-4.28 (m, IH), 3.68-3.58 (m, 2H), 3.43-3.31 (m, 5H), 3.23-3.12 (m, 5H), 2.31 (s, 3H), 2.29 (s, 3H).
MH+ 578.
Example 297: l-^-chlorophenyty-Λ'-P-^-^vS-dichlorophenytypiperaziii-l- yI)-2-hydroxypropyl)-5-methyl-2-phenyl-l//-imidazole-4-carboxainide dihydrochloride
1H NMR (400 MHz, DMSO-d6) δ 10.51 (s, IH), 8.30-8.27 (m, IH), 7.78-
7.58 (m, 4H), 7.42-7.31 (m, 6H), 7.26-7.22 (m, IH), 4.31-4.29 (m, IH), 3.73-3.59 (m, 2H), 3.48-3.17 (m, 10H), 2.30 (s, 3H).
MH+ 598.
Example 298: 7V-(3-(4-(2,3-dimethyIphenyl)piperazin-l-yl)propyl)-5-methyI- 2-phenyl-l-o-tolyl-l//-imidazole-4-carboxamide dihydrochloride 1H NMR (400 MHz, MeOH-d4) δ 7.58-7.51 (m, 5H), 7.47-7.43 (m, 4H),
7.08 (t, J = 7.6 Hz, IH), 6.97 (t, J = 8.4 Hz, 2H), 3.72-3.67 (m, 2H), 3.62-3.59 (m, 2H), 3.44-3.38(m, 4H), 3.26-3.15 (m, 4H), 2.38 (s, 3H), 2.27 (s, 6H), 2.24-2.19 (m, 2H), 1.99 (s, 3H).
MH+522 (-2HC1).
Example 299: /V-(3-(4-(3-chloro-2-methylphenyl)piperazin-l-yl)propyl)-5- methyl-2-phenyl-l-o-toIyl-l//-imidazole-4-carboxamide dihydrochloride
1H NMR (400 MHz, MeOH-d4) δ 7.63 (d, J = 6.4 Hz, 2H), 7.59-7.55 (m, IH), 7.50-7.47 (m, 5H), 7.20-7.15 (m, 2H), 7.13-7.09 (m, IH), 3.72-3.67 (m, 2H), 3.62-3.59 (m, 2H), 3.44-3.38(m, 4H), 3.26-3.15 (m, 4H), 2.39 (s, 3H), 2.25 (s, 3H), 2.24-2.19 (m, 2H), 2.01 (s, 3H).
MH+542 (-2HC1). Example 300: jV-(3-(4-(2,3-dichIorophenyl)piperazin-l-yl)propyl)-5-methyl-2- phenyl-l-o-tolyl-l/T-imidazoIe-4-carboxamide dihydrochloride 1H NMR (400 MHz, MeOH-d4) δ 7.57-7.39 (m, 8H), 7.32-7.27 (m, 2H), 7.19-7.17 (m, IH), 3.76-3.73 (m, 2H), 3.68-3.65 (m, 5H), 3.46-3.34 (m, 4H), 3.25-3.19 (m, 3H), 2.41 (s, 3H), 2.29-2.22 (m, 2H), 2.00 (s, 3H).
MH+562 (-2HC1).
Example 301: ΛM3-(4-(2v3-dimethvlphenvl)piperazin-l-v0-2-hvdroxvpropvr)- 5-methyI-2-phenyl-l-o-tolyl-l//-imidazole-4-carboxamide dihydrochloride 1H NMR (400 MHz, MeOH-(I4) δ 7.57-7.51 (m, 5H), 7.48-7.43 (m, 4H),
7.07 (t, J = 7.6 Hz, IH), 6.98 (t, J = 8.0 Hz, 2H), 4.14-4.12 (m, IH), 3.72-3.67 (m, 2H), 3.62-3.59 (m, 3H), 3.44-3.38(m, 4H), 3.26-3.15 (m, 4H), 2.37 (s, 3H), 2.28 (s, 6H), 1.98 (s, 3H).
MH+538 (-2HCl).
Example 302: 7V-(3-(4-(3-chIoro-2-methylphenyl)piperazin-l-yl)-2- hydroxypropyl)-5-methyl-2-phenyl-l-o-tolyl-l/f-imidazoIe-4-carboxamide dihydrochloride 1H NMR (400 MHz, MeOH-d4) δ 7.57-7.40 (m, 7H), 7.16 (d, 4.4 Hz, 2H),
7.10-7.07 (m, IH), 4.38-4.37 (m, IH), 3.76-3.73 (m, 2H), 3.68-3.65 (m, IH), 3.62-3.58 (m, 3H), 3.56-3.36 (m, 3H), 3.29-3.15 (m, 3H), 2.37 (s, 3H), 2.17 (s, 3H), 1.97 (s, 3H).
MH+558 (-2HC1).
Example 303: Λ^3-(4-(2,3-dichlorophenyl)piperazin-l-yI)-2-hydroxypropyl)- 5-methyI-2-phenyl-l-o-toIyl-l//-imidazole-4-carboxamide dihydrochloride
1H NMR (400 MHz, MeOH-d4) δ 7.57-7.41 (m, 6H), 7.17-7.15 (m, 2H), 7.10-7.07 (m, IH), 4.37-4.37 (m, IH), 3.75-3.71 (m, 2H), 3.69-3.62 (m, 3H), 3.62-3.58 (m, 3H), 3.56-3.37 (m, 3H), 3.27-3.15 (m, 4H), 2.36 (s, 3H), 1.99 (s, 3H).
MH+578 (-2HC1). Example 304: τV-(3-(4-(3-chloro-2-methylphenyl)piperazin-l-yl)-2- hydroxypropyI)-2,5-dimethyl-l-(4-(trifluoromethyl)phenyl)-l//-imidazole-4- carboxamide dihydrochloride
1H NMR (400 MHz, CD3OD) δ 8.03 (d, J = 8.0 Hz, 2H), 7.78 (U9 J = 8.4 Hz, 2H), 7.17-7.15 (m, 2H), 7.10-7.06 (m, IH), 4.38-4.34 (m, IH), 3.75-3.72 (m, 2H), 3.60-3.49 (m, 2H), 3.47-3.36 (m, 4H), 3.29-3.10 (m, 4H), 2.48 (s, 3H), 2.37 (s, 3H), 2.36 (s, 3H).
MH+ 550.
Example 305: 7V-(3-(4-(3-chloro-2-methylphenyl)piperazin-l-yl)propyl)-2,5- dimethyl-l-(4-(trifluoromethyI)phenyl)-l//-imidazoIe-4-carboxamide dihydrochloride
1H NMR (400 MHz, DMSO-d6) δ 11.24 (br s, IH), 8.82 (br s, IH), 8.07 (d, J= 8.4 Hz, 2H), 7.84 (d, J= 8.4 Hz, 2H), 7.24-7.18 (m, 2H), 7.06 (dd, J= 7.6, 2.4 Hz, IH), 3.56-3.53 (m, 2H), 3.43-3.38 (m, 2H), 3.28-3.24 (m, 4H), 3.23-3.20 (m, 4H), 2.35 (s, 3H), 2.31 (s, 6H), 2.10-2.03 (m, 2H).
MH+ 534.
Example 306: Λr-(3-(4-(3-chIoro-2-methylphenyl)piperazin-l-yl)propyl)-5- methyl-2-phenyl-l-/Molyl-l//-imidazole-4-carboxamide dihydrochloride
1H NMR (400 MHz, DMSO-d6) δ 1 1.21 (br s, IH), 8.83 (br s, IH), 7.43- 7.41 (m, 3H), 7.40-7.20 (m, 6H), 7.18-7.12 (m, 2H), 7.07-7.02 (m, IH), 3.55-3.53 (m, 2H), 3.44-3.39 (m, 2H), 3.26-3.22 (m, 4H), 3.20-3.16 (m, 4H), 2.38 (s, 3H), 2.34 (s, 3H), 2.30 (s, 3H), 2.10-2.03 (m, 2H).
MH+ 542.
Example 307: N-(3-(4-(3-chloro-2-methylphenyl)piperazin-l-yl)propyI)-./V,5- dimethyl-l,2-diphenyl-l//-imidazole-4-carboxamide dihydrochloride
1H NMR (400 MHz, MeOH-d4) δ 7.61-7.41 (m, 8H), 7.16 (d, J = 4.0 Hz, 2H), 7.08-7.07 (m, IH), 3.74-3.72 (m, 4H), 3.67-3.28 (m, 4H), 3.27-3.09 (m, 4H), 2.86 (s, 3H), 2.37 (s, 3H).
MH+542 (-2HC1).
Example 308: Λ^-(4-(2,3-dichlorophenyl)piperazin-l-yl)propyl)-./V,5- dimethyl-l,2-diphenyI-l//-imidazole-4-carboxamide dihydrochloride
1H NMR (400 MHz, MeOH-d4) δ 7.64-7.41 (m, 10H)5 7.31-7.26 (m, 2H), 7.17-7.15 (m, IH), 3.76-3.72 (m, 4H), 3.58-3.51 (m, 2H), 3.49-3.29 (m, 6H), 3.28-3.20 (m, 3H), 2.55 (s, 3H).
MH+562 (-2HC1).
Example 309: iV-(3-(4-(2,3-dimethyIphenyl)piperazin-l-yl)propyl)-7V,5- dimethyI-l,2-diphenyl-l//-imidazole-4-carboxamide dihydrochloride
1H NMR (400 MHz, MeOH-d4) δ 7.64-7.40 (m, 10H), 7.32-7.27 (m, 2H), 7.19-7.15 (m, IH), 3.77-3.72 (m, 4H), 3.57-3.53 (m, 2H), 3.50-3.29 (m, 6H), 3.28-3.20 (m, 3H), 2.84 (s, 3H), 2.55 (s, 3H), 2.10 (s, 3H), 2.04 (s, 3H).
MH+522 (-2HC1).
Example 310: 7V-(3-(4-(3-chloro-2-methyIphenyl)piperazin-l-yl)propyl)-l- cyclopentyl-A^S-trimethyl-l/Z-imidazole-^-carboxamide dihydrochloride
1H NMR (400 MHz, MeOH-d4) δ 7.16 (d, J = 4.8 Hz, 2H), 7.10-7.06 (m, IH), 4.88-4.83 (m, IH), 3.67-3.64 (m, 4H), 3.35-3.30 (m, 4H), 3.29-3.12 (m, 5H), 2.72 (s, 3H), 2.44 (s, 3H), 2.36 (s, 3H), 2.29-2.20 (m, 4H), 2.04-1.98 (m, 4H), 1.77-1.76 (m, 2H).
MH+472 (-2HC1). Example 311: l-cyclopentyl-./V-β-^-^^-dichlorophenyOpiperaziii-l- yl)propyI)-N,2,5-trimethyl-l//-imidazole-4-carboxamide dihydrochloride
1H NMR (400 MHz, MeOH-d4) δ 7.31-7.26 (m, 2H), 7.17-7.15 (m, IH), 4.86-4.81 (m, IH), 3.69-3.65 (m, 4H), 3.37-3.31 (m, 4H), 3.29-3.14 (m, 6H), 2.46 (s, 3H), 2.31 (s, 3H), 2.28-2.21 (m, 4H), 2.01-1.96 (m, 4H), 1.75-1.71 (m, 2H).
MH+492 (-2HC1).
Example 312: l-cyclopentyl-Λ^-^-^^-dimethylphenyOpiperazin-l- yI)propyl)-./V,2,5-trimethyI-l/-r-imidazo-e-4-carboxamide dihydrochloride
1H NMR (400 MHz, MeOH-d4) δ 7.32-7.27 (m, 2H), 7.19-7.15 (m, IH), 4.94-4.90 (m, IH), 3.72-3.68 (m, 4H), 3.34-3.28 (m, 4H), 3.27-3.14 (m, 6H)5 2.72 (s, 3H), 2.42 (s, 3H), 2.29 (s, 3H), 2.22-2.19 (m, 4H), 2.13 (s, 3H), 2.06 (s, 3H), 2.01-1.96 (m, 4H), 1.75-1.70 (m, 2H).
MH+452 (-2HC1).
Example 313: N-P-^-^^-dimethylpheny^piperaziii-l-ytypropyl)-!-^- methoxyphenyl)-N,5-dimethyl-2-phenyl-l//-imidazole-4-carboxamide
dihydrochloride 1H NMR (400 MHz, DMSO-d6) δ 11.10 (br s, IH), 7.44-7.41 (m, 5H),
7.37 (d, J = 10.4 Hz, 2H), 7.10-7.05 (m, 3H), 6.93 (d, J = 7.6 Hz, 2H), 3.81 (s, 3H), 3.59-3.52 (m, 4H)5 3.32-3.25 (m, 5H), 3.16-2.95 (m, 6H), 2.21 (s, 3H), 2.16- 2.15 (m, 2H), 2.14 (s, 6H).
MH+ 552.
Example 314: l-(3-chlorophenyl)-jV-(3-(4-(2,3-dimethylphenyl)piperazin-l- yl)propyI)-7V,2,5-trimethyl-l/-f-imidazoIe-4-carboxamide dihydrochloride
1H NMR (400 MHz, DMSO-d6) δ 11.22 (br s, IH), 7.90 (br s, IH), 7.78- 7.70 (m, 3H), 7.07 (t, J = 7.6 Hz, IH), 6.93 (d, J = 7.2 Hz5 IH), 6.89 (d, J = 8.0 Hz, IH), 3.61-3.56 (m, 4H), 3.27-3.24 (m, 5H), 3.19-3.12 (m, 6H), 2.42 (s, 3H), 2.22(s, 3H), 2.17 (s, 3H), 2.16-2.14 (m, 2H), 2.08(s, 3H).
MH+ 494. Example 315: N-(3-(4-(3-chloro-2-methylphenyl)piperazin-l-yl)propyl)-l-(4- methoxyphenyty-Λ^S-dimethyl-l-phenyl-l/y-imidazole-^-carboxaiiiide dihydrochloride
1H NMR (400 MHz, DMSO-d6) δ 11.16 (br s, IH), 7.49-7.40 (m, 7H), 7.22-7.18 (m, 2H), 7.1 1-7.09 (m, 3H), 3.81 (s, 3H), 3.59-3.52 (m, 4H), 3.34-3.30 (m, 5H), 3.19-3.16 (m, 6H), 2.30 (s, 3H), 2.17-2.16 (m, 2H), 2.14 (s, 3H).
MH+ 572.
Example 316: yV-(3-(4-(3-chloro-2-methylphenyl)piperazin-l-yl)propyl)-l-(3- chloropheny^-TV^jS-trimethyl-l/f-imidazole^-carboxamide dihydrochloride 1H NMR (400 MHz, DMSO-d6) δ 11.33 (br s, IH), 7.91 (br s, IH)5 7.79- 7.70 (m, 3H), 7.24-7.18 (m, 2H), 7.05 (d, J = 6.4 Hz, IH), 3.61-3.57 (m, 4H), 3.28-3.24 (m, 5H), 3.19-3.16 (m, 6H), 2.43 (s, 3H), 2.30(s, 3H), 2.16-2.14 (m, 2H), 2.08(s, 3H).
MH+ 514.
Example 317: l-(2-chlorophenyI)-7V-(3-(4-(2,3-dimethyIphenyl)piperazin-l- yOpropyO-A^S-trimethyl-liZ-imidazole^-carboxamide dihydrochloride 1H NMR (400 MHz, DMSO-d6) δ 7.03-7.01 (m, IH), 6.96-6.92 (m, 2H),
6.88-6.85 (m, IH), 6.28-6.24 (m, IH), 6.18-6.13 (m, 2H), 2.89 (m, 4H), 2.57-2.53 (m, 2H), 2.52 (s, 3H), 2.42-2.35 (m, 6H), 1.66 (s, 3H), 1.44 (s, 6H), 1.44-1.40 (m, 2H), 1.33 (s, 3H).
MH+ 494.
Example 318: 7V-(3-(4-(3-chloro-2-methyIphenyI)piperazin-l-yl)propyl)-l-(2- chlorophenyl)-Λr,2,5-trimethyl-l//-imidazole-4-carboxamide dihydrochloride
1H NMR (400 MHz, DMSO-d6) δ 7.03-7.01 (m, IH), 6.96-6.92 (m, 2H), 6.89-6.85 (m, IH), 6.35 (d, J= 4.4 Hz, 2H), 6.29-6.26 (m, IH), 2.91-2.89 (m, 4H), 2.58-2.53 (m, 2H), 2.52 (s, 3H), 2.44-2.29 (m, 6H), 1.66 (s, 3H), 1.56 (s, 3H), 1.44-1.43 (m, 2H), 1.33 (s, 3H).
MH+ 514. Example 319: l-^-chlorophenyO-N-β-^-^vS-dichlorophenytypiperaziii-l- yl)propy-)-Λr,2,5-trimethyl-li/-imidazole-4-carboxamide dihydrochloride
1H NMR (400 MHz, DMSO-d6) δ 7.03-7.01 (m, IH), 6.96-6.92 (m, 2H), 6.89-6.85 (m, IH), 6.50-6.47 (m, 2H), 6.38-6.35 (m, IH), 2.94-2.89 (m, 4H), • 2.74-2.70 (m, 2H), 2.55-2.52 (m, 2H), 2.52 (s, 3H), 2.46-2.40 (m, 4H), 1.66 (s, 3H), 1.44 (s, 2H), 1.33 (s, 3H).
MH+ 534.
Example 320: A^(3-(4-(2,3-dimethylphenyl)piperazin-l-yl)propyl)-.V,2,5- trimethy 1-1-phenyl-l /f-imidazole-4-carboxamide dihydrochloride 1H NMR (400 MHz, DMSO-d6) δ 1 1.41 (br s, IH), 7.75-7.70 (m, 5H), 7.10-7.06 (m, IH), 6.95-6.89 (m, 2H), 3.64-3.56 (m, 4H), 3.29-3.20 (m, 4H), 3.18-3.06 (m, 7H), 2.43 (s, 3H), 2.22 (s, 3H), 2.17 (s, 3H), 2.15-2.10 (m, 2H), 2.07 (s, 3H).
MH+ 460.
Example 321; Λr-(3-(4-(3-chloro-2-methyIphenyl)piperazin-l-yI)propyl)- Λf,2,5-trimethyl-l-phenyl-l//-imidazole-4-carboxaiiiide dihydrochloride 1H NMR (400 MHz, DMSO-d6) δ 1 1.85 (br s, IH), 7.70-7.65 (m, 5H),
7.24-7.18 (m, 2H), 7.07-7.04 (m, IH), 3.62-3.57 (m, 4H), 3.29-3.26 (m, 4H), 3.20-3.16 (m, 7H), 2.42 (s, 3H), 2.31 (s, 3H), 2.17-2.13 (m, 2H), 2.07 (s, 3H).
MH+ 480. Example 322: jV-(3-(4-(2,3-dichlorophenyl)piperazin-l-yl)propyl)-jV,2,5- trimethyl-l-pheny--l/-r-imidazole-4-carboxamide dihydrochloride
1H NMR (400 MHz, DMSO-(I6) δ 1 1.51 (br s, IH), 7.69-7.66 (m, 5H), 7.39-7.35 (m, 2H), 7.22-7.19 (m, IH), 3.63-3.61 (m, 4H), 3.45-3.37 (m, 2H), 3.28-3.25 (m, 4H), 3.17-3.06 (m, 5H), 2.42 (s, 3H), 2.16-2.13 (m, 2H), 2.07 (s, 3H).
MH+ 500.
Example 323: 7V-(3-(4-(2,3-dimethylphenyI)piperazin-l-yl)propyl)-l-(4- fluorophenyl)-N,5-dimethyl-2-phenyl-l//-imidazole-4-carboxamide
dihydrochloride
1H NMR (400 MHz, DMSO-d6) δ 1 1.40 (br s, IH), 7.68-7.66 (m, 2H), 7.51-7.31 (m, 7H), 7.09-7.05 (m, IH), 6.94-6.83 (m, 2H), 3.88-.82 (m, IH), 3.63- 3.52 (m, 5H), 3.32-2.95 (m, 9H), 2.22 (s, 3H), 2.17-2.16 (m, 2H), 2.15 (s, 3H).
MH+ 540.
Example 324: 7V-(3-(4-(3-chloro-2-methylphenyl)piperazin-l-yl)propyl)-l-(4- fluorophenyl)-Λf,5-dimethyl-2-phenyl-li7-imidazoIe-4-carboxamide
dihydrochloride 1H NMR (400 MHz, DMSO-d6) δ 11.40 (br s, IH), 7.64-6.62 (m, 2H)5 7.42-7.37 (m, 7H), 7.23-7.18 (m, 2H)5 7.06-6.96 (m, IH)5 3.84-3.82 (m, IH)5 3.60-3.51 (m, 3H)5 3.33-3.32 (m, 3H)5 3.28-3.16 (m, 6H)5 3.06-3.03 (m, 2H)5 2.30-2.20 (m, 2H)5 2.16 (s, 6H).
MH+ 560.
Example 325; 7V-(3-(4-(2,3-dichlorophenyl)piperazin-l-yl)propyl)-l-(4- fluorophenyty-Λ^S-dimethyl^-phenyl-l/f-iinidazole^-carboxainide
dihydrochloride
1H NMR (400 MHz5 DMSO-d6) δ 11.60 (br s, IH)5 7.66-7.64 (m, 2H), 7.44-7.42 (m, 7H)5 7.38-7.35 (m, 2H)5 7.21-7.11 (m, IH)5 3.83-3.82 (m, IH)5 3.63-3.61 (m, 3H)5 3.44-3.42 (m, 2H)5 3.33-3.12 (m, 7H)5 3.06-3.03 (m, 2H)5 2.22-2.20 (m, 2H)5 2.16 (s, 3H).
MH+ 580.
Example 326: l-(2,3-dihydrobenzo[Z>] [l,4]dioxin-6-yl)-Λ^-(3-(4-(2,3- dimethyIphenyl)piperazin-l-yl)propyl)-Λr,5-dimethyl-2-phenyl-l//-imidazole- 4-carboxamide dihydrochloride
1H NMR (400 MHz5 DMSO-d6) δ 11.20 (br S5 IH), 7.48-7.39 (m, 5H)5 7.15 (s, H), 7.09-6.82 (m, 5H)5 4.31-4.28 (m, 4H)5 3.82-3.81 (m, IH)5 3.59-3.51 (m, 3H)5 3.31-3.26 (m, 4H)5 3.17-3.12 (m, 5H)5 3.03-2.96 (m, 2H)5 2.22 (s, 3H), 2.18-2.16 (m, 3H), 2.15 (s, 6H).
MH+ 580.
Example 327: Λr-(3-(4-(3-chloro-2-methyIphenyl)piperazin-l-yl)propyl)-l- (2,3-dihydrobenzo[Λ][l,4]dioxin-6-yl)-7V,5-dimethyl-2-phenyI-l/-r-imidazoIe- 4-carboxamide dihydrochloride
1H NMR (400 MHz, DMSO-U6) δ 11.40 (br s, IH), 7.49-7.41 (m, 5H)5 7.24-7.18 (m, 3H)5 7.04-6.97 (m, 3H)5 4.31-4.28 (m, 4H)5 3.82-3.80 (m, IH)5 3.60-3.51 (m, 3H)5 3.30-3.29 (m, 3H), 3.19-3.16 (m, 6H), 3.06-3.03 (m, 2H)5 2.30-2.17 (m, 2H)5 2.15 (s, 6H).
MH+ 600. Example 328: .V-(3-(4-(2,3-dichlorophenyl)piperazin-l-yl)propyl)-l-(2,3- dihydrobenzo[Λ] [l,4Jdioxin-6-yl)-Λr,5-dimethyI-2-phenyl-l//-imidazole-4- carboxamide dihydrochloride
Figure imgf000140_0001
1H NMR (400 MHz, DMSO-d6) δ 1 1.45 (br s, IH), 7.47-7.33 (m, 7H), 7.21-7.15 (m, 2H), 7.03-6.91 (m, 2H), 4.30-4.24 (m, 4H), 3.82-3.78 (m, IH), 3.62-3.58 (m, 2H), 3.45-3.43 (m, IH), 3.30-3.16 (m, 8H), 2.18-2.16 (m, 2H), 2.18 (s, 3H), 2.15 (s, 3H).
MH+ 620.
Example 329: (Λ)-l-(2,3-dihydrobenzo[Λ] [l,4]dioxin-6-yl)-Λ^-(3-(4-(2,3- dimethylphenyl)piperazin-l-yl)-2-hydroxypropyl)-2,5-dimethyI-l//- imidazole-4-carboxamide dihydrochloride
Figure imgf000140_0002
1H NMR (400 MHz, DMSO-d6) δ 10.36 (br s, IH), 8.68 (br s, IH), 7.16- 7.06 (m, 3H), 7.00 (dd, J= 8.8, 2.8 Hz, IH), 6.94-6.89 (m, 2H), 4.34-4.33 (m, 4H), 4.28-4.24 (m, IH), 3.65 (d, J= 12.0 Hz, IH), 3.56 (d, J= 10.4 Hz, IH), 3.44-3.30 (m, 6H), 3.22-3.12 (m, 4H), 2.35 (s, 3H), 2.29 (s, 3H), 2.22 (s, 3H), 2.17 (s, 3H).
MH+ 520.
Example 330: (Λ)-Λ'-(3-(4-(3-chloro-2-methylphenyl)piperaziii-l-yl)-2- hydroxypropyl)-l-(2,3-dihydrobenzo[ft][l,4]dioxin-6-yl)-2,5-dimethyl-l//- imidazoIe-4-carboxamide dihydrochloride
Figure imgf000140_0003
1H NMR (400 MHz, DMSO-(I6) δ 10.56 (br s, IH), 8.71 (br s, IH), 7.24- 7.16 (m, 3H), 7.13-7.10 (m, IH), 7.08-6.99 (m, 2H), 4.34-4.33 (m, 4H), 4.29-4.26 (m, IH), 3.67 (d, J = 12.0 Hz, IH), 3.57 (d, J = 1 1.6 Hz, IH), 3.46-3.39 (m, 2H), 3.38-3.32 (m, 2H), 3.22-3.12 (m, 6H), 2.35 (s, 3H), 2.30 (s, 3H), 2.29 (s, 3H).
MH+ 540.
Example 331: (Λ)-jV-(3-(4-(2,3-dichlorophenyl)piperazin-l-yl)-2- hydroxypropyl)-l-(2,3-dihydrobenzo[Λ][l,4]dioxin-6-yl)-2,5-diraethyl-ljy- imidazoIe-4-carboxamide dihydrochloride
Figure imgf000141_0001
1H NMR (400 MHz, DMSO-d6) δ 10.68 (br s, IH), 8.69 (br s IH), 7.39- 7.34 (m, 2H), 7.21 (dd, J = 7.2, 2.8 Hz, IH), 7.16 (d, J = 2.4 Hz, IH), 7.1 1 (d, J = 8.0 Hz, IH), 7.00 (dd, J= 8.4, 2.4 Hz, IH), 4.34-4.33 (m, 4H), 4.30-4.25 (m, IH), 3.70 (d, J = 8.0 Hz, IH), 3.60 (d, J = 10.8 Hz, IH), 3.46-3.38 (m, 4H), 3.36-3.18 (m, 6H), 2.35 (s, 3H), 2.29 (s, 3H).
MH+ 560.
Experimental Examples
Experimental Example 1 : Measurement of binding affinity for serotonin 5- HT2A and 5-HT2C receptors
Receptor binding affinities of the compounds for serotonin receptors were measured by the method described in the literature [Park WK et al, Pharmacol Biochem Behav. 2005, 82(2), 361-372].
For serotonin 5-HT2A binding, an aliquot of human recombinant serotonin 5-HT2A receptor (PerkinElmer Life and Analytical Sciences, USA) expressed in CHO-Kl cells (5 ug/well) and 1 nM [3H]Ketanserin (PerkinElmer) were used in the presence of mianserin (20 uM) as a nonspecific. The reaction mixture was incubated for 60 min at 27 °C using 50 mM Tris-HCl (pH 7.4) buffer containing 4 mM CaCl2 and 0.1% ascorbic acid, and harvested through filtermate A glass fiber filter (Wallac, Finland) presoaked in 0.5% polyethyleneimine (PEI) by microbeta filtermate-96 harvester (PerkinElmer) to terminate the reaction, and then washed with ice cold 50 mM Tris-HCl buffer solution (pH 7.4). The filter was then covered with MeltiLex, sealed in a sample bag, dried in an oven. The radioactivity retained in the filter was finally counted using MicroBeta Plus (Wallac).
The binding affinity (IC50) of a compound for the receptor was calculated by computerized nonlinear regression analysis (GraphPad Prism Program, San Diego, USA) using 7-8 varied concentrations of the compound run in duplicate tubes.
For serotonin 5-HT2c binding, frozen membranes from stable CHO-Kl cell line expressing the human recombinant 5-HT2C receptor (PerkinElmer, 4 ug/well), [3H]Mesulergine (Amersham, 1.3 nM) and test compounds were added into 50 mM Tris-HCl (pH 7.4) buffer containing 0.1% ascorbic acid and 4 mM CaCl2. Nonspecific binding was determined using 100 uM mianserin. The incubations were performed for 60 min at 27 °C , and these were terminated by rapid filtration through filtermate A glass fiber filter presoaked in 0.5% PEL The results are shown in Table 1.
Experimental Example 2 : Measurement of binding affinity for serotonin transporter
For serotonin transporter binding assays, a reaction mixture with a final volume of 0.25 ml was prepared by mixing a test compound, human serotonin transporter membrane expressed in HEK-293 cells (PerkinElmer, 5 ug/well), [3H]Imipramine (PerkinElmer, 2 nM) and 50 mM Tris-HCl (pH 7.4) buffer containing 120 mM NaCl and 5 mM KCl. The reaction mixture was incubated for 30 min at 27 °C , and harvested through filtermate A glass fiber filter presoaked in 0.5% PEI with ice cold 50 mM Tris-HCl buffer (pH 7.4) containing 0.9% NaCl. The results are shown in Table 1. Table 1.
Binding affinity to serotonin receptor 5-HT2A, 5-HT2C and serotonin transporter (SERT): IC50 (nM)
Figure imgf000143_0001
Figure imgf000144_0001
Experimental Example 3 : Measurement of anti-depressants activity in forced swimming test
To evaluate the anti-depressants activity of the compounds, the inhibitory effects on immobility in forced swimming test in mice were measured according to the methods described by Porsolt et al. [Porsolt RD et al, Eur J Pharmacol 1978, 51, 291-294].
Each mouse was placed in a 25 cm glass cylinder (10 cm diameter) containing 15 cm of water maintained at 22 ± 1 0C , and was forced to swim for 10 min. 24 hours later, the mouse was replaced into the cylinder and the total duration of immobility was recorded during the last 5 min of the 6 min testing period. Mice are judged immobile when they float in an upright position and make only small movements to keep their head above water. Test drugs were suspended in 3% Tween 80 solution, and administered orally (po) 60 min before the testing. The results are shown in Table 2.
Table 2. Antidepressants activity-Immobility in forced swimming test on mice (unit: %)
Figure imgf000145_0001
Figure imgf000146_0001
Figure imgf000147_0001
As shown in Tables 1 and 2, the inventive compounds of formula (I) exhibited good in vitro binding affinities to serotonin receptor 5-HT2A, 5-HT2C and/or inhibitory activity against serotonin transporter (SERT), and in vivo anti- depressant activity on FST (forced swimming test) animal model as well. Thus, the current inventive compounds are useful in preventing or treating depressive disorders.
While the invention has been described with respect to the above specific embodiments, it should be recognized that various modifications and changes may be made to the invention by those skilled in the art which also fall within the scope of the invention as defined by the appended claims.

Claims

WHAT IS CLAIMED IS:
1. A compound of formula (I) or a pharmaceutically acceptable salt thereof:
Figure imgf000148_0001
Wherein,
Ri is hydrogen, C1.3 alkyl, or C1.3 alkoxy;
R2 is selected from the group consisting of hydrogen, carbocycle, substituted carbocycle, aryl, substituted aryl, heteroaryl, substituted heteroaryl, heterocycle, substituted heterocycle, Cj.g alkyl optionally substituted with hydroxyl or acyloxy, Ci.6 alkoxy, substituted Cj-6 alkoxy, C3.5 alkenyloxy, substituted C3-5 alkenyloxy, C3-5 alkynyloxy, substituted C3-5 alkynyloxy, aryloxy, substituted aryloxy, heteroaryloxy, substituted heteroaryloxy or halogen, C2-6 alkenyl optionally substituted with alkoxy or halogen, C2-6 alkynyl optionally substituted with alkoxy or halogen, -(CH2)n-C3.6 carbocycle optionally substituted with alkoxy or halogen, and -(CH2)n-R7, n being 1 or 2;
R3 is selected from the group consisting of hydrogen, Cj-4 alkyl, substituted C1-4 alkyl, C3.7 cycloalkyl, substituted C3-7 cycloalkyl, aryl, substituted aryl, heteroaryl, substituted heteroaryl, heterocycloalkyl, and substituted heterocycloalkyl;
R4 is hydrogen or Ci-3 alkyl;
R5 and R6 are each independently hydrogen, halogen, Ci_3 alkyl, Ci_3 alkoxy, cyano, monofluoromethyl, difluoromethyl or trifluoromethyl; or R5 and R6, together with the carbon atoms to which they are bonded, form a 5- to 7- membered saturated or unsaturated heterocyclic ring or aryl ring which is optionally substituted by one or more Ci-3 alkyl, Ci-3 alkoxy, halogen, trifluoromethyl, or cyano;
R7 is phenyl, furanyl, benzofuranyl, thienyl, benzothienyl, pyridinyl, pyridiminyl, pyrazinyl, pyridizinyl, tetrahydrofuranyl, tetrahydropyranyl, dioxanyl, 1,4-benzodioxanyl, or benzo[l,3]dioxolyl, each of which is optionally substituted with one or more halogen, Cj-3 alkyl, or Ci.3 alkoxy, wherein Ci-3 alkyl and Ci-3 alkoxy optionally have one to three fluorine substituents;
m is an integer of 0 to 2;
X is -CH2- when m is 0 or 2, and X is -CH(OH)-, -CHF-, or -CF2- when m is 1 ; and
Y is -N= or «ΛW with the proviso that when Y is -N=, R5 or R^ are not bonded to Y.
2. The compound of formula (I) according to claim 1, which is selected from the group consisting of:
l-(4-chlorophenyl)-N-(3-(4-(2,3-dichlorophenyl)piperazin-l-yl)-2- hydroxypropyl)-2-propyl-l//-imidazole-4-carboxamide;
l-(4-chlorophenyl)-N-(3-(4-(2,3-dichlorophenyl)piperazin-l-yl)propyl)-2- propyl- lH-imidazole-4-carboxamide dihydrochloride;
l-(4-chlorophenyl)-N-(3-(4-(2,3-dimethylphenyl)piperazin-l-yl)propyl)- 2-propyl-lH-imidazole-4-carboxamide;
l-(4-chlorophenyl)-N-(2-(4-(2,3-dichlorophenyl)piperazin-l-yl)ethyl)-2- propyl-lH-imidazole-4-carboxamide;
N-(3-(4-(2,3-dichlorophenyl)piperazin-l-yl)-2-hydroxypropyl)-2,5- dimethyl- 1 -phenyl- lH-imidazole-4-carboxamide;
N-(3-(4-(2,3-dichlorophenyl)piperazin-l-yl)propyl)-2,5-dimethyl-l- phenyl-lH-imidazole-4-carboxamide;
N-(3-(4-(2,3-dichlorophenyl)piperazin- 1 -yl)propyl)-5-methyl- 1 -phenyls- propyl- lH-imidazole-4-carboxamide dihydrochloride;
N-(2-(4-(2,3-dichlorophenyl)piperazin- 1 -yl)ethyl)-2,5-dimethyl- 1 -phenyl- lH-imidazole-4-carboxamide;
N-(2-(4-(2,3-dichlorophenyl)piperazin-l-yl)ethyl)-5-methyl-l-phenyl-2- propyl-lH-imidazole-4-carboxamide;
N-(3-(4-(2,3-dichlorophenyl)piperazin-l-yl)propyl)-l-(4- methoxyphenyl)-2,5-dimethyl-lH-imidazole-4-carboxamide;
l-(4-chlorophenyl)-N-(3-(4-(2,3-dichlorophenyl)piperazin-l-yl)propyl)- 2,5-dimethyl-l//-imidazole-4-carboxamide;
N-(3-(4-(2,3-dichlorophenyl)piperazin-l-yl)propyl)-2-ethyl-5-methyl-l- phenyl- lH-imidazole-4-carboxamide;
N-(2-(4-(2,3-dichlorophenyl)piperazin-l-yl)ethyl)-2-ethyl-5-methyl-l- phenyl- 1 H-imidazole-4-carboxamide;
N-(2-(4-(2,3-dimethylphenyl)piperazin-l-yl)ethyl)-2,5-dimethyl- l- pheny 1-1 H-imidazole-4-carboxamide;
N-(3-(4-(2,3-dimethylphenyl)piperazin-l-yl)propyl)-2,5-dimethyl-l- phenyl-1 H-imidazole-4-carboxamide;
N-(3-(4-(2,3-dimethylphenyl)piperazin-l-yl)propyl)-2-ethyl-5-methyl-l- phenyl-1 H-imidazole-4-carboxamide;
N-(3-(4-(2,3-dimethylphenyl)piperazin- 1 -yl)propy l)-5-methyl- 1 -phenyl- 2 -propyl- 1 H-imidazole-4-carboxamide dihydrochloride;
N-(2-(4-(2,3-dimethylphenyl)piperazin-l-yl)ethyl)-2-ethyl-5-methyl- l- phenyl-lH-imidazole-4-carboxamide;
N-(2-(4-(2,3-dimethylphenyl)piperazin-l-yl)ethyl)-5-methyl-l-phenyl-2- propyl- 1 H-imidazole-4-carboxamide dihydrochloride;
N-(3-(4-(2,3-dichlorophenyl)piperazin- 1 -yl)propyl)- 1 -(4-fluoropheny I)- 2,5-dimethyl-lH-imidazole-4-carboxamide;
N-(2-(4-(2,3-dichlorophenyl)piperazin-l-yl)ethyl)-l-(4-fluorophenyl)-2,5- dimethyl-1 H-imidazole-4-carboxamide;
1 -(4-chlorophenyl)-N-(3-(4-(2,3-dimethylphenyl)piperazin- 1 -yl)propy I)- 2,5-dimethy 1-1 H-imidazole-4-carboxamide;
N-(3-(4-(2,3-dichlorophenyl)piperazin-l-yl)-2-hydroxypropyl)-2-ethyl-5- methyl-1 -phenyl- 1 H-imidazole-4-carboxamide;
N-(3-(4-(2,3-dichlorophenyl)piperazin-l-yl)-2-hydroxypropyl)-5-methyl- 1 -phenyl-2-propyl- lH-imidazole-4-carboxamide;
1 -(4-chlorophenyl)-N-(3-(4-(2,3-dichlorophenyl)piperazin- 1 -yl)propy l)-2- ethyl-5-methyl-lH-imidazole-4-carboxamide;
N-(3-(4-(2,3-dichlorophenyl)piperazin-l-yl)-2-hydroxypropyl)-l-(4- fluorophenyl)-2,5-dimethyl-lH-imidazole-4-carboxamide;
l-(4-chlorophenyl)-N-(2-(4-(2,3-dichlorophenyl)piperazin-l-yl)ethyl)- 2,5-dimethyl-lH-imidazole-4-carboxamide;
l-(4-chlorophenyl)-N-(2-(4-(2,3-dichlorophenyl)piperazin-l-yl)ethyl)-2- ethyl-5-methyl-lH-imidazole-4-carboxamide;
N-(3-(4-(2,3-dichlorophenyl)piperazin-l-yl)propyl)-2,5-dimethyl-l-p- toly 1-1 H-imidazole-4-carboxamide;
N-(2-(4-(2,3-dichlorophenyl)piperazin- 1 -yl)ethyl)-2,5-dimethy 1- 1 -p-tolyl- lH-imidazole-4-carboxamide;
N-(3-(4-(2,3-dichlorophenyl)piperazin-l-yl)-2-hydroxypropyl)-2,5- dimethyl- 1 -p-tolyl- lH-imidazole-4-carboxamide;
l-(4-chlorophenyl)-N-(3-(4-(2,3-dichlorophenyl)piperazin-l-yl)-2- hydroxypropyl)-2,5-dimethyl-lH-imidazole-4-carboxamide;
l-(4-chlorophenyl)-N-(3-(4-(2,3-dichlorophenyl)piperazin-l-yl)-2- hydroxypropyl)-2-ethyl-5-methyl-lH-imidazole-4-carboxamide;
N-(3-(4-(2,3-dimethylphenyl)piperazin-l-yl)propyl)-l-(4-fluorophenyl)- 2,5-dimethyl-lH-imidazole-4-carboxamide;
N-(3-(4-(2,3-dimethylphenyl)piperazin-l-yl)-2-hydroxypropyl)-l-(4- fluorophenyl)-2,5-dimethyl-lH-imidazole-4-carboxamide;
N-(3-(4-(2,3-dimethylphenyl)piperazin-l-yl)-2-hydroxypropyl)-2,5- dimethyl- 1 -phenyl- lH-imidazole-4-carboxamide;
N-(3-(4-(2,3-dimethylphenyl)piperazin-l-yl)propyl)-2,5-dimethyl-l-(4- (trifluoromethyl)phenyl)-lH-imidazole-4-carboxamide;
l-(benzo[f/][l,3]dioxol-5-yl)-N-(3-(4-(2,3-dimethylphenyl)piperazin-l- yl)propyl)-2,5-dimethyl-lH-imidazole-4-carboxamide;
l-(benzo[c(][l,3]dioxol-5-yl)-N-(3-(4-(2,3-dimethylphenyl)piperazin-l- yl)-2-hydroxypropyl)-2,5-dimethyl-lH-imidazole-4-carboxamide;
l-(2,3-dihydrobenzo[b][l,4]dioxin-6-yl)-N-(3-(4-(2,3-dimethylphenyl) piperazin-l-yl)propyl)-2,5-dimethyl-lH-imidazole-4-carboxamide;
l-(2,3-dihydrobenzo[b][l,4]dioxin-6-yl)-N-(3-(4-(2,3-dimethylphenyl) piperazin- 1 -yl)-2-hydroxypropyl)-2,5-dimethyl- lH-imidazole-4-carboxamide;
N-(2-(4-(2,3-dichlorophenyl)piperazin-l-yl)ethyl)-l-(4-methoxyphenyl)- 2,5-dimethyl-lH-imidazole-4-carboxamide;
N-(3-(4-(2,3-dichlorophenyl)piperazin-l-yl)-2-hydroxypropyl)-l-(4- methoxyphenyl)-2,5-dimethyl-lH-imidazole-4-carboxamide;
N-(3-(4-(2,3-dichlorophenyl)piperazin-l-yl)propyl)-2-ethyl-l-(4- methoxyphenyl)-5-methyl-lH-imidazole-4-carboxamide;
N-(3-(4-(2,3-dichlorophenyl)piperazin- 1 -y l)-2-hydroxypropyl)-2-ethyl- 1 - (4-methoxyphenyl)-5-methyl-lH-imidazole-4-carboxamide;
N-(2-(4-(2,3-dimethylphenyl)piperazin-l-yl)ethyl)-l-(4-methoxyphenyl)- 2,5-dimethyl-lH-imidazole-4-carboxamide;
N-(3-(4-(2,3-dimethylphenyl)piperazin-l-yl)propyl)-l-(4- methoxyphenyl)-2,5-dimethyl-lH-imidazole-4-carboxamide;
l-(3-chlorophenyl)-N-(3-(4-(2,3-dimethylphenyl)piperazin-l-yl)propyl)- 2,5-dimethyl-lH-imidazole-4-carboxamide;
l-(3-chlorophenyl)-N-(3-(4-(2,3-dimethylphenyl)piperazin-l-yl)-2- hydroxypropyl)-2,5-dimethyl-lH-imidazole-4-carboxamide;
N-(3-(4-(3-chloro-2-methylphenyl)piperazin- 1 -yl)propy I)- 1 -(3- chlorophenyl)-2,5-dimethyl-lH-imidazole-4-carboxamide;
N-(3-(4-(3-chloro-2-methylphenyl)piperazin-l-yl)-2-hydroxypropyl)-l- (3-chlorophenyl)-2,5-dimethyl-lH-imidazole-4-carboxamide;
N-(3-(4-(2,3-dimethylphenyl)piperazin-l-yl)propyl)-l-(3-fluorophenyl)- 2,5-dimethyl-lH-imidazole-4-carboxamide;
N-(3-(4-(2,3-dimethylphenyl)piperazin-l-yl)-2-hydroxypropyl)-l-(3- fluorophenyl)-2,5-dimethyl-lH-imidazole-4-carboxamide;
l-(3,4-dimethoxyphenyl)-N-(3-(4-(2,3-dimethylphenyl)piperazin-l- yl)propyl)-2,5-dimethyl-lH-imidazole-4-carboxamide;
l-(3,4-dimethoxyphenyl)-N-(3-(4-(2,3-dimethylphenyl)piperazin-l-yl)-2- hydroxypropyl)-2,5-dimethyl-lH-imidazole-4-carboxamide;
N-(3-(4-(2,3-dimethylphenyl)piperazin-l-yl)-2-hydroxypropyl)-l-(4- methoxyphenyl)-2,5-dimethyl-lH-imidazole-4-carboxamide;
N-(3-(4-(2,3-dimethylphenyl)piperazin-l-yl)propyl)-2,5-dimethyl-l-(4- (methylthio)phenyl)- 1 H-imidazole-4-carboxamide;
N-(3-(4-(2,3-dimethylphenyl)piperazin-l-yl)-2-hydroxypropyl)-2,5- dimethyl- 1 -(4-(methy lthio)pheny I)- 1 H-imidazole-4-carboxamide;
N-(3-(4-(2,3-dimethy lphenyl)piperazin- 1 -yl)propyl)- 1 -(3- methoxyphenyl)-2,5-dimethyl-lH-imidazole-4-carboxamide;
N-(3-(4-(2,3-dimethylphenyl)piperazin-l-yl)-2-hydroxypropyl)-l-(3- methoxyphenyl)-2,5-dimethyl-lH-imidazole-4-carboxamide;
l-(2,4-dimethoxyphenyl)-N-(3-(4-(2,3-dimethylphenyl)piperazin-l- yl)propyl)-2,5-dimethy 1-1 H-imidazole-4-carboxamide;
l-(2,4-dimethoxyphenyl)-N-(3-(4-(2,3-dimethylphenyl)piperazin-l-yl)-2- hydroxypropyl)-2,5-dimethyl-lH-imidazole-4-carboxamide;
(S)-N-(3-(4-(2,3-dichlorophenyl)piperazin-l-yl)-2-hydroxypropyl)-2,5- dimethyl-l-phenyl-lH-imidazole-4-carboxamide;
(.S)-N-(3-(4-(2,3-dichlorophenyl)piperazin-l-yl)-2-hydroxypropyl)-5- methyl-l-phenyl-2-propyl-l H-imidazole-4-carboxamide;
N-(3-(4-(2,3-dichlorophenyl)piperazin-l-yl)-2,2-difluoropropyl)-2,5- dimethyl-1 -phenyl- lH-imidazole-4-carboxamide;
N-(3-(4-(2,3-dichlorophenyl)piperazin-l-yl)-2,2-difluoropropyl)-5- methyl- 1 -pheny 1-2-propyl- lH-imidazole-4-carboxamide;
N-(3-(4-(2,3-dimethylphenyl)piperazin-l-yl)propyl)-l-(2-fluorophenyl)- 2,5-dimethyl-lH-imidazole-4-carboxamide;
N-(3-(4-(2,3-dimethylphenyl)piperazin-l-yl)-2-hydroxypropyl)-l-(2- fluorophenyl)-2,5-dimethyl-lH-imidazole-4-carboxamide;
N-(2-(4-(3-chloro-2-fluorophenyl)piperazin-l-yl)ethyl)-2,5-dimethyl-l- phenyl-lH-imidazole-4-carboxamide;
N-(3-(4-(3-chloro-2-fluorophenyl)piperazin-l-yl)propyl)-2,5-dimethyl-l- phenyl-lH-imidazole-4-carboxamide;
N-(2-(4-(3-chloro-2-methylphenyl)piperazin-l-yl)ethyl)-2,5-dimethyl-l- phenyl-lH-imidazole-4-carboxamide;
N-(3-(4-(3-chloro-2-methylphenyl)piperazin-l-yl)propyl)-2,5-dimethyl-l- phenyl-lH-imidazole-4-carboxamide;
2,5-dimethyl-N-(2-(4-(2-methylquinolin-8-yl)piperazin- 1 -yl)ethyl)- 1 - phenyl-lH-imidazole-4-carboxamide;
2,5-dimethyl- 1 -pheny l-N-(2-(4-(quinolin-8-yl)piperazin- 1 -yl)ethyl)- 1 H- imidazole-4-carboxamide;
N-(3-(4-(3-chloro-2-methylphenyl)piperazin-l-yl)-2-hydroxypropyl)-2,5- dimethyl- 1 -phenyl- lH-imidazole-4-carboxamide;
l-cyclopentyl-N-(3-(4-(2,3-dimethylphenyl)piperazin-l-yl)propyl)-2,5- dimethy 1- 1 H-imidazole-4-carboxamide;
l-cyclopentyl-N-(3-(4-(2,3-dimethylphenyl)piperazin-l-yl)-2- hydroxypropyl)-2,5-dimethyl-lH-imidazole-4-carboxamide;
N-(3-(4-(3-chloro-2-methylphenyl)piperazin-l-yl)propyl)-l-cyclopentyl- 2,5-dimethyl-lH-imidazole-4-carboxamide;
N-(3-(4-(3-chloro-2-methylphenyl)piperazin-l-yl)-2-hydroxypropyl)-l- cyclopentyl-2,5-dimethyl-lH-imidazole-4-carboxamide;
l-cyclopentyl-N-(4-(4-(2,3-dimethylphenyl)piperazin-l-yl)butyl)-2,5- dimethyl- 1 H-imidazole-4-carboxamide;
l-cyclopentyl-N-(2-(4-(2,3-dichlorophenyl)piperazin-l-yl)ethyl)-2,5- dimethyl- 1 H-imidazole-4-carboxamide;
N-(3-(4-(2,3-dimethylphenyl)piperazin-l-yl)-2-hydroxypropyl)-l-(4- fluorophenyl)-5-methyl-2-pheny 1-1 H-imidazole-4-carboxamide;
N-(3-(4-(2,3-dimethylphenyl)piperazin- 1 -yl)propyl)- 1 -(4-fluoropheny I)- 5-methyl-2-phenyl-lH-imidazole-4-carboxamide;
N-(3-(4-(3-chloro-2-methylphenyl)piperazin-l-yl)-2-hydroxypropyl)-l- (4-fluorophenyl)-5-methyl-2-phenyl-lH-imidazole-4-carboxamide;
N-(3-(4-(3-chloro-2-methylphenyl)piperazin- 1 -yl)propyl)- 1 -(4- fluorophenyl)-5-methyl-2-phenyl-lH-imidazole-4-carboxamide;
N-(3-(4-(2,3-dimethylphenyl)piperazin-l-yl)propyl)-5-methyl-l,2- dipheny 1- 1 H-imidazole-4-carboxamide;
N-(3-(4-(3-chloro-2-methylphenyl)piperazin-l-yl)propyl)-5-methyl-l,2- dipheny 1- 1 H-imidazole-4-carboxamide;
l-(4-bromophenyl)-N-(3-(4-(3-chlorophenyl)piperazin-l-yl)propyl)-2- (2,4-dichlorophenyl)-5-ethyl-lH-imidazole-4-carboxamide;
l-(4-bromophenyl)-2-(2,4-dichlorophenyl)-N-(3-(4-(2,3- dichlorophenyl)piperazin-l-yl)propyl)-5-ethyl-l H-imidazole-4-carboxamide;
l-(4-bromophenyl)-2-(2,4-dichlorophenyl)-N-(3-(4-(2,3- dimethylphenyl)piperazin-l-yl)propyl)-5-ethy 1-1 H-imidazole-4-carboxamide;
5-(( IH- 1 ,2,4-triazol- 1 -yl)methyl)-N-(3-(4-(3-chloro-2- methylphenyl)piperazin-l-yl)propyl)-l,2-dipheny 1-1 H-imidazole-4-carboxamide;
N-(3-(4-(2,3-dimethylphenyl)piperazin-l-yl)propyl)-l-isobutyl-2,5- dimethy 1-1 H-imidazole-4-carboxamide;
N-(3-(4-(3-chloro-2-methylphenyl)piperazin-l-yl)propyl)- l-isobutyl-2,5- dimethyl-1 H-imidazole-4-carboxamide
N-(3-(4-(2,3-dimethylphenyl)piperazin-l-yl)-2-hydroxypropyl)-l- isobutyl-2,5-dimethyl-lH-imidazole-4-carboxamide
N-(3-(4-(2,3-dimethylphenyl)piperazin-l-yl)propyl)-2,5-dimethyl-l- propyl-lH-imidazole-4-carboxamide;
N-(3-(4-(2,3-dimethylphenyl)piperazin-l-yl)-2-hydroxypropyl)-2,5- dimethyl-1 -propyl- 1 H-imidazole-4-carboxamide;
N-(3-(4-(3-chloro-2-methylphenyl)piperazin-l-yl)propyl)-2,5-dimethyl-l- propyl-1 H-imidazole-4-carboxamide;
N-(3-(4-(3-chloro-2-methylphenyl)piperazin-l-yl)-2-hydroxypropyl)-2,5- dimethyl- 1 -propyl- lH-imidazole-4-carboxamide;
N-(3-(4-(2,3-dimethylphenyl)piperazin- 1 -yl)propyl)- 1 -(2- methoxyphenyl)-2,5-dimethyl-lH-imidazole-4-carboxamide;
N-(3-(4-(2,3-dimethylphenyl)piperazin-l-yl)-2-hydroxypropyl)-l-(2- methoxyphenyl)-2,5-dimethyl-lH-imidazole-4-carboxamide;
l-(2-chlorophenyl)-N-(3-(4-(2,3-dimethylphenyl)piperazin-l-yl)propyl)- 2,5-dimethyl-lH-imidazole-4-carboxamide;
l-(2-chlorophenyl)-N-(3-(4-(2,3-dimethylphenyl)piperazin-l-yl)-2- hydroxypropyl)-2,5-dimethyl-lH-imidazole-4-carboxamide;
l-(2-chlorophenyl)-N-(4-(4-(2,3-dimethylphenyl)piperazin- l-yl)butyl)- 2,5-dimethyl-lH-imidazole-4-carboxamide;
N-(3-(4-(2,3-dimethylphenyl)piperazin-l-yl)propyl)-2-isopropyl-5- methyl-l-phenyl-lH-imidazole-4-carboxamide;
l-(3,5-dimethoxyphenyl)-N-(3-(4-(2,3-dimethylphenyl)piperazin-l- yl)propyl)-2,5-dimethyl-lH-imidazole-4-carboxamide;
N-(3-(4-(2,3-dimethylphenyl)piperazin-l-yl)-2-hydroxypropyl)-2- isopropyl-5-methyl-l-phenyl-lH-imidazole-4-carboxamide;
l-(3,5-dimethoxyphenyl)-N-(3-(4-(2,3-dimethylphenyl)piperazin-l-yl)-2- hydroxypropyl)-2,5-dimethyl-lH-imidazole-4-carboxamide;
N-(3-(4-(2,3-dimethylphenyl)piperazin-l-yl)-2-hydroxypropyl)-2,5- dimethyl- 1 -(4-(trifluoromethyl)phenyl)- lH-imidazole-4-carboxamide;
N-(3-(4-(2,3-dimethylphenyl)piperazin-l-yl)-2-hydroxypropyl)-2-ethyl-5- methy 1- 1 -phenyl- 1 H-imidazole-4-carboxamide;
N-(3-(4-(2,3-dimethylphenyl)piperazin-l-yl)-2-hydroxypropyl)-5-methyl- l-phenyl-2-propyl-lH-imidazole-4-carboxamide;
l-(4-chlorophenyl)-N-(3-(4-(2,3-dimethylphenyl)piperazin-l-yl)-2- hydroxypropyl)-2-propy 1-1 H-imidazole-4-carboxamide;
l-(3,5-dimethoxyphenyl)-N-(2-(4-(2,3-dimethylphenyl)piperazin-l- yl)ethyl)-2,5-dimethyl-lH-imidazole-4-carboxamide;
N-(2-(4-(2,3-dimethylphenyl)piperazin-l-yl)ethyl)-2-isopropyl-5-methyl- 1 -phenyl- 1 H-imidazole-4-carboxamide;
N-(2-(4-(2,3-dimethylphenyl)piperazin-l-yl)ethyl)-l-(4-fluorophenyl)- 2,5-dimethyl-lH-imidazole-4-carboxamide;
1 -(benzoic [ 1 ,3]dioxol-5-yl)-N-(2-(4-(2,3-dimethylphenyl)piperazin- 1 - yl)ethyl)-2,5-dimethyl-lH-imidazole-4-carboxamide;
1 -(2,3-dihydrobenzo[b] [ 1 ,4]dioxin-6-y l)-N-(2-(4-(2,3 - dimethylphenyl)piperazin-l-yl)ethyl)-2,5-dimethyl-lH-imidazole-4-carboxamide;
N-(3-(4-(2,3-dimethylphenyl)piperazin-l-yl)propyl)-l-phenyl-2-propyl- 1 H-imidazole-4-carboxamide;
N-(3-(4-(2,3-dichlorophenyl)piperazin-l-yl)propyl)-l-phenyl-2-propyl- 1 H-imidazole-4-carboxamide;
N-(2-(4-(2,3 -dichloropheny l)piperazin- 1 -y l)ethy I)- 1 -pheny 1-2-propy 1- 1 H- imidazole-4-carboxamide;
N-(2-(4-(2,3-dimethylphenyl)piperazin-l-yl)ethyl)-l-phenyl-2-propyl- lH-imidazole-4-carboxamide;
N-(3-(4-(2,3-dimethylphenyl)piperazin-l-yl)-2-hydroxypropyl)-l-phenyl- 2-propy 1- 1 H-imidazole-4-carboxamide;
N-(3-(4-(2,3-dimethylphenyl)piperazin- 1 -yl)propyl)- 1 -(4- methoxyphenyl)-5-methyl-2-propy 1-1 H-imidazole-4-carboxamide;
N-(2-(4-(2,3-dimethylphenyl)piperazin-l-yl)ethyl)-l-(4-methoxyphenyl)- 5-methyl-2-propyl-lH-imidazole-4-carboxamide;
N-(3-(4-(2,3-dimethylphenyl)piperazin- 1 -yl)propyl)-2,5-dimethyl- 1 - (quinolin-6-y I)-I H-imidazole-4-carboxamide;
N-(3-(4-(2,3-dichlorophenyl)piperazin-l-yl)-2-hydroxypropyl)-2,5- dimethyl-1 -(quinolin-6-y I)-I H-imidazole-4-carboxamide;
N-(3-(4-(2,3-dichlorophenyl)piperazin-l-yl)-2-hydroxypropyl)-l-phenyl- 2-propy 1-1 H-imidazole-4-carboxamide;
N-(3-(4-(2,3-dichlorophenyl)piperazin-l-yl)-2-hydroxypropyl)-l-(4- fluoropheny l)-2-propyl- 1 H-imidazole-4-carboxamide;
N-(3-(4-(2,3-dimethylphenyl)piperazin-l-yl)-2-hydroxypropyl)-l-(4- fluorophenyl)-2-propyl-lH-imidazole-4-carboxamide;
N-(3-(4-(2,3-dimethylphenyl)piperazin-l-yl)propyl)-l-(4-fluorophenyl)- 2-propy 1-1 H-imidazole-4-carboxamide;
N-(3-(4-(2,3-dichlorophenyl)piperazin-l-yl)-2-hydroxypropyl)-l,2- dipheny 1-1 H-imidazole-4-carboxamide;
N-(3-(4-(2,3-dimethylphenyl)piperazin- 1 -yl)propyl)- 1 ,2-diphenyl- IH- imidazole-4-carboxamide;
N-(3-(4-(2,3-dimethylphenyl)piperazin-l-yl)propyl)-2,5-dimethyl-l- (pyridin-2-yl)-lH-imidazole-4-carboxamide trihydrochloride;
N-(3-(4-(2,3-dichlorophenyl)piperazin-l-yl)-2-hydroxypropyl)-l-(4- methoxyphenyl)-2-phenyl-l H-imidazole-4-carboxamide;
N-(3-(4-(2,3-dimethylphenyl)piperazin-l-yl)propyl)-l-(4- methoxyphenyl)-2-phenyl- 1 H-imidazole-4-carboxamide ;
N-(3-(4-(3-chloro-2-methylphenyl)piperazin- 1 -yl)propyl)- 1 -(4- methoxyphenyl)-5-methyl-2-propyl-lH-imidazole-4-carboxamide;
N-(3-(4-(2,3-dichlorophenyl)piperazin-l-yl)-2-hydroxypropyl)-l-(4- methoxyphenyl)-5-methyl-2-propyl-lH-imidazole-4-carboxamide;
N-(3-(4-(2,3-dimethylphenyl)piperazin-l-yl)-2-hydroxypropyl)-l-(4- methoxyphenyl)-5-methyl-2-propyl-lH-imidazole-4-carboxamide;
N-(3-(4-(3-chloro-2-methylphenyl)piperazin- 1 -yl)propyl)- 1-(4- methoxyphenyl)-2,5-dimethyl-lH-imidazole-4-carboxamide;
(S)-N-(3-(4-(2,3-dimethylphenyl)piperazin-l-yl)-2-hydroxypropyl)-2,5- dimethyl- 1 -phenyl- lH-imidazole-4-carboxamide;
N-((6)-3-(4-(2,3-dimethylphenyl)piperazin- 1 -yl)-2-hydroxypropyl)- 1 -(2- fluorophenyl)-2,5-dimethyl-lH-imidazole-4-carboxamide;
(S)-l-(4-chlorophenyl)-N-(3-(4-(2,3-dichlorophenyl)piperazin-l-yl)-2- hydroxypropyl)-2-propyl-lH-imidazole-4-carboxamide;
(iS)-N-(3-(4-(3-chloro-2-methylphenyl)piperazin-l-yl)-2-hydroxypropyl)- l-(4-fluorophenyl)-5-methyl-2-phenyl-lH-imidazole-4-carboxamide;
N-(3-(4-(2,3-dichlorophenyl)piperazin-l-yl)propyl)-l-(4- methoxyphenyl)-5-methyl-2-propyl-lH-imidazole-4-carboxamide;
N-(3-(4-(3-chloro-2-methylphenyl)piperazin- 1 -yl)propyl)- 1 -(2- methoxyphenyl)-2,5-dimethyl-lH-imidazole-4-carboxamide;
N-(3-(4-(2,3-dichlorophenyl)piperazin-l-yl)propyl)-l-(2- methoxyphenyl)-2,5-dimethyl-lH-imidazole-4-carboxamide;
N-(3 -(4-(2, 3 -dichloropheny l)piperazin- 1 -y l)-2-hy droxypropy I)- 1 -(2- methoxyphenyl)-2,5-dimethyl-lH-imidazole-4-carboxamide;
N-(3-(4-(2,3-dimethylphenyl)piperazin-l-yl)propyl)-2,5-dimethyl-l-/7- tolyl-lH-imidazole-4-carboxamide;
N-(3-(4-(2,3-dimethylphenyl)piperazin-l-yl)-2-hydroxypropyl)-2,5- dimethyl- 1 -p-tolyl- lH-imidazole-4-carboxamide;
N-(3-(4-(2,3-dichlorophenyl)piperazin-l-yl)-2-hydroxypropyl)-l-(2,3- dihydrobenzo[b][l,4]dioxin-6-yl)-2,5-dimethyl-lH-imidazole-4-carboxamide;
N-(3-(4-(2,3-dichlorophenyl)piperazin-l-yl)propyl)-l-(2,3- dihydrobenzo[b][l,4]dioxin-6-yl)-2,5-dimethyl-lH-imidazole-4-carboxamide;
(R)-N-(3-(4-(2,3-dimethylphenyl)piperazin-l-yl)-2-hydroxypropyl)-2,5- dimethyl- 1 -phenyl- lH-imidazole-4-carboxamide;
N-((R)-3 -(4-(2,3 -dimethylpheny Opiperazin- 1 -yl)-2-hy droxypropy I)- 1 -(2- fluorophenyl)-2,5-dimethyl-lH-imidazole-4-carboxamide;
N-(3-(4-(3-chloro-2-methylphenyl)piperazin-l-yl)propyl)-l-(2- fluorophenyl)-2,5-dimethyl-lH-imidazole-4-carboxamide;
N-(3-(4-(2,3-dichlorophenyl)piperazin-l-yl)propyl)-l-(2-fluorophenyl)- 2,5-dimethyl-lH-imidazole-4-carboxamide;
N-(3-(4-(2,3-dimethylphenyl)piperazin-l-yl)-2-hydroxypropyl)-5-methyl- l,2-diphenyl-lH-imidazole-4-carboxamide;
N-(3-(4-(2,3-dichlorophenyl)piperazin-l-yl)-2-hydroxypropyl)-5-methyl- 1 ,2-diphenyl- lH-imidazole-4-carboxamide;
N-(3-(4-(2,3-dichlorophenyl)piperazin-l-yl)-2-hydroxypropyl)-l-(4- fluorophenyl)-5-methyl-2-phenyl-lH-imidazole-4-carboxamide;
N-(3-(4-(2,3-dichlorophenyl)piperazin-l-yl)propyl)-5-methyl-l,2- diphenyl- 1 H-imidazole-4-carboxamide;
N-(3-(4-(2,3-dichlorophenyl)piperazin-l-yl)propyl)-l-(4-fluorophenyl)-5- methyl-2-pheny 1-1 H-imidazole-4-carboxamide;
N-(3-(4-(3-chloro-2-methylphenyl)piperazin-l-yl)-2-hydroxypropyl)-5- methy 1- 1 ,2-diphenyl- 1 H-imidazole-4-carboxamide;
N-(3-(4-(3-chloro-2-methylphenyl)piperazin-l-yl)-2-hydroxypropyl)-l- (4-fluorophenyl)-5-methyl-2-propyl-lH-imidazole-4-carboxamide;
N-(3-(4-(3-chloro-2-methylphenyl)piperazin-l-yl)-2-hydroxypropyl)- l- (4-fluorophenyl)-2,5-dimethyl-lH-imidazole-4-carboxamide;
l-cyclopentyl-N-(3-(4-(2,3-dichlorophenyl)piperazin-l-yl)propyl)-2,5- dimethyl-1 H-imidazole-4-carboxamide;
l-cyclopentyl-N-(3-(4-(2,3-dichlorophenyl)piperazin-l-yl)-2- hydroxypropyl)-2,5-dimethyl-lH-imidazole-4-carboxamide;
N-(3-(4-(2,3-dichlorophenyl)piperazin- 1 -yl)propyl)-2,5-dimethyl- 1 - propyl-lH-imidazole-4-carboxamide;
N-(3-(4-(2,3-dichlorophenyl)piperazin-l-yl)-2-hydroxypropyl)-2,5- dimethyl- 1 -propyl- 1 H-imidazole-4-carboxamide;
N-(3-(4-(2,3-dimethylphenyl)piperazin-l-yl)propyl)-l-(2- methoxyphenyl)-5-methyl-2-propyl-l H-imidazole-4-carboxamide;
N-(3-(4-(3-chloro-2-methylphenyl)piperazin-l-yl)propyl)-l-(2- methoxyphenyl)-5-methyl-2-propyl-lH-imidazole-4-carboxamide;
N-(3 -(4-(2,3 -dichloropheny l)piperazin- 1 -y l)propy I)- 1 -(2- methoxyphenyl)-5-methyl-2-propy 1-1 H-imidazole-4-carboxamide;
N-(3-(4-(2,3-dimethylphenyl)piperazin-l-yl)-2-hydroxypropyl)-l-(2- methoxyphenyl)-5-methyl-2-propyl-lH-imidazole-4-carboxamide;
N-(3-(4-(3-chloro-2-methylphenyl)piperazin-l-yl)-2-hydroxypropyl)-l- (2-methoxyphenyl)-5-methyl-2-propyl-lH-imidazole-4-carboxamide;
N-(3-(4-(2,3-dichlorophenyl)piperazin-l-yl)-2-hydroxypropyl)-l-(2- methoxyphenyl)-5-methyl-2-propyl-lH-imidazole-4-carboxamide;
N-(3-(4-(2,3-dimethylphenyl)piperazin-l-yl)propyl)-2,5-dimethyl-l-(2- (trifluoromethyl)pheny I)-I H-imidazole-4-carboxamide;
N-(3-(4-(3-chloro-2-methylphenyl)piperazin-l-yl)propyl)-2,5-dimethyl-l- (2-(trifluoromethyl)phenyl)-lH-imidazole-4-carboxamide;
N-(3-(4-(2,3-dichlorophenyl)piperazin-l-yl)propyl)-2,5-dimethyl-l-(2- (trifluoromethyl)phenyl)-lH-imidazole-4-carboxamide;
N-(3-(4-(3-chloro-2-methylphenyl)piperazin-l-yl)-2-hydroxypropyl)-2,5- dimethyl- 1 -(2-(trifluoromethyl)phenyl)- lH-imidazole-4-carboxamide;
N-(3-(4-(2,3-dichlorophenyl)piperazin-l-yl)-2-hydroxypropyl)-2,5- dimethyl- 1 -(2-(trifluoromethy l)phenyl)- 1 H-imidazole-4-carboxamide;
N-(3-(4-(3-chloro-2-methylphenyl)piperazin-l-yl)-2-hydroxypropyl)-l- (4-methoxyphenyl)-5-methyl-2-propyl-lH-imidazole-4-carboxamide;
N-(3-(4-(3-chloro-2-methylphenyl)piperazin-l-yl)-2-hydroxypropyl)-l- (2-methoxyphenyl)-2,5-dimethyl-lH-imidazole-4-carboxamide;
N-(3-(4-(3-chloro-2-methylphenyl)piperazin-l-yl)-2-hydroxypropyl)-l- (4-chlorophenyl)-2-propyl-/H-imidazole-4-carboxamide;
N-(3-(4-(3-chloro-2-methylphenyl)piperazin- 1 -y l)propyl)- 1 -(4- chlorophenyl)-2-propyl-lH-imidazole-4-carboxamide;
N-(3-(4-(3-chloro-2-methylphenyl)piperazin- 1 -yl)-2-hydroxypropyl)- 1 - (2,3-dihydrobenzo[b][l,4]dioxin-6-yl)-2,5-dimethyl-lH-imidazole-4- carboxamide;
N-(3-(4-(3-chloro-2-methylphenyl)piperazin-l-yl)propyl)-l-(2,3- dihydrobenzo[b][l,4]dioxin-6-yl)-2,5-dimethyl-lH-imidazole-4-carboxamide;
l-(2,3-dihydrobenzo[b][l,4]dioxin-6-yl)-N-(3-(4-(2,3- dimethylphenyl)piperazin-l-yl)propyl)-5-methyl-2-propyl-lH-imidazole-4- carboxamide;
N-(3-(4-(2,3-dichlorophenyl)piperazin- 1 -y l)propyl)- 1 -(2,3- dihydrobenzo[b][l,4]dioxin-6-yl)-5-methyl-2-propyl-lH-imidazole-4- carboxamide;
N-(3-(4-(3-chloro-2-methylphenyl)piperazin- 1 -yl)propyl)-5-methyl- 1 - phenyl-2-propyl-l H-imidazole-4-carboxamide;
N-(3-(4-(3-chloro-2-methylphenyl)piperazin-l-yl)-2-hydroxypropyl)-5- methy 1- 1 -pheny 1-2-propy 1- 1 H-imidazole-4-carboxamide;
N-(3-(4-(3-chloro-2-methylphenyl)piperazin-l-yl)propyl)-l-(2,3- dihydrobenzo[b][l,4]dioxin-6-yl)-5-methyl-2-propyl-lH-imidazole-4- carboxamide;
N-(3-(4-(3-chloro-2-methylphenyl)piperazin-l-yl)-2-hydroxypropyl)-l- (2,3-dihydrobenzo[b][l,4]dioxin-6-yl)-5-methyl-2-propyl-lH-imidazole-4- carboxamide; l-(2,3-dihydrobenzo[b][ l,4]dioxin-6-yl)-N-(3-(4-(2,3- dimethylphenyl)piperazin-l-yl)-2-hydroxypropyl)-5-methyl-2-propyl-lH- imidazole-4-carboxamide;
N-(3-(4-(2,3-dichlorophenyl)piperazin-l-yl)-2-hydroxypropyl)-l-(2,3- dihydrobenzo[b][l,4]dioxin-6-yl)-5-methyl-2-propyl-lH-imidazole-4- carboxamide;
N-(3-(4-(2,3-dimethylphenyl)piperazin-l-yl)propyl)-l-(4-fluorophenyl)- 5-methyl-2-propyl-lH-imidazole-4-carboxamide;
N-(3-(4-(2,3-dichlorophenyl)piperazin- 1 -yl)propyl)- 1 -(4-fluoropheny l)-5- methy 1-2-propy 1- 1 H-imidazole-4-carboxamide;
N-(3-(4-(2,3-dimethylphenyl)piperazin-l-yl)-2-hydroxypropyl)-l-(4- fluorophenyl)-5-methy 1-2-propy 1-1 H-imidazole-4-carboxamide;
N-(3-(4-(2,3-dichlorophenyl)piperazin- 1 -yl)-2-hydroxypropyl)- 1 -(4- fluorophenyl)-5-methyl-2-propyl-lH-imidazole-4-carboxamide;
N-(3-(4-(3-chloro-2-methylphenyl)piperazin-l-yl)propyl)-l-(4- fluorophenyl)-2,5-dimethyl-lH-imidazole-4-carboxamide;
N-(3-(4-(3-chloro-2-methylphenyl)piperazin- 1 -y l)propyl)- 1 -(4- fluorophenyl)-5-methyl-2-propy 1-1 H-imidazole-4-carboxamide;
N-(3-(4-(2,3-dichlorophenyl)piperazin- 1 -yl)-2-hydroxypropy I)- 1 -(2- fluorophenyl)-2,5-dimethyl-l H-imidazole-4-carboxamide;
l-(2-chlorophenyl)-Ν-(3-(4-(2,3-dimethylphenyl)piperazin-l-yl)-2- hydroxypropyl)-5-methyl-2-propyl-l H-imidazole-4-carboxamide;
l-(2-chlorophenyl)-N-(3-(4-(2,3-dimethylphenyl)piperazin-l-yl)propyl)- 5-methy 1-2-propy 1-1 H-imidazole-4-carboxamide;
(7?)-N-(3-(4-(3-chloro-2-methylphenyl)piperazin-l-yl)-2-hydroxypropyl)- 1 -(4-fluoropheny l)-5-methyl-2-phenyl-l H-imidazole-4-carboxamide;
(R)-l-(4-chlorophenyl)-N-(3-(4-(2,3-dichlorophenyl)piperazin-l-yl)-2- hydroxypropyl)-2-propyl-lH-imidazole-4-carboxamide;
N-(3-(4-(3-chloro-2-methylphenyl)piperazin-l-yl)propyl)-l-(2- chlorophenyl)-2,5-dimethyl-lH-imidazole-4-carboxamide;
N-(3-(4-(3-chloro-2-methylphenyl)piperazin-l-yl)-2-hydroxypropyl)-l- (2-fluorophenyl)-2,5-dimethyl-lH-imidazole-4-carboxamide;
N-(3-(4-(3-chloro-2-methylphenyl)piperazin-l-yl)-2-hydroxypropyl)-l- (4-methoxyphenyl)-2,5-dimethyl-l H-imidazole-4-carboxamide;
N-(3 -(4-(2,3 -dimethylpheny l)piperazin- 1 -yl)propy I)- 1 -(4- methoxyphenyl)-5-methyl-2-phenyl-l H-imidazole-4-carboxamide; N-(3-(4-(3-chloro-2-methylphenyl)piperazin-l-yl)propyl)-l-(4- methoxyphenyl)-5-methyl-2-phenyl-lH-imidazole-4-carboxamide;
N-(3-(4-(2,3-dichlorophenyl)piperazin- 1 -yl)propyl)- 1 -(4- methoxyphenyl)-5-methyl-2-phenyl-lH-imidazole-4-carboxamide;
N-(3-(4-(2,3-dimethylphenyl)piperazin-l-yl)-2-hydroxypropyl)-l-(4- methoxyphenyl)-5-methyl-2-phenyl-l//-imidazole-4-carboxamide;
N-(3-(4-(3-chloro-2-methylphenyl)piperazin-l-yl)-2-hydroxypropyl)-l- (4-methoxyphenyl)-5-methyl-2-phenyl-lH-imidazole-4-carboxamide;
N-(3-(4-(2,3-dichlorophenyl)piperazin-l-yl)-2-hydroxypropyl)-l-(4- methoxyphenyl)-5-methyl-2-phenyl-lH-imidazole-4-carboxamide;
l-(2,3-dihydrobenzo[b][l,4]dioxin-6-yl)-N-(3-(4-(2,3- dimethylphenyl)piperazin-l-yl)propyl)-5-methyl-2-phenyl-lH-imidazole-4- carboxamide;
N-(3-(4-(3-chloro-2-methylpheny l)piperazin- 1 -yl)propyl)- 1 -(2,3- dihydrobenzo[b][l,4]dioxin-6-yl)-5-methyl-2-phenyl-lH-imidazole-4- carboxamide;
N-(3-(4-(2,3-dichlorophenyl)piperazin-l-yl)propyl)-l-(2,3- dihydrobenzo[b][ 1 ,4]dioxin-6-yl)-5-methyl-2-phenyl- lH-imidazole-4- carboxamide;
l-(2,3-dihydrobenzo[b][l,4]dioxin-6-yl)-N-(3-(4-(2,3- dimethylphenyl)piperazin-l-yl)-2-hydroxypropyl)-5-methyl-2-phenyl-lH- imidazole-4-carboxamide;
N-(3-(4-(3-chloro-2-methylphenyl)piperazin- 1 -yl)-2-hydroxypropy I)- 1 - (2,3-dihydrobenzo[b][l,4]dioxin-6-yl)-5-methyl-2-phenyl-lH-imidazole-4- carboxamide;
N-(3-(4-(2,3-dichlorophenyl)piperazin-l-yl)-2-hydroxypropyl)-l-(2,3- dihydrobenzo[b][l,4]dioxin-6-yl)-5-methyl-2-phenyl-lH-imidazole-4- carboxamide;
l-(benzo[J][l,3]dioxol-5-yl)-N-(3-(4-(3-chloro-2- methylphenyl)piperazin-l-yl)propyl)-2,5-dimethyl-lH-imidazole-4-carboxamide;
l-(benzo[^][l,3]dioxol-5-yl)-N-(3-(4-(3-chloro-2- methylphenyl)piperazin-l-yl)propyl)-5-methyl-2-propyl-lH-imidazole-4- carboxamide;
N-(3-(4-(2,3-dimethylphenyl)piperazin-l-yl)propyl)-2,5-dimethyl-l-o- tolyl-lH-imidazole-4-carboxamide;
N-(3-(4-(3-chloro-2-methylphenyl)piperazin-l-yl)propyl)-2,5-dimethyl-l- o-tolyl-lH-imidazole-4-carboxamide;
N-(3-(4-(2,3-dichlorophenyl)piperazin-l-yl)propyl)-2,5-dimethyl-l-o- tolyl-lH-imidazole-4-carboxamide;
N-(3-(4-(2,3-dimethylphenyl)piperazin-l-yl)-2-hydroxypropyl)-2,5- dimethyl- 1 -o-tolyl- lH-imidazole-4-carboxamide;
N-(3-(4-(3-chloro-2-methylphenyl)piperazin-l-yl)-2-hydroxypropyl)-2,5- dimethy 1- 1 -o-tolyl- lH-imidazole-4-carboxamide;
N-(3-(4-(2,3-dichlorophenyl)piperazin-l-yl)-2-hydroxypropyl)-2,5- dimethyl- 1 -o-tolyl- lH-imidazole-4-carboxamide;
N-(3-(4-(3-chloro-2-methylphenyl)piperazin- 1 -yl)propyl)- 1 -(4- chlorophenyl)-2,5-dimethyl-lH-imidazole-4-carboxamide;
l-(4-chlorophenyl)-N-(3-(4-(2,3-dimethylphenyl)piperazin-l-yl)-2- hydroxypropyl)-2,5-dimethyl-lH-imidazole-4-carboxamide;
N-(3-(4-(3-chloro-2-methylphenyl)piperazin- 1 -yl)-2-hydroxypropyl)- 1 - (4-chlorophenyl)-2,5-dimethyl-lH-imidazole-4-carboxamide;
l-(4-chlorophenyl)-N-(3-(4-(2,3-dichlorophenyl)piperazin-l-yl)-2- hydroxypropyl)-2,5-dimethyl-lH-imidazole-4-carboxamide;
l-(4-chlorophenyl)-N-(3-(4-(2,3-dimethylphenyl)piperazin-l-yl)propyl)- 5-methyl-2-propyl- lH-imidazole-4-carboxamide;
N-(3-(4-(3-chloro-2-methylphenyl)piperazin-l-yl)propyl)-l-(4- chlorophenyl)-5-methyl-2-propyl-lH-imidazole-4-carboxamide;
l-(4-chlorophenyl)-N-(3-(4-(2,3-dichlorophenyl)piperazin-l-yl)propyl)-5- methyl-2-propyl-lH-imidazole-4-carboxamide;
l-(4-chlorophenyl)-N-(3-(4-(2,3-dimethylphenyl)piperazin-l-yl)-2- hydroxypropyl)-5-methyl-2-propyl-lH-imidazole-4-carboxamide;
N-(3-(4-(3-chloro-2-methylphenyl)piperazin- 1 -yl)-2-hydroxypropyl)- 1 - (4-chlorophenyl)-5-methyl-2-propyl-lH-imidazole-4-carboxamide;
l-(4-chlorophenyl)-N-(3-(4-(2,3-dichlorophenyl)piperazin-l-yl)-2- hydroxypropyl)-5-methyl-2-propyl-lH-imidazole-4-carboxamide;
l-(2-chlorophenyl)-N-(3-(4-(2,3-dichlorophenyl)piperazin-l-yl)-2- hydroxypropyl)-5-methyl-2-propyl-lH-imidazole-4-carboxamide;
l-(2-chlorophenyl)-N-(3-(4-(2,3-dichlorophenyl)piperazin- l-yl)propyl)- 2,5-dimethyl-lH-imidazole-4-carboxamide;
l-(2-chlorophenyl)-N-(3-(4-(2,3-dichlorophenyl)piperazin-l-yl)-2- hydroxypropyl)-2,5-dimethyl-lH-imidazole-4-carboxamide;
N-(3-(4-(3-chloro-2-methy lphenyl)piperazin- 1 -yl)propyl)- 1 -(2- fluorophenyl)-5-methyl-2-propyl-lH-imidazole-4-carboxamide;
N-(3-(4-(2,3-dimethylphenyl)piperazin- 1 -yl)propyl)- 1 -(2- methoxyphenyl)-5-methyl-2-phenyl-lH-imidazole-4-carboxamide;
N-(3-(4-(3-chloro-2-methylphenyl)piperazin- 1 -yl)propyl)- 1 -(2- methoxyphenyl)-5-methyl-2-phenyl-lH-imidazole-4-carboxamide;
N-(3-(4-(2,3-dichlorophenyl)piperazin-l-yl)propyl)-l-(2- methoxyphenyl)-5-methyl-2-phenyl-lH-imidazole-4-carboxamide;
N-(3-(4-(2,3-dimethylphenyl)piperazin-l-yl)propyl)-l-(2-fluorophenyl)- 5-methyl-2-propyl-lH-imidazole-4-carboxamide;
N-(3-(4-(2,3-dimethylphenyl)piperazin-l-yl)-2-hydroxypropyl)-l-(2- fluorophenyl)-5-methyl-2-propyl-lH-imidazole-4-carboxamide;
N-(3-(4-(2,3-dichlorophenyl)piperazin-l-yl)-2-hydroxypropyl)-l-(2- fluorophenyl)-5-methyl-2-propyl-lH-imidazole-4-carboxamide;
N-(3-(4-(2,3-dimethylphenyl)piperazin-l-yl)propyl)-5-methyl-2-propyl-l- o-tolyl-lH-imidazole-4-carboxamide;
N-(3-(4-(3-chloro-2-methylphenyl)piperazin-l-yl)propyl)-5-methyl-2- propyl-l-o-tolyl-lH-imidazole-4-carboxamide;
N-(3-(4-(2,3-dichlorophenyl)piperazin-l-yl)propyl)-5-methyl-2-propyl-l- o-tolyl-lH-imidazole-4-carboxamide;
l-(4-chlorophenyl)-N-(3-(4-(2,3-dimethylphenyl)piperazin-l-yl)propyl)- 5-methyl-2-phenyl- lH-imidazole-4-carboxamide;
N-(3-(4-(3-chloro-2-methylphenyl)piperazin- 1 -yl)propyl)- 1 -(4- chlorophenyl)-5-methyl-2-phenyl-lH-imidazole-4-carboxamide;
l-(4-chlorophenyl)-N-(3-(4-(2,3-dichlorophenyl)piperazin-l-yl)propyl)-5- methyl-2-pheny 1- 1 H-imidazole-4-carboxamide;
l-(4-chlorophenyl)-N-(3-(4-(2,3-dimethylphenyl)piperazin-l-yl)-2- hydroxypropyl)-5-methyl-2-pheny 1-1 H-imidazole-4-carboxamide;
N-(3-(4-(3-chloro-2-methylphenyl)piperazin-l-yl)-2-hydroxypropyl)-l- (4-chlorophenyl)-5-methyl-2-phenyl-lH-imidazole-4-carboxamide;
1 -(4-chlorophenyl)-N-(3-(4-(2,3-dichlorophenyl)piperazin- 1 -yl)-2- hydroxypropyl)-5-methyl-2-phenyl-lH-imidazole-4-carboxamide; .
l-(benzo[ύf][l,3]dioxol-5-yl)-N-(3-(4-(2,3-dichlorophenyl)piperazin-l- yl)propyl)-2,5-dimethyl-lH-imidazole-4-carboxamide;
l-(benzo[oG[l,3]dioxol-5-yl)-N-(3-(4-(2,3-dichlorophenyl)piperazin-l- yl)-2-hydroxypropyl)-2,5-dimethyl-lH-imidazole-4-carboxamide;
l-(benzo[-i][l,3]dioxol-5-yl)-N-(3-(4-(2,3-dimethylphenyl)piperazin-l- yl)propyl)-5-methyl-2-propyl-lH-imidazole-4-carboxamide;
l-(benzo[cQ[l,3]dioxol-5-yl)-N-(3-(4-(2,3-dichlorophenyl)piperazin-l- yl)propyl)-5-methyl-2-propyl-lH-imidazole-4-carboxamide;
1 -(benzo[d] [ 1 ,3]dioxol-5-yl)-N-(3-(4-(2,3-dimethylphenyl)piperazin- 1 - yl)-2-hydroxypropyl)-5-methyl-2-propyl-lH-imidazole-4-carboxamide;
1 -(benzol [l,3]dioxol-5-y l)-N-(3-(4-(2,3-dichlorophenyl)piperazin-l- yl)-2-hydroxypropyl)-5-methyl-2-propyl-lH-imidazole-4-carboxamide;
N-(3-(4-(3-chloro-2-methylphenyl)piperazin-l-yl)propyl)-2,5-dimethyl-l- /?-tolyl-lH-imidazole-4-carboxamide;
N-(3-(4-(2,3-dimethylphenyl)piperazin- 1 -yl)propyl)-5-methyl-2-propy 1- 1■ /?-tolyl-lH-imidazole-4-carboxamide;
N-(3-(4-(3-chloro-2-methylphenyl)piperazin-l-yl)propyl)-5-methyl-2- propyl- 1 -p-tolyl- lH-imidazole-4-carboxamide;
N-(3-(4-(2,3-dimethylphenyl)piperazin-l-yl)-2-hydroxypropyl)-l-(2- methoxyphenyl)-5-methyl-2-phenyl-lH-imidazole-4-carboxamide;
N-(3-(4-(3-chloro-2-methylphenyl)piperazin-l-yl)-2-hydroxypropyl)-l- (2-methoxyphenyl)-5-methyl-2-phenyl-lH-imidazole-4-carboxamide;
N-(3-(4-(2,3-dichlorophenyl)piperazin-l-yl)-2-hydroxypropyl)-l-(2- methoxyphenyl)-5-methyl-2-phenyl-lH-imidazole-4-carboxamide;
l-(benzo[</][l,3]dioxol-5-yl)-N-(3-(4-(2,3-dimethylphenyl)piperazin- l- yl)propyl)-5-methyl-2-phenyl-lH-imidazole-4-carboxamide;
l-(benzo[αQ[l,3]dioxol-5-yl)-N-(3-(4-(3-chloro-2- methylphenyl)piperazin- 1 -yl)propyl)-5-methyl-2-phenyl- lH-imidazole-4- carboxamide;
l-(benzo[fiG[l,3]dioxol-5-yl)-N-(3-(4-(2,3-dichlorophenyl)piperazin-l- yl)propyl)-5-methyl-2-phenyl-lH-imidazole-4-carboxamide;
l-(benzo[</][l,3]dioxol-5-yl)-N-(3-(4-(2,3-dimethylphenyl)piperazin-l- yl)-2-hydroxypropyl)-5-methyl-2-phenyl-lH-imidazole-4-carboxamide;
l-(benzo[^][l,3]dioxol-5-yl)-N-(3-(4-(3-chloro-2- methylphenyl)piperazin- 1 -yl)-2-hydroxypropyl)-5-methyl-2-phenyl- IH- imidazole-4-carboxamide;
l-(benzo[<|[l,3]dioxol-5-yl)-N-(3-(4-(2,3-dichlorophenyl)piperazin-l- yl)-2-hydroxypropyl)-5-methyl-2-phenyl-lH-imidazole-4-carboxamide;
N-(3-(4-(2,3-dimethylpheny l)piperazin- 1 -yl)propyl)- 1 -(2-fluoropheny I)- 5-methyl-2-phenyl-lH-imidazole-4-carboxamide;
N-(3-(4-(3-chloro-2-methylphenyl)piperazin- 1 -yl)propyl)- 1 -(2- fluorophenyl)-5-methyl-2-phenyl-lH-imidazole-4-carboxamide;
N-(3-(4-(2,3-dichlorophenyl)piperazin-l-yl)propyl)-l-(2-fluorophenyl)-5- methy 1-2-pheny 1- 1 H-imidazole-4-carboxamide ;
N-(3-(4-(2,3-dimethy lphenyl)piperazin- 1 -yl)-2-hydroxypropyl)- 1 -(2- fluorophenyl)-5-methy 1-2-pheny 1-1 H-imidazole-4-carboxamide;
N-(3-(4-(3-chloro-2-methylphenyl)piperazin-l-yl)-2-hydroxypropyl)-l- (2-fluorophenyl)-5-methyl-2-phenyl-lH-imidazole-4-carboxamide;
N-(3-(4-(2,3-dichlorophenyl)piperazin-l-yl)-2-hydroxypropyl)-l-(2- fluorophenyl)-5-methyl-2-phenyl-lH-imidazole-4-carboxamide;
N-(3-(4-(2,3-dichlorophenyl)piperazin- 1 -yl)propyl)-5-methyl-2-propyl- 1 - /j-tolyl-lH-imidazole-4-carboxamide;
l-(benzo[J][l,3]dioxol-5-yl)-N-(3-(4-(3-chloro-2- methy lphenyl)piperazin- 1 -y l)-2-hydroxypropy l)-2,5-dimethy 1- 1 H-imidazole-4- carboxamide;
l-(benzo[^[l,3]dioxol-5-yl)-N-(3-(4-(3-chloro-2- methylphenyl)piperazin- 1 -yl)-2-hydroxypropyl)-5-methyl-2-propyl- IH- imidazole-4-carboxamide;
N-(3-(4-(3-chloro-2-methylphenyl)piperazin-l-yl)-2-hydroxypropyl)-2,5- dimethyl- 1 -p-tolyl- 1 H-imidazole-4-carboxamide;
N-(3-(4-(2,3-dimethylphenyl)piperazin-l-yl)-2-hydroxypropyl)-5-methyl- 2-propyl- 1 -p-toly 1- lH-imidazole-4-carboxamide;
N-(3-(4-(3-chloro-2-methylphenyl)piperazin-l-yl)-2-hydroxypropyl)-5- methyl-2-propyl- l-p-to\y\- 1 H-imidazole-4-carboxamide;
N-(3-(4-(2,3-dichlorophenyl)piperazin-l-yl)-2-hydroxypropyl)-5-methyl- 2-propyl-l-/?-tolyl-lH-imidazole-4-carboxamide;
N-(3-(4-(2,3-dimethylphenyl)piperazin-l-yl)propyl)-5-methyl-2-phenyl- 1 -/7-toly 1- 1 H-imidazole-4-carboxamide;
N-(3-(4-(3-chloro-2-methylphenyl)piperazin-l-yl)-2-hydroxypropyl)-5- methyl-2-phenyl-l-/?-tolyl-l H-imidazole-4-carboxamide;
N-(3-(4-(2,3-dichlorophenyl)piperazin-l-yl)propyl)-5-methyl-2-phenyl-l- p-toly 1-1 H-imidazole-4-carboxamide;
N-(3-(4-(2,3-dimethylphenyl)piperazin-l-yl)-2-hydroxypropyl)-5-methyl- 2-phenyl-l-p-tolyl-lH-imidazole-4-carboxamide;
N-(3-(4-(2,3-dichlorophenyl)piperazin-l-yl)-2-hydroxypropyl)-5-methyl- 2-phenyl-l-p-tolyl-l H-imidazole-4-carboxamide;
N-(3-(4-(3-chloro-2-methylphenyl)piperazin-l-yl)-2-hydroxypropyl)-l- (2-chlorophenyl)-2,5-dimethyl-lH-imidazole-4-carboxamide;
l-(2-chlorophenyl)-N-(3-(4-(2,3-dimethylphenyl)piperazin-l-yl)propyl)- 5-methyl-2-phenyl-lH-imidazole-4-carboxamide;
N-(3-(4-(3-chloro-2-methylphenyl)piperazin- 1 -yl)propyl)- 1 -(2- chlorophenyl)-5-methyl-2-phenyl-lH-imidazole-4-carboxamide;
l-(2-chlorophenyl)-N-(3-(4-(2,3-dichlorophenyl)piperazin-l-yl)propyl)-5- methy 1-2-pheny 1- 1 H-imidazole-4-carboxamide;
l-(2-chlorophenyl)-N-(3-(4-(2,3-dimethylphenyl)piperazin-l-yl)-2- hydroxypropyl)-5-methyl-2-phenyl-lH-imidazole-4-carboxamide;
N-(3-(4-(3-chloro-2-methylphenyl)piperazin-l-yl)-2-hydroxypropyl)-l- (2-chlorophenyl)-5-methyl-2-phenyl-lH-imidazole-4-carboxamide;
l-(2-chlorophenyl)-N-(3-(4-(2,3-dichlorophenyl)piperazin-l-yl)-2- hydroxypropyl)-5-methyl-2-phenyl-l H-imidazole-4-carboxamide;
N-(3-(4-(2,3-dimethylphenyl)piperazin-l-yl)propyl)-5-methyl-2-phenyl- 1-o-tolyl-l H-imidazole-4-carboxamide;
N-(3-(4-(3-chloro-2-methylphenyl)piperazin-l-yl)propyl)-5-methyl-2- phenyl- 1 -o-tolyl- 1 H-imidazole-4-carboxamide;
N-(3-(4-(2,3-dichlorophenyl)piperazin- 1 -yl)propyl)-5-methyl-2-phenyl- 1 - o-tolyl- 1 H-imidazole-4-carboxamide;
N-(3-(4-(2,3-dimethylphenyl)piperazin-l-yl)-2-hydroxypropyl)-5-methyl- 2-phenyl-l -o-tolyl- 1 H-imidazole-4-carboxamide;
N-(3-(4-(3-chloro-2-methylphenyl)piperazin-l-yl)-2-hydroxypropyl)-5- methy 1-2-pheny 1-1 -o-tolyl- 1 H-imidazole-4-carboxamide;
N-(3-(4-(2,3-dichlorophenyl)piperazin-l-yl)-2-hydroxypropyl)-5-methyl- 2-phenyl-l -o-tolyl- lH-imidazole-4-carboxamide;
N-(3-(4-(3-chloro-2-methylphenyl)piperazin-l-yl)-2-hydroxypropyl)-2,5- dimethyl-l-(4-(trifluoromethyl)phenyl)-l H-imidazole-4-carboxamide;
N-(3-(4-(3-chloro-2-methylphenyl)piperazin- 1 -yl)propyl)-2,5-dimethyl- 1 - (4-(trifluoromethyl)phenyl)-lH-imidazole-4-carboxamide;
N-(3-(4-(3-chloro-2-methylphenyl)piperazin-l-yl)propyl)-5-methyl-2- phenyl-l-/?-tolyl-l H-imidazole-4-carboxamide;
N-(3-(4-(3-chloro-2-methylphenyl)piperazin-l-yl)propyl)-N,5-dimethyl- 1,2-dipheny 1-1 H-imidazole-4-carboxamide;
N-(3-(4-(2,3-dichlorophenyl)piperazin-l-yl)propyl)-N,5-dimethyl-l,2- dipheny 1-1 H-imidazole-4-carboxamide;
N-(3-(4-(2,3-dimethylphenyl)piperazin-l-yl)propyl)-N,5-dimethyl-l,2- diphenyl-lH-imidazole-4-carboxamide;
N-(3-(4-(3-chloro-2-methylphenyl)piperazin- 1 -yl)propyl)- 1-cyclopentyl- N,2,5-trimethyl-lH-imidazole-4-carboxamide;
l-cyclopentyl-N-(3-(4-(2,3-dichlorophenyl)piperazin-l-yl)propyl)-N,2,5- trimethy 1- 1 H-imidazole-4-carboxamide;
l-cyclopentyl-N-(3-(4-(2,3-dimethylphenyl)piperazin-l-yl)propyl)-N,2,5- trimethyl-1 H-imidazole-4-carboxamide;
N-(3-(4-(2,3-dimethylphenyl)piperazin-l-yl)propyl)-l-(4- methoxyphenyl)-N,5-dimethyl-2-phenyl-lH-imidazole-4-carboxamide;
l-(3-chlorophenyl)-N-(3-(4-(2,3-dimethylphenyl)piperazin-l-yl)propyl)- N,2,5-trimethyl-l H-imidazole-4-carboxamide;
N-(3-(4-(3-chloro-2-methylphenyl)piperazin-l-yl)propyl)-l-(4- methoxyphenyl)-N,5-dimethyl-2-phenyl-lH-imidazole-4-carboxamide;
N-(3-(4-(3-chloro-2-methylpheny l)piperazin- 1 -yl)propyl)- 1 -(3- chlorophenyl)-N,2,5-trimethyl-lH-imidazole-4-carboxamide;
l-(2-chlorophenyl)-N-(3-(4-(2,3-dimethylphenyl)piperazin-l-yl)propyl)- N,2,5-trimethy 1-1 H-imidazole-4-carboxamide;
N-(3-(4-(3-chloro-2-methylphenyl)piperazin- 1 -yl)propyl)- 1 -(2- chlorophenyl)-N,2,5-trimethyl-lH-imidazole-4-carboxamide;
1 -(2-chlorophenyl)-N-(3-(4-(2,3-dichloropheny l)piperazin- 1 -yl)propyl)- N,2,5-trimethyl-l H-imidazole-4-carboxamide;
N-(3-(4-(2,3-dimethylphenyl)piperazin-l-yl)propyl)-N,2,5-trimethyl-l- phenyl-1 H-imidazole-4-carboxamide;
N-(3-(4-(3-chloro-2-methylphenyl)piperazin-l-yl)propyl)-N,2,5- trimethyl- 1 -phenyl- 1 H-imidazole-4-carboxamide;
N-(3-(4-(2,3-dichlorophenyl)piperazin-l-yl)propyl)-N,2,5-trimethyl-l- pheny 1-1 H-imidazole-4-carboxamide;
N-(3-(4-(2,3-dimethy lphenyl)piperazin- 1 -yl)propyl)- 1 -(4-fluorophenyl)- N,5-dimethyl-2-phenyl-lH-imidazole-4-carboxamide;
N-(3-(4-(3-chloro-2-methylphenyl)piperazin-l-yl)propyl)-l-(4- fluorophenyl)-N,5-dimethyl-2-phenyl-lH-imidazole-4-carboxamide;
N-(3-(4-(2,3-dichlorophenyl)piperazin- 1 -yl)propyl)- 1 -(4-fluorophenyl)- N,5-dimethyl-2-phenyl-lH-imidazole-4-carboxamide;
l-(2,3-dihydrobenzo[b][l,4]dioxin-6-yl)-N-(3-(4-(2,3- dimethylphenyl)piperazin-l-yl)propyl)-N,5-dimethyl-2-phenyl-lH-imidazole-4- carboxamide; N-(3-(4-(3-chloro-2-methylphenyl)piperazin-l-yl)propyl)- l-(2,3- dihydrobenzo[b][l,4]dioxin-6-yl)-N,5-dimethyl-2-phenyl-lH-imidazole-4- carboxamide
N-(3-(4-(2,3-dichlorophenyl)piperazin-l-yl)propyl)-l-(2,3- dihydrobenzo[6][l,4]dioxin-6-yl)-N,5-dimethyl-2-phenyl-lH-imidazole-4- carboxamide;
(R)-l-(2,3-dihydrobenzo[b][l,4]dioxin-6-yl)-N-(3-(4-(2,3- dimethylphenyl)piperazin-l-yl)-2-hydroxypropyl)-2,5-dimethyl-lH-imidazole-4- carboxamide;
(R)-N-(3-(4-(3-chloro-2-methylphenyl)piperazin-l-yl)-2-hydroxypropyl)- l-(2,3-dihydrobenzo[b][l,4]dioxin-6-yl)-2,5-dimethyl-lH-imidazole-4- carboxamide; and
(R)-N-(3-(4-(2,3-dichlorophenyl)piperazin-l-yl)-2-hydroxypropyl)-l- (2,3-dihydrobenzo[Z>][ 1 ,4]dioxin-6-yl)-2,5-dimethyl- lH-imidazole-4-carboxamide.
3. A pharmaceutical composition for preventing or treating a depressive disorder, which comprises the compound of formula (I) according to claim 1 or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier.
4. A method for preventing or treating a depressive disorder in a mammal, comprising administering the compound of formula (I) according to claim 1 or a pharmaceutically acceptable salt thereof to the mammal in need thereof.
5. A use of the compound of formula (I) according to claim 1 or a pharmaceutically acceptable salt thereof for the manufacture of a medicament for preventing or treating a depressive disorder.
PCT/KR2010/004479 2009-07-10 2010-07-09 Novel arylpiperazine-containing imidazole 4-carboxamide derivatives and pharmaceutical composition comprising same WO2011005052A2 (en)

Priority Applications (2)

Application Number Priority Date Filing Date Title
KR1020127003530A KR101386679B1 (en) 2009-07-10 2010-07-09 Novel arylpiperazine-containing imidazole 4-carboxamide derivatives and pharmaceutical composition comprising same
US13/383,143 US8835436B2 (en) 2009-07-10 2010-07-09 Arylpiperazine-containing imidazole 4-carboxamide derivatives and pharmaceutical composition comprising same

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US22467309P 2009-07-10 2009-07-10
US61/224,673 2009-07-10

Publications (3)

Publication Number Publication Date
WO2011005052A2 true WO2011005052A2 (en) 2011-01-13
WO2011005052A3 WO2011005052A3 (en) 2011-05-26
WO2011005052A8 WO2011005052A8 (en) 2012-02-02

Family

ID=43429693

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/KR2010/004479 WO2011005052A2 (en) 2009-07-10 2010-07-09 Novel arylpiperazine-containing imidazole 4-carboxamide derivatives and pharmaceutical composition comprising same

Country Status (3)

Country Link
US (1) US8835436B2 (en)
KR (1) KR101386679B1 (en)
WO (1) WO2011005052A2 (en)

Cited By (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2012030953A1 (en) 2010-09-01 2012-03-08 Arena Pharmaceuticals, Inc. 5-ht2c receptor agonists in the treatment of disorders ameliorated by reduction of norepinephrine level
WO2014046544A1 (en) 2012-09-21 2014-03-27 Aapa B.V. Substituted 3-heteroaryloxy-3-(hetero)aryl-propylamines as serotonin transporter and serotonin ht2c receptor modulators
WO2014133291A1 (en) * 2013-02-26 2014-09-04 주식회사 아미노로직스 Method for preparing (2rs)-amino-(3s)-hydroxy-butyric acid or derivative thereof
WO2015136947A1 (en) 2014-03-14 2015-09-17 Raqualia Pharma Inc. Azaspiro derivatives as trpm8 antagonists
CN105338812A (en) * 2013-03-15 2016-02-17 怀特黑德生物医学研究院 Benzimidazole derivatives and uses thereof
WO2018024188A1 (en) * 2016-08-02 2018-02-08 上海迪诺医药科技有限公司 Polycyclic compound, and manufacturing method, pharmaceutical composition, and application thereof
CN108129343A (en) * 2017-12-08 2018-06-08 浙江工业大学 A kind of preparation method of R-2- acyl aminos -3- methoxy methyl propionates
JP2019534848A (en) * 2016-10-12 2019-12-05 アールティーアイ インターナショナル Heterocyclic apelin receptor (APJ) agonists and their use
US11401244B2 (en) 2014-06-06 2022-08-02 Research Triangle Institute Apelin receptor (APJ) agonists and uses thereof
US11535630B2 (en) 2015-12-09 2022-12-27 Research Triangle Institute Apelin receptor (APJ) agonists and uses thereof

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4988814A (en) * 1989-04-22 1991-01-29 American Home Products Corp. Tertiary alkyl functionalized piperazine derivatives
US5380725A (en) * 1988-05-24 1995-01-10 American Home Products Corporation Aryl- and heteroaryl piperazinyl carboxamides having central nervous system activity
KR20080100765A (en) * 2007-05-14 2008-11-19 에스케이 주식회사 Novel carbamoyloxy arylalkanoyl arylpiperazine compound, pharmaceutical compositions comprising the compound and method for treating pain, anxiety and depression by administering the compound

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW200831498A (en) * 2006-10-13 2008-08-01 Otsuka Pharma Co Ltd Heterocyclic compound

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5380725A (en) * 1988-05-24 1995-01-10 American Home Products Corporation Aryl- and heteroaryl piperazinyl carboxamides having central nervous system activity
US4988814A (en) * 1989-04-22 1991-01-29 American Home Products Corp. Tertiary alkyl functionalized piperazine derivatives
KR20080100765A (en) * 2007-05-14 2008-11-19 에스케이 주식회사 Novel carbamoyloxy arylalkanoyl arylpiperazine compound, pharmaceutical compositions comprising the compound and method for treating pain, anxiety and depression by administering the compound

Cited By (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2012030953A1 (en) 2010-09-01 2012-03-08 Arena Pharmaceuticals, Inc. 5-ht2c receptor agonists in the treatment of disorders ameliorated by reduction of norepinephrine level
WO2014046544A1 (en) 2012-09-21 2014-03-27 Aapa B.V. Substituted 3-heteroaryloxy-3-(hetero)aryl-propylamines as serotonin transporter and serotonin ht2c receptor modulators
WO2014133291A1 (en) * 2013-02-26 2014-09-04 주식회사 아미노로직스 Method for preparing (2rs)-amino-(3s)-hydroxy-butyric acid or derivative thereof
KR101446551B1 (en) 2013-02-26 2014-10-06 주식회사 아미노로직스 Process of preparing (2RS)-Amino-(3S)-hydroxy-butyric acid or its derivatives
US9862978B2 (en) 2013-02-26 2018-01-09 Aminologics Co. Ltd. Method for preparing (2RS)-amino-(3S)-hydroxy-butyric acid and its derivatives
CN105338812A (en) * 2013-03-15 2016-02-17 怀特黑德生物医学研究院 Benzimidazole derivatives and uses thereof
US9790188B2 (en) 2013-03-15 2017-10-17 Whitehead Institute For Biomedical Research Benzimidazole derivatives and uses thereof
WO2015136947A1 (en) 2014-03-14 2015-09-17 Raqualia Pharma Inc. Azaspiro derivatives as trpm8 antagonists
US11401244B2 (en) 2014-06-06 2022-08-02 Research Triangle Institute Apelin receptor (APJ) agonists and uses thereof
USRE49594E1 (en) 2015-12-09 2023-08-01 Research Triangle Institute Apelin receptor (APJ) agonists and uses thereof
US11535630B2 (en) 2015-12-09 2022-12-27 Research Triangle Institute Apelin receptor (APJ) agonists and uses thereof
WO2018024188A1 (en) * 2016-08-02 2018-02-08 上海迪诺医药科技有限公司 Polycyclic compound, and manufacturing method, pharmaceutical composition, and application thereof
CN107674013B (en) * 2016-08-02 2022-05-24 上海迪诺医药科技有限公司 Polycyclic compound, preparation method, pharmaceutical composition and application thereof
CN107674013A (en) * 2016-08-02 2018-02-09 上海迪诺医药科技有限公司 Polycyclic compound, its preparation method, pharmaceutical composition and application
JP7104690B2 (en) 2016-10-12 2022-07-21 リサーチ トライアングル インスティテュート Heterocyclic apelin receptor (APJ) agonists and their use
JP2019534848A (en) * 2016-10-12 2019-12-05 アールティーアイ インターナショナル Heterocyclic apelin receptor (APJ) agonists and their use
US11926612B2 (en) 2016-10-12 2024-03-12 Research Triangle Institute Heterocyclic apelin receptor (APJ) agonists and uses thereof
CN108129343A (en) * 2017-12-08 2018-06-08 浙江工业大学 A kind of preparation method of R-2- acyl aminos -3- methoxy methyl propionates

Also Published As

Publication number Publication date
KR20120048618A (en) 2012-05-15
KR101386679B1 (en) 2014-04-17
US8835436B2 (en) 2014-09-16
WO2011005052A3 (en) 2011-05-26
US20120115881A1 (en) 2012-05-10
WO2011005052A8 (en) 2012-02-02

Similar Documents

Publication Publication Date Title
US8835436B2 (en) Arylpiperazine-containing imidazole 4-carboxamide derivatives and pharmaceutical composition comprising same
JP5542962B2 (en) Substituted isoquinolinones and quinazolinones
AP1122A (en) Therapeutically active compounds based on based on based on indazole bioisostere replacement of catechol in PDE4 inhibitors.
KR101715190B1 (en) Pharmaceutical compounds
JP3893878B2 (en) Phenoxypropylamine compound
WO2015179559A2 (en) Pyrazole compounds and methods of making and using same
JPH08109169A (en) Nonpeptide taxiquinine receptor antagonist
BG107959A (en) Substituted triazole diamine derivatives as kinase inhibitors
KR100384906B1 (en) 2-arylethyl-(piperidin-4-ylmethyl)amine derivatives as muscarinic receptor antagonists
WO2009095394A1 (en) Diazepanes as histamine h3 receptor antagonists
US8895558B2 (en) Arylpiperazine-containing pyrrole 3-carboxamide derivatives for treating depressive disorders
EP3055293A1 (en) Diarylalkylamine rev-erb antagonists and their use as medicaments
US20050209274A1 (en) Antagonists of melanin concentrating hormone effects on the melanin concentrating hormone receptor
UA108746C2 (en) Substituted isoquinolinones and quinazolinones
US8785453B2 (en) Arylpiperazine-containing purine derivatives and uses thereof
US20080207704A1 (en) Heteroaryl-imidazole derivatives as cannabinoid cb1 receptor antagonists
KR101070176B1 (en) 1H-pyrazole-3-amide derivatives having CB1-antagonistic activity and pharmaceutical composition comprising the same
JP2006527266A (en) Hepatitis C virus inhibitor
WO2009078498A1 (en) Biarylpyrazole 4-carboxamides as cannabinoid cb1 receptor ligands
US20080081815A1 (en) Heteroaryl-pyrazole derivatives as cannabinoid CB1 receptor antagonists
US20080207705A1 (en) Heteroaryl-Imidazole Derivatives as Cannabinoid CB1 Receptor Antagonists
KR101318689B1 (en) Sulfur containing pyrazole-heterocycle derivatives as cannabinoid cb1 receptor antagonists
CZ2000947A3 (en) Substituted chroman derivatives

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 10797326

Country of ref document: EP

Kind code of ref document: A2

WWE Wipo information: entry into national phase

Ref document number: 13383143

Country of ref document: US

NENP Non-entry into the national phase

Ref country code: DE

ENP Entry into the national phase

Ref document number: 20127003530

Country of ref document: KR

Kind code of ref document: A

122 Ep: pct application non-entry in european phase

Ref document number: 10797326

Country of ref document: EP

Kind code of ref document: A2